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A Toxicological Profile for 1,3-Dichloropropene, Draft for Public Comment, was released in 2006.  This
edition supersedes any previously released draft or final profile.  
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at:
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
 

































    
 
 















    




   














This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the hazardous substance described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a hazardous substance’s toxicologic properties.  Other pertinent
literature is also presented, but is described in less detail than the key studies.  The profile is not intended 
to be an exhaustive document; however, more comprehensive sources of specialty information are 
referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile
begins with a public health statement that describes, in nontechnical language, a substance’s relevant
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance’s health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or 
levels of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other Federal scientists have 






























   
 
   










and was made available for public review.  Final responsibility for the contents and views expressed in 
this toxicological profile resides with ATSDR.
Howard Frumkin M.D., Dr.P.H. Julie Louise Gerberding, M.D., M.P.H.
Director Administrator
National Center for Environmental Health/ Agency for Toxic Substances and
Agency for Toxic Substances and Disease Registry
Disease Registry
*Legislative Background
The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization 
Act (SARA) of 1986 (Public Law 99 499) which amended the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This public law directed ATSDR to 
prepare toxicological profiles for hazardous substances most commonly found at facilities on the
CERCLA National Priorities List and that pose the most significant potential threat to human health, as
determined by ATSDR and the EPA.  The availability of the revised priority list of 275 hazardous 
substances was announced in the Federal Register on December 7, 2005 (70 FR 72840).  For prior
versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866);
October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17,1990 (55 FR 42067);
October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486);
April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999(64 FR 56792);
October 25, 2001 (66 FR 54014) and November 7, 2003 (68 FR 63098).  Section 104(i)(3) of CERCLA, 






















    
  















   
    
   
   
 
 
   




            
   





   
   
viiDICHLOROPROPENES
QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 3.7 Children’s Susceptibility
 
Section 6.6 Exposures of Children
 
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or Fax: (770) 488-4178
1-888-232-6348 (TTY)
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure











   
 
 
   
 
   














   




















Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide
Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, 



















































ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA
 
Julie M. Klotzbach, Ph.D.
 
Daniel J. Plewak, B.S.
 
Syracuse Research Corporation, North Syracuse, NY
 
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1.	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2.	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs.
3.	 Data Needs Review.  The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance.












































    
   








A peer review panel was assembled in 2006 for dichloropropenes.  The panel consisted of the following
members:
1.	 Dr. Mary Davis, Professor, Department of Physiology and Pharmacology, West Virginia 
University Medical Center, Morgantown, West Virginia;
2.	 Dr. Rogene Henderson, Senior Scientist (retired), Lovelace Respiratory Research Institute, 
Alburquerque, New Mexico; and 
3.	 Dr. Lisa M. Kamendulis, Assistant Professor, Department of Pharmacology and Toxicology, 
Indiana University School of Medicine, Indianapolis, Indiana.
These experts collectively have knowledge of 1,3-dichloropropene's physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
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1.  PUBLIC HEALTH STATEMENT
This public health statement tells you about dichloropropenes and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the
nation.  These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities.  1,1-, 1,2-, 1,3-, and 2,3-Dichloropropene have been found in at least 2, 9, 107, 
and 3 of the 1,699 current or former NPL sites, respectively.  3,3-Dichloropropene was not identified in 
any of the 1,699 current or former NPL sites.  Although the total number of NPL sites evaluated for this
substance is not known, the possibility exists that the number of sites at which dichloropropenes are found 
may increase in the future as more sites are evaluated.  This information is important because these sites
may be sources of exposure and exposure to dichloropropenes may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If you are exposed to dichloropropenes, many factors will determine whether you will be harmed.  These
factors include the dose (how much), the duration (how long), and how you come in contact with these
substances.  You must also consider any other chemicals you are exposed to and your age, sex, diet, 
family traits, lifestyle, and state of health.
Most of the information on dichloropropenes is for one type of dichloropropene, 1,3-dichloropropene.  
There is much less information for 2,3-dichloropropene, almost no information on 1,2-dichloropropene, 
and no information on 1,1- and 3,3-dichloropropene.
1.1  WHAT ARE DICHLOROPROPENES?
Description Five types (or isomers) of dichloropropene exist: 1,1-dichloropropene,
1,2-dichloropropene, 1,3-dichloropropene, 2,3-dichloropropene, and 
3,3-dichloropropene.
1,3-Dichloropropene is a colorless liquid with a sweet smell.  It dissolves in 
water and evaporates easily.
   
 



















   
 
 














   
 
 

























1.  PUBLIC HEALTH STATEMENT
Uses 1,3-Dichloropropene is used mainly in farming to kill tiny pests called 
nematodes that eat the roots of important crops.
2,3-Dichloropropene is produced and used in industry to make other
chemicals.
For more information on the physical and chemical properties of dichloropropenes and their production, 
disposal and use, see Chapters 4 and 5.
1.2  	 WHAT HAPPENS TO DICHLOROPROPENES WHEN THEY ENTER THE
ENVIRONMENT?
Sources When 1,3-dichloropropene is used in farm fields, it is sprayed into the ground.
Some of the 1,3-dichloropropene in air may be washed down onto the 





1,3-Dichloropropene is quickly broken down in air, usually within several
days.
Some of the 1,3-dichloropropene in soil and water will evaporate into the air.
The rest will be broken down through biodegradation pathways and 
hydrolysis.
Information on what happens to 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene 
when they enter the environment is not available.  Based on their physical
and chemical properties, these substances are expected to behave similarly
to 1,3-dichloropropene.
For more information on dichloropropenes in the environment, see Chapter 6.
1.3  	 HOW MIGHT I BE EXPOSED TO DICHLOROPROPENES?
Data regarding human exposure to 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene were not located in 
the available literature.  Exposure of the general population to these substances is expected to 




The primary way you can be exposed to 1,3-dichloropropene is by breathing 
air containing it.
1,3-Dichloropropene is rarely detected in urban air samples; measured 
levels are usually less than 0.5 parts per billion (ppb). Higher levels (5 ppb 
and lower) were measured in areas with high 1,3-dichloropropene use.
   
 

































    









     

























1.  PUBLIC HEALTH STATEMENT
Water and soil Low levels of 1,3-dichloropropene have been measured in water samples;
the average concentration was 0.5 ppb.
1,3-Dichloropropene is rarely detected in soil samples.
Workplace Workers involved in the handling and application of 1,3-dichloropropene as a
soil fumigant can be exposed to the chemical in air and through dermal
contact.
Crops 1,3-Dichloropropene has not been detected in foods grown in fields treated 
with the chemical.
For more information on human exposure to dichloropropenes, see Chapter 6.






When you breathe air containing 1,3- dichloropropene or
2,3-dichloropropene, most of the chemical will rapidly enter your body
through your lungs.
1,3-Dichloropropene and 2,3-dichloropropene in food or water may also 
rapidly enter your body through the digestive tract.
It is likely that dichloropropenes will enter through your skin when you come 
into contact with liquids containing them.
Leave your body Once in your body, dichloropropenes are broken down into other chemicals.
Most of these other chemicals leave your body in the urine within few days.
For more information on how dichloropropenes get into and leave your body, see Chapter 3.
1.5  HOW CAN DICHLOROPROPENES AFFECT MY HEALTH?





Inhalation of dichloropropenes may cause respiratory effects such as
irritation, chest pain, and cough.
Oral exposure may cause gastrointestinal effects that include irritation,
erosion of the stomach lining, diarrhea, and bleeding.
Dermal exposure may cause dermatitis and dermal sensitization.
   
 






































   
    
 





   
  
   
 
 




     










Animal studies have shown that inhalation of 1,3- or 2,3-dichloropropene 
can result in changes in the lining of the nose.
Long-term exposure to 1,3-dichloropropene can cause damage to the lining 
of the urinary bladder and anemia.
Oral exposure to 1,3-dichloropropene can result in damage to the stomach 
lining and anemia in animals.
Skin and eye irritation are seen in animals after 1,3-dichloropropene gets on 
their skin or in their eyes.
Cancer The Department of Health and Human Services has determined that
1,3-dichloropropene is reasonably anticipated to be a human carcinogen.
The International Agency for Research on Cancer (IARC) determined that
1,3-dichloropropene is a possible carcinogen. EPA classified 
1,3-dichloropropene as a probable human carcinogen.
Further information on the health effects of dichloropropenes in humans and animals can be found in 
Chapters 2 and 3.
1.6 HOW CAN DICHLOROPROPENES AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from
conception to maturity at 18 years of age.
Effects in children There are no studies evaluating the effect of dichloropropenes exposure on 
children or immature animals.  It is likely that children would have the same 
health effects as adults. We do not know whether children would be more 
sensitive than adults to the effects of dichloropropenes.
Birth defects We do not know if dichlororpropenes will cause birth defects in people.
Birth defects have not been seen in animals.
1,3-Dichloropropene did not cause birth defects in animals, but pregnant
rats that breathed it gave birth to fewer rat pups or pups with lower body
weight.  These effects only happened at exposures high enough to be toxic
to the mother and reduce her food intake.
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1.  PUBLIC HEALTH STATEMENT





Families can reduce their exposure to 1,3-dichloropropene by staying away
from treated fields during pesticide application.
Workers who handle 1,3-dichloropropene should wash their hands before 
entering their homes and keep contaminated clothing isolated before it is
washed.
Children should be encouraged to wash their hands after playing near
treated soil and discouraged from putting their hands in their mouths.




It is possible to measure 1,3- or 2,3-dichloropropene or their breakdown 
products in blood and urine.
Measuring
exposure
In humans, the levels of 1,3-dichloropropene break down products in the
urine could be used to predict how much 1,3-dichloropropene has been 
inhaled.
Tests for 1,3- or 2,3-dichloropropene in the blood and urine would only be 
useful for recent exposures, because dichloropropenes leave the body
within 1–2 days.
You can find more information about these tests in Chapters 3 and 7.
1.9  	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances.  Recommendations provide valuable guidelines to protect public health, but cannot be
enforced by law.  The Agency for Toxic Substances and Disease Registry (ATSDR) and the National
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value that is usually based on levels that
affect animals; they are then adjusted to levels that will help protect humans.  Sometimes these not-to-
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exceed levels differ among federal organizations because they used different exposure times (an 8-hour
workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available.  
For the most current information, check with the federal agency or organization that provides it.
Some regulations and recommendations for dichloropropenes include the following:
Drinking water The EPA has determined that exposure to 1,3-dichloropropene in drinking 
water at concentrations of 0.03 parts per million (ppm) for 1 or 10 days is 
not expected to cause any noncancerous adverse effects in a child.
1.10  WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing
to:
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology and Environmental Medicine
 








Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS)
 


































     
  













2. RELEVANCE TO PUBLIC HEALTH
 
2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO DICHLOROPROPENES IN
THE UNITED STATES
1,3-Dichloropropene is a mixture of volatile cis and trans isomers and is primarily used as a nematocide 
to fumigate soil before planting.  Commercial formulations of 1,3-dichloropropene contain stabilizers to
inhibit degradation of the compound (Table 3-1).  Older formulations contained chroropicrin or
epichlorohydrin, whereas currently, the less toxic epoxidized soybean oil is used as a stabilizer.  1,3-Di-
chloropropene is released to the atmosphere in fugitive or accidental emissions from industrial sources 
(e.g., petroleum refineries, sewage treatment facilities, and electricity-generating power facilities) and 
also during its use as a fumigant.  Accidental discharges into surface waters from industrial sources or 
leaching into groundwater from hazardous waste sites or agricultural uses also occur. 
A significant proportion of the 1,3-dichloropropene released into soil or surface waters is expected to 
volatize into the atmosphere where it is degraded by photooxidation with hydroxyl radicals or reaction 
with ozone.  The half-life of 1,3-dichloropropene in ambient air is expected to range between 7 and 
50 hours, depending on the concentrations of cis- and trans- isomers and reactive hydroxyl radicals.  
1,3-Dichloropropene may also undergo biodegradation or hydrolysis in natural waters and in soil.  
Experimental data indicate increased rates of hydrolysis with higher temperature, the hydrolysis half-life
in deionized water being about 10 days at 20 °C.  
1,3-Dichloropropene is not a widely-occurring atmospheric pollutant.  Mean concentrations in positive air
samples from urban and rural regions have ranged between 0.088 and 0.33 ppb in one report, but
concentrations as high as 35.2 ppb have been measured in high-use agricultural regions.  1,3-Dichloro-
propene has been detected in 40% of 12,673 water samples, but only 6% of the samples contained 1,3-di-
chloropropene above the quantifiable limit.  The range of quantifiable concentrations in water was 0.002– 
25 ppb, with a mean of 0.5 ppb.  1,3-Dichloropropene was detected in only 0.1% of 70,631 public water
system samples collected in the United States between 1993 and 1997.  1,3-Dichloropropene has not been 
detected in food.
Possible routes of human exposure to 1,3-dichloropropene include inhalation of contaminated air, 
ingestion of contaminated drinking water, and dermal contact with pesticides containing 1,3-dichloro-
   
 









   
  
  





      
  
 
    
 




    











2. RELEVANCE TO PUBLIC HEALTH
propene.  Due to the volatility of 1,3-dichloropropene, inhalation exposure, particularly in regions where
the pesticide is used commercially to fumigate soil, appears to be the major route of exposure for the
general population.  Children residing in regions of pesticide use are likely to be exposed to 1,3-dichloro-
propene by the same routes that affect adults.  Occupational exposure or accidental exposure resulting
from a spill is likely to occur through inhalation and dermal contact. 
Information on the release, environmental fate and partitioning, concentrations in environmental media, 
and potential for human exposure is very limited for 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene.  Based on 
their physical and chemical properties, these substances are expected to behave similarly to 1,3-dichloro-
propene when they are released into the environment.  However, hydrolysis of 1,1- and 1,2-dichloro-
propene is expected to be much slower than hydrolysis of the other dichloropropene isomers due to the
inhibiting effect of the vinylic chlorine atoms.
1,1-, 1,2-, 2,3-, and 3,3-Dichloropropene are not commonly found at measurable concentrations in air, 
surface water, drinking water, groundwater, soil or food.  1,1-Dichloropropene has been detected in 64%
of 5,348 water samples collected in the United States, but only 1% of the samples contained 1,1-dichloro-
propene above the quantifiable limit.  The range of quantifiable concentrations in water was 0.001–5 ppb, 
with a mean of 0.4 ppb.  1,1-Dichloropropene was detected in only 0.01% of 97,698 public water system
samples collected in the United States between 1993 and 1997.
The potential for human exposure to 1,1-, 1,2-, and 3,3-dichloropropene is expected to be low because 
these chemicals are not produced or used in high amounts.  Higher amounts of 2,3-dichloropropene may
be released from facilities where this substance is produced or used.  Individuals who work or live near
these facilities may be exposed to 2,3-dichloropropene; however, exposure of the general population to 
this chemical is not expected to be important.
2.2  SUMMARY OF HEALTH EFFECTS 
As volatile halogenated alkenes, dichloropropenes are reactive and cause irritant effects at the point of
contact. Their small molecular size and lipid solubility facilitate rapid absorption and distribution 
throughout the body.  Metabolism, primarily in the liver, but also in other tissues, results either in 
detoxification and elimination, or bioactivation to more a toxic or mutagenic metabolite.  Since there is
some evidence that the isomers behave differently with respect to metabolic pathways, and the available 
toxicity data are not necessarily comparable, health effects are discussed for each isomer individually.  No 
   
 








   
 
 








   
  
 
   
 
   
 








    
     
9DICHLOROPROPENES
2. RELEVANCE TO PUBLIC HEALTH
studies have compared the relative toxicity of dichloropropenes in mammals, but limited data suggest that
inhaled 2,3-dichloropropene is more damaging to the respiratory tract than 1,3-dichloropropene.
1,3-Dichloropropene.  1,3-Dichloropropene is readily absorbed by all routes of exposure.  The compound 
does not accumulate in the body and is readily excreted in the urine following conjugation to glutathione
and metabolic conversion to mercapturic acid derivatives.  Consistent with its reactive properties, some of 
the major effects of exposure occur at the point of contact:  nasal epithelium following inhalation 
exposure, stomach following oral exposure, and skin following dermal exposure.  The urinary bladder in 
mice exposed by inhalation and erythrocytes in dogs exposed orally are also targets of 1,3-dichloro-
propene.  
The available information on the toxicity of 1,3-dichloropropene in humans is largely limited to case
reports lacking exposure quantification and occupational studies.  Case reports of high level
(unquantified) exposures confirm portal-of-entry effects in the respiratory system after inhalation 
exposure, gastrointestinal effects following accidental ingestion, and contact dermatis leading to 
sensitization reactions following dermal exposure.  Additional effects noted following high-level
exposure included cardiovascular effects (tachycardia and hypovolemia) prior to multiorgan failure and 
death.  No hepatic or renal urinary biomarkers were elevated following repeated occupational exposures 
to cis-1,3-dichloropropene at relatively low levels (0.6 ppm).  An association was reported between 
occupational exposure to 0.06 to 2.1 ppm 1,3-dichloropropene and urinary excretion of biomarkers 
indicative of renal damage, but the levels were subclinical and could be considered nonadverse.
Experimental studies of 1,3-dichloropropene in animals have been conducted using various commercial
formulations, most of which contained chloropicrin (Telone C-17 contains 19–21% chloropicrin) or
epichlorohydrin (Telone II®a contains 1% epichlorohydrin) as stabilizers, or significant amounts of
1,2-dichloropropane (DD contains 25–29% 1,2-dichloropropane).  More recent studies have tested 
Telone II®b, which was relatively pure (≥90% 1,3-dichloropropene) and contained 2% epoxidized 
soybean oil (ESO) as a stabilizer.  Comparison of results of the new dietary studies with results of earlier
oral gavage studies, suggest that either bolus dosing and/or the presence of epichlorohydrin may have 
been responsible for some effects in observed in earlier studies.  
Results from repeated-dose animal studies indicate that respiratory effects (hyperplasia of the nasal
respiratory epithelium in rats and mice) and urinary effects (hyperplasia of the urinary bladder in mice)
following chronic inhalation exposure at ≥20 ppm 6 hours/day, 5 days/week, and gastrointestinal 
   
 









     
   
 
    




    
 
    
  
  
   
    
  
 















2. RELEVANCE TO PUBLIC HEALTH
(hyperplasia of the forestomach in rats) and hematological effects (microcytic anemia in dogs) following
long-term oral exposure to Telone II®b at ~12–15 mg/kg/day or to Telone II®a at 11 mg/kg/day 
(25 mg/kg/day, 3 days/week) are the most sensitive effects induced by exposure to 1,3-dichloropropene.  
Renal effects or urinary bladder hyperplasia were not observed in animals treated in the diet with 
Telone II®b, but hyperplasia of the urinary bladder was observed in animals treated by gavage with 
Telone II®a at 21 mg/kg/day (50 mg/kg/day, 3 days/week) for 2 years.  These effects are discussed in 
greater detail below.  
Other effects of exposure to 1,3-dichloropropene involve the skin and eyes, liver, and nervous system.  
Liquid 1,3-dichloropropene is irritating to the eyes of rabbits, a 0.1 mL application causing erythema, 
lacrimation, or palpbral closure.  Liquid application to skin of rats, rabbits, or guinea pigs resulted in 
erythema/edema from a single 4-hour application at 0.5 mL or repeated applications at 0.1 mL, and 
necrosis resulted from a single 24-hour application at 200 mg/kg.  Contact sensitization was noted in 
guinea pigs following repeated dermal application at 0.2 mL.  Neurological effects included ataxia and 
loss of the righting reflex in pregnant rabbits exposed by inhalation to 300 ppm for 13 days, but this
exposure level was fatal to six of seven does.  No direct developmental effects were noted in animals 
exposed at <120 ppm by inhalation for 10 days or <90 ppm for 3 months, but reduced litter sizes were 
observed in pregnant rats exposed to 150 ppm, a level causing maternal toxicity (reductions in feed 
intake, water intake, and body weight).  No adverse effect on reproduction was noted in rats exposed by
inhalation at <90 ppm for two generations.
Extremely limited data (a few case reports and one epidemiological study) are available for carcinogenic 
effects of 1,3-dichloropropenes in humans.  In chronic animal bioassays using Telone II®b increases in 
benign tumors (adenomas) were reported in the mouse lung following inhalation exposure and rat liver
following oral dietary exposure.  A chronic oral gavage bioassay using Telone II®a resulted in more
severe carcinogenic effects, but it is not known whether that was a consequence of the presence of
epichlorohydrin in Telone II®a or bolus dosing.  Carcinogenicity of 1,3-dichloropropene is discussed in 
greater detail below. 
The health effects of 1,3-dichloropropene exposure are discussed in detail in Chapter 3.
The following section discuss the most significant effects of exposure to 1,3-dichloropropene, which 
involve the gastrointestinal, hematological, respiratory, and urinary systems and cancer. 
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Respiratory Effects. Due to the reactivity of 1,3-dichloropropene, irritant effects on the respiratory
tract can be expected from inhalation exposure in humans and animals.  In humans accidentally exposed 
to presumably high concentrations of 1,3-dichloropropene, respiratory effects included mucous membrane
irritation, chest pain, and cough.  In one case, repeated exposure for 30 days to pesticide spray from a 
leaky hose (presumably a combined vapor and droplet exposure) resulted in hyperemia and superficial
ulcerations of the nasal mucosa and inflammation of the pharynx.  No data are available for effects in
humans repeatedly exposed at lower levels.
Respiratory effects in rats exposed to 1,3-dichloropropene vapor at high concentrations in acute lethality
studies included atelectasis after 1 hour at 206 ppm for TC-17 (21.1% chloropicrin), and in 4-hour
exposures, lung edema at 595 ppm, congestion at 676 ppm for Telone II®a, and hemorrhage at 1,035 ppm.  
Nasal turbinates were not examined for histopathology in these acute-duration studies.  In intermediate-
duration studies using sublethal exposures to Telone II®b or Telone II®a vapor, hyperplasia/hypertrophy
of the nasal respiratory epithelium was observed in rats at ≥90ppm or mice at ≥60 ppm and degeneration 
of the nasal olfactory epithelium was observed in rats at ≥90 ppm.  Exposure for 2 years to Telone II®b 
vapor resulted in hyperplasia/hypertrophy of the nasal respiratory epithelium in mice at ≥20ppm and rats
at 60 ppm and degeneration of the nasal olfactory epithelium in rats and mice at 60 ppm.  
Lung effects (congestion, hemorrhage) that were observed in rats during acute lethality studies by the oral
or dermal routes may have arisen from inhalation of 1,3-dichloropropene vapor during administration of
high doses of the test material.  
Gastrointestinal Effects. Irritant effects on the gastrointestinal system have been observed in 
humans and animals following oral exposure to 1,3-dichloropropene.  Gastrointestinal effects observed in 
one case of fatal ingestion included initial acute gastroenteritis and abdominal pain on deep palpation, 
subsequent bloody diarrhea, hemorrhagic exudate of the stomach at autopsy, histopathological evidence
of congestion of gastric mucosal vessels, autolysis, and mucosal erosions of the stomach.  Nausea and 
vomiting were observed following accidental exposure to a high concentration of 1,3-dichloropropene
vapor, but it is possible that these could be a nonspecific effect of neurotoxicity.  No data are available for 
effects in humans repeatedly exposed at lower doses.
Gastrointestinal effects observed in rats following exposure to 1,3-dichloropropene as single oral gavage 
doses of various pesticide formulations include hyperkeratosis of the forestomach at ≥75 mg/kg and 
hemorrhaging of the small intestine at ≥110 mg/kg.  In repeated-dose oral studies at sublethal exposures, 
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basal cell hyperplasia of the nonglandular stomach developed in rats ingesting 15 mg/kg/day 1,3-dichloro-
propene as microencapsulated Telone II®b in the diet for 13 weeks or 12.5 mg/kg/day for 2 years, or in 
rats and mice exposed by oral gavage to respective TWA doses of 11 or 21 mg/kg (25 or 50 mg/kg/day, 
3 days/week) Telone II®a for 2 years.  Mice exposed to 60 ppm Telone II®b for 2 years by inhalation
developed hyperplasia and hyperkeratosis of the forestomach.  
Hematological Effects. Limited human data suggest that hematological malignancies (histiocytic 
lymphoma, acute myelomonocytic leukemia) may be associated with accidental inhalation exposure to 
1,3-dichloropropene vapor or aerosol at relatively high levels.  In one of these cases, pallor and a reduced 
hemoglobin count accompanied the leukemia.  The only significant hematological effects reported in 
animals were reductions in hemoglobin and hematocrit counts consistent with microcytic anemia in dogs
exposed to 15 mg/kg/day microencapsulated Telone II®b in the diet for 13 weeks or 1 year.  The
NOAELs for hematological effects in dogs were 5 mg/kg/day in the 13-week study and 2.5 mg/kg/day in 
the 1-year study.
Urinary System Effects. Urinary bladder hyperplasia was a consistent finding in mice exposed to 
≥60 ppm 1,3-dichloropropene Telone II®b by inhalation for 6 months or ≥20 ppm for 2 years.  Oral
gavage administration of epichlorohydrin-containing Telone II®a at doses of 21 mg/kg/day (50 mg/kg, 
3 days/week) to mice also increased the incidence of urinary bladder hyperplasia, but this lesion was not
observed in mice exposed to Telone II®b in the diet at doses up to 50 mg/kg/day.  The degree to which 
oral bolus dosing, which could overwhelm the major detoxification pathway, and/or epichlorohydrin, 
which is a mutagen, contributed to the different results of the two chronic mouse studies is not known.  
Cancer. Evidence for the carcinogenicity of 1,3-dichloropropene in humans is inadequate.  Clinical
reports describing the development of neoplasms in three men following inhalation (and possibly dermal)
exposure suggest a possible association between exposure and cancer in humans, but are inadequate to 
establish the association.  One source of uncertainty is the lack of information about the specific pesticide
formulation and possible carcinogenic additives to which the individuals may have been exposed (see
discussion of animal studies below).  Two of the men were exposed to 1,3-dichloropropene during the
cleanup of a tank truck spill.  Six years later, both men simultaneously developed and succumbed to 
histiocytic lymphoma that was refractory to treatment.  The same report described a farmer who 
developed acute myelomonocytic leukemia after being exposed to 1,3-dichloropropene while applying the
chemical to his fields.  This leukemia was also refractory to treatment, and the man died approximately
1 year later.  A case-control study provided suggestive evidence that populations living for 20 years in 
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regions with high usage of 1,3-dichloropropene pesticide may be at increased risk for death from
pancreatic cancer.
Results from several cancer bioassays provide adequate evidence of carcinogenicity in animals.  In 
chronic bioassays using Telone II®b, the only observed increased tumor incidences were for
bronchioalveolar adenomas in mice exposed by inhalation to 60 ppm and for hepatocellular adenomas and
carcinomas (combined) in rats exposed in the diet at 25 mg/kg/day.  In a chronic oral gavage bioassay
using Telone II®a, increased incidences were observed for squamous cell papillomas and carcinomas in 
the forestomach of rats exposed at 11 mg/kg/day (25 mg/kg/day, 3 days/week) and for squamous cell
papillomas and carcinomas in the forestomach, bronchioalveolar adenomas, and transitional cell
carcinomas of the urinary bladder in mice exposed at 21 mg/kg/day (50 mg/kg/day, 3 days/week).  There
is some uncertainty as to whether bolus dosing or the presence of epichlorohydrin in Telone II®a 
contributed to increased incidences of forestomach squamous cell papillomas and carcinomas in rats and 
mice or urinary bladder transitional cell carcinomas in mice, thyroid adenomas and carcinomas, or adrenal
gland pheochromocytomas.  Aspiration of Telone II®a may have contributed to the increased incidence of
bronchioalveolar adenomas in mice treated by oral gavage for 2 years.  Positive development of sarcomas 
in mice subcutaneously injected with 1,3-dichloropropene and positive results for chromosomal
aberration and deoxyribonucleic acid (DNA) fragmentation in short-term genotoxicity assays (see 
Section 3.3) lend support to the carcinogenic potential of 1,3-dichloropropene.  It should be noted that
positive results in mutagenicity assays have been attributed to impurities in the test material (see 
Section 3.3).  The Department of Health and Human Services has determined that 1,3-dichloropropene
may reasonably be anticipated to be a carcinogen based on sufficient evidence of carcinogencity in 
experimental animals.  The International Agency for Research on Cancer has determined that 1,3-di-
chloropropene is possibly carcinogenic to humans.  In 2000, IRIS classified 1,3-dichloropropene as a 
probable human carcinogen.
2,3-Dichloropropene. The toxicokinetic properties of 2,3-dichloropropene appear to be similar to those
of 1,3-dichloropropene.  It is readily absorbed in animals exposed by the inhalation and oral routes, and 
once absorbed, is distributed rapidly throughout the body.  It is a weakly alkylating compound that can 
react directly with biological macromolecules.  The major metabolic pathway for 2,3-dichloropropene is a
detoxifying conjugation to glutathione, leading to the elimination of mercapturic acid metabolites in the
urine.  Two minor pathways result in the formation of the mutagens 1,2-dichloroacetone or 2-chloro-
acrolein.  Saturation of the detoxifying conjugation pathways, which might occur under high exposure
conditions, could result in the production of proportionally more mutagens via the alternate pathways. 
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Reliable data in rats and mice suggest that the most sensitive effect of repeated acute-duration inhalation 
exposure to 2,3-dichloropropene at 5 ppm is damage to the respiratory tract.  Limited data in 13-week
studies appear to confirm the sensitivity of the respiratory tract to inhalation exposure (see below).  In 
these 13-week studies, hepatic and renal organ weight increases and altered serum chemistry or urinalysis 
parameters occur in rats exposed at 40–80 ppm, but not at 15 ppm.  Acute inhalation exposure at high 
levels (>500 ppm) may result in signs indicative of suppression of the central system (unconsciousness)
and/or death.  An acute-duration study is the only study that allows reliable identification of NOAELs and 
LOAELs for all systemic end points.  No data are available for developmental or carcinogenic effects of 
exposure to 2,3-dichloropropene.
Repeated exposure to 5–75 ppm for 6 hours/day for 9 out of 11 days resulted in significant concentration-
related increases in the incidence and severity of lesions of the respiratory tract in rats and mice.  Nearly 
all rats and mice were affected at the 5 ppm level, with hyperplasia of the nasal respiratory epithelium in 
both species and diffuse degeneration of the bronchial/bronchiolar epithelium in mice.  At ≥25 ppm, all
rats and mice exhibited hyperplasia of the nasal olfactory epithelium and mice had hyperplasia of the
laryngeal epithelium.  Rats and mice differed in that nasal tissues were the only respiratory tract target in 
rats, whereas the lungs were also affected in mice.  A NOAEL for respiratory effects was not identified in
this study.
Intermediate-duration studies provide supportive evidence for respiratory tract effects, but the data do not
adequately identify reliable NOAELs or LOAELs.  Rats exposed to 15 ppm 6 hours/day, 5 days/week for
13 weeks did not have alterations in lung histology, but did show an increase in red nasal discharge, a
sign of nasal irritation.  Since the nasal turbinates, the most sensitive target in rats exposed acutely, were 
not examined for histopathology, a LOAEL for respiratory effects cannot be assigned reliably.  An 
unfinished bioassay NTP, terminated when a drop in U.S. production volumes indicated the compound 
was of low priority, showed increases in absolute and relative lung weights in female mice exposed at
≥5 ppm and male mice exposed at ≥10 ppm for 6 hours/day, 5 days/week for 13 weeks.  Although no 
histopathology data are available for this bioassay, the fact that the lung was the only organ to show
weight increases at 5 ppm appears to confirm that the respiratory tract is a specific target of inhaled 
2,3-dichloropropene.
1,2-Dichloropropene. No information is available about the toxicokinetic properties of 1,2-dichloro-
propene.  Toxicity information is limited to a brief summary of results of acute-duration studies in 
   
 











   
   
 
 
       





     
 

















2. RELEVANCE TO PUBLIC HEALTH
animals exposed at high or unreported exposure levels.  Rats exposed for a few minutes to a saturated 
vapor atmosphere estimated at 63,764 ppm experienced unconsciousness, with liver, lung, and kidney
injury occurring in those that died.  Kidney and liver injury were also observed in rats exposed by oral
gavage at 2,000 mg/kg.  Irritant effects in eyes and skin were observed following topical application of
1,2-dichloropropene at an unspecified dose.  The scant information on this isomer suggests that it shares 
irritant properties with 1,3-dichloropropene and 2,3-dichloropropene.  
1,1-Dichloropropene. No in vivo toxicity or toxicokinetic data were located for 1,1-dichoropropene.
In vitro metabolism results of one study indicate that this isomer differs from 1,3-dichloropropene and 
2,3-dichloropropene in that conjugation to glutathione results in bioactivation to a mutagenic metabolite, 
rather than the production of innocuous mercapturic acid metabolites.  This finding indicates that 
estimates of toxicity based on 1,3- or 2,3-dichloropropene may not necessarily apply to 1,1-dichloro-
propene.  
3,3-Dichloropropene. No toxicity or toxicokinetic data were located for 3,3-dichloropropene.
2.3 MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for 1,3- and 2,3-di-
chloropropene.  An MRL is defined as an estimate of daily human exposure to a substance that is likely to 
be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  
MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the
most sensitive health effect(s) for a specific duration within a given route of exposure.  MRLs are based 
on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised.
   
 









    
  
 






   
   
    
    
   
     
    
     
      
    
       
  
    
 
       
 
     
  
 




2. RELEVANCE TO PUBLIC HEALTH
The following discussion of inhalation and oral MRLs and the supporting databases is organized by
isomer.  Intermediate- and chronic-duration inhalation and oral MRLs have been derived for 1,3-dichloro-
propene and an acute-duration inhalation MRL has been derived for 2,3-dichloropropene (Table 2-1).  
Additional details of MRL derivations are presented in Appendix A.
1,3-Dichloropropene.
Inhalation MRLs.  
The data for acute toxic effects in human exposed by inhalation to 1,3-dichloropropene came from
accidental exposures for which the concentrations in air were not measured.  Acute effects in humans
involved the respiratory system (mucous membrane irritation, chest pain, cough, and breathing
difficulties) (Flessel et al. 1978; Markovitz and Crosby 1984).  Most of the acute-duration inhalation data
in animals comes from 1–4-hour acute lethality rat studies that did not employ a control group.  Eye
irritation was reported at 206 ppm for Telone C-17® (21.1% chloropicrin) (Streeter and Lomax 1988) and 
775–1,146 ppm for Telone II®a (Streeter et al. 1987; Yakel and Kociba 1977).  Respiratory effects 
included atelectasis at 206 ppm for Telone C-17® (21.1% chloropicrin) (Streeter and Lomax 1988), lung
edema at 595 ppm and congestion at 676 ppm for Telone II®a (Cracknell et al. 1987) and hemorrhage at
1,035 ppm (Streeter et al. 1987).  Adrenal congestion was noted at 676 ppm for Telone II®a (Cracknell et
al. 1987).  The 1-hour LC50 for Telone C-17 (21.1% chloropicrin) was 253 ppm (Streeter and Lomax 
1988), and 4-hour LC50 values of 676 and 904 ppm were reported for Telone II®a (Cracknell et al. 1987;
Streeter et al. 1987).  In repeated-dose developmental studies, no maternal effects were noted in rat dams 
exposed to Telone II®a at 300 ppm, but litter sizes were decreased (Kloes et al. 1983).  Conversely, 
300 ppm had no effect on rabbit development, but resulted in ataxia and death in six of seven does (Kloes
et al. 1983).  The no-observed-adverse-effect level (NOAEL) of 150 ppm for maternal effects in rats or 
developmental effects in rabbits exposed to Telone II®a (Kloes et al. 1983) cannot be used as the basis for
an acute-duration inhalation MRL, because the lack of histopathological examination of the nasal
turbinates, the likely target organ, in dams casts doubt on the reliability of 150 ppm as a NOAEL for
systemic effects, although it appears to be a reliable NOAEL for developmental effects.  
•	 An MRL of 0.008 ppm has been derived for intermediate-duration inhalation exposure (15– 
354 days) to 1,3-dichloropropene.
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In the only intermediate-duration inhalation study in humans, no evidence of renal or hepatic damage was 
detected in clinical chemistry analyses of blood and serum in pesticide applicators using cis-1,3-dichloro-
propene for an average of 521 (±230) minutes/day at a geometric mean concentration (8-hour TWA) of
2.7 mg/m3 (range 0.1–9.5 mg/m3) (0.594 [0.22–2.09] ppm) over a 117-day period compared to unexposed
controls (Verplanke et al. 2000).  No other end points were examined in this study.  Respiratory effects
(mucous membrane irritation, chest pain, cough, and breathing difficulties) have been observed following
accidental acute exposure to high concentrations (Flessel et al. 1978; Markovitz and Crosby 1984).
The available data from the inhalation exposure animal studies indicate that hypertrophy/hyperplasia of
the nasal respiratory epithelium and hyperplasia of the urinary bladder in mice are the most sensitive
effects associated with intermediate-duration exposure to 1,3-dichloropropene.  Increased incidences of
hypertrophy/hyperplasia of the nasal respiratory epithelium occurred in male and female B6C3F1 mice 
exposed to 60 ppm Telone II®b (92.1% 1,3-dichloropropene with 2% ESO) vapor 6 hours/day, 
5 days/week for 6 months (Lomax et al. 1989).  Female mice in this study exposed at 60 ppm also had a
marginally increased incidence of hyperplasia of the urinary bladder.  Fischer 344 rats exposed in this
study under the same protocol did not exhibit increased incidences of histologically detected lesions in 
any organs or tissues after 6 months of exposure (Lomax et al. 1989).  Slight reductions in body weights
were observed in rats and mice exposed at 60 ppm, but the differences were not biologically significant
(<10% lower than controls) at 6 months (Lomax et al. 1989).  Nasal lesions were also observed in rats 
exposed to ≥90 ppm Telone II®b 6 hours/day, 5–7 days/week for 3 months in a reproductive toxicity
assay (Breslin et al. 1989). Nasal hyperplasia in rats and mice and urinary bladder hyperplasia in mice 
occurred in groups exposed to ≥90 ppm Telone II®a (90.9% 1,3-dichloropropene with 1.2% epichloro-
hydrin) 6 hours/day, 5 days/week for 13 weeks (Stott et al. 1988).  One 13-week study by Coate (1979a)
reported nasal lesions in rats exposed 6 hours/day, 5 days/week to Telone II®a at 30 ppm, but since the
purity of the test material was not reported, the significance of the result is uncertain.
Although increased incidences of hypertrophy/hyperplasia of the nasal respiratory epithelium and 
hyperplasia of the urinary bladder were both sensitive effects in mice at a LOAEL of 60 ppm, the urinary
bladder lesions were observed only in females and at a marginal increase (p=0.043; Fisher Exact Test)
over controls.  Since the nasal lesions were observed in both sexes at a higher incidence, they are selected 
as the critical effect for development of the intermediate-duration MRL for 1,3-dichloropropene.  The
6-month study with male and female mice exposed to Telone II®b by Lomax et al. (1989) is selected as
the principal study because the study was adequately designed and reported and the test material was a 
relatively high concentration of 1,3-dichloropropene without the confounding presence of
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epichlorohydrin.  Lomax et al. (1989) exposed groups (10/sex/concentration) of B6C3F1 mice to vapors
of 1,3-dichloropropene 6 hours/day, 5 days/week for 6 months at concentrations of 0, 5, 20, or 60 ppm.  
These were designed as interim satellite groups for a 2-year study.  The test material was 92.1% pure 
(49.5% cis; 42.6% trans) and contained 2.0% ESO as a stabilizer, 0.7% 1,2-dichloropropane, and 5.2%
mixtures of hexanes and hexadienes.  Mice were examined for clinical signs of toxicity, body weight
changes, and terminal hematology and clinical chemistry parameters.  Terminal examinations of all
animals included gross necropsy, measurement of selected organ weights (brain, heart, kidney, liver, and 
testes) and histopathological examination of an extensive array of organs and tissues.  Exposure to 1,3-di-
chloropropene for 6 months had no adverse effect on survival, clinical signs, or hematological or clinical
chemistry parameters in mice.  Significant histological lesions included hypertrophy/hyperplasia of the
nasal respiratory epithelium in male and female mice and hyperplasia of the urinary bladder in female
mice at 60 ppm.  NOAELs of 20 ppm and LOAELs of 60 ppm are identified for hypertrophy/hyperplasia 
of the nasal respiratory epithelium in male and female mice and hyperplasia of the urinary bladder in 
female mice.  As the increased incidence of hyperplasia of the urinary bladder in female mice was only
marginally significant, hypertrophy/hyperplasia of the nasal respiratory epithelium in male and female 
mice is chosen as the critical effect for MRL derivation.
Potential points of departure for deriving the intermediate-duration MRL were derived using benchmark
concentration analysis, the details of which are provided in Appendix A.  Before the analysis, exposure
concentrations were adjusted for 92.1% purity and discontinuous exposure.  For increased incidence of
hypertrophy/hyperplasia of nasal epithelium in male and female mice, the potential point of departure was 
the benchmark concentration limit (BMCL) associated with 10% extra risk, the default benchmark
response (BMR) recommended by EPA (2000a).  Models for dichotomous data were fit to the incidence
data in the key study.  The best fitting model for nasal lesions in male and female mice was the gamma 
model, which generated a BMC10 of 2.8 ppm and a BMCL10 of 1.3 ppm for males and BMC10 of 6.3 ppm
and a BMCL10 of 3.0 ppm for females.
The respective BMCL10 values for nasal lesions in male and female mice were converted to human 
equivalent concentrations ([BMCL10 ]HEC) by multiplying by the extrathoracic regional gas dose ratio 
(B6C3F1 mouse/human) for males (0.1779) and females (0.1368) according to EPA (1994) guidance for
inhalation dosimetry for a category 1 gas, as a default for a category 2 gas.  The resulting [BMCL10]HEC 
values were 0.23 ppm for male mice and 0.41 ppm for female mice.  The lower [BMCL10]HEC value of
0.23 ppm derived from male mice was used as the point of departure for deriving the MRL.  A total
uncertainty factor of 30 (3 for conversion from animals to humans using dosimetric adjustment and 10 for
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human variability) was applied to the male [BMCL10]HEC to calculate an intermediate-duration inhalation 
MRL of 0.008 ppm for 1,3-dichloropropene.  
•	 An MRL of 0.007 ppm has been derived for chronic-duration inhalation exposure (≥1 year) to 
1,3-dichloropropene.
No data are available for effects in humans following chronic-duration inhalation exposure to 1,3-di-
chloropropene.  Fischer F344 rats and B6C3F1 mice were evaluated for chronic-duration inhalation 
exposure to Telone II®b (92.1% 1,3-dichloropropene stabilized with 2% epoxidized soybean oil, ESO) for
1 or 2 years (Lomax et al. 1989).
The available data from chronic-duration studies indicate that lesions of the nasal epithelium and urinary
bladder in mice are the most sensitive effects associated with chronic-duration inhalation exposure to
1,3-dichloropropene.  After 1 year, incidences of hypertrophy/hyperplasia of the nasal respiratory
epithelium were increased in male mice exposed at ≥20 ppm and female mice at 60 ppm.  In addition, the
incidences of hyperplasia and inflammation of the urinary bladder were increased in female mice exposed 
to 60 ppm for 1 year.  After 2 years of exposure, increased incidences of hypertrophy/hyperplasia of the
nasal respiratory epithelium occurred in female mice at ≥20 ppm and males exposed at 60 ppm, and 
increased degeneration of the nasal olfactory epithelium occurred in male and female mice exposed at
60 ppm.  In rats, nasal lesions (decreased thickness of the olfactory epithelium in males and females, 
erosion of the olfactory epithelium in males, and submucosal fibrosis in males) were only detected at
60 ppm after 2 years of exposure and at lower incidences than in exposed mice. The incidences of 
epithelial hyperplasia of the urinary bladder were increased in female mice exposed for 2 years at
≥20 ppm and male mice exposed at 60 ppm; the incidence of inflammation of the bladder epithelium was
increased in female mice exposed for 2 years at ≥20 ppm, but not in males.  No histopathology of the
urinary bladder was observed in rats.
Based on these findings, hypertrophy/hyperplasia of the nasal respiratory epithelium and hyperplasia of
the urinary bladder epithelium in mice exposed for 2 years were selected as co-critical effects for the
development of the chronic-duration inhalation MRL for 1,3-dichloropropene.  The mouse study by
Lomax et al. (1989) is the principal study because the test material in this adequately designed and 
reported study had a purity of 92.1% and did not contain epichlorohydrin or chloropicrin as a possibly 
confounding toxic additive.  Lomax et al. (1989) exposed groups (50/sex/concentration) of B6C3F1 mice
to vapors of 1,3-dichloropropene (Telone II®b) 6 hours/day, 5 days/week for 2 years at concentrations of
0, 5, 20, or 60 ppm.  Additional satellite groups (10/sex/concentration) were established for interim
   
 








   
   
  
  






     
    
   
  





     





      
    
      




2. RELEVANCE TO PUBLIC HEALTH
sacrifices at 6 and 12 months (results for the 6-month sacrifice are given under the description for the
intermediate-duration inhalation MRL).  The test material was 92.1% pure (49.5% cis; 42.6% trans) and 
contained 2.0% ESO as a stabilizer, 0.7% 1,2-dichloropropane, and 5.2% mixtures of hexanes and 
hexadienes.  Mice were examined for clinical signs of toxicity, body weight changes, and terminal
hematology and clinical chemistry parameters.  Terminal examinations of all animals included gross
necropsy, measurement of selected organ weights (brain, heart, kidney, liver, and testes), and histo-
pathological examination of an extensive array of organs and tissues.  Exposure to Telone II®b vapor for
2 years had no significant adverse effect on survival, body weight, the incidence of clinical signs, 
hematology, or clinical chemistry parameters in mice.  In the 1-year satellite group, incidences of 
hypertrophy/hyperplasia of the nasal respiratory epithelium were significantly higher than controls in 
males at ≥20 ppm and in females at 60 ppm; females at 60 ppm also had increased incidences of epithelial
hyperplasia and inflammation of the urinary bladder.  After 2 years of exposure, incidences nasal and 
urinary bladder hyperplasia were elevated in males at 60 ppm and in females at ≥20 ppm.  Increases in 
inflammation of the urinary bladder were not observed in males and were relatively small in females.  
Degeneration of the nasal olfactory epithelium was not statistically elevated in either sex at concentrations
<60 ppm.  NOAELs of 5 ppm and LOAELs of 20 ppm were identified for hypertrophy/hyperplasia of the
nasal respiratory epithelium and epithelial hyperplasia of the urinary bladder in females.
Potential points of departure for deriving the chronic-duration inhalation MRL were calculated using
benchmark concentration analysis, the details of which are provided in Appendix A.  Before the analysis, 
exposure concentrations in ppm were adjusted for 92.1% purity and discontinuous exposure.  Models for
dichotomous data were fit to the incidence data in the key study.  None of the models in the EPA
benchmark dose (BMD) software provided an adequate fit to the data for hypertrophy/hyperplasia of the
nasal respiratory epithelium in male mice, so no BMCL could be calculated.  For increased incidences of 
hypertrophy/hyperplasia of nasal respiratory epithelium in female mice or hypertrophy of urinary bladder
epithelium in male and female mice, the potential points of departure were the 95% lower confidence 
limits on estimated concentrations (BMCLs) associated with 10% extra risk compared to control values. 
This benchmark response (BMR) level is the default recommended by EPA (2000a).  The log-probit
model gave the best fit to data for nasal lesions in female mice, resulting in a BMC10 of 1.56 ppm and a
BMCL10 of 1.0 ppm.  The logistic model gave the best fit to data for urinary bladder lesions in male mice, 
resulting in a BMC10 of 2.18 ppm and a BMCL10 of 1.78 ppm.  The quantal-quadratic model gave the best
fit to data for urinary bladder lesions in female mice, resulting in a BMC10 of 1.52 ppm and a BMCL10 of
1.30 ppm.  
   
 








   
    
 
  
   
   
 
       
  
 











   
  
       
   
   
  
     
   
  




2. RELEVANCE TO PUBLIC HEALTH
Mouse BMCL values were converted to human equivalent concentrations (HECs) using EPA (1994)
dosimetry methods.  The BMCL10 of 1.0 ppm for hypertrophy/hyperplasia of nasal respiratory epithelium
in female mice was multiplied by the extrathoracic regional dose ratio (mouse/human) of 0.1999, 
resulting in a HEC of 0.20 ppm.  As no mouse or human blood:air partition coefficients were available for
1,3-dichloropropene, the BMCL10 values for urinary bladder lesions in male and female mice were 
multiplied by the default blood:gas partition coefficient ratio of 1 (for calculating the HECs for the
extrarespiratory effects), resulting in [BMCL10]HEC values for male and female mice of 1.78 and 
1.30 ppm, respectively. The [BMCL10]HEC value of 0.20 ppm for hypertrophy/hyperplasia of nasal
respiratory epithelium in female mice was selected as the more sensitive point of departure.  A total
uncertainty factor of 30 (3 for extrapolation from animal to human using dosimetric adjustment and 10 for
human variability) was applied to the [BMCL10]HEC of 0.20 ppm, resulting in a chronic-duration 
inhalation MRL of 0.007 ppm for 1,3-dichloropropene.  
Oral MRLs.  No acute-duration oral MRL was derived for 1,3-dichloropropene. The only information on 
toxic effects in humans following oral exposure to 1,3-dichloropropene comes from a case report of 
effects following accidental ingestion of an undetermined fatal dose (Hernandez et al. 1994).  The
gastrointestinal effects observed in this case (initially acute gastroenteritis and abdominal pain on deep 
palpation, subsequent bloody diarrhea, hemorrhagic exudate of the stomach at autopsy, histopathological
evidence of congestion of gastric mucosal vessels, autolysis, and mucosal erosions of the stomach) 
support the significance of portal-of-entry effects of ingested 1,3-dichloropropene.  Other effects included 
tachycardia, tachypnea, hypovolemia, adult respiratory distress syndrome, and multiorgan failure prior to 
death.  The database for oral toxicity of 1,3-dichloropropene in animals consists entirely of several acute 
lethality studies in rats conducted by oral gavage under protocols that do not include a control group.  
Suppression of the central nervous system following exposure to Telone II®a was indicated by clinical
signs such as reduced respiratory rate at ≥75 mg/kg, lethargy at ≥110 mg/kg, and ataxia at ≥170 mg/kg
(Jones and Collier 1986a).  Hemorrhaging was observed in the gastrointestinal tract and lungs of rats
dosed at ≥170 or 250 mg/kg, respectively, with 97.2% mixed isomers (Jones and Collier 1986a).  
Hyperkeratosis of the stomach was observed in rats exposed to ≥75 mg/kg 1,3-dichloropropene (97.2%
mixed isomers) (Jones and Collier 1986a) or 100 mg/kg 79.1% 1,3-dichloropropene with 19%
chloropicrin (Mizell et al. 1988a).  LD50 values in rats were 121 mg/kg for the cis isomer (97.2%), 
304 mg/kg for 79.1% 1,3-dichloropropene with 19% chloropicrin (Mizell et al. 1988a), and 150– 
470 mg/kg for mixed isomer formulations with purities between 92 and 97.54% (Jeffrey et al. 1987a;
Jones and Collier 1986a; Lichy and Olson 1975).  
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•	 An MRL of 0.04 mg/kg/day has been derived for intermediate-duration oral exposure (15– 
364 days) to 1,3-dichloropropene.
No data are available for effects in humans following intermediate-duration oral exposure to 1,3-dichloro-
propene.  Intermediate-duration oral exposure studies with rats, mice, and dogs exposed to different
commercial formulations of 1,3-dichloropropene isomers have been conducted by oral gavage or dietary
exposure. 
As shown in the following overview, available data from the oral exposure animal studies indicate that
lesions in the nonglandular stomach mucosa in rats and microcytic anemia in dogs are the most sensitive 
effects associated with intermediate-duration oral exposure to 1,3-dichloropropene.  Increased incidences 
of basal cell hyperplasia of the nonglandular stomach occurred in male Fischer 344 rats exposed to doses 
≥15 mg/kg/day Telone II®b microencapsulated in feed for 13 weeks; female rats displayed hyperkeratosis
of the nonglandular stomach epithelium at doses of 100 mg/kg/day in this study (Haut et al. 1996).  
B6C3F1 mice exposed to Telone II®b via the same protocol for 13 weeks did not display any adverse 
effects on histologic or hematologic end points (Haut et al. 1996).  Microcytic anemia (decreased 
hematocrit, hemoglobin concentration, and corpuscular volume) occurred in beagle dogs exposed to doses
≥15 mg/kg/day Telone II®b encapsulated in feed for 13 weeks (Stebbins et al. 1999).  Reductions in 
terminal body weight were observed in rats, mice, and dogs exposed to Telone II®b in feed for 13 weeks, 
but reduced food intake associated with decreased palatability may have contributed to these effects (Haut
et al. 1996; Stebbins et al. 1999).  In an earlier 13-week study with Telone®, a commercial formulation of
lesser 1,3-dichloropropene purity than Telone II®b, increased liver or kidney weights were observed in 
rats at doses as low as 10 and 30 mg/kg/day, respectively, but the lack of renal or kidney adverse 
noncancer effects in the intermediate- or chronic-duration studies with Telone II®b suggests that these 
organs are not consistently observed noncancer toxicity targets of 1,3-dichloropropene.  
The study describing hematological effects in dogs was not selected for MRL derivation due to the small
group sizes (4/sex/group) and the lack of histopathological examination.  Therefore, the other sensitive
effect, basal cell hyperplasia in the nonglandular stomach of male rats, was selected the critical effect for
development of the intermediate-duration MRL for 1,3-dichloropropene.  The 13-week study with male 
rats (Haut et al. 1996) exposed to microencapsulated Telone II®b was selected as the principal study, 
because the test material in this adequately designed and reported study was the most purified 1,3-di-
chloropropene formulation tested and did not contain potentially confounding toxic materials such as
epichlorohydrin or chloropicrin.  The test material, Telone II®b, was 95.8% pure 1,3-dichloropropene
(50.7% cis; 45.1% trans) and was microencapsulated in a starch/sucrose (80:20) microsphere matrix
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before addition to the diets for 13 weeks.  In the Haut et al. (1996) study, groups of male and female
Fischer 344 rats (10/sex/group) received 1,3-dichloropropene at reported doses of 0, 5, 15, 50, or
100 mg/kg/day.  Animals were evaluated for clinical signs of toxicity, body weight changes, feed intake, 
and hematological, clinical chemistry, and urinalysis parameters.  All rats received a gross necropsy
examination and were evaluated for histopathology in a full array of tissues and organs.  Ingestion of
Telone II®b had no effect on survival in rats.  Significant histopathological lesions in this study included 
basal cell hyperplasia of the nonglandular stomach in male rats exposed at ≥15mg/kg/day and 
hyperkeratosis of the nonglandular stomach epithelium at 100 mg/kg/day.  In this study, a NOAEL of
5 mg/kg/day and a LOAEL of 15 mg/kg/day were identified for cell hyperplasia in the nonglandular
stomach of male rats (Haut et al. 1996).
Potential points of departure for deriving the intermediate-duration MRL were derived using benchmark
dose analysis, the details of which are described in Appendix A.  For increased incidence of basal
hyperplasia in nonglandular stomach mucosa of rats, the potential point of departure was the BMDL
associated with 10% extra risk; this BMR was selected as the default following EPA (2000a) guidance.  
Models for dichotomous data in the BMD software were fit to the incidence data in the key study.  The
best fitting model for forestomach lesions in male rats was the multistage model, which generated a
BMD10 of 9.0 mg/kg/day and a BMDL10 of 3.6 mg/kg/day.  The BMDL10 of 3.6 mg/kg/day for basal cell
hyperplasia in male rats was selected as the point of departure for deriving the intermediate-duration oral
MRL.
An intermediate-duration oral MRL of 0.04 mg/kg/day was derived by dividing the BMDL10 of
3.6 mg/kg/day by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for
human variability).  
•	 An MRL of 0.03 mg/kg/day has been derived for chronic-duration oral exposure (≥1 year) to 
1,3-dichloropropene.
No data are available for effects in humans following chronic-duration oral exposure to 1,3-dichloro-
propene.  Chronic-duration oral exposure studies with rats, mice, and dogs exposed to different
commercial formulations of 1,3-dichloropropene isomers have been conducted by oral gavage or dietary
exposure. 
As shown in the following overview, the available data indicate that lesions in the nonglandular stomach 
mucosa in rats and microcytic anemia in dogs are the most sensitive effects associated with chronic-
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duration oral exposure to 1,3-dichloropropene.  Basal cell hyperplasia of the nonglandular stomach 
mucosa was observed in male and female Fischer 344 rats exposed to doses as low as 12.5 mg/kg/day 
Telone II®b (but not 2.5 mg/kg/day) encapsulated in feed for 1 or 2 years (Stebbins et al. 2000), and in 
male and female F344 rats and female B6C3F1 mice exposed to gavage doses of 25 mg/kg/day 
Telone II®a (89% dichloropropene isomers plus 1% epichlorohydrin) 3 times/week for up to 2 years (NTP
1985).  Increased incidences of this lesion did not occur in male or female B6C3F1 mice exposed to 2.5, 
25, or 50 mg/kg/day Telone II®b encapsulated in feed for 1 or 2 years (Stebbins et al. 2000) or in male or
female beagle dogs exposed to 0.5, 2.5, or 15 mg/kg/day Telone II®b encapsulated in feed for 1 year
(Stebbins et al. 1999).  However, male and female beagle dogs exposed to 15 mg/kg/day, but not
2.5 mg/kg/day, Telone II®b encapsulated in feed for 1 year showed decreased values for mean hematocrit, 
hemoglobin concentration, and corpuscular volume, compared with control values, which are indicative
of microcytic anemia.  Exposure-related reductions in terminal body weight were observed in rats, mice, 
and dogs exposed to Telone II®b in feed for 1 or 2 years, but reduced food intake associated with 
decreased palatability may have contributed to these effects (Stebbins et al. 1999, 2000).  
Adverse noncancer effects on the liver or kidney are not as clearly associated with chronic-duration oral
exposure to 1,3-dichloropropene as forestomach basal cell hyperplasia in rats or microcytic anemia in 
dogs.  Exposure-related kidney effects include increased incidence of hydronephrosis in female, but not
male, B6C3F1 mice exposed to gavage doses of 100 mg/kg/day Telone II®a, but not 50 mg/kg/day, for up 
to 2 years (NTP 1985) and increased incidence of nephropathy in female, but not male, Fischer 344 rats
exposed to 25 or 50 mg/kg/day Telone II®a for up to 2 years (NTP 1985).  However, no exposure-related 
kidney effects were observed in Fischer 344 rats, B6C3F1 mice, or beagle dogs exposed to Telone II®b 
encapsulated in feed for 1 or 2 years at doses as high as 25 mg/kg/day for rats, 50 mg/kg/day for mice, 
and 15 mg/kg/day for dogs (Stebbins et al. 1999, 2000).  Observed noncancer effects in the liver include
decreased size of hepatocytes in male, but not female, B6C3F1 mice exposed to 50 mg/kg/day, but not
25 mg/kg/day, Telone II®b encapsulated in feed for 1 year, but not in mice exposed for 2 years (Stebbins
et al. 2000) and increased incidence of slight or very slight eosinophilic foci of altered liver cells in male
and female Fischer 344 rats exposed to 2.5, 12.5, or 25 mg/kg/day Telone II®b encapsulated in feed for
2 years.  The toxicological significance of these apparent liver effects is equivocal given the inconsistency
of the findings in the mouse study and the common spontaneous occurrence of liver foci (eosinophilic or
basophilic) in aged Fischer 344 rats. 
Based on the findings from the chronic-duration oral exposure animal studies, basal cell hyperplasia in the
nonglandular stomach of male rats and decreased hemoglobin concentration and corpuscular volume in 
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male or female dogs were selected as co-critical effects for development of the chronic-duration MRL for
1,3-dichloropropene.  The 2-year rat study (Stebbins et al. 2000) and 1-year dog study (Stebbins et al. 
1999) involving exposure to microencapsulated Telone II®b were selected as the principal studies, 
because the test material in these adequately designed and reported studies was the most purified 1,3-di-
chloropropene formulation tested (95.8% pure 1,3-dichloropropene—50.7% cis; 45.1% trans—with 2%
ESO as a stabilizer) and did not contain potentially confounding toxic materials such as epichlorohydrin 
or chloropicrin.  In the study by Stebbins et al. (2000), the main group of male and female Fischer 344
rats (50/sex/group) received doses of 0, 2.5, 12.5, or 25 mg/kg/day for 2 years and a satellite group of
10/sex/group received the same treatment for 12 months.  In the Stebbins et al. (1999) study, groups of
beagle dogs (4/sex/dose) had intakes of 0, 0.5, 2.5, or 15 mg/kg/day for 12 months.  Both studies
evaluated animals for clinical signs of toxicity, body weight changes, feed intake, and hematological, 
clinical chemistry, and urinalysis parameters.  All animals received a gross necropsy examination, with 
evaluation of a full array of tissues and organs for histopathological examination.  Ingestion of
Telone II®b had no effect on survival in rats or dogs.  The primary histological lesion in rats was basal
cell hyperplasia of the nonglandular stomach mucosa observed in males and females exposed to 
≥12.5 mg/kg/day.  In these studies, a NOAEL of 2.5 mg/kg/day and a LOAEL of 12.5 mg/kg/day were
identified for cell hyperplasia in the nonglandular stomach of male rats (Stebbins et al. 2000) and a
NOAEL of 2.5 mg/kg/day and a LOAEL of 15 mg/kg/day were identified for decreased hemoglobin 
concentration and corpuscular volume in male or female dogs (Stebbins et al. 1999).
Potential points of departure for deriving the chronic-duration MRL were derived with benchmark dose
analysis, the details of which are described in Appendix A.  For decreased hemoglobin concentration, 
which was as an index of 1,3-dichloropropene-induced microcytic anemia in dogs, potential points of
departure were 95% lower confidence limits on estimated doses (i.e., BMDLs) associated with a value
lower than 10th percentile values for the distribution of hemoglobin concentrations in a sample of normal
beagle dogs.  The linear model for continuous data was modeled to the hemoglobin data in dogs, resulting
in a BMD10th%ile of 8.35 mg/kg/day and a BMDL10th%ile of 6.05 mg/kg/day for male dogs and a BMD10th%ile 
of 10.98 mg/kg/day and a BMDL10th%ile of 8.83 mg/kg/day for female dogs.  For increased incidence of
basal hyperplasia in nonglandular stomach mucosa of rats, the potential point of departure was the BMDL
associated with 10% extra risk.  This BMR is the default recommended by EPA (2000a).  Models for
dichotomous data were applied to the incidence data in rats.  The log-probit model gave the best fit to the
data for male rats, resulting in a BMD10 of 5.34 mg/kg/day and a BMDL10 of 4.26 mg/kg/day.  The log-
logistic model gave the best fit to the data for female rats, resulting in a BMD10 of 5.42 mg/kg/day and a
BMDL10 of 3.51 mg/kg/day.  The lowest BMDL is the BMDL10 of 3.51 mg/kg/day for increased 
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incidence of nonglandular stomach basal cell hyperplasia in rats.  A chronic-duration oral MRL based on 
the BMDL10 of 3.51 mg/kg/day for basal cell hyperplasia in rats divided by an uncertainty factor of 100 
(10 for extrapolation from animals to humans and 10 for human variability) would be 0.04 mg/kg/day.  
This value is in agreement with EPA’s chronic oral RfD of 0.03 mg/kg/day, which was based on a point
of departure of 3.4 mg/kg/day (see Chapter 8 and Appendix A). Therefore, 0.03 mg/kg/day was selected 
as the chronic oral MRL for 1,3-dichloropropene.
2,3-Dichloropropene
Inhalation MRLs
•	 An MRL of 0.002 ppm has been derived for acute-duration inhalation exposure (<15 days) to 
2,3-dichloropropene.
No information was located regarding the acute inhalation toxicity of 2,3-dichloropropene in humans.
The available data from inhalation studies in animals indicate that hyperplasia of the nasal respiratory
epithelium in male and female rats and mice and degeneration of the bronchial/bronchiolar epithelium in 
male and female mice are the most sensitive effects associated with acute-duration exposure to 2,3-di-
chloropropene.  Increased concentration-related incidences and severity (see Table 2-2, the same as 
Table A-1 in Appendix A) of hyperplasia of the nasal respiratory epithelium occurred in male and female 
Fischer 344 rats and B6C3F1 mice, and slight diffuse degeneration of bronchial/bronchial epithelium
occurred in male and female B6C3F1 mice exposed to 5 ppm 2,3-dichloropropene (>99% purity) vapor
6 hours/day for nine exposures over 11 days (Zempel et al. 1987).  Male and female rats and mice in this 
study exposed at ≥25 ppm had slight-to-moderate hyperplasia of the nasal olfactory epithelium, and male 
and female mice exposed at ≥25 ppm had very slight-to-slight hyperplasia of the laryngeal epithelium.  
Reductions (12–25%) in terminal body weights in male and female mice exposed at 25 or 75 ppm
appeared to be related to reduced feed intake.  
Respiratory lesions were also observed in single-exposure acute lethality studies described in cursory
and/or incomplete reports.  In a 6-hour exposure study, crusted noses were observed in rats exposed at
250 ppm and bloody noses at 500 ppm, whereas in a 1-hour study, gasping and shallow respiration were 
observed during exposure at ≥693 ppm and labored respiration was observed after exposure at 1,963 ppm
in rats (Dietz et al. 1985b).  Exposure to an unquantified concentrated vapor atmosphere resulted in 
gasping, labored breathing, and nasal discharge as clinical signs, as well as hemorrhagic lungs and
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Table 2-2.  Incidence of Significant Lesions in Fischer 344 Rats and B6C3F1 Mice 

Exposed to 2,3-Dichloropropene (>99%) Vapor 6 Hours/Day, for 9/11 Daysa
 
Control 5 ppm 25 ppm 75 ppm
Rats


































aSeverity:  *very slight; **slight;***moderate;****severe
Source:  Zempel et al. 1987
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inflammation of the nasal mucosal in rats (Monsanto 1967).  In these studies, evidence of suppression of
the central nervous system was observed at concentrations in excess of 500 ppm (Dietz et al. 1985b;
Monsanto 1967).
The acute study in male and female rats and mice by Zempel et al. (1987) is selected as the principal
study because it was adequately designed and reported, the purity of the test material was high, and it
reported critical effects at the lowest tested concentration.
Zempel et al. (1987) exposed (whole body) groups of B6C3F1 mice and F344 rats (5/sex/species/group)
to vapors of 2,3-dichloropropene (>99% purity) 6 hours/day for nine exposures over 11 days at
concentrations of 0, 5, 25, or 75 ppm.  Rats and mice were examined for clinical signs of toxicity, body
weight changes, hematology and serum chemistry analyses of terminal blood samples, and, in rats only, 
urinalyses. Terminal examinations of all rats and mice included a complete necropsy (for rats, including
the eyes), measurement of selected organ weights (brain, heart, liver, thymus, kidneys, and testes), and 
microscopic examination of all tissues for animals in the control and 75 ppm groups, and for target tissues
(liver, kidneys, bone marrow, lungs, and nasal tissues, and in mice, thymus, trachea, and larynx) in the
5 and 25 ppm groups.  Exposure to 2,3-dichloropropene had no significant effect on survival in rats or 
mice.  No alterations in activity levels or hematology, serum chemistry, or urinalysis results were 
observed in rats.  Alterations in hematology and clinical chemistry parameters observed in mice were 
ascribed by the study authors to mild dehydration (and resulting hemoconcentration) and stress.  
Significant histological lesions of the respiratory tract are presented in Table 2-2.  Other histopathological
lesions were not considered to be compound related:  stress-related cortical atrophy of the thymus and 
dehydration-related reduced extramedullary hematopoeisis in the liver and spleen of mice at 75 ppm.  The
lowest exposure level, 5 ppm, was a minimal LOAEL for very slight hyperplasia of the nasal respiratory
epithelium in male and female rats and mice and slight diffuse degeneration of the bronchial/bronchiolar
epithelium in male and female mice.
Potential points of departure for deriving the acute-duration inhalation MRL were obtained by first
adjusting for intermittent exposure, resulting in a duration-adjusted LOAEL of 1.25 ppm.  Using EPA
(1994) dosimetry adjustments, regional gas dose ratios (RGDRs) were calculated for extrathoracic (ET)
effects (nasal lesions) in rats and mice and tracheobronchial (TB) effects (bronchial/bronchiolar lesions)
in mice.  Although 2,3-dichloropropene is a category 2 gas, the equations for a category 1 gas were used 
by default since an equation is not available for category 2 gases.  The calculated RGDRs were applied to 
the duration adjusted LOAEL of 1.25 ppm to obtain the human equivalent concentrations (LOAELHEC):
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0.20 and 0.14 ppm for extrathoracic effects in male and female rats, respectively, 0.18 and 0.15 ppm for
extrathoracic effects in male and female mice, respectively, and 2.22 and 1.79 ppm for tracheobronchial
effects in male and female mice, respectively.  The lowest LOAELHEC of 0.14 ppm for hyperplasia of the
nasal respiratory epithelium in female rats was chosen as the point of departure for the MRL since it
would be protective against all observed effects.  A composite uncertainty factor of 90 (3 for the use of a 
minimal LOAEL, 3 for extrapolation from animals to humans using dosimetric adjustments, and 10 for
human variability) was applied to the LOAELHEC of 0.14 ppm for hyperplasia of the nasal respiratory
epithelium in female rats, resulting in an MRL of 0.002 ppm.
No intermediate-duration inhalation MRL was derived for 2,3-dichloropropene because of a lack of 
suitable data.  No studies were located regarding the intermediate-duration inhalation toxicity of 2,3-di-
chloropropene in humans.  Intermediate-duration inhalation studies in animals exposed to 2,3-dichloro-
propene are not adequate for derivation of an intermediate-duration inhalation MRL because of
deficiencies that prevent the accurate determination of reliable NOAELs or LOAELs for respiratory
lesions (Johannsen et al. 1991; NTP 1989).  NTP (1989) began 13-week studies (Study No. C61881) in 
Fischer 344 rats and B6C3F1 mice exposed 6 hours/day, 5 days/week to 0, 5, 10, 20, 40, or 80 ppm
2,3-dichloropropene, but terminated the postexposure work on the studies when new data showed that
production volumes of 2,3-dichloropropene in the United States had dropped below 100 kg/year (NTP
2006; communication from NTP to SRC).  Some data tables are available for this study on the NTP
website, providing definitive concentration-response information for body weights and hematology
parameters, but not for most other end points because no histopathology data are available.  The 13-week
systemic toxicity and 13–16-week reproductive toxicity studies by Johannsen et al. (1991), in which 
Sprague-Dawley rats were exposed 6 hours/day, 5 days/week at concentrations of 0, 1, 5, or 15 ppm or 0, 
1, or 5 ppm, respectively, are deficient in the failure to examine the likely target organ, the nasal
turbinates.
The following results were reported in the 13-week studies in rats and mice.  No effects on survival, 
hematology, serum chemistry, histopathology, body weight, or organ weights were observed in rats
exposed at ≤15 ppm (Johannsen et al. 1991).  In rats, respiratory effects in rats included red nasal
discharge (increasing in frequency during the study), but no observed lung histopathology, at ≤15 ppm
(Johannsen et al. 1991), and no lung weight increases at ≤80 ppm (NTP 1989).  Female mice exposed at
5–40 ppm had 25–33% increases in absolute lung weight and 25–47% increases in relative lung weight, 
whereas male mice had absolute lung weights increased by 13–36% at 10–80 ppm and relative lung
weights increased by 22–33% at 10–40 ppm and by 200% at 80 ppm (NTP 1989).  No female mice
   
 








   
  
  
   
 
   
  
  
        
   
 
    












     
     







2. RELEVANCE TO PUBLIC HEALTH
exposed at 80 ppm survived to 13 weeks (NTP 1989); no mortality data were available for male and 
female rats or male mice exposed to ≤80 ppm (NTP 1989).  Significant concentration-related (>10%)
reductions in terminal body weights compared to controls were observed in male rats and male and 
female mice exposed at 40 or 80 ppm (NTP 1989).  Hepatic toxicity was observed in female rats:  33%
increased absolute and 37% increased relative liver weights, a 60% increase in serum alkaline
phosphatase, and a 6-fold increase in total serum bile acids at 80 ppm, and >3-fold increases in serum
alanine aminotransferase (ALT) and sorbitol dehydrogenase (SDH) at 40–80 ppm (NTP 1989).  No 
hepatic weight changes were observed in female mice exposed at ≤40 ppm, or male rats or mice exposed 
at ≤80 ppm (NTP 1989).  A 17% increase in absolute and 23% increase in relative kidney weights were
observed in female rats at 80 ppm (NTP 1989); urine volume was increased with exposure in female rats, 
but decreased in male rats.  No kidney weight changes were observed in female mice exposed at
≤40 ppm, or male rats or mice exposed at ≤80 ppm (NTP 1989).  No significant compound-related effects 
were observed on hematology parameters in rats or mice exposed at ≤80 ppm (NTP 1989).  No significant
effects were observed on reproductive parameters—gonadal weight or sperm parameters in male or estrus
cycling in female rats or mice exposed at ≤80 ppm (Johannsen et al. 1991; NTP 1989) or mating and 
fertility indices in rats exposed at ≤5 ppm (Johannsen et al. 1991).  The available limited data provide
suggestive evidence that the respiratory system is the primary target of intermediate-duration inhalation 
exposure to 2,3-dichloropropene, presumably a portal-of-entry effect related to repeated irritation.  The 
lung weight effects at 5 ppm in the NTP study are consistent with the acute-duration inhalation study by
Zempel et al. (1987) in that lung effects were observed in mice, but not in rats. 
Neither of the available studies provide a suitable basis for derivation of an intermediate-duration 
inhalation MRL for 2,3-dichloropropene.  Although Johannsen et al. (1991) appears to identify irritation 
of the respiratory tract as the most sensitive effect of exposure, an accurate NOAEL or LOAEL for
respiratory effects cannot be determined for this study because no incidence data were reported for red 
nasal discharge at 15 ppm and no histopathological examination was conducted for the nasal turbinates.
Furthermore, the incomplete NTP (1989) study in mice appears to show lung effects in mice at 5 ppm, but
also lacks histopathology data for the lung and nasal turbinates.  Consequently, no intermediate-duration 
inhalation MRL was derived. 
No chronic-duration inhalation MRL was derived for 2,3-dichloropropene because of a lack of data in 
humans or animals.  
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Oral MRLs.  No oral MRLs were derived for 2,3-dichloropropene. No information was located regarding
the oral toxicity of 2,3-dichloropropene.  Animal data are limited to two acute lethality studies in rats that 
did not include control groups.  A study by Monsanto (1967) was only available as a summary that
reported an acute oral LD50 of 285 (250–326) mg/kg for male and female rats combined and did not report
target organ specificity.  A study by Union Carbide Corp. (1958), results of which were published in 
Smyth et al. (1962), reported an acute oral LD50 of 320 (260–400) mg/kg (Smyth et al. [1962] mis-
reported the unit as mL/kg).  Necropsy results included congestion in lungs, liver, and kidney, and opacity
of the gastrointestinal tract.  These studies are not suitable for MRL derivation because they provide no 
dose-response information for nonlethal effects.   
1,2-Dichloropropene
Inhalation MRLs.  No inhalation MRLs were derived for 1,2-dichloropropene.  No information was
located regarding the acute inhalation toxicity of 1,2-dichloropropene in humans.  Animal data are limited 
to an unpublished summary of an acute lethality study in which small numbers of rats (3 or 4) were
exposed to saturated vapor at an estimated concentration of 63,764 ppm and 1/4 died after 6 minutes and 
3/3 died after 12 minutes (Dow 1962); the study included no other exposure levels and no control group.  
Effects noted in this study were unconsciousness and, in one rat at necropsy, considerable (unspecified)
injury to lung, liver, and kidney.  The numerous deficiencies in design (small group size, lack of control
group, single exposure level, lack of a nonlethal exposure level) and reporting, render this study
unsuitable for MRL derivation.  
Oral MRLs.  No oral MRLs were derived for 1,2-dichloropropene.  No information was located regarding
the oral toxicity of 1,2-dichloropropene in humans.  Animal data are limited to an unpublished summary
of a range-finding study in which two rats were given 1,2-dichloropropene by oral gavage in corn oil at a
dose of 2,000 mg/kg (Dow 1962).  Neither animal died, but necropsy revealed considerable (unspecified)
injury to the liver and kidney.  This study is unreliable because of the inadequate design (small group size,
lack of control group) and inadequate reporting of methods and results. 
1,1-Dichloropropene and 3,3-Dichloropropene
No MRLs were derived for 1,1- or 3,3-dichloropropene because of a lack of toxicity data in humans or 
animals exposed to these isomers by the inhalation or oral routes.
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3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of dichloropropenes.  
It contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
The majority of toxicity and toxicokinetic information on dichloropropenes relates to the 1,3-dichloro-
propene isomer.  1,3-Dichloropropene is widely used as a preplanting soil fumigant for the control of
nematodes, and it has been available for agricultural use in many formulations.  Formulations, instead of
pure 1,3-dichloropropene, were used in most of the studies discussed here.  The trade names and 
components of these formulations are listed in Table 3-1.
In some studies, the investigation of the toxicity of 1,3-dichloropropene may have been confounded by
other components in a formulation (e.g., chloropicrin and epichlorohydrin). This possibility is discussed 
in the appropriate sections of the text. The most recent toxicity studies have been conducted using
Telone II®b (stabilized with 2% epoxidized soybean oil); recent dietary studies administered this material
microencapsulated in a starch/sucrose matrix (80/20%) to avoid loss from evaporation and degradation in 
feed.  Intermediate- and chronic-duration MRLs for 1,3-dichloropropene are based on studies that tested 
Telone II®b. Separate tables and figures for each formulation of 1,3-dichloropropene are not presented.  
Instead, the formulation used in each study is identified in the appropriate table; purity data and 
noteworthy impurities/additives are also provided as reported in the original studies.  Further information 
on the formulations of 1,3-dichloropropene can be found in Chapter 5.  Previously cited toxicity studies
that examined formulations with a relatively low content of 1,3-dichloropropene, such as DD® (52%
1,3-dichloropropene; ≤29% 1,2-dichloropropane), have been removed from this profile because they have
been superceded by studies on higher-purity formulations.
Little toxicity information, none for exposed humans, is available for other isomers of dichloropropene.
No in vivo mammalian toxicity data are available for 1,1-dichloropropene, which is sometimes detected in 
   
 












   
    
    
    
 
    
 
    
   











Telone® 40.2% cis, 38.3% trans Not otherwise specified
Telone C-17® 40–41% cis, 38–39%trans 19–21% chloropicrin
Telone II®aa 48–53% cis, 42–45% trans 1% epichlorohydrin, not
otherwise specific
Telone II®b 48–53% cis, 42–45% trans 2% epoxidized soybean oil
(ESO)
DD® 25–28% cis, 25–27% trans 25–29% 1,2-dichloropropene
DD-92® 92% cis/trans Not otherwise specified
DD-95® 95% cis/trans Not otherwise specified
aAlso called M-3993
   
 














    
    
   
  
 
   
 
     
  
 






    
  
 







water systems, or 3,3-dichloropropene, which was present in some older pesticide formulations.  A few
acute-duration toxicity studies have been conducted on 1,2-dichloropropene, and both acute- and 
intermediate-duration studies have been conducted on 2,3-dichloropropene.  An 11-day inhalation study
on 2,3-dichloropropene was the basis for an acute-duration inhalation MRL (Zempel et al. 1987).  NTP
(1989) began a 13-week inhalation assay on 2,3-dichloropropene, but disbanded the postexposure data
analysis when a new report indicated that production of the chemical in the United States had fallen 
below 100 kg/year (NTP 2006).  The available records of that study are discussed in Chapter 3, since they
provide some evidence for target-organ specificity of 2,3-dichloropropene following repeated exposure, 
but the data are not used for derivation of an intermediate-duration inhalation MRL.  In vivo toxicokinetic
studies have been conducted on 2,3-dichloropropene and one in vitro study has been conducted on 1,1-di-
chloropropene.  All of the isomers except 3,3-dichloropropene have been investigated for genotoxicity. 
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
   
 





















     
   
 
    













major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.  MRLs
derived for dichloropropenes are summarized in Table 2-1, briefly described in Section 2.3 and described 
in detail in Appendix A.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of 1,3-dichloro-
propene are indicated in Tables 3-2 and 3-4 and Figures 3-1 and 3-3.  Because cancer effects could occur
at lower exposure levels, Figures 3-1 and 3-3 also show ranges for the upper bound of estimated excess 
risks, ranging from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA.  
Carcinogenicity studies were not available for other isomers of dichloropropene.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
In Section 3.2, data for individual isomers (1,3-, 2,3-, and 1,2-dichloropropene) are presented under
italicized subheadings under each end point.  No subheading was created for an isomer if no data were
located for that end point.  
3.2.1 Inhalation Exposure 
Reliable inhalation toxicity data are available for 1,3-dichloropropene and, to a lesser extent, for 2,3-di-
chloropropene.  The highest NOAEL and all reliable LOAEL values after inhalation exposure to 1,3- and 
2,3-dichloropropene are recorded in Tables 3-2 and 3-3, respectively, and plotted in Figures 3-1 and 3-2, 
respectively.  Median lethal concentrations and other reliable mortality data are recorded as serious









































675 (6/10 died) 
Reference 
Chemical Form 
Cracknell et al. 1987 
T IIa 
Comments 




1 hr/d 253 (LC50) Streeter and Lomax 1988 
T C-17 





4 hr/d 904 (LC50 females) Streeter et al. 1987 
T IIa 











4 hr/d Resp 581 M 
300 F (6/7 died) 
594 M (lung edema) 
Kloes et al. 1983 
T IIa 
Cracknell et al. 1987 
T IIa 
Purity: 92.1% 1,3-DCP; 
1% epichlorohydrin. 
Purity: 98.4% 1,3-DCP. 
Endocr 594 675  (adrenal congestion in 
decedents) 
Bd Wt 356 M (final body weight 10% 




1 hr/d Resp 206 (atelectasis, multifocal) Streeter and Lomax 1988 
T C-17 
Purity: 78.9% 1,3-DCP; 
21.1% chloropicrin. 































































Ocular 775 (eye irritation) 


















1146 (eye irritation) 
300 F (ataxia) 
Yakel and Kociba 1977 
T IIa 
Kloes et al. 1983 
T IIa 





















Kloes et al. 1983 
T 
Verplanke et al. 2000 
cis 















SPurity: 97.5% 1,3-DCP. 
Purity: 92% 1,3-DCP. 
Purity: 92.1% 1,3-DCP; 
1% epichlorohydrin. 
1.3-DCP: 47.7% cis; 
42.4% trans. 
Purity: 92.1% 1,3-DCP; 
1% epichlorohydrin. 





















































Rat	 180 d 
5-7 d/wk(Fischer- 344) 
6 hr/d 
Rat	 13 wk 
5 d/wk(Fischer- 344) 
6 hr/d 































Less Serious	 Serious 
(ppm)	 (ppm) 
90	 (nasal lesions) 
30	 (decreased cytoplasm, 
disorganization of nuclei 
in epithelium 











Purity: 92% 1,3-DCP; 
2% ESO. 
Purity not reported. 

































Key to Species Frequency 














S17 Rat	 13 wk 
5 d/wk(Fischer- 344) 
6 hr/d 
18 Rat	 6 mo 
5 d/wk 
7 hr/d 




























Chemical Form Comments 
30 90 (nasal hyperplasia) Stott et al. 1988 
T IIa 









3 Torkelson and Oyen 1977 
T IIa 





90 (decreased epithelial 







































Key to Species Frequency 





















































of nasal respiratory 
epithelium) 
Lomax et al. 1989 
T IIb 









60 F (bladder hyperplasia) 
30 90 (nasal hyperplasia) Stott et al. 1988 
T IIa 








































Key to Species Frequency 
Figure (Strain) (Route) 
22 Gn Pig 6 mo 
5 d/wk 
.5-4 hr/d 
23 Dog 6 mo 
5 d/wk 
.5-4 hr/d 










































Chemical Form Comments 
3 Torkelson and Oyen 1977 
T IIa 






3 Torkelson and Oyen 1977 
T IIa 







3 Torkelson and Oyen 1977 
T IIa 






















































































Stott et al. 1988 
T IIa 





































SPurity: 92.1% 1,3-DCP. 
Purity: 90.9% 1,3-DCP; 
1.2% epichlorohydrin. 
Purity: 92.1% 1,3-DCP. 
Purity: 90.9% 1,3-DCP; 
1.2% epichlorohydrin. 
Purity: 92.1% 1,3-DCP. 
Purity: 90.9% 1,3-DCP; 
1.2% epichlorohydrin. 
Purity not reported. 



















































150 Stott et al. 1988 
T IIa 
34 Gn Pig 6 mo 
5 d/wk 
.5-4 hr/d 
3 Torkelson and Oyen 1977 
T IIa 
35 Dog 6 mo 
5 d/wk 
.5-4 hr/d 
3 Torkelson and Oyen 1977 
T IIa 











Torkelson and Oyen 1977 
T IIa 





































SPurity: 90.9% 1,3-DCP; 
1.2% epichlorohydrin. 
Purity: 99% 1,3-DCP; 
1% epichlorohydrin. 
Purity: 99% 1,3-DCP; 
1% epichlorohydrin. 
Purity: 99% 1,3-DCP; 
1% epichlorohydrin. 
Purity: 92% 1,3-DCP; 
2% ESO. 
Purity: 92.1% 1,3-DCP. 
Purity: 90.9% 1,3-DCP; 
1.2% epichlorohydrin. 



























Key to Species Frequency 
Figure (Strain) (Route) 
41 Mouse 13 wk 
(B6C3F1) 5 d/wk 
6 hr/d 
Developmental 
42 Rat 180 d 




43 Rat 2 yr 
























Less Serious Serious 
(ppm) (ppm) 
















SStott et al. 1988 
T IIa 
Breslin et al. 1989 
T IIb 
Lomax et al. 1989 
T IIb 
Comments 
Purity: 90.9% 1,3-DCP; 
1.2% epichlorohydrin. 
Purity: 92% 1,3-DCP; 
2% ESO. 
































Key to Species Frequency 
Figure (Strain) (Route) 


























45 Rat 2 yr 
5 d/wk(Fischer- 344) 
6 hr/d 
Neurological 
46 Rat 2 yr 
5 d/wk(Fischer- 344) 
6 hr/d 


























Less Serious	 Serious 
(ppm)	 (ppm) 
c 
20 F	 (hypertrophy/hyperplasia 
of nasal respiratory 
epithelium) 
60 M  (hyperplasia and 
hyperkeratosis of 
forestomach) 




Lomax et al. 1989 
T IIb 
Lomax et al. 1989 
T IIb 
Lomax et al. 1989 
T IIb 
Lomax et al. 1989 
T IIb 
Comments 
Purity: 92.1% 1,3-DCP. 
Purity: 92.1% 1,3-DCP. 
Purity: 92.1% 1,3-DCP. 


































60 Lomax et al. 1989 
T IIb 













60 M (CEL: bronchioalveolar 
adenoma) 
Lomax et al. 1989 
T IIb 
Lomax et al. 1989 
T IIb 
Purity: 92.1% 1,3-DCP. 















a The number corresponds to entries in Figure 3-1. 
b Study results used to derive an intermediate-duration inhalation minimal risk level (MRL) of 0.008 ppm for 1,3-dichloropropene, as described in detail in Appendix A.  Benchmark 
dose analysis was performed using reported concentrations (adjusted for <100% purity and intermittent exposure) and incidences of hypertrophy/hyperplasia of the nasal respiratory 
epithelium in male and female mice to select a point of departure. The selected point of departure, based on nasal lesions in male mice, was adjusted to a human equivalent 
concentration, and then divided by an uncertainty factor of 30 (3 for extrapolation from animals to humans using dosimetric adjustment and 10 for human variability) (See Appendix A). 
c Study results used to derive a chronic-duration inhalation minimal risk level (MRL) of 0.007 ppm for 1,3-dichloropropene, as described in detail in Appendix A.  Benchmark dose 
analysis was performed using reported concentrations (adjusted for <100% purity and intermittent exposure) and incidences of hypertrophy/hyperplasia of the nasal respiratory 
epithelium in female mice to select a point of departure, which was adjusted to a human equivalent concentration, and then divided by an uncertainty factor of 30 (3 for extrapolation 
from animals to humans using dosimetric adjustment and 10 for human variability) (See Appendix A). 
Bd Wt = body weight; ESO = epoxidized soybean oil; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); F = female; Gastro = gastrointestinal; Gd = gestational day; Gn 
pig = guinea pig; hemato = hematological; hr = hour(s); Immuno/Lymphoret = immunological/lymphoretic; LC50 = lethal concentration, 50% kill; LOAEL = 









































Figure 3-1 Levels of Significant Exposure to 1,3-Dichloropropene - Inhalation 

























4h 9h 11r 
2r 
6r 6r 




























 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans



































Figure 3-1 Levels of Significant Exposure to 1,3-Dichloropropene - Inhalation (Continued) 
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Figure 3-1 Levels of Significant Exposure to 1,3-Dichloropropene - Inhalation (Continued) 













































*Doses represent the lowest dose tested per study that produced a tumorigenic 


























 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
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1331 F (1-hour LC50) 
Reference 
Chemical Form 











9 d/11 d 
6 hr/d Resp 
b 
5 (very slight hyperplasia of 
nasal respiratory 
epithelium in 9/10) 
500 (3/6 rats died) Smyth et al. 1962; Union 
Carbide Corp 1958 
2,3-dichloropropene 
Zempel et al. 1987 
2,3-dichloropropene 
Purity not reported. 
Purity: >99%; NOAELs 


















































Key to Species Frequency 














S4 Mouse	 9 d/11 d 
6 hr/d(B6C3F1) 
Neurological 
5 Rat 9 d/11 d 


















Chemical Form Comments 
5 (very slight hyperplasia of 
nasal respiratory 
epithelium in 7/10; slight 
diffuse degeneration of 
bronchial/bronchiolar 
epithelium in 10/10) 
Zempel et al. 1987 
2,3-dichloropropene 
Purity: >99%; NOAELs 








5 25 (final bd wt 12% lower in 
males and 16% lower in 
females compared to 
controls) 
75 Zempel et al. 1987 
2,3-dichloropropene 
Purity: >99%; NOAELs 







































Chemical Form Comments 
6 Mouse 
(B6C3F1) 
9 d/11 d 
6 hr/d 75 Zempel et al. 1987 
2,3-dichloropropene 
Purity: >99%; NOAELs 










Cardio 15 Johannsen et al. 1991 
2,3-dichloropropene 
Purity: >99%; nasal 
turbinates were not 
examined for 
histopathology; 







































































Hemato 80 NTP 1989, 2006 
2,3-dichloropropene 




Hepatic 40 F 80 F (absolute and relative 
liver weights increased 
>30%) 
Renal 20 F 40 F (urine volume doubled) 
Bd Wt 20 M 
80 F 
40 M (terminal body weight 






Resp 5 F (absolute lung weight 
increased 29% and 
relative lung weight 
increased 25% in 
females compared to 
control) 
NTP 1989, 2006 
2,3-dichloropropene 




Hemato 80 M 
Hepatic 20 F 40 F (3-fold increases in 








5 Johannsen et al. 1991 
2,3-dichloropropene 
Purity: >99%; nasal 
























































80 NTP 1989, 2006 
2,3-dichloropropene 








20 NTP 1989, 2006 
2,3-dichloropropene 

















a The number corresponds to entries in Figure 3-2. 
b The minimal LOAEL was used to derive an acute-duration inhalation minimal risk level (MRL) of 0.002 ppm for 2,3-dichloropropene, as described in detail in Appendix A.  The 
minimal LOAEL was adjusted for intermittent exposure [multiplied by (6 hours/24 hours)] and multiplied by the regional gas dose ratio for extrathoracic effects in female rats (0.1143) 
to obtain the human equivalent concentration of 0.14 ppm. This was divided by uncertainty factor of 90 (3 for use of a minimal LOAEL, 3 for extrapolation from animal to human using 
dosimetric adjustment, and 10 for human variability) to derive the MRL (See Appendix A). 
ALT = alanine aminotransferase; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = Female; Gastro = gastrointestinal; Hemato = hematological; hr = 
hour(s); LC50 = lethal concentration, 50% kill, LOAEL = lowest-observed-adverse-effect level; Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; Resp = 

































































Figure 3-2 Levels of Significant Exposure to 2,3-Dichloropropene - Inhalation 
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Figure 3-2 Levels of Significant Exposure to 2,3-Dichloropropene - Inhalation (Continued) 
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60DICHLOROPROPENES
3. HEALTH EFFECTS
3.2.1.1  Death 
1,3-Dichloropropene.  No studies were located regarding death in humans after inhalation exposure to 
1,3-dichloropropene.
LC50 values for inhalation exposure to 1,3-dichloropropene have been determined in rats (Streeter and 
Lomax 1988; Streeter et al. 1987).  The LC50 for female rats exposed to Telone II®a for 4 hours was
904 ppm (95% confidence interval [CI]=846–990 ppm) (Streeter et al. 1987).  The LC50 for male rats 
could not be determined in this study, but fell in the range of 855–1,035 ppm 1,3-dichloropropene.  
Telone C-17® appears to be more toxic than Telone II®a; the LC50 for rats after a 1-hour exposure to 
Telone C-17® was 253 ppm (no range reported) (Streeter and Lomax 1988).  Telone C-17® contains a
relatively high proportion of chloropicrin, which may account for the enhanced toxicity.  Six of 10 rats 
died after a 4-hour exposure to 676 ppm Telone II®a. In the same study, no rats died after a 4-hour
exposure to ≤595 ppm of Telone II®a (Cracknell et al. 1987).
Rabbits exposed to 300 ppm during gestation days 6–18 developed ataxia and died (Kloes et al. 1983).  
The cause of death was not determined, although lung congestion and edema were noted on necropsy.
Intermediate- or chronic-duration exposures of mice, rats, guinea pigs, rabbits, and dogs to Telone II®a or
Telone II®b (1–150 ppm for 4 weeks to 2 years) had no effect on survival rates compared to control
groups that were untreated or exposed to filtered room air (Coate 1979a, 1979b; Lomax et al. 1989; Stott 
et al. 1988; Torkelson and Oyen 1977).
2,3-Dichloropropene. No mortality data are available for humans exposed to 2,3-dichloropropene by
inhalation.
Acute-duration animal studies indicate that single exposures at high concentrations may be fatal, possibly
from suppression of the central nervous system.  Exposure to 2,3-dichloropropene at high (unspecified) 
vapor concentrations was fatal to rats within 15–30 minutes (Monsanto 1967).  As described in an 
incomplete report (even-numbered pages were missing), a 1-hour LC50 of 1,331 ppm (1,250–1,406 ppm, 
95% confidence interval [CI]) in males and 1,461 ppm (1,326–1,639 ppm) for females was reported for
rats exposed to 2,3-dichloropropene vapor (Dietz et al. 1985b).  After 4 hours of exposure to 500 ppm
2,3-dichloropropene vapor, three of six rats died within 2 weeks, whereas none exposed at 250 ppm died 
   
 









    
 
     
     
    
   
   
      
  
 
     
      
    
 
 





   
 
 
      
 
   
   
   
 
    
 
      
   
61DICHLOROPROPENES
3. HEALTH EFFECTS
(Smyth et al. 1962).  No rats or mice died following exposure to ≤75 ppm 2,3-dichloropropene for
6 hours/day on 9 out of 11 days (Zempel et al. 1987).
No mortality was observed in rats exposed to 2,3-dichloropropene vapor at ≤15 ppm for 6 hours/day for
13 weeks (Johannsen et al. 1991).  As indicated in the available records of an unfinished 13-week
bioassay, no female mice exposed to 80 ppm for 6 hours/day, 5 days/week survived to termination (NTP
1989, 2006); no mortality records were available for female mice exposed to ≤40ppm or male mice, male 
rats, or female rats exposed to ≤80 ppm in this study.  Based on the available lung weight data, and results
of the acute-duration study by Zempel et al. (1987), it is possible that toxicity of the respiratory tract from
repeated irritation was a contributing factor to reduced survival in female mice.
1,2-Dichloropropene. As described in a brief summary, exposure to a saturated atmosphere of 1,2-di-
chloropropene estimated at 63,764 ppm was fatal to all three rats exposed for 12 minutes and one of four
rats exposed for 6 minutes (Dow 1962).  It is likely that death was caused by suppression of the nervous
system, since all exposed animals exhibited unconsciousness before the end of the exposure.
3.2.1.2  Systemic Effects
The systemic effects observed in humans or animals after inhalation exposure to 1,3-dichloropropene, 
2,3-dichloropropene, or 1,2-dichloropropene are discussed below.  The highest NOAEL values and all
reliable LOAEL values for each systemic effect for each species and duration category are recorded in 
Table 3-2 and 3-3, respectively, and plotted in Figure 3-1 and 3-2, respectively, for the 1,3- and 2,3-di-
chloropropenes.
Respiratory Effects.
1,3-Dichloropropene.  Humans exposed to 1,3-dichloropropene (formulation unknown) after a tank truck
spill complained of mucous membrane irritation, chest pain, cough, and breathing difficulties (Flessel
et al. 1978; Markovitz and Crosby 1984).
Acute-duration exposures of rats to various formulations of 1,3-dichloropropene caused respiratory
effects.  Gross pathological examination revealed atelectasis, emphysema, and/or edema in rats exposed 
to 206 ppm of Telone C-17® for 1 hour.  Atelectasis was still present in animals surviving the 2-week
observation period (Streeter and Lomax 1988).  As noted for death in Section 3.2.1.1, Telone C-17® also 
   
 









    
     
     
    
   





     
      
   
  
    
      
  
    
  
        




      
 
 
   
  
    
     
      
   
62DICHLOROPROPENES
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appears to be more toxic than Telone II®a after acute-duration exposure.  The presence of chloropicrin 
may enhance the toxicity of Telone C-17®. No respiratory effects were noted in rats after a 4-hour
exposure to 581 ppm of Telone II®a, although swollen lungs were observed in 2 out of 10 rats after a
4-hour exposure to 594 ppm (Cracknell et al. 1987).  In the same study, rats that died following exposure
to 675 ppm of Telone II®a had lung congestion, tracheal congestion, and fluid in the thoracic cavity, but
survivors had no respiratory lesions (Cracknell et al. 1987).  Multifocal lung hemorrhage was observed in
rats exposed for 4 hours to 1,035 ppm of Telone II®a (Streeter et al. 1987).
Intermediate-duration exposure studies indicate that effects on the upper respiratory tract appear to be
concentration- and duration-related.  Rats and mice had no respiratory lesions attributable to Telone II®a 
after exposure to ≤30 ppm for 4 weeks (Coate 1979b).  No respiratory effects were observed in rats 
exposed to 10 ppm Telone II®a for 13 weeks (Coate 1979a).  In contrast, rats exposed to ≥30 ppm
Telone II®a for 13 weeks developed epithelial changes in the nasal turbinates that included loss of
cytoplasm, nuclei disorganization, and occasional necrotic cells (Coate 1979a).  No information was
available as to the 1,3-dichloropropene concentration or the amount or types of impurities/additives
present in the test material.  The epithelial lesions were more severe in rats exposed to ≥90 ppm of
Telone II®a or Telone II®b for ≥13 weeks and included hyperplasia and focal necrosis (Breslin et al. 1989;
Coate 1979a; Stott et al. 1988).  No significant respiratory effects were observed in rats exposed to 
60 ppm Telone II®b, the highest concentration tested, for 6 months (Lomax et al. 1989).  Mice also 
developed hyperplastic and/or degenerative lesions of the nasal epithelium after exposure to 90 ppm
Telone II®a for 13 weeks (Stott et al. 1988) or to 60 ppm Telone II®b for 6 months (Lomax et al. 1989).  
Based on nasal lesion data in mice exposed for 6 months, an intermediate-duration inhalation MRL for
1,3-dichloropropene of 0.008 ppm was calculated using benchmark concentration modeling as described 
in Appendix A and the footnote to Table 3-2.  No respiratory effects were noted on gross or 
histopathological examinations after an intermediate inhalation exposure of rats, guinea pigs, rabbits, or
dogs to 3 ppm Telone II®a for 6 months (Torkelson and Oyen 1977).  Higher concentrations were not
tested in this study.
Exposure to 60 ppm of Telone II®b for 6–12 months did not result in respiratory effects in rats, but 
exposure to the same concentration for 2 years caused nasal olfactory epithelium degeneration (Lomax 
et al. 1989).  A statistically significant increase in bronchioalveolar adenomas, benign lung tumors, was
also noted in male rats exposed to 60 ppm for 2 years, but not in females.  In mice exposed to
20 or 60 ppm Telone II®b, hypertrophy/hyperplasia of the nasal respiratory epithelium did not progress in 
severity between 6 and 24 months, but occurred in ≥96% of mice treated at 60 ppm.  Degeneration of the
   
 








   
     











   
 
   
  
 
       
   
     
  
    
  
   
 
    
  
      




nasal olfactory epithelium, however, was noted in ≥90% of male and female mice exposed to 60 ppm, for
2 years (Lomax et al. 1989).  Based on benchmark concentration modeling of the nasal lesion data in 
mice, a chronic inhalation MRL of 0.007 ppm was calculated as described in Appendix A and the
footnote in Table 3-2.
These data indicate that acute exposure to 1,3-dichloropropene at high concentrations has effects on the
lungs of rats, whereas intermediate or chronic inhalation exposure to 1,3-dichloropropene at lower
concentrations produces hyperplastic lesions of the upper respiratory tract in rats and mice and 
degeneration of the olfactory epithelium in mice.
2,3-Dichloropropene. No data are available for respiratory effects in humans exposed to 2,3-dichloro-
propene by inhalation.  
Irritation of the respiratory tract is a major effect of inhalation exposure to 2,3-dichloropropene in 
animals.  In acute lethality studies, respiratory effects included gasping, shallow respiration, labored
breathing, hemorrhage of the lungs, and inflammation of nasal mucosae (Dietz et al. 1985b; Monsanto 
1967; Smyth et al. 1962; Union Carbide Corp. 1958).  Concentration-related increases in the incidence 
and severity of respiratory tract effects were observed in rats and mice exposed to 2,3-dichloropropene
vapor 6 hours/day for 9 out of 11 days (Zempel et al. 1987).  At ≥5 ppm, hyperplasia of the nasal
respiratory epithelium occurred in 9/10 rats and 7/10 mice and diffuse degeneration occurred in the
bronchial/bronchiolar epithelium of 10/10 mice.  At ≥25 ppm, all rats and mice exhibited hyperplasia of
the nasal olfactory epithelium and mice exhibited hyperplasia of the laryngeal epithelium.  As described
in Appendix A and the footnote to Table 3-3, an acute-duration inhalation exposure MRL of 0.002 ppm
was derived for 2,3-dichloropropene based on the human equivalent to a minimal LOAEL of 5 ppm for
very slight hyperplasia of the nasal respiratory epithelium in female rats (Zempel et al. 1987).  
Studies in rodents indicate that the respiratory tract is vulnerable to irritant effects from repeated exposure 
to 2,3-dichloropropene.  Red nasal discharge, an indicator of nasal irritation, was the only effect observed 
in rats exposed to 2,3-dichloropropene vapor at 15 ppm, 6 hours/day, 5 days/week for 13 weeks 
(Johannsen et al. 1991).  Although the frequency was reported to increase during the course of the study, 
the nasal turbinates were not evaluated for histopathology.  No lung histopathology was observed at
≥15 ppm in rats in this study, but because of the lack of histopathology data for the nasal turbinates, the
likely target organ in rats, a NOAEL for the respiratory tract was not entered into the Table 3-3.  The
available records from an unfinished 13-week inhalation study indicate significant 25% increases in 
   
 









     
 
      
    
  
      
 
     
 
 
    
  
 
     
 
   
 
 
     
    
     
 







    





absolute and relative lung weight in female mice exposed at 5 ppm and 13 and 22% increases, 
respectively, in absolute and relative lung weight in male mice exposed at 10 ppm (NTP 1989, 2006).
Lung weight increases generally increased with concentration, the relative increase in male mice reaching
200% in the 80 ppm group compared with controls.  Despite the lack of histological data for this study, it
provides suggestive evidence that the respiratory tract is the most sensitive target of inhaled 2,3-dichloro-
propene.  The NTP (1989) study is consistent with the acute-duration study by Zempel et al. (1987) in 
that lung effects were observed in mice, but not rats at low exposure levels.
1,2-Dichloropropene. No information was available on respiratory effects in humans exposed to 1,2-di-
chloropropene.
As described in a brief summary, lethal exposure for 6–12 minutes to a saturated atmosphere of 1,2-di-
chloropropene estimated at 63,764 ppm resulted in unspecified lung damage in rats (Dow 1962).  
Cardiovascular Effects.
1,3-Dichloropropene. No studies were located regarding cardiovascular effects in humans after
inhalation exposure to 1,3-dichloropropene.
No lesions attributable to Telone II®a were found upon histological evaluation of the heart and aorta from
rats and mice exposed to ≤150 ppm for up to 13 weeks (Coate 1979a, 1979b; Stott et al. 1988), or rats and 
mice exposed to 60 ppm Telone II®b for 6, 12, or 24 months (Lomax et al. 1989).
Although other indices of cardiovascular toxicity were not examined, 1,3-dichloropropene does not
appear to have cardiovascular effects.
2,3-Dichloropropene. No data are available for cardiovascular effects in humans exposed to 2,3-di-
chloropropene by inhalation.  
No cardiovascular histopathology was observed in rats or mice exposed to ≤75 ppm 2,3-dichloropropene
vapor for 6 hours/day, for 9 out of 11 days (Zempel et al. 1987).  No histopathology was observed in the
heart of rats exposed to ≤75 ppm 2,3-dichloropropene vapor for 6 hours/day, 5 days/week for 13 weeks 
(Johannsen et al. 1991).
   
 













       
    
  
      
       






   
    
     
  
 
      
 





   
      





1,3-Dichloropropene.  No studies were located regarding gastrointestinal effects in humans after
inhalation exposure to 1,3-dichloropropene.
No gastrointestinal effects were noted after gross and histologic examinations of the stomachs and 
intestines of rats or mice exposed to ≤150 ppm Telone II®a for 13 weeks (Stott et al. 1988), or rats or
mice exposed to 60 ppm of Telone II®b for 6 or 12 months (Lomax et al. 1989).  Similarly, no 
gastrointestinal lesions attributable to 1,3-dichloropropene were observed in rats exposed to 60 ppm of
Telone II®b for 2 years (Lomax et al. 1989).  In contrast, 8 of 50 male mice exposed to 60 ppm
Telone II®b for 2 years had hyperplasia and hyperkeratosis of the forestomach.  The NOAEL for this
effect was 20 ppm in the male mice. Female mice did not develop hyperplasia or hyperkeratosis of the
forestomach (Lomax et al. 1989).
2,3-Dichloropropene. No data are available for gastrointestinal effects in humans exposed to 2,3-di-
chloropropene by inhalation.  
No gastrointestinal histopathology was observed in rats or mice exposed to ≤75 ppm 2,3-dichloropropene
vapor for 6 hours/day, for 9 out of 11 days (Zempel et al. 1987).  No histopathology was observed in the
gastrointestinal tract of rats exposed to ≤15ppm 2,3-dichloropropene vapor for 6 hours/day, 5 days/week
for 13 weeks (Johannsen et al. 1991).
Hematological Effects.
1,3-Dichloropropene. No studies were located regarding hematological effects in humans after
inhalation exposure to 1,3-dichloropropene.
Hematological parameters have been examined in many studies of intermediate or chronic duration in 
which several species were exposed by inhalation to formulations of 1,3-dichloropropene.  No exposure-
related hematological effects were observed in rats, guinea pigs, rabbits, or dogs exposed to 3 ppm
Telone II®a for 6 months (Torkelson and Oyen 1977), in rats and mice exposed to 150 ppm Telone II®a 
for 13 weeks (Stott et al. 1988), or to 60 ppm Telone II®b for 6–24 months (Lomax et al. 1989).
   
 








    
    
 
   
 
 
   
     
     
   
    
 
      
 




    





   
    
     
 
 







Histological examination of bone marrow also did not reveal any adverse effects in either intermediate- or
chronic-duration exposure studies (Lomax et al. 1989; Stott et al. 1988).
2,3-Dichloropropene. No data are available for hematological effects in humans exposed to 2,3-dichloro-
propene by inhalation.  
No hematological effects were observed in rats or mice exposed to ≤75 ppm 2,3-dichloropropene vapor
for 6 hours/day, for 9 out of 11 days (Zempel et al. 1987).  No hematological effects were observed in rats
exposed to 2,3-dichloropropene vapor at ≤15 ppm for 6 hours/day, 5 days/week for 13 weeks (Johannsen 
et al. 1991).  Available records from an unfinished 13-week study indicate that no hematological effects
were observed in rats or mice exposed to ≤80 ppm 6 hours/day, 5 days/week (NTP 1989, 2006).
Musculoskeletal Effects.
1,3-Dichloropropene. No studies were located regarding musculoskeletal effects in humans after
inhalation exposure to 1,3-dichloropropene.
Gross and histopathological examination of bone and skeletal muscle did not reveal any differences
between exposed and control groups of rats and mice exposed to ≤150 ppm Telone II®a for 13 weeks 
(Stott et al. 1988), or 60 ppm Telone II®b for 6–24 months (Lomax et al. 1989).
2,3-Dichloropropene. No data are available for musculoskeletal effects in humans exposed to 2,3-di-
chloropropene by inhalation.  
No musculoskeletal effects were observed in rats or mice exposed to ≤75ppm 2,3-dichloropropene vapor
for 6 hours/day, for 9 out of 11 days (Zempel et al. 1987).  No musculoskeletal effects were observed in 
rats exposed to 2,3-dichloropropene vapor at ≤15 ppm for 6 hours/day, 5 days/week for 13 weeks 
(Johannsen et al. 1991).
Hepatic Effects.
1,3-Dichloropropene.  A few studies assessed hepatic toxicity in workers exposed to 1,3-dichloro-
propene, but found no differences in urinary or serum biomarkers between the exposed group and 
matched controls.  Verplanke et al. (2000) measured hepatic effect variables in 13 commercial pesticide 
   
 









    
     
    
  
      
 
     
   
 
       
 
 
       





   
     
  
     
     
   
    
  
   
   
 




application workers exposed to cis-1,3-dichloropropene at a (8-hour time-weighted average [TWA])
geometric mean exposure of 0.59 ppm (range 0.2–2.1 ppm) (2.7 mg/m3; range, 0.1–9.5 mg/m3) for an 
average of 521 (230) minutes/day for 117 days and 22 matched control workers.  Based on results from
urine and blood data collected before, during, and after fumigation, no significant difference in hepatic
parameters was detected between the exposed and control group.  Boogard et al. (1993) compared 
73 male operators who had worked at an average of 8.2 years (0.5–23 years) in a chemical plant where 
they were exposed to 1,3-dichloropropene at geometric mean (8-hour TWA) concentrations between 
0.03 and 0.31 ppm (0.14 and 1.39 mg/m3) between 1981 and 1984 and 35 matched control male workers.  
Although no significant difference in hepatic biomarkers was observed between the exposed and control
group, the study does not provide useful information about 1,3-dichloropropene since the exposures had 
ended 7 years prior to testing and exposures to other compounds were more recent.
Gross and histopathological examination of livers did not reveal any differences between exposed and 
control groups of rats and mice after inhalation exposure to ≤150ppm of Telone II®a for ≤13 weeks 
(Coate 1979b; Stott et al. 1988), or to ≤60 ppm Telone II®b for ≤24 months (Lomax et al. 1989).
2,3-Dichloropropene. No data are available for hepatic effects in humans exposed to 2,3-dichloro-
propene by inhalation.  
Hepatic effects in animals have been observed following exposure to relatively high exposure levels, but
not consistently across studies.  No effects on hepatic histology or serum parameters were observed in rats 
or mice exposed to ≤75 ppm 2,3-dichloropropene vapor for 6 hours/day, for 9 out of 11 days (Zempel et
al. 1987).  No effects on hepatic histology or serum parameters were observed in rats exposed to 2,3-di-
chloropropene vapor at ≤15 ppm for 6 hours/day, 5 days/week for 13 weeks (Johannsen et al. 1991).  
Available records from an unfinished 13-week inhalation bioassay indicate that hepatic toxicity increases 
in female, but not male rats exposed at higher concentrations 6 hours/day, 5 days/week (NTP 1989, 2006).
Three-fold and higher increases in serum ALT and SDH occurred in female mice at 40–80 ppm and a
60% increase in alkaline phosphatase and a six-fold increase in total bile acids were observed at 80 ppm
(NTP 1989, 2006).  In female rats at 80 ppm, absolute liver weights were increased by 33% and relative 
liver weights by 37% compared to controls (NTP 1989, 2006).  Hepatic LOAELs and NOAELs were
entered into Table 3-3, although the lack of histopathology data was noted.
1,2-Dichloropropene. No information was available on hepatic effects in humans exposed to 1,2-di-
chloropropene.
   
 









    
  
 





    
     
    
   
  
    
     
  





   
 
 
     
   
   
  
  
     
  




As described in a brief summary, lethal exposure for 6–12 minutes to a saturated atmosphere of 1,2-di-
chloropropene estimated at 63,764 ppm resulted in unspecified liver damage in rats (Dow 1962).  
Renal Effects.
1,3-Dichloropropene.  A few studies assessed renal toxicity in workers exposed to 1,3-dichloropropene, 
but found no differences in urinary or serum biomarkers between the exposed group and matched
controls.  Verplanke et al. (2000) measured renal effect variables in 13 commercial pesticide application 
workers exposed to cis-1,3-dichloropropene at a (8-hour TWA) geometric mean exposure of 0.59 ppm
(range 0.2–2.1 ppm (2.7 mg/m3; range, 0.1–9.5 mg/m3) for an average of 521 (±230) minutes/day for
117 days and 22 matched control workers.  Based on results from urine and blood data collected before, 
during, and after fumigation, no significant difference in renal parameters was detected between the
exposed and control group.  Boogard et al. (1993) compared 73 male operators who had worked at an 
average of 8.2 years (0.5–23 years) in a chemical plant where they were exposed to 1,3-dichloropropene
at geometric mean (8-hour TWA) concentrations between 0.03 and 0.31 ppm (0.14 and 1.39 mg/m3) 
between 1981 and 1984 and 35 matched control male workers.  Although no significant difference in 
renal biomarkers was observed between the exposed and control group, the study does not provide useful
information about 1,3-dichloropropene since the exposures had ended 7 years prior to testing and 
exposures to other compounds were more recent.  
Other studies showed an association between exposure to 1,3-dichloropropene and the urinary excretion
of enzymes possibly indicative of damage to renal tubules (Osterloh and Feldman 1993; Osterloh et al.
1989a, 1989b).  Fumigation workers were exposed to Telone® (formulation not specified) at a mean 
concentration of 0.6 ppm (range 0.06–2.1 ppm) 2–7 hours/day for 5 days and urine samples were 
collected at intervals.  The studies did not include unexposed groups or urinary measurements >24 hours
after exposure.  Urinalysis showed a correlation between exposure (concentration x duration) and 
cumulative 24-hour excretion of the metabolite N-acetyl-S-(cis-3-chloroprop-2-enyl)-cysteine (3CNAC)
and excretion of the enzymes N-acetylglucosanimidase (NAG, indicative of damage to renal tubules) and 
retinol binding protein (RBP, indicative of impaired tubular reabsorption of filtered protein).  The RBP
data were based on urine that had been stored at -70°C for several years (Osterloh and Feldman 1993).  
For daily urine excretions of 3CNAC in excess of 1.5 mg/day (7 workers), mean amounts of NAG and 
RBP excreted over 24 hours were slightly, but significantly increased 2-fold compared to values for
3CNAC <1.5 mg/day (7 workers).  These results were considered evidence of possible low-level
   
 













    
    
   
  
    
    
 
   
      
    
 
   
       
    
   
       
    
   
 




     
     
 




subclinical (nonadverse) renal tissue damage but demonstrate that the enzymes could be employed as
biomarkers for renal toxicity.  These studies are not included in Table 3-2 because the exposure levels 
were expressed in terms of excretion of 3CNAC and cannot be directly compared to atmospheric
concentrations of 1,3-dichloropropene.
Male and female rats exposed to 3 ppm Telone II®a for 6 months developed reversible cloudy swelling of
the renal tubular epithelium (Torkelson and Oyen 1977).  No adverse renal effects were observed in rats
allowed to recover for 3 months following the last exposure. The cloudy swelling observed in these rats
was not confirmed in more recent studies, even at longer durations and/or higher concentrations.  
Exposure to 1 ppm in this study had no renal effects in the rats.  Guinea pigs, rabbits, and dogs exposed to 
3 ppm suffered no renal effects under the same exposure protocol (Torkelson and Oyen 1977).
Gross and histological examination of the kidneys from rats and mice exposed to up to ≤150ppm
Telone II®a for 4–13 weeks (Coate 1979b; Stott et al. 1988) revealed no differences in the incidence of
renal lesions between exposed and control groups.  Urinalysis also revealed no differences between 
exposed and control groups of rats and mice (Lomax et al. 1989; Stott et al. 1988).
Moderate hyperplasia of the transitional epithelium of the urinary bladder was found in female mice
exposed to 90 or 150 ppm Telone II®a for 13 weeks (Stott et al. 1988).  Mice exposed to 30 ppm did not
show hyperplasia of the urinary bladder.  Rats exposed for 6–24 months and mice exposed for 6 months
to ≤60 ppm Telone II®b did not show hyperplasia of the urinary bladder (Lomax et al. 1989).  However, 
female mice exposed to Telone II®b for 1 year at 60 ppm or 2 years at 20 or 60 ppm showed an increase
in epithelial hyperplasia and inflammation of the urinary bladder (Lomax et al. 1989); epithelial
hyperplasia of the urinary bladder occurred in male mice exposed at 60 ppm for 2 years.
2,3-Dichloropropene. No data are available for renal effects in humans exposed to 2,3-dichloropropene
by inhalation.  
Renal effects in animals have been observed at relatively high exposure levels.  Slight mineralization of 
the corticomedullary junction was observed in 2/5 female rats following exposure to 5–75 ppm 2,3-di-
chloropropene vapor for 6 hours/day, for 9 out of 11 days (Zempel et al. 1987).  The significance of this
lesion is uncertain, given the small group size and the fact that that neither the incidence nor severity
showed concentration-related increases; because of this ambiguity, neither a NOAEL nor a LOAEL is
specified for renal effects in rats in Table 3-3.  No effects on renal histology in male rats or male or
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female mice or urinalysis parameters in male rats were observed following exposure to ≤75 ppm in the
same study.  No effects on renal histology or urinalysis parameters were observed in rats exposed to 
2,3-dichloropropene vapor at ≤15 ppm for 6 hours/day, 5 days/week for 13 weeks (Johannsen et al. 1991).  
Available records from an unfinished 13-week inhalation bioassay indicate that renal effects may occur in 
rats exposed at ≥40 ppm for 6 hours/day, 5 days/week (NTP 1989, 2006).  Urine volumes compared to 
control values were increased 2- and 5-fold, respectively, in female rats at 40 and 80 ppm, but reduced by
one third in male rats at 40–80 ppm.  Urinary alkaline phosphatase was increased by 48–59% in male rats
at 20–80 ppm, but the magnitudes of these increases are not biologically significant (NTP 1989, 2006).  
In female rats at 80 ppm, absolute kidney weights were increased by 17% and relative weights by 23%
compared to controls (NTP 1989, 2006).  NOAELs and LOAELs for kidney effects in rats were entered 
into Table 3-3, although the lack of histopathology data was noted.
1,2-Dichloropropene. No information was available on renal effects in humans exposed by inhalation to 
1,2-dichloropropene.
As described in a brief summary, lethal exposure for 6–12 minutes to a saturated atmosphere of 1,2-di-
chloropropene estimated at 63,764 ppm resulted in unspecified kidney damage in rats (Dow 1962).  
Dermal and Ocular Effects.
1,3-Dichloropropene.  No studies were located regarding dermal or ocular effects in humans after
inhalation exposure to 1,3-dichloropropene.
Gross and histological examination of the eyes and skin of rats and mice exposed to up to 150 ppm
Telone II®a for 13 weeks (Stott et al. 1988) or to 60 ppm for 6–24 months (Lomax et al. 1989) revealed 
no differences between exposed and control groups.
3.2.1.3  Immunological and Lymphoreticular Effects 
1,3-Dichloropropene.  No studies were located regarding immunological effects in humans after
inhalation exposure to 1,3-dichloropropene.
Gross and histological examination of the thymus and lymph nodes of rats and mice exposed to ≤150ppm
of Telone II®a for 13 weeks (Stott et al. 1988), or to 60 ppm Telone II®b for 6–24 months (Lomax et al. 
   
 















     
   
   




    
      
        
   







     
     
   
     
 




1989), revealed no lesions attributable to 1,3-dichloropropene exposure.  However, more sensitive tests 
for immune system function were not used.
3.2.1.4  Neurological Effects 
1,3-Dichloropropene. No neurological effects were observed in humans occupationally exposed to 
1,3-dichloropropene at levels high enough to require medical attention (Markovitz and Crosby 1984).
Ataxia of the hindlimbs and loss of the righting reflex was observed in six of seven pregnant rabbits
exposed 6 hours/day to 300 ppm of Telone II®a during gestation days 6–18; the onset of ataxia was 
observed during gestation days 14–19 (Kloes et al. 1983).  In the same study, no neurological signs of
toxicity were observed in pregnant rabbits exposed to 50 or 150 ppm or in pregnant rats exposed to 
≤300 ppm.
No gross clinical signs of neurotoxicity were observed in rats, guinea pigs, rabbits, or dogs after
inhalation exposure to 3 ppm Telone II®a for 6 months (Torkelson and Oyen 1977), in rats or mice
exposed to up to 150 ppm Telone II®a for 13 weeks (Coate 1979a; Stott et al. 1988), or to 60 ppm
Telone II®b for 6–24 months (Lomax et al. 1989). The absence of clinical signs is supported by
histological examinations of brain and spinal cords in rats and mice that revealed no lesions attributable to 
1,3-dichloropropene exposure (Coate 1979a; Lomax et al. 1989; Stott et al. 1988).  More sensitive tests 
for neurological effects, however, were not included in these studies.
2,3-Dichloropropene. No data are available for neurological effects in humans exposed to 2,3-dichloro-
propene by inhalation.  
Neurological effects in animals have been observed at relatively high exposure levels.  Rats exposed to 
high vapor concentrations in acute lethality studies exhibited lethargy and hyperactivity (Dietz et al. 
1985b).  No histopathology of brain or spinal cord was observed in rats or mice exposed to ≤75ppm
2,3-dichloropropene vapor for 6 hours/day, for 9 out of 11 days (Zempel et al. 1987).  No histopathology
was observed in the brain or spinal cord of rats or mice to 2,3-dichloropropene vapor at ≤15 ppm for
6 hours/day, 5 days/week for 13 weeks (Johannsen et al. 1991).  
1,2-Dichloropropene. No data were available for neurological effects in humans exposed by inhalation to
1,2-dichloropropene.
   
 


















   
    
  
 
    








      
  
 
      
      




As mentioned in a brief summary, exposure to a saturated atmosphere of 1,2-dichloropropene estimated at
63,764 ppm resulted in signs of central nervous system depression (unconsciousness) in rats within 
6 minutes of exposure (Dow 1962).
3.2.1.5  Reproductive Effects
1,3-Dichloropropene.  No studies were located regarding reproductive effects in humans after inhalation
exposure to 1,3-dichloropropene.
No adverse reproductive effects and no histological changes in reproductive organs were observed in 
parental groups or progeny of male and female rats exposed to up to 90 ppm Telone II®b for two 
generations (Breslin et al. 1989).  
Gross and histological examination of reproductive organs and tissues of rats and mice exposed to 
≤150 ppm of Telone II®a for 13 weeks (Stott et al. 1988) or ≤60 ppm Telone II®a for 6–24 months
(Lomax et al. 1989) revealed no lesions attributable to 1,3-dichloropropene.  More sensitive tests for
reproductive effects, however, were not included in these studies.
2,3-Dichloropropene.  No studies were located regarding reproductive effects in humans after inhalation
exposure to 2,3-dichloropropene.
No significant adverse effects were observed in a one-generation reproductive assay in rats exposed to
2,3-dichloropropene vapor at ≤5 ppm for 6 hours/day, 5 days/week although there was a statistically
insignificant reduction in mating in treated groups (Johannsen et al. 1991).  Available reports from an 
incomplete study indicated that there were no adverse effects on estrus cycling or sperm parameters in 
rats or mice exposed to 2,3-dichloropropene vapor at ≤80 ppm for 6 hours/day, 5 days/week for 13 weeks 
(NTP 1989, 2006); no female mice exposed at 80 ppm survived for analysis of the estrus cycle, but no 
adverse effects were observed in those exposed at ≤40 ppm. 
   
 













     
    
  





     
    
   




      
   
    
   
    
   
 
   
 
 






3.2.1.6  Developmental Effects 
1,3-Dichloropropene.  No studies were located regarding developmental effects in humans after
inhalation exposure to 1,3-dichloropropene.
No developmental effects were found in groups of rats exposed to 50 or 150 ppm Telone II®a during
gestation days 6–15 (Kloes et al. 1983).  In contrast, rats exposed to 300 ppm Telone II®a during gestation 
days 6–15 had fewer fetuses per litter, an increase in the incidence of litters totally resorbed, and an 
increase in the number of litters with resorptions.  Rats exposed to 300 ppm Telone II®a had urine and
fecal staining, nasal exudate, a red crusty material around the eyes, and significantly decreased food and 
water consumption and body weight.  These observations indicate serious maternal toxicity in rats
exposed to 300 ppm, which could account for the decreased litter size, increased resorptions, and 
increased number of litters with resorptions.  Rabbits were evaluated for developmental effects after
exposure to up to 300 ppm Telone II®a during gestation days 6–18 (Kloes et al. 1983).  No developmental
effects attributable to 1,3-dichloropropene exposure were observed in the 50 and 150 ppm groups. In 
contrast, marked maternal toxicity in the 300 ppm group precluded evaluation of developmental effects;
signs of maternal toxicity included ataxia, loss of the righting reflex, significantly decreased body weight, 
and the death of six of seven rabbits.
No developmental effects were observed in the progeny of groups of male and female rats exposed to 
≤90 ppm Telone II®b for two generations (Breslin et al. 1989), or in pregnant rats exposed for 6 hours/day
during gestation days 6–15 and rabbits exposed during gestation days 6–18 to ≤120 ppm 1,3-dichloro-
propene (90.1% purity) (Hanley et al. 1987). The parameters monitored included pup survival, pup body
weight, pup crown-rump length, and gross pathology.  Delayed ossification was noted in 14 rat pups of
21 litters exposed in utero to 120 ppm, but this may have been due to the decreased food and water
consumption and body weight of the dams during the exposure period (Hanley et al. 1987).
3.2.1.7  Cancer
1,3-Dichloropropene.  Few studies are available that link inhalation exposure to 1,3-dichloropropene with 
the development of cancer in humans.  
Clary and Ritz (2003) conducted a case-control study using mortality odds ratios to compare deaths from
pancreatic cancer (1989–1996) with a random sample of noncancer deaths in three agricultural counties in 
   
 









   
 
   





   
 
 
   
   
   
  




     











California.  A total of 1,002 cases in which pancreatic cancer was named as the cause of death (data from
state records) were identified within 102 zip codes in the three-county area.  About 10 controls (total 
10,002) were selected for each case at random from all noncancer deaths in these counties.  The state’s 
pesticide use reporting (PUR) database was used to classify pesticide use within each zip code.  The 
analysis showed an increased risk of death from pancreatic cancer for long-term residence (20 years) in 
the three-county area and residence at the time of death in zip codes showing the highest quartile of
1,3-dichloropropene application (107 cases, prevalence odds ratio of 1.89 [95% CI=1.13–3.15]).  This
study provides suggestive, but not definitive, evidence that exposure to 1,3-dichloropropene may be a risk
factor for pancreatic cancer.
A clinical report describing three cases of neoplasms that developed after exposure to 1,3-dichloro-
propene provides other suggestive evidence that there may be an association between exposure and cancer
(Markovitz and Crosby 1984).  Nine firemen were exposed to 1,3-dichloropropene during cleanup of a
tank truck spill.  Six years later, two of the men developed histiocytic lymphomas that were refractory to 
treatment.  Both men soon died.  In addition, a 52-year-old farmer who had been in good health 
developed pain in the right ear, nasal mucosa, and pharynx after being exposed to 1,3-dichloropropene
(not otherwise specified) from his tractor for 30 days.  The hose carrying the 1,3-dichloropropene had a
small leak that sprayed the chemical near the right side of the man's face.  Over the next year, the man 
developed leukemia that was refractory to treatment.  He died of pneumonia 5 weeks after hospital
admission.  None of these reports identified the formulation of 1,3-dichloropropene or stated whether the
chemical included additives such as epichlorohydrin.
In the only study regarding the carcinogenic potential of 1,3-dichloropropene in animals after inhalation 
exposure, a statistically significant increase in the incidence of bronchioalveolar adenomas was observed 
in male mice exposed to 60 ppm Telone II®b for 24 months (Lomax et al. 1989).  An increased incidence
of this benign lung tumor, however, was not observed in female mice nor in male or female rats exposed 
to Telone II®b under the same protocol.
The cancer effect level (CEL) in male mice is recorded in Table 3-2 and plotted in Figure 3-1.
3.2.2 Oral Exposure 
Reliable oral toxicity data are available for 1,3-dichloropropene and for acute toxicity of 2,3-dichloro-
propene; a brief summary of an acute lethality study is available for 1,2-dichloropropene.  The highest
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NOAEL and all reliable LOAEL values after oral exposure to 1,3- and 2,3-dichloropropene are recorded 
in Tables 3-4 and 3-5, respectively, and plotted in Figures 3-3 and 3-4, respectively.  Median lethal
concentrations and other reliable mortality data are recorded as serious LOAELs in these tables and 
figures.  
3.2.2.1  Death 
1,3-Dichloropropene.  A 27-year-old male died 40 hours after accidentally drinking 1,3-dichloropropene
(mixed cis and trans isomers) (Hernandez et al. 1994).  Upon recognizing his error, he vomited, but
2 hours later in an emergency room, he exhibited acute gastrointestinal distress, tachypnea, tachycardia, 
sweating, and hypovolemia; abdominal pain was evident at deep palpation.  The level of 1,3-dichloro-
propene at this time was 1.13 micromol/L in blood and 0.20 micromol/L in urine.  Subsequent effects
included bloody diarrhea, metabolic acidosis, adult respiratory distress syndrome, and release of
pancreatic enzymes into peritoneal fluid.  Multiorgan failure preceded death.
Several studies were located that reported oral LD50 values for 1,3-dichloropropene in various
formulations (95% confidence limits are given in parentheses).  The oral LD50 for M-3993 was 713 mg/kg 
(no range calculable) in male rats and 470 (337–636) mg/kg in female rats (Lichy and Olson 1975).  In a
similar study, the oral LD50 for Telone C-17® was 519 (305–1,009) mg/kg in male rats and 304 (147– 
516) mg/kg in female rats (Mizell et al. 1988b).  These data indicate that female rats are more sensitive to 
1,3-dichloropropene in its various formulations than male rats.  Much lower LD50 values of 150 (130– 
170) mg/kg were reported for Telone II®a in CFY-strain Sprague-Dawley rats (Jones and Collier 1986a)
and 224 mg/kg for Telone II®a in female F344 rats (Jeffrey et al. 1987a).  The variability in LD50 values 
could result from different rat stocks or strains, or from differences in the 1,3-dichloropropene
formulations used.
No deaths were reported among rats that received gavage doses up to 30 mg/kg/day of Telone® for 
13 weeks (Til et al. 1973), rats or mice exposed to up to 50 or 100 mg/kg/day, respectively, Telone II®b in 
feed for 13 weeks (Haut et al. 1996), or dogs exposed to up to 41 mg/kg/day Telone II®b in feed for
13 weeks (Stebbins et al. 1999).  No differences were observed in the survival rates of rats that received 0,
25, or 50 mg/kg, or of mice that received 0, 50, or 100 mg/kg Telone II®b by gavage in corn oil for
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Resp 75 (lung congestion) Jones and Collier 1986a 
T IIa 
250 (lung hemorrhage) Purity: 97.2% 1,3-DCP. 
Gastro 75 M  (hyperkeratosis of 
stomach) 
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Key to Species Frequency 
Figure (Strain) (Route) 
INTERMEDIATE EXPOSURE 
Systemic 
10 Rat 13 wk 
ad lib(Fischer- 344) 
(F) 
11 Rat	 9 mo 





















Chemical Form Comments 
100 M Haut et al. 1996 
T IIb 











15 M 50 M (terminal weight 16% 
lower than control) 
50 NTP 1985 
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Hemato 5 15 (19-29% reductions in 
hemoglobin and 
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Stebbins et al. 1999 
T IIb 





Bd Wt 5 F 15 F (terminal weight 12% 







100 Haut et al. 1996 
T IIb 
Purity: 95.8% 1,3-DCP; 
2% ESO; 
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100 Haut et al. 1996 
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Purity: 89% 1,3-DCP; 
1% epichlorohydrin. 
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Key to Species Frequency NOAEL Less Serious Serious Reference 



























Stebbins et al. 2000 
T IIb 
Purity: 95.8% 1,3-DCP; 
2% ESO; 
microencapsulated. 
(basal cell hyperplasia of 
nonglandular stomach 
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Resp 100 NTP 1985 
T IIa 
Purity: 89% 1,3-DCP; 
1% epichlorohydrin. 
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Resp 50 Stebbins et al. 2000 
T IIb 
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Key to Species Frequency 
Figure (Strain) (Route) 




22 Rat 2 yr 



















Chemical Form Comments 
15 Stebbins et al. 1999 
T IIb 





2.5 15 (microcytic anemia; 
increased extramedullary 
hematopoeisis in spleen) 
15 
15 
2.5 15 (terminal weight 13-19% 
lower than control) 
50 NTP 1985 
T IIa 
Purity: 89% 1,3-DCP; 
1% epichlorohydrin; 
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histological 

















































































15 Stebbins et al. 1999 
T IIb 
Comments 
Purity: 95.8% 1,3-DCP; 
2% ESO; 
microencapsulated; 
spleen, lymph nodes, 
and thymus were 
examined. 
Purity: 89% 1,3-DCP; 
1% epichlorohydrin; 
immunological 
endpoints restricted to 
histological 
examination of spleen 
and thymus. 
Purity: 95.8% 1,3-DCP; 
2% ESO; 
microencapsulated; 
spleen, lymph nodes, 
and thymus were 
examined. 
Purity 95.8% 1,3-DCP; 
2% ESO; 
microencapsulated; 





















































































50 Stebbins et al. 2000 
T IIb 
Comments 
Purity: 89% 1,3-DCP; 
1% epichlorohydrin; 
histopathology of brain 
and spinal cord were 
examined. 




clinical signs and 
histopathology. 
Purity: 89% 1,3-DCP; 
1% epichlorohydrin; 
brain and spinal cord 
were examined for 
histopathology. 






















































































100 NTP 1985 
T IIa 
Comments 
Purity 95.8% 1,3-DCP; 
2% ESO; 
microencapsulated; 
brain weight and gross 
clinical signs were 
examined. 
Purity: 89% 1,3-DCP; 
1% epichlorohydrin; 
NOAELs based on 
histological 
examination of 
reproductive organs in 
males and females. 




seminal vesicle, testes, 
uterus, ovaries and 
vagina were examined. 
Purity: 89% 1,3-DCP; 
1% epichlorohydrin; 
NOAELs based on 
histological 
examination of 
reproductive organs in 














































































25 (forestomach squamous 
cell tumors; neoplastic 
hepatic nodules) 
25 M (CEL: hepatocellular 
adenoma in 9/50, 
carcinoma in 1/50) 
NTP 1985 
T IIa 
Stebbins et al. 2000 
T IIb 
Comments 




seminal vesicle, testes, 
uterus, ovaries and 
vagina were examined. 
Purity 95.8% 1,3-DCP; 
2% ESO; 
microencapsulated; 
ovary and testes weight 
and histopathology 
were examined. 
Purity: 89% 1,3-DCP; 
1% epichlorohydrin. 
























































50 (CEL: bronchioalveolar 
adenoma of lung; 
transitional cell 
carcinoma of urinary 
bladder; forestomach 
squamous cell tumors) 
















a The number corresponds to entries in Figure 3-3. 
b Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-4. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
c Study results used to derive an intermediate-duration oral minimal risk level (MRL) of 0.04 mg/kg/day for 1,3-dichloropropene, as described in detail in Appendix A.  Benchmark 
dose analysis was performed for incidences of hyperplasia of the nonglandular stomach mucosa in male rats to select a point of departure, which was divided by an uncertainty factor 
of 100 (10 for extrapolation from animals to humans using dosimetric adjustment and 10 for human variability) (See Appendix A). 
d Study results used to derive a chronic-duration oral minimal risk level (MRL) of 0.04 mg/kg/day for 1,3-dichloropropene, as described in detail in Appendix A.  Benchmark dose 
analysis was performed for incidences of hyperplasia of the nonglandular stomach mucosa in male and female rats and for reduced hemoglobin concentrations in male and female 
dogs to select a point of departure. The selected point of departure, based on stomach hyperplasia in female rats, was divided by an uncertainty factor of 100 (10 for extrapolation 
from animals to humans using dosimetric adjustment and 10 for human variability) (See Appendix A). 
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); ESO = epoxidized soybean oil; (F) = feed; Gastro = gastrointestinal; (G)= 
gavage; (GO) = gavage in oil; hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; mo = month(s); Musc/skel = musculoskeletal; 


































Figure 3-3 Levels of Significant Exposure to 1,3-Dichloropropene - Oral 
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Figure 3-3 Levels of Significant Exposure to 1,3-Dichloropropene - Oral (Continued) 
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Figure 3-3 Levels of Significant Exposure to 1,3-Dichloropropene - Oral (Continued) 
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Figure 3-4 Levels of Significant Exposure to 2,3-Dichloropropene - Oral 
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feed as high as 15 mg/kg/day for 1 year (Stebbins et al. 1999) or in rats or mice exposed to doses up to
25 or 50 mg/kg/day, respectively, for 2 years (Stebbins et al. 2000).  
2,3-Dichloropropene. No mortality data were available for humans orally exposed to 2,3-dichloro-
propene.
The oral LD50 for 2,3-dichloropropene in rats was 320 (260–400) mg/kg (Smyth et al. 1962). 
1,2-Dichloropropene. No mortality data were available for humans orally exposed to 1,2-dichloro-
propene.
As mentioned in a brief summary, two rats survived that were given 2,000 mg/kg 1,2-dichloropropene by
oral gavage (Dow 1962). 
3.2.2.2  Systemic Effects
The systemic effects observed in humans or animals after oral exposure to 1,3-, 2,3-, or 1,2-dichloro-
propene are discussed below.  The highest NOAELs and all reliable LOAELs for each systemic effect for 
each species and duration category are recorded in Tables 3-4 and 3-5, respectively, and plotted in 
Figures 3-3 and 3-4, respectively, for the 1,3- and 2,3-dichloropropenes.
Respiratory Effects.
1,3-Dichloropropene.  In the 27-year-old male who died after accidentally ingesting 1,3-dichloropropene, 
tachypnea was an early sign of toxicity, and diffuse bilateral edema of the lungs consistent with adult
respiratory distress syndrome developed several hours before death (Hernandez et al. 1994).
In a rat LD50 study, a single oral administration of Telone II®a caused dose-related respiratory effects 
including lung congestion and lung hemorrhage (Jones and Collier 1986a).  
Gross and microscopic examination revealed no respiratory effects in male and female rats exposed to 
≤30 mg Telone®/kg/day by gavage for 13 weeks (Til et al. 1973), ≤50 mg Telone II®a/kg/day by gavage
for 9 months (NTP 1985), or ≤100 mg Telone II®b/kg/day in the feed for 13 weeks (Haut et al. 1996).  
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Likewise, no exposure-related histologic lesions were found in the lungs of male and female mice 
exposed to doses ≤100 mg Telone II®b /kg/day in feed for 13 weeks (Haut et al. 1996).  
Gross and histological examination revealed no neoplastic or nonneoplastic respiratory lesions in rats and 
no nonneoplastic respiratory lesions in mice receiving Telone II®a for 2 years at gavage doses of 
≤50 mg/kg/day for rats or ≤100 mg/kg/day for mice (NTP 1985).  In contrast, an increased incidence of
bronchioalveolar adenomas was observed in female mice receiving Telone II®a for 2 years 
(Section 3.2.2.8).  With dietary administration of microencapsulated Telone II®b in feed, no increased 
incidences of nonneoplastic respiratory lesions were found in rats or mice exposed to doses ≤25 or
≤50 mg/kg/day, respectively, for 2 years (Stebbins et al. 2000) or in dogs exposed to ≤41 mg/kg/day for
1 year (Stebbins et al. 1999).  
2,3-Dichloropropene. No data were available for respiratory effects in humans orally exposed to 2,3-di-
chloropropene.
Congestion of the lungs was observed in rats that died in following ingestion of lethal doses of 2,3-di-
chloropropene (Smyth et al. 1962; Union Carbide Corp. 1958). 
Cardiovascular Effects.
1,3-Dichloropropene.  In the 27-year-old male who died after accidentally ingesting 1,3-dichloropropene, 
tachycardia was an early sign of toxicity and hypovolemia subsequently developed (Hernandez et al. 
1994).  At autopsy, there was evidence of hemorrhages in the stomach and brain.
Histological evaluation of the hearts revealed no exposure-related lesions in rats exposed to ≤30 mg/kg of
Telone® by gavage for 13 weeks (Til et al. 1973).
Following chronic-duration exposure, gross and histological examination of hearts revealed no 
cardiovascular lesions in rats that received ≤50 mg/kg or in mice that received ≤100 mg Telone II®a/kg by 
gavage for 2 years (NTP 1985).  Data in male mice were of limited value, because 25 of 50 vehicle 
controls died of myocarditis after 48–51 weeks.  With dietary administration of microencapsulated 
Telone II®b in feed, no increased incidences of nonneoplastic cardiovascular lesions were found in rats or
mice exposed to doses ≤25 or ≤50 mg/kg/day, respectively, for 2 years (Stebbins et al. 2000) or in dogs
exposed to ≤41 mg/kg/day for 1 year (Stebbins et al. 1999).  
   
 














   




   
        
 
    
  
   
       
     
      
  
     
  





    
    





1,3-Dichloropropene.  The only information on gastrointestinal effects in humans following oral
exposure to 1,3-dichloropropene comes from a fatal accidental poisoning case (Hernandez et al. 1994).  
Acute gastrointestinal distress and abdominal pain were among the initial symptoms in a 27-year-old male
who died 40 hours after accidentally drinking 1,3-dichloropropene.  Subsequent signs included bloody
diarrhea and the presence of pancreatic enzymes in the peritoneal fluid; the study authors could not rule
out the possibility of a preexisting pancreatic illness.  Hemorrhagic exudate of the stomach was observed 
at autopsy.  Histopathological analysis of the stomach revealed congestion of gastric mucosal vessels, 
autolysis, and mucosal erosions.
Hyperkeratosis of the nonglandular stomach was found in rats that received a single gavage dose of 
100 mg/kg Telone C-17® (Mizell et al. 1988b) or 75 mg/kg Telone II®a (Jones and Collier 1986a). 
In rats exposed to microencapsulated Telone II®b in the diet for 13 weeks, basal cell hyperplasia of the 
nonglandular stomach was observed at doses of ≥15 mg/kg/day and hyperkeratosis was observed at
100 mg/kg/day (Haut et al. 1996).  Gross and microscopic evaluation of the gastrointestinal tract revealed 
no lesions attributable to oral administration of ≤30mg/kg of 78% Telone® to rats for 13 weeks (Til et al. 
1973).  Similarly, no gastrointestinal lesions were found in rats that received ≤50mg/kg of 89%
Telone II®a for 9 months (NTP 1985) or in mice exposed to ≤100 mg/kg/day Telone II®b in feed for
13 weeks (Haut et al. 1996).  As described in Appendix A and the footnote to Table 3-4, an intermediate-
duration oral MRL of 0.04 mg/kg/day was derived for 1,3-dichloropropene based on benchmark dose
analysis of incidence data for basal cell hyperplasia of the nonglandular stomach in rats exposed to 
microencapsulated Telone II®b in the diet for 13 weeks. 
Chronic oral exposure to 1,3-dichloropropene causes nonneoplastic and neoplastic lesions in the
gastrointestinal systems of rats and mice. 
Significant dose-related increases in basal cell or epithelial cell hyperplasia of the forestomach were 
observed in male and female rats that received ≥25 mg/kg Telone II®a for 2 years (NTP 1985).  
Additionally, female rats that received 50 mg/kg had hyperkeratosis of the forestomach.  Male rats 
suffered an increase in pancreatic periarteritis at both 25 and 50 mg/kg.
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Dose-related increases in epithelial cell hyperplasia of the forestomach were observed in female mice 
receiving ≥50 mg/kg Telone II®a by oral gavage (NTP 1985).  Although data in male mice were limited,
the incidence of forestomach epithelial cell hyperplasia was similar to that in the females.  Neoplastic 
lesions of the stomach were also observed in rats and mice that received gavage doses of Telone II®a for
2 years (Section 3.2.2.7).
In chronic oral studies involving microencapsulated Telone II®b (95.8% 1,3-dichloropropene) in feed, 
basal cell hyperplasia of the nonglandular stomach mucosa was observed in male and female rats 
receiving 12.5 mg/kg/day for 2 years (Stebbins et al. 2000), but not in mice receiving doses of
≤50 mg/kg/day for 2 years (Stebbins et al. 2000) or dogs receiving ≤15 mg/kg/day for 1 year (Stebbins et
al. 1999).  A portal-of-entry effect in dogs was indicated by inflammation of the tongue in some dogs
exposed at ≤15 mg/kg/day for 1 year (Stebbins et al. 1999); the study authors suggested that some of the
microcapsules dissolved in saliva, releasing 1,3-dichloropropene into the oral cavity with resulting irritant
effects.  No gastric tumors were observed in rats, mice, or dogs exposed to Telone II®b in the diet.  As
described in Appendix A and a footnote to Table 3-4, a chronic-duration oral exposure MRL of
0.03 mg/kg/day was derived from benchmark dose analysis of incidence data for basal cell hyperplasia of
the nonglandular stomach in female rats exposed to microencapsulated Telone II®b in the diet for 2 years. 
Hematological Effects.
1,3-Dichloropropene.  No studies were located regarding hematological effects in humans after oral
exposure to 1,3-dichloropropene.
Evaluation of hematological profiles and clinical chemistry revealed no adverse effects in rats that
received ≤30 mg/kg 78% Telone® by oral gavage for 13 weeks (Til et al. 1973).  In 13-week studies 
administering microencapsulated 95.8% Telone II®b in the diet, no significant hematological effects were
noted in rats or mice exposed at ≤100 mg/kg/day (Haut et al. 1996).  Conversely, dogs exposed to the
same test material at concentrations of ≥15 mg/kg/day exhibited microcytic anemia (19–29% reductions
in hemoglobin and hematocrit counts) (Stebbins et al. 1999).
Extensive clinical chemistry and hematological profiles of male and female rats exposed by gavage to 
≤50 mg/kg 1,3-dichloropropene (89% plus 1% epichlorohydrin) (NTP 1985) or to microencapsulated 
Telone II®b at ≤25 mg/kg/day (Stebbins et al. 2000) for 2 years revealed no signs of adverse effects (NTP
1985).  However, dogs exposed to the microencapsulated Telone II®b in the diet at concentrations of
   
 









    
 
    
   
 






     
 
   
      
   
   
      
 




      
 
 
    
    
 




≥15 mg/kg/day exhibited macrocytic anemia (reductions in hemoglobin, hematocrit, and mean 
corpuscular volumes) (Stebbins et al. 1999). This hematological effect in dogs was selected as a co-
critical effect for chronic oral exposure.  As described in Appendix A, hematological effects in dogs were
not selected as the basis for the chronic-duration oral MRL because benchmark dose analysis of the other
co-critical effect, stomach lesions in rats, provided a lower, more protective point of departure.
Musculoskeletal Effects.
1,3-Dichloropropene.  No studies were located regarding musculoskeletal effects in humans after oral
exposure to 1,3-dichloropropene.
Histological evaluation of musculoskeletal tissue revealed no exposure-related lesions in rats exposed to
≤30 mg/kg of Telone® by gavage for 13 weeks (Til et al. 1973).
Gross and histological examination of musculoskeletal tissue revealed no lesions in rats that received up 
to 50 mg/kg or in mice that received up to 100 mg Telone II®a/kg by gavage for 2 years (NTP 1985).  
With dietary administration of microencapsulated Telone II®b in feed, no increased incidences of
musculoskeletal lesions were found in rats or mice exposed to doses ≤25 or ≤50mg/kg/day, respectively, 
for 2 years (Stebbins et al. 2000) or in dogs exposed to ≤41 mg/kg/day for 1 year (Stebbins et al. 1999).  
Hepatic Effects.
1,3-Dichloropropene.  No studies were located regarding hepatic effects in humans after oral exposure to 
1,3-dichloropropene.
A single gavage dose of 170 mg/kg Telone II®a produced mottled and dark livers in rats (Jones and 
Collier 1986a).
An increased liver:body weight ratio was observed in rats that received 30 mg/kg, but not ≤10 mg/kg, of
Telone® for 13 weeks (Til et al. 1973).  Histological examination and clinical chemistry variables 
revealed no adverse hepatic effects in rats or mice exposed to 100 or 50 mg/kg/day, respectively, 
Telone II®b in feed for 13 weeks (Haut et al. 1996).
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Histological examination revealed no hepatic lesions that were attributable to oral gavage administration 
of 50 mg/kg Telone II®a to rats for 9–24 months (NTP 1985).  Similarly, no hepatic lesions attributable to 
Telone II®a were found in mice after they received gavage doses for 2 years.  In contrast, an increased 
incidence of hepatic neoplastic nodules was observed in male rats that received Telone II®a by gavage for
2 years (Section 3.2.2.7).  In male and female rats ingesting microencapsulated Telone II®b in the diet for
2 years, there was no increase in the total number of hepatic foci, but treated rats had more eosinophilic
foci than basophilic foci (Stebbins et al. 2000).  In the same study, an increase in benign hepatic tumors 
(adenomas) was observed in male rats exposed at 25 mg/kg/day (see Section 3.2.2.7). No nonneoplastic
or neoplastic hepatic effects were found in mice exposed to ≤50mg/kg/day Telone II®b in feed for 2 years 
(Stebbins et al. 2000), or in dogs exposed to ≤41 mg/kg/day for 1 year (Stebbins et al. 1999). 
2,3-Dichloropropene. No data were available for hepatic effects in humans orally exposed to 2,3-di-
chloropropene.
Congestion of the liver was observed in rats that died in following ingestion of lethal doses of 2,3-di-
chloropropene (Smyth et al. 1962; Union Carbide Corp. 1958). 
1,2-Dichloropropene. No data were available for hepatic effects in humans orally exposed to 1,2-di-
chloropropene.
As mentioned in a brief summary, two rats that survived a single oral dose of 2,000 mg/kg 1,2-dichloro-
propene exhibited considerable (unspecified) injury to the liver at necropsy (Dow 1962). 
Renal Effects.
1,3-Dichloropropene.  The autopsy of a 27-year-old male who died 40 hours after accidentally ingesting
1,3-dichloropropene revealed acute tubular necrosis of the kidney (Hernandez et al. 1994).
A single gavage dose of 170 mg/kg Telone II®a produced dark kidneys in rats (Jones and Collier 1986a).  
The toxicological significance of this observation was not discussed.  The NOAEL for this effect was 
110 mg/kg.
An increase in the kidney:body weight ratio was observed in rats that received 10 mg/kg, but not 3 mg/kg, 
Telone® (78% purity) for 13 weeks (Til et al. 1973).  In contrast, no renal lesions were observed after
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gross and microscopic examination in rats that received ≤50 mg/kg of Telone II®a for 9–24 months (NTP
1985).  No adverse renal effects were observed in rats, mice, or dogs that received Telone II®b in the diet 
for 13 weeks (Haut et al. 1996; Stebbins et al. 1999).
Female mice developed a dose-related increase in kidney hydronephrosis after oral exposure to
50 or 100 mg/kg Telone II®a for 2 years (NTP 1985).  A primary target organ of 1,3-dichloropropene in 
female mice was the urinary bladder, where a dose-related increase in epithelial cell hyperplasia and 
transitional cell carcinoma (Section 3.2.2.7) was observed.  Although data for male mice were not
adequate, there was some indication that Telone II®a also caused transitional cell carcinomas in the
urinary bladder.  Similar neoplastic and nonneoplastic lesions were not found in male and female rats 
exposed to up to 50 mg/kg 1,3-dichloropropene for 2 years (NTP 1985).  No adverse renal effects were 
observed in rats or mice that received Telone II®b in the diet for 2 years, or in dogs similarly exposed for
1 year (Stebbins et al. 1999, 2000).
2,3-Dichloropropene. No data were available for renal effects in humans orally exposed to 2,3-dichloro-
propene.
Congestion of the kidneys was observed in rats that died following ingestion of lethal doses of 2,3-di-
chloropropene (Smyth et al. 1962; Union Carbide Corp. 1958). 
1,2-Dichloropropene. No data were available for renal effects in humans orally exposed to 1,2-dichloro-
propene.
As mentioned in a brief summary, two rats that survived a single oral dose of 2,000 mg/kg 1,2-dichloro-
propene exhibited considerable (unspecified) injury to the kidneys at necropsy (Dow 1962). 
Dermal and Ocular Effects.
1,3-Dichloropropene.  No studies were located regarding dermal/ocular effects in humans after oral
exposure to 1,3-dichloropropene.
Gross and histological examination of the eyes and skin in rats and of the skin only in mice that received 
gavage doses of Telone II®a for 2 years revealed no lesions attributable to Telone II®a (NTP 1985).  
Likewise, no exposure-related adverse effects were apparent from histologic examination of skin and eyes 
   
 








      
     
 
 










    
    
 
   
  
 













of rats or mice exposed to ≤25 mg/kg/day and ≤50 mg/kg/day Telone II®b in the feed for 2 years 
(Stebbins et al. 2000) or eyes of dogs exposed to ≤41 mg/kg/day Telone II®b in the feed for 1 year
(Stebbins et al. 1999).
Body Weight Effects.
1,3-Dichloropropene.  No data were available for body weight effects in humans following oral exposure
to 1,3-dichloropropene.  
Reductions in terminal body weights compared to controls were observed in dogs exposed at
≥15 mg/kg/day (Stebbins et al. 1999), rats at ≥50 mg/kg/day, and mice at ≥100 mg/kg/day (Haut et al. 
1996) in 13-week studies in which microencapsulated Telone II®b was added to the diet.
Reductions in body weights compared to controls were observed studies in rats and mice exposed to 
microencapsulated Telone II®b in the diet at 25 mg/kg/day for 2 years (Stebbins et al. 2000) or dogs
exposed at 15 mg/kg/day for 1 year (Stebbins et al. 1999).
In the intermediate- and chronic-duration studies using Telone II®b, the authors reported that reduced feed 
intake was largely responsible for the reduced body weight gains.
Metabolic Effects.
1,3-Dichloropropene.  Metabolic acidosis developed in a 27-year-old male within hours after fatal 
ingestion of 1,3-dichloropropene (Hernandez et al. 1994).  
No studies were located regarding metabolic effects in animals after oral exposure to 1,3-dichloro-
propene.
3.2.2.3  Immunological and Lymphoreticular Effects 
1,3-Dichloropropene.  No studies were located regarding immunological effects in humans or animals 
after oral exposure to 1,3-dichloropropene.  
   
 









   







    
   
 
     
     
    
    
 
 






     








Histological examination of spleen and thymus revealed no exposure-related adverse changes in rats or
mice exposed to ≤25 and ≤50 mg/kg/day Telone II®b, respectively, in the feed for 2 years (Stebbins et al. 
2000) or in dogs exposed to ≤41 mg/kg/day Telone II®b in the feed for 1 year (Stebbins et al. 1999).  
3.2.2.4  Neurological Effects 
1,3-Dichloropropene.  No studies were located regarding neurological effects in humans after oral
exposure to 1,3-dichloropropene.
Studies specifically designed to examine neurological end points in animals after acute-, intermediate-, or
chronic-duration oral exposure to 1,3-dichloropropene were not located.
No histologic changes in brain or spinal cord tissue or gross clinical signs of toxicity were found in rats
and mice exposed to ≤25 and ≤50 mg/kg/day, respectively, Telone II®b in the feed for 2 years (Stebbins et
al. 2000), in dogs exposed to ≤41 mg/kg/day Telone II®b in the feed for 1 year (Stebbins et al. 1999), or
in rats and mice exposed to ≤50 and ≤100 mg/kg/day, respectively, Telone II®a by gavage for 2 years 
(NTP 1985).  
3.2.2.5  Reproductive Effects
1,3-Dichloropropene.  No studies were located regarding reproductive effects in humans following oral
exposure to 1,3-dichloropropene.
Histological evaluation of reproductive organs and tissues from rats and mice that received oral doses of 
Telone II®a by gavage or dietary exposure to Telone II®b for 2 years revealed no lesions attributable to 
the exposure (NTP 1985; Stebbins et al. 2000).  More sensitive tests for reproductive effects, however,
were not performed in these studies.
Studies specifically designed to examine reproductive performance end points in animals after acute-,
intermediate-, or chronic-duration oral exposure to 1,3-dichloropropene were not located.
   
 


















     
    
   








    
    
    
  
     
  
   






3.2.2.6  Developmental Effects 
No studies were located regarding developmental effects in humans or animals after oral exposure to any
isomer of dichloropropene.
3.2.2.7  Cancer
1,3-Dichloropropene.  No studies were located regarding cancer in humans after oral exposure to 1,3-di-
chloropropene.
In a 2-year gavage study, rats that received 25 or 50 mg Telone II®a/kg/day developed squamous cell
papillomas and carcinomas of the forestomach (NTP 1985).  Male rats also developed neoplastic nodules 
of the liver.  Female mice that received 50 or 100 mg/kg/day developed squamous cell papillomas and 
carcinomas of the forestomach, transitional cell carcinomas of the urinary bladder, and an increased 
incidence of alveolar/bronchiolar adenomas.  The data in male mice were considered inadequate for
assessment of carcinogenicity, because 25 of 50 vehicle controls died of myocarditis during weeks 48–51 
of the study; however, there was some indication that the same neoplastic lesions found in increased 
incidences in female mice also occurred in male mice (NTP 1985).  
More recent 2-year studies testing microencapsulated Telone II®b (a formulation in which 
epichlorohydrin was replaced with epoxidized soybean oil) suggest that epichlorohydrin enhances the 
carcinogenicity of 1,3-dichloropropene in animals (Stebbins et al. 1999, 2000). In contrast to the
carcinogenic responses observed in mice exposed by gavage to Telone II®a (a formulation with 
epichlorohydrin), mice receiving dietary doses of ≤50 mg/kg/day encapsulated Telone II®b did not show
any statistically significant carcinogenic response (Stebbins et al. 2000).  In male rats receiving doses of
25 mg/kg/day via dietary exposure to Telone II®b, the incidence of benign hepatocellular adenomas was
significantly increased compared to controls and one male had a hepatocellular carcinoma (Stebbins et al. 
2000).  Female rats exhibited a significant positive trend for these liver tumors, although the incidence at
25 mg/kg/day, the highest dose tested, was not significantly increased compared to controls (Stebbins et
al. 2000).  No increased tumor incidence was observed in dogs receiving doses of ≤41 mg/kg/day for
1 year (Stebbins et al. 1999).  From these results, it appears that lifetime oral exposure to 1,3-dichloro-
propene increased hepatic tumors in rats (either with gavage exposure to Telone II®a or dietary exposure
to Telone II®b), but that tumors at other locations in rats (such as the forestomach) or at any locations in 
mice or dogs may arise only from an interaction with epichlorohydrin or with gavage exposure.  
   
 









    
 
















   
     
    
     
   





   
  




The CELs in rats and mice are recorded in Table 3-4 and plotted in Figure 3-3.
3.2.3 Dermal Exposure 
Dermal toxicity data are available for 1,3-dichloropropene and, to a lesser extent, for 2,3-dichloropropene
and 1,2-dichloropropene.  The highest NOAEL and all reliable LOAEL values after dermal exposure to 
1,3- and 2,3-dichloropropene are recorded in Tables 3-6 and 3-7, respectively.  Median lethal doses and 
other reliable quantifiable mortality data are recorded as serious LOAELs in these tables and figures.
Unless otherwise noted, dermal toxicity studies employed occlusive or semiocclusive coverings of the
application site, protected to prevent evaporation or ingestion of the test material.
3.2.3.1  Death 
1,3-Dichloropropene.  No studies were located regarding death in humans after dermal exposure to 
1,3-dichloropropene.
Several acute dermal lethality studies have been conducted for 1,3-dichloropropene (95% confidence
limits are given in parentheses).  The acute dermal LD50 for Telone II®a in rats was 1,200 (1,000– 
1,400) mg/kg (Jones and Collier 1986b).  The acute dermal LD50 in rabbits for M-3993 was 713 mg/kg 
for males and 407 mg/kg for females, for an average of 504 (220–1,150) mg/kg (Lichy and Olson 1975).  
In a similar study, the dermal LD50 for Telone II®a in rabbits was 333 (102–610) mg/kg (Jeffrey et al. 
1987b).  Six of 10 rabbits died or were submitted to pathology in a moribund condition within 4 days
after receiving a dermal application of 500 mg/kg Telone C-17® (Mizell et al. 1988b).
2,3-Dichloropropene. No data were available for mortality in humans following dermal exposure to 
2,3-dichloropropene.
The dermal LD50 for 2,3-dichloropropene in rabbits was 1,913 (1,405–2,579) mg/kg for a single 24-hour
exposure period (Smyth et al. 1962; Union Carbide Corp. 1958).  The minimum lethal dose for dermal
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Jones and Collier 1986b 
T IIa 
Comments 
Purity: 97.2% 1,3-DCP. 
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Rabbit 1 d 
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Rabbit 1 d 
24 hr/d 504 B 
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(LD50) 
Lichy and Olson 1975 
M-3993 
Purity: 92% 1,3-DCP. 
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Zealand) 
Rabbit 1 d 
24 hr/d 500 
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(6/10 died) 
Mizell et al. 1988b 
T C-17 
Purity: 79.1% 1,3-DCP, 
19.4% chloropicrin. 
Systemic 
Rat 1 d 
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(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
(New 
Zealand) 
Rabbit 1 d 









Rabbit 1 d 









Rabbit 1 d 
24 hr/d Dermal 200 B 
mg/kg 
(erythema, necrosis) 




Rabbit 3 d 
24 hr/d 0.5 
ml 
(erythema/edema) 
Lichy and Olson 1975 
M-3993 
Purity: 92% 1,3-DCP. 
Rabbit 3 d 
24 hr/d Dermal 0.5 B 
ml 
(erythema/edema) 
Lichy and Olson 1975 
M-3993 
Purity: 92% 1,3-DCP. 
Rabbit 1 d 
1 x/d Ocular 0.1 
ml 
(eye irritation) 
Lichy and Olson 1975 
M-3993 
Purity: 92% 1,3-DCP. 
(New 
Zealand) 
Rabbit 1 d 



















































(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
Rabbit 1 d 




Mizell et al. 1988b 
T C-17 
Purity: 79.1% 1,3-DCP, 
19.4% chloropicrin. 




Gn Pig 1 wk 
4 x/wk Dermal 0.1 
ml 
(erythema) 
Carreon and Wall 1983 
T IIa 
Purity: 92% 1,3-DCP. 
(Hartley) 
Gn Pig 1 wk 
4 x/wk 0.1 M 
ml 
(positive sensitization 
reaction in 4/10) 
Carreon and Wall 1983 
T IIa 







































































Smyth et al. 1962; Union 
Carbide Corp 1958
2,3-dichloropropene 





24 hr Ocular 0.1 
ml 
(moderate eye irritation) 
Monsanto 1967 
2,3-dichloropropene 

























   
 
















    
 
    
  
 
      
 
   
 
 
   
    
    
 
     
 
   
 
 
   
   
 
     
 
   
    
112DICHLOROPROPENES
3. HEALTH EFFECTS
3.2.3.2  Systemic Effects
No studies were located regarding cardiovascular, hematological, renal, hepatic, endocrine, or body
weight effects in humans or animals after dermal exposure to any isomer of dichloropropene.  No studies
were located regarding respiratory, gastrointestinal, or musculoskeletal effects in humans following
dermal exposure to any isomer of dichloropropene.  
Respiratory Effects.
1,3-Dichloropropene. Rats that received a single dermal application of 500 mg/kg Telone II®a developed 
lung congestion, and at 800 mg/kg, lung hemorrhage (Jones and Collier 1986b).
Gastrointestinal Effects.
1,3-Dichloropropene. No studies were located regarding gastrointestinal effects in humans following
dermal exposure to 1,3-dichloropropene.
Rats that received a single dermal application of 800 mg/kg Telone II®a suffered hemorrhage of the
stomach and congestion and hemorrhage of the intestines (Jones and Collier 1986b).  No gastrointestinal
effects were observed in rats that received 500 mg/kg cis-1,3-dichloropropene or 500 mg/kg Telone II®a.
Musculoskeletal Effects.
1,3-Dichloropropene. No studies were located regarding musculoskeletal effects in humans following
dermal exposure to 1,3-dichloropropene.
Of six rabbits that died following dermal application of 500 mg/kg Telone C-17®, two had developed 
skeletal muscle hemorrhage underneath the site of application (Mizell et al. 1988b).
Dermal and Ocular Effects.
1,3-Dichloropropene. Contact dermatitis has been reported in several agricultural workers following
dermal exposure to 1,3-dichloropropene as a pesticide (Bousema et al. 1991; Corazza et al. 2003; Vozza
   
 















   
     
   
 




   
 
 




   
   
  
   
 







et al. 1996).  In cases where the liquid was in direct contact with the skin, dermatitis (erythema)
developed immediately or within hours (Corazza et al. 2003; Vozza et al. 1996). In one case, a farmer
developed acute bullous dermatitis on his feet 10 days after soiling his shoes in DD-95 (95% 1,3-di-
chloropropene), during which time he continued to wear the shoes (Bousema et al. 1991).  In all three
cases, allergic reactions subsequently developed (see Section 3.2.3.3).
Acute dermal application of dilute or full strength Telone II®a or M-3993 rapidly produced erythema and 
edema in rats, rabbits, and guinea pigs (Carreon and Wall 1983; Jeffrey 1987c; Jones and Collier 1986b;
Lichy and Olson 1975; Mizell 1988a).  At concentrations of ≥200mg/kg, necrosis and subcutaneous/ 
skeletal muscle hemorrhage were observed (Jones and Collier 1986b; Mizell 1988a; Mizell et al. 1988b).
Telone II®a and Telone C-17® also produced a delayed-type hypersensitivity in guinea pigs (Carreon and 
Wall 1983; Jeffrey 1987a; Mizell 1988b).
Severe conjunctival irritation, corneal injury, and corneal opacity were observed after instillation of
0.1 mL Telone II®a or M-3993 into the conjunctival sacs of rabbits (Jeffrey 1987b; Lichy and Olson 
1975).
2,3-Dichloropropene. No data were available for dermal or ocular effects in humans following dermal
exposure to 2,3-dichloropropene.
Results of primary eye and dermal irritation studies on 2,3-dichloropropene were described brief reports
with little experimental detail. Moderate damage to the eye was observed in rabbits receiving a topical
dose of 6.15 mg 2,3-dichloropropene (Smyth et al. 1962; Union Carbide Corp. 1958) or 0.1 mL
(Monsanto 1967).  In 24-hour dermal studies, moderate dermal irritation (erythema) was observed in 
rabbits that were exposed at a dose of 12 mg (Smyth et al. 1962; Union Carbide Corp. 1958) and mild 
dermal irritation was observed following exposure to an unspecified dose (Monsanto 1967). 
1,2-Dichloropropene. No data were available for dermal or ocular effects in humans topically exposed to 
1,2-dichloropropene.  
A brief summary of results of a primary skin irritation assay in rabbits reported moderate hyperemia, 
edema, and deep burn with scarring following dermal exposure to an unspecified amount of 1,2-dichloro-
propene (Dow 1962).  As reported in the same summary, effects in rabbits exposed to an unreported
   
 



















   
 
    
   
    
 
 








     
  
 




amount of 1,2-dichloropropene in a primary eye irritation assay included pain, moderate-to-extensive 
conjunctivitis, and slight iritis that subsided within a week.
3.2.3.3  Immunological and Lymphoreticular Effects 
1,3-Dichloropropene.  Skin sensitization reactions have been reported in workers involved in the
production or use of pesticides containing 1,3-dichloropropene.  A 28-year-old male who developed 
dermatitis on his hands, abdomen, and flanks from spilled 1,3-dichloropropene developed erythema, 
vesicles, and itching at the previous sites of exposure 3 weeks later (Corazza et al. 2003).  A 44-year-old 
male who had developed acute bullous dermatitis on his feet from shoes contaminated with DD-95 (95%
1,3-dichloropropene) developed the same dermatitis following a similar exposure a year later (Bousema et
al. 1991).  A 23-year-old male who developed dermatitis on his hands and abdomen from accidental
exposure to liquid 1,3-dichloropropene developed itching vesicles at the sites of exposure 1 week later
(Vozza et al. 1996).  The authors diagnosed this as a case of ‘contact pemphigus’, a type of autoimmune
reaction initially triggered from contact dermatitis. Skin sensitization to DD-92® was noted as an itchy
rash on the hands and feet of a 26-year-old male exposed during the manufacture of a soil fumigant
(van Joost and de Jong 1988).  Positive patch tests for 1,3-dichloropropene confirmed the sensitization in 
all four cases.
Delayed-type hypersensitivity reactions to Telone II®a and Telone C-17® were observed in guinea pigs 
(Carreon and Wall 1983; Jeffrey 1987a; Mizell 1988b).  
3.2.3.4  Neurological Effects 
1,3-Dichloropropene.  No studies were located regarding neurological effects in humans after dermal
exposure to 1,3-dichloropropene.
Rats that received a single dermal application of ≥1,300 mg/kg of Telone II®a became ataxic and lost the
righting reflex, indicating neurological deficits (Jones and Collier 1986b).  Several studies reported 
clinical signs in rats and rabbits that possibly indicate a neurological effect of 1,3-dichloropropene after
dermal application.  These signs included lethargy, salivation, lacrimation, and labored respiration 
(Jeffrey et al. 1987b; Jones and Collier 1986b; Mizell et al. 1988b).
   
 








   
 
   
  
 





      
    
    










   
 
    
    
 
   




No studies were located regarding the following effects in humans or animals after dermal exposure to 
any isomer of dichloropropene:
3.2.3.5  Reproductive Effects
3.2.3.6  Developmental Effects 
3.2.3.7  Cancer
1,3-Dichloropropene.  No studies were located regarding cancer in humans after dermal exposure to 
1,3-dichloropropene.
1,3-Dichloropropene was not a tumor-initiator in mice treated with a single application of 122 mg per
mouse, followed by repeated applications of the tumor-promoter, phorbol myristic acid, for 58 weeks.  
1,3-Dichloropropene did not induce skin-papilloma formation in mice after dermal application of 122 mg
per mouse three times weekly for 74 weeks—averaging 1481 mg/kg/day (Van Duuren et al. 1979); in 
addition there was no significant increase in lung or forestomach tumors compared to untreated or
acetone-treated controls.  Therefore, 1,3-dichloropropene does not appear able to initiate or induce skin 
tumors in mice.
3.2.4 Other Routes of Exposure 
No studies were located regarding effects in humans or animals exposed to any isomer of dichloropropene
by routes of exposure other than oral, inhalation, or dermal.
3.3  GENOTOXICITY
Genotoxicity data for dichloropropenes are presented in Table 3-8 for in vivo studies and Table 3-9 for
in vitro studies.  Formulations are given in the tables.
Genotoxic Effects in Vivo. No studies were located regarding genotoxic effects in humans after
inhalation, oral, or dermal exposure to any isomer of dichloropropene.  Genotoxic effects were observed 
in animals in vivo following exposure to 1,1- and 1,3-dichloropropene (Table 3-8). 
   
 








   
 
        
    
   
 
 
   
 
    












































   
  
























   
116DICHLOROPROPENES
3. HEALTH EFFECTS
Table 3-8.  Genotoxicity of Dichloropropenes In Vivo
Isomer/ 
Species (test system) End point Results Reference formulation 
1,1-Dichloropropene
Fish (λ transgenic Mutation at cII bacterial + Winn et al. 2006 Purity not reported
medaka), immersion locus (liver)
at 0.44–16.60 mg/L for
6 weeks
1,3-Dichloropropene
Drosophila Sex-linked lethal + Valencia et al. cis, trans; 





Rat (Sprague- DNA fragmentation + Kitchin and Brown NS
 
Dawley); females; by (alkaline elution) (liver) 1994
 




Rat (Sprague- DNA fragmentation – Kitchin and Brown NS
 
Dawley); females; by (alkaline elution) (liver) 1994
 




Rat (Sprague- DNA fragmentation – Ghia et al. 1993 cis, trans
 
Dawley); males; by (lung, bone marrow,
 




Rat (Sprague- DNA fragmentation + Ghia et al. 1993 cis, trans
 
Dawley); males; by (liver, gastric mucosa;
 




Mouse (CD-1), male; DNA fragmentation + Sasaki et al. 1998 cis, trans
 
by oral gavage in olive (stomach, liver, kidney,
 
oil; 150 mg/kg bladder, lung, brain,
 
bone marrow)
Rat (CD); males Dominant lethal – Gollapudi et al. Telone II®b
exposed by inhalation mutation 1998 49.3–49.9% cis/





Rat (Sprague- Unscheduled DNA – Ghia et al. 1993 cis, trans
 
Dawley); males; by synthesis (hepatocytes)
 




Mouse (ICR), male; by Increased – Sasaki et al. 1994 NS
i.p. injection in olive micronucleated 





Rat (Sprague- Increased micronuclei – Ghia et al. 1993 cis, trans
 
Dawley); males; by (bone marrow)
 




   
 








   
 
























     






   
 







   
 




Table 3-8.  Genotoxicity of Dichloropropenes In Vivo
Isomer/ 
Species (test system) End point Results Reference formulation 
Mouse (NMRI), female Increased micronuclei + Kevekordes et al. cis, trans; 95%
and female; by oral (bone marrow) 1996 pure
gavage in corn oil;
187 mg/kg
Mouse (NMRI), male Increased micronuclei – Kevekordes et al. cis, trans; 95%
and female; by oral (bone marrow) 1996 pure
gavage in corn oil;
≤280 mg/kg
Mouse (CD-1), male; Micronucleus induction – Morita et al. 1997a Technical grade
by i.p. injection; single 
treatment
Mouse (CD-1), male; DNA fragmentation + Sasaki et al. 1998 cis, trans
by oral gavage in olive (stomach, liver, kidney,
oil; 150 mg/kg bladder, lung, brain,
bone marrow)
acis- and trans-1,3-dichloropropene supplied by K&K Laboratories
bcis- and trans-1,3-dichloropropene supplied by Pfaltz and Bauer, Inc.
cLow-boiling 1,3-dichloropropene supplied by K&K Laboratories
dHigh-boiling 1,3-dichloropropene supplied by K&K Laboratories
ePfaltz and Bauer 1,3-dichloropropene was purified; impurities were then added back (refluxed) for the mutagenicity
assay.
fcis-l, 3-dichloropropene
gImpurities from purified cis-1,3-dichloropropene
+ = positive response; – = negative response; DMSO = dimethyl sulfoxide; NS = not specified
   
 









   
 









      















    
 
 
       
        




    
 
 
      
      
 
 
      
       
 
  





































Table 3-9.  Genotoxicity of Dichloropropenes In Vitro
Results
With Without Isomer/
Species (test system) End point activation activation Reference formulation 
1,1-Dichloropropene
Prokaryotic organisms:














Aspergillus nidulans Mitotic segregation No data _ Crebelli et al. 1992 97% pure
 
A. nidulans Induced aneuploidy No data _ Rosenkranz and NS
 
Klopman 1996
Human lymphoblastoid DNA damage _ _ Granville et al. 98% pure
cells 2005
1,2-Dichloropropene






S. typhimurium Reverse mutation + + Creedy et al. 1984 cis, trans 
(TA100)




























S. typhimurium Reverse mutation + +	 Neudecker et al. cis, trans 

(TA100)	 1980; Neudecker 99.5% pure
and Henschler
1986
   
 








   
 





































































         
  
 
    
 












      
 
 
      
 
 
      
 
 
    
  
 
      
        
     
 
 
    
  




Table 3-9.  Genotoxicity of Dichloropropenes In Vitro








S. typhimurium Reverse mutation + + Stolzenberg and cis, trans 
(TA100) Hine 1980 
S. typhimurium Reverse mutation No data – Talcott and King Not purea 
(TA100) 1984 85%
S. typhimurium Reverse mutation No data – Talcott and King Purifieda
(TA100) 1984 92%
S. typhimurium Reverse mutation No data + Talcott and King Not pureb 
(TA100) 1984 77%
S. typhimurium Reverse mutation No data – Talcott and King Purifiedb 
(TA100) 1984 85%
S. typhimurium Reverse mutation No data + Talcott and King Not purec 
(TA100) 1984 75%
S. typhimurium Reverse mutation No data – Talcott and King Purifiedc 
(TA100) 1984 86%
S. typhimurium Reverse mutation No data + Talcott and King Not pured 
(TA100) 1984 88%
S. typhimurium Reverse mutation No data – Talcott and King Purifiedd 
(TA100) 1984 95%
S. typhimurium Reverse mutation No data + Talcott and King 	 cis + transe 
(TA100)	 1984 80% plus
impurities
S. typhimurium (TA98) Reverse mutation No data + Vithayathil et al. cis, trans 
1983
S. typhimurium (TA98) Rifampicin No data + Vithayathil et al.	 cis, trans 
resistance 1983
Escherichia coli DNA damage (SOS No data + von der Hude et al. cis, trans
(PQ37) induction) 1988
S. typhimurium Reverse mutation + + Watson et al. 1987 Not puref 
(TA100)
S. typhimurium Reverse mutation – – Watson et al. 1987 Purifiedf 
(TA100)
S. typhimurium Reverse mutation + + Watson et al. 1987 Impuritiesg 
(TA100)
S. typhimurium Reverse mutation – + Connors et al.	 cis or trans; 
(TA100, TA102, TA97)	 1990 3-chloroallyl
alcoholh 
Eukaryotic organisms:
A. nidulans Mitotic segregation No data – Crebelli et al. 1992	 95% pure




HeLa cells	 Unscheduled DNA No data + Eder et al. 1987 cis, trans
synthesis
   
 








   
 









   
  






















    







   
 
 
   
 
    
   
 
    
  
 


















      
 
 






      










     
 
 





Table 3-9.  Genotoxicity of Dichloropropenes In Vitro
Results
With Without Isomer/
Species (test system) End point activation activation Reference formulation 




Mouse lymphoma cell Mutagenesis No data + Myhr and Caspary Telone II
 
L5178Y 1991 cis, trans
 
Chinese hamster Sister chromatid + + Loveday et al.	 97.1% pure
ovary cells exchange 1989
Chinese hamster Chromosomal – – Loveday et al. 97.1% pure
ovary cells aberrations 1989
Chinese hamster V79 Sister chromatid – + von der Hude et al.	 cis, trans
cells exchange 1987
Chinese hamster lung Chromosomal + + Matsuoka et al. 96.5% pure 
cells aberrations 1998
Rat hepatocytes Unscheduled DNA No data + Martelli 1997 NS
synthesis
Human lymphocytes Unscheduled DNA No data + Martelli 1997 NS
synthesis
Human lymphocytes Sister chromatid + + Kevekordes et al. cis, trans
exchange 1996 95% pure
Acellular test system






























S. typhimurium Reverse mutation – – Lag et al. 1994 98% pure
(TA100)
S. typhimurium Reverse mutation No data + Neudecker and 99.5% pure
(TA100) Henschler 1986
   
 








   
 






















     
 
 
      
        

















    
 
 
        
   
  











   
  
 





Table 3-9.  Genotoxicity of Dichloropropenes In Vitro








S. typhimurium Reverse mutation + + Stolzenberg and 98% pure
(TA100) Hine 1980
S. typhimurium Reverse mutation + + De Lorenzo et al. cis, trans 
(TA1535, TA1978, 1977
TA100)
S. typhimurium Reverse mutation + + Eder et al. 1982a, NS
(TA100) 1986
Eukaryotic organisms:
A. nidulans Mitotic segregation No data + Crebelli et al. 1992 98% pure
A. nidulans Induced aneuploidy No data + Rosenkranz and NS
Klopman 1996
Chinese hamster Sister chromatid + + Loveday et al. 98% pure
ovary cells exchange 1990
Chinese hamster V79 Sister chromatid + + von der Hude et al. 99% pure
cells exchange 1987
Chinese hamster Chromosomal + + Loveday et al. 98% pure
ovary cells aberrations 1990
Rat hepatocyte DNA repair No data – Williams et al. 1989 NS
 




acis- and trans-1,3-dichloropropene supplied by K&K Laboratories
bcis- and trans-1,3-dichloropropene supplied by Pfaltz and Bauer, Inc.
cLow-boiling 1,3-dichloropropene supplied by K&K Laboratories
dHigh-boiling 1,3-dichloropropene supplied by K&K Laboratories
ePfaltz and Bauer 1,3-dichloropropene was purified; impurities were then added back (refluxed) for the mutagenicity
assay.
fcis-l, 3-dichloropropene
gImpurities from purified cis-1,3-dichloropropene
hMetabolites of 1,3-dichloropropene
+ = positive response; – = negative response 
   
 








   
 
   
   
 
     
 
   
  
 




   
     
    
   
 
   
      





     
    
  
 





1,1-Dichloropropene. Positive evidence for the mutagenicity of 1,1-dichloropropene was reported for the
λ (lambda) transgenic medaka fish that were exposed in aquaria water continuously for 6 weeks (Winn et
al. 2006).  The transgenic medaka is homozygous for the lambda bacteriophage vector that expresses lacI
and cII bacterial genes.  Assays of liver DNA for mutations in the cII gene revealed concentration-related
increases in mutation frequencies in exposed fish compared to controls:  from a 6-fold increase at
0.44 mg/L to a 32-fold increase at 16.60 mg/L.  The pattern of induced mutation types was distinct from
that produced spontaneously in controls, with the most frequent induced type being a +1 frameshift
mutation (comprising 69.4% of the mutations) occurring at a 166-fold increase in fish treated at
16.6 mg/L compared to controls.
1,3-Dichloropropene. A single inhalation-exposure study reported no evidence of an increase in 
dominant lethal mutations in rats exposed intermittently at 150 ppm for up to 10 weeks (Gollapudi et al. 
1998).
Positive evidence for genotoxicity of 1,3-dichloropropene was reported in several oral-exposure studies.  
In a Drosophila melanogaster feeding study 1,3-dichloropropene produced sex-linked recessive lethal
mutations (Valencia et al. 1985).  DNA fragmentation was detected by alkaline elution in livers of female 
rats orally dosed with 94 mg/kg (Kitchin and Brown 1994), the livers and gastric mucosa of male rats
orally dosed with ≥62.5 mg/kg and kidneys of male rats orally dosed with 125 mg/kg (Ghia et al. 1993), 
and the stomach, liver, kidney, bladder, lung, brain, and bone marrow of male mice orally dosed with 
150 mg/kg (Sasaki et al. 1998).  No DNA fragmentation was observed in rat lung, bone marrow, or brain 
of rats orally dosed with up to 125 mg/kg (Ghia et al. 1993).  Some of the studies reported positive
evidence of DNA damage a few hours after exposure, but apparent recovery to normal conditions by
24 hours after exposure was noted.
No increase in unscheduled DNA synthesis was observed in rats dosed orally with 125 mg/kg (Ghia et al. 
1993).  One study reported positive results for increased micronucleus production in bone marrow of mice
that received an oral dose of 187 mg/kg 1,3-dichloropropene (Kevekordes et al. 1996), but all other
micronucleus assays in rats or mice were negative (Ghia et al. 1993; Kevekordes et al. 1996; Morita et al. 
1997a; Sasaki et al. 1994).
Studies examining genotoxic endpoints in mammals following in vivo exposure to 1,1-, 1,2- and 2,3-di-
chloropropene were not located.
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Genotoxic Effects in Vitro. Four of the isomers, 1,1-dichloropropene, 1,2-dichloropropene, 1,3-di-
chloropropene, and 2,3-dichloropropene, have been tested for genotoxicity in vitro (Table 3-9).
1,1-Dichloropropene.  Positive results following exposure to 1,1-dichloropropene were reported for
reverse mutation in Salmonella typhimurium strain TA100 with or without metabolic activation 
(Neudecker et al. 1986).  However, a more recent study reported negative results in TA100, but positive
results in strain RSJ100, which expresses glutathione transferase (Granville et al. 2005).  This isomer
apparently is bioactivated by glutathione (directly or by catalysis by glutathione transferase) to form a 
mutagenic epoxide (Granville et al. 2005).  Other negative results were reported for mutagenicity in 
S. typhimurium strains TA1535 and TA104 (Granville et al. 2005), mitotic segregation or induced 
aneuploidy in yeast (Crebelli et al. 1992; Rosenkranz and Klopman 1996), and DNA fragmentation in 
cultured human lymphoblastoid cells (Granville et al. 2005).
1,2-Dichloropropene.  A single study reported no increase in the frequency of reverse mutations in 
S. typhimurium strain TA100 exposed to 1,2-dichloropropene (Neudecker et al. 1986).
1,3-Dichloropropene.  A significant amount of evidence is available for the genotoxicity of 1,3-dichloro-
propene in vitro. Several groups have reported that 1,3-dichloropropene is mutagenic in vitro with and 
without metabolic activation in S. typhimurium (Creedy et al. 1984; De Lorenzo et al. 1977; Eder et al. 
1982a, 1982b; Haworth et al. 1983; Neudecker and Henschler 1986; Neudecker et al. 1977, 1980;
Stolzenberg and Hine 1980; Vithayathil et al. 1983).  In contrast, 1,3-dichloropropene purified on silic
acid columns was not mutagenic in S. typhimurium strain TA100 without activation (Talcott and King
1984).  Silic acid removes polar impurities, which when added back to the purified 1,3-dichloropropene,
restore the mutagenic activity (Talcott and King 1984).  For one of the batches (indicated by footnote b in 
Table 3-9), the mutagenic impurities were identified as oxidation products of 1,3-dichloropropene, 
namely epichlorohydrin and 1,3-dichloro-2-propanol.  An independent group confirmed the lack of
mutagenicity of purified 1,3-dichloropropene in strain TA100 without activation and also found that the
trace impurities alone, cis- and trans-2-chloro-3-(chloromethyl)oxiranes (dichloropropene oxides), formed 
slowly by autoxidation were mutagenic (Watson et al. 1987).  As Watson et al. (1987) determined that 
storage under nitrogen prevented the production of the mutagenic dichloropropene oxides, it seems likely
that relatively pure 1,3-dichloropropene will develop trace amounts of mutagenic autoxidation products if
stored in contact with oxygen in air.  Watson et al. (1987) also demonstrated that the presence of
physiological levels of glutathione were sufficient to block mutagenicity of bioactivated 1,3-dichloro-
   
 














    
      



















   
   
   
  





propene.  Positive evidence of DNA damage, as indicated by SOS induction, were observed in 
Escherichia coli PQ37 without activation (von der Hude et al. 1988).
In cultured eukaryotic systems, 1,3-dichloropropene was mutagenic in mouse lymphoma L5178Y cells
without exogenous activation (Myhr and Caspary 1991).  Exposure to 1,3-dichloropropene did not induce
aberrant mitotic segregation or aneuploidy in yeast cells (Crebelli et al. 1992; Rosenkranz and Klopman 
1996).  Increases in the frequency of sister chromatid exchange were observed in exposed Chinese
hamster V79 cells without activation (von der Hude et al. 1987), human lymphocytes with or without
activation (Kevekordes et al. 1996), and Chinese hamster ovary cells with or without activation (Loveday
et al. 1989).  1,3-Dichloropropene triggered unscheduled DNA synthesis in HeLa cells (Eder et al. 1987;
Schiffmann et al. 1983), and in human lymphocytes and rat hepatocytes without exogenous activation 
(Martelli 1997).
In an acellular test system, three metabolites of 1,3-dichloropropene, namely the cis and trans epoxides of
1,3-dichloropropene and 3-chloro-3-hydroxypropanal, formed adducts with 2’-deoxyguanosine, but not
with 2’-deoxyadenosine or 2’-deoxycytidine (Schneider et al. 1998b). 
2,3-Dichloropropene. There is positive evidence for genotoxicity of 2,3-dichloropropene in prokaryotic
and eukaryotic systems.
Increases in the frequency of reverse mutations, with or without activation, were observed for most
studies in S. typhimurium strains TA100, TA102, TA97, TA98, TA1535, TA1978, and TA2638 
(De Lorenzo et al. 1977; Eder et al. 1982a; Neudecker and Henschler 1986; Stolzenberg and Hine 1980;
Watanabe et al. 1998; Zeiger et al. 1988).  An increase in reverse mutations was observed in E. coli strain 
WP2 uvr/pkM101, with or without activation, but not in strain WP2/pkM101 (Watanabe et al. 1998).
In eukaryotic systems, 2,3-dichloropropene increased aberrent mitotic segregation and aneuploidy in 
yeast (Crebelli et al. 1992; Rosenkranz and Klopman 1996), the frequency of sister chromatid exchanges
in Chinese hamster ovary cells (Loveday et al. 1990) and Chinese hamster V79 cells (von der Hude et al. 
1987), and the frequency of chromosomal aberrations in Chinese Hamster ovary cells (Loveday et al.
1990).  An increase in unscheduled DNA synthesis was observed in HeLa cells exposed without
activation (Schiffmann et al. 1983), but there was no evidence of increased DNA repair in cultured rat
hepatocytes (Williams et al. 1989).
   
 
















   
 
 









   
    
   
 
   
 
 
    
 





1,3-Dichloropropene is quickly and extensively absorbed though both the respiratory tract and 
gastrointestinal tract; 1,3-dichloropropene vapor can be absorbed through the skin.  Absorbed 1,3-di-
chloropropene is distributed widely throughout the body, at greatest levels in the stomach and urinary
bladder after oral exposure.  1,3-Dichloropropene is primarily metabolized in the liver by conjugation to 
glutathione, resulting in the excretion of mercapturic acid metabolite in urine.  Two minor metabolic
pathways include hydrolysis with dechlorination resulting in intermediates that are substrates for alcohol
dehydrogenase, and reaction with cytochrome P-450, resulting in the formation of mutagenic epoxides.  
Elimination of 1,3-dichloropropene is very rapid, irrespective of the route of absorption.
2,3-Dichloropropene is rapidly and extensively absorbed through the gastrointestinal tract and respiratory
tract; no toxicokinetic data are available for absorption of this isomer through the skin.  Absorbed 2,3-di-
chloropropene is distributed widely throughout the body, especially the urinary bladder, nasal turbinates, 
and kidney after inhalation exposure, and liver, kidney, testes, and lung after oral exposure.  The primary
metabolic pathway of 2,3-dichloropropene is similar to that of 1,3-dichloropropene, with conjugation to 
glutathione resulting in the urinary elimination of a mercapturic acid metabolite.  Minor pathways include
a hydrolysis and dechlorination pathway resulting in the formation of glucuronide metabolite or an 
epoxidation pathway.  The majority of absorbed 2,3-dichloropropene is eliminated within the first 
24 hours of exposure.
No data are available for the absorption, distribution, or elimination of 1,1-dichloropropene by any route
of exposure.  Data from an in vitro metabolism study indicate that bioactivation of 1,1-dichloropropene
by reaction with glutathione results in the formation of a mutagenic episulfonium ion.
No data are available for the absorption, distribution, metabolism, or elimination of 1,2- or 3,3-dichloro-
propene.
3.4.1 Absorption 
The absorption of 1,3- and 2,3-dichloropropene is rapid by the inhalation and oral routes.
   
 












   
 
 




   
 




   
  
 
   
 
       
   
     
    
   
    
 
  





3.4.1.1  Inhalation Exposure 
1,3-Dichloropropene.  Published quantitative data are not available for the absorption of 1,3-dichloro-
propene in humans following inhalation exposure.  An unpublished study by Waechter et al. (1992)
described absorption pharmacokinetics in six male human volunteers exposed to 1 ppm Telone II® 
(50.6% cis isomer; 42% trans isomer) for 6 hours.  Specimens of expired air and venous blood collected 
5, 15, 30, 45, 60, 180, 240, and 360 minutes from the start of exposure and 5, 10, 15, 20, 30, 60, 120, and 
240 minutes after the end of exposure were assayed for the presence of cis and trans isomers.  Urine 
samples collected for two consecutive 12-hour periods just before exposure, a short period just before
exposure, the 6 hours of exposure, and the first 6 hours and seven consecutive 12-hour periods after
exposure were assayed for the presence of creatinine and mercapturic acid metabolites (cis- and trans-
N-acetyl-S-(3-chloroprop-2-enyl)cysteine).  Calculation of the percent absorption of 1,3-dichloropropene
for the six individuals ranged from 72 to 80% for the cis isomer and from 77 to 82% for the trans isomer.  
Indirect evidence for absorption comes from the detection of the N-acetyl-cysteine conjugate of 1,3-di-
chloropropene in the urine of four men 24 hours after field application of Telone II®a (Osterloh et al. 
1984).
Quantitative data from animal studies support this observation in humans.  Mixtures of cis and trans
isomers of 1,3-dichloropropene were rapidly absorbed by rats after inhalation exposure (Stott and Kastl
1986).  The rates of vapor uptake in rats exposed to 30, 90, 300, or 900 ppm were 144±14, 307±13, 
880±83, or 1810±76 nmol/minute, respectively.  However, because a decrease in the respiratory rate was 
observed in rats exposed to ≥90 ppm, the average calculated percentages of inhaled vapors that were
absorbed were similar:  82, 65, 66, and 62%, respectively for the low-to-high exposures.  Steady-state 
blood levels were reached within 1 hour at 30 and 90 ppm and within 2–3 hours at 300 ppm, but did not
reach steady state within 3 hours at 900 ppm.  The increased length of time required to reach steady state 
at 300 and 900 ppm was likely a function of the observed decrease in respiratory rate.  Nonlinear
excretion kinetics also contributed to the decreased uptake observed at 300 and 900 ppm; disproportionate
increases in the blood levels of cis-1,3-dichloropropene at 900 ppm and of trans-1,3-dichloropropene at
300 and 900 ppm could indicate changes in distribution and/or metabolism.
An apparent steady state in blood levels of the glutathione conjugate of 1,3-dichloropropene was detected 
in rats first assayed within 1 hour after exposure to 78, 155, or 404 ppm Telone II®a (Fisher and Kilgore
1989).  No exposure-response relationship was detected:  each of these exposure conditions produced 
similar concentrations of the glutathione conjugate in blood.
   
 









    
  
      
    
  
    
     
   
 
 





   
  
  
   
 
 
   
 
    
   
 
   
  
  




2,3-Dichloropropene. Quantitative data are not available on the absorption of 2,3-dichloropropene in
humans following inhalation exposure, but data are available for animals.  In Fischer 344 rats exposed 
(nose-only) to radiolabeled 2,3-dichloropropene vapor at 0.4 ppm for 6 hours, 5.9 ppm for 5.1 hours, or
40.3 ppm for 6 hours (17, 240, or 1,650 nmol/L), the percentages of inhaled compound that was absorbed 
were 40, 35, or 39%, respectively, or 38% on average (Dutcher et al. 1985).  A 25% decrease in the
respiratory rate during exposure at 40.3 ppm compared to 0.4 ppm resulted in a statistically significant
15% reduction in the minute volume (170 mL/minute compared to 200 mL/minute), but this had no effect
on the percentage of compound absorbed.  No data were located for steady-state blood levels of 2,3-di-
chloropropene following inhalation exposure.
3.4.1.2  Oral Exposure
1,3-Dichloropropene.  No studies were located regarding absorption of 1,3-dichloropropene in humans
after oral exposure.
1,3-Dichloropropene was well absorbed following gavage administration of 14C-labeled cis- and/or trans-
1,3-dichloropropene in rats (Climie et al. 1979; Hutson et al. 1971).  Recovery of [14C]cis-1,3-dichloro-
propene in 24-hour urine collections was 82–84% in rats (Climie et al. 1979).  Similarly, 82–84% of
14C-labeled cis-1,3-dichloropropene was recovered in urine, and 2–3% was recovered in feces during a 
96-hour urine collection period after gavage administration in rats (Hutson et al. 1971).  In contrast, only
55–60% of the 14C-labeled trans-1,3-dichloropropene was recovered in the urine and 2% was recovered in 
the feces during the same period.  These data indicate that both isomers of 1,3-dichloropropene are 
extensively absorbed by the oral route of exposure, which could lead to distribution throughout the body.
Since a microencapsulation method was developed for administering 1,3-dichloropropene as Telone II®b 
in diets, Stott et al. (1998) conducted experiments to verify that the compound would be bioavailable in 
that form.  The absorption of neat 13C-labeled-1,3-dichloropropene and 1,3-dichloropropene
microencapsulated in a starch/sucrose matrix was compared in rats dosed simultaneously with equal
amounts (25 mg/kg) of the two forms by oral gavage (Stott et al. 1998).  Absorption of either form was
rapid, peak blood concentrations being reached within 10 minutes of dosing.  The half-lives of absorption 
into the blood (not defined, but presumably the half-times to reach maximal levels in blood) were short: 
2.5 minutes for the neat cis isomer, 1.3 minutes for the encapsulated cis isomer, 2.7 minutes for the neat
trans isomer, and 2.3 minutes for the encapsulated trans isomer.  Blood area under the curve (AUC)
   
 








   
  
  















       
  
 
   
    
  
 
    
  
 
    
      




values were 1.239 mg · minute/L for the neat cis isomer, 1.601 mg · minute/L for the encapsulated cis 
isomer, 4.369 · minute/L for the neat trans isomer, and 5.552 mg · minute/L for the encapsulated trans 
isomer.  Encapsulated compound represented a larger proportion of the total AUC:  56 versus 44%.  In a
real-time monitoring experiment, the half-life of absorption of neat 1,3-dichloropropene was 5.5 minutes
and that of encapsulated compound was 3.2 minutes. Under these conditions, neat compound represented 
34% of the AUC and encapsulated represented 66%.  This study confirmed the bioavailability of 1,3-di-
chloropropene administered microencapsulated in feed.
2,3-Dichloropropene. No studies were located regarding absorption of 2,3-dichloropropene in humans
after oral exposure.
2,3-Dichloropropene was well absorbed following oral gavage administration in rats (Medinsky et al. 
1984).  In rats given 32 mg/kg of 14C-labeled 2,3-dichloropropene by oral gavage, approximately 91% of
the oral dose was absorbed, as estimated from recovery of radioactivity from urine.
3.4.1.3  Dermal Exposure 
1,3-Dichloropropene.  In an experiment in which volunteers exposed forearm skin to cis-1,3-dichloro-
propene vapor at a concentration of 86 mg/m3 (19 ppm) for 45 minutes, penetration of the compound was
detected by the presence of the metabolite cis-1,3-dichloropropene-mercapturic acid in urine over a 
20-hour period (Kezic et al. 1996).  The authors estimated that dermal absorption would account for 2– 
5% of absorption from inhalation in a whole-body exposure scenario.  No studies were located regarding
the absorption of 1,3-dichloropropene after dermal exposure in humans or animals.  The dermal LD50 for
1,3-dichloropropene in rabbits has been determined and indicates that this compound is absorbed by the
dermal route of exposure (Lichy and Olson 1975).
3.4.2 Distribution 
3.4.2.1  Inhalation Exposure 
1,3-Dichloropropene. In six volunteers who inhaled 1 ppm of 1,3-dichloropropene (50.6% cis;
45% trans; 2% epoxidized soybean oil) for 6 hours, blood concentrations ranged from 0.3 to 2 ppb for the
cis isomer and from 1 to 3.6 ppb for the trans isomer (Waechter et al. 1992).
   
 








    
  
      
  
   
   
    
   
 
 
    
      
    
 
 
     
 






   
 
 
    







2,3-Dichloropropene. In male Fischer rats immediately following a 6-hour inhalation exposure to 
radiolabeled 2,3-dichloropropene vapor at a concentration of 250 nmol/L, peak concentrations of label in 
blood (8 nmol/mL) occurred at the end of exposure (Bond et al. 1985).  Immediately after exposure, about
9% of the absorbed radioactivity was detected in tissues:  150 nmol/g in urinary bladder, 125 nmol/g in 
nasal turbinates, 84 nmol/g in kidneys, 61 nmol/g in small intestine, 35 nmol/g in liver, 15.6 nmol/g in 
trachea, 11.9 nmol/g in larynx, and smaller concentrations in other tissues.  Immediately after exposure, 
the carcass (muscle, bone, pelt, and fat) accounted for 15% of absorbed label.  Tissue concentrations of
label were reduced by 80% after 60 hours.  
Following inhalation exposure of male Fischer 344 rats to radiolabeled 2,3-dichloropropene at
concentrations between 0.4 and 40 ppm, the percentages of initial burden detected in tissues (per gram of 
tissue) 60 hours after exposure were highest for nasal turbinates (0.43%), kidney (0.35%), pelt (0.21%), 
and lung (0.09%) (Dutcher et al. 1985).  Radioactivity associated with hair accounted for 75% of that
found in the pelt.
3.4.2.2 Oral Exposure
1,3-Dichloropropene. No studies were located regarding distribution of 1,3-dichloropropene in humans
after oral exposure.
Analysis of the distribution of radioactivity 48 hours after gavage administration of 14C-cis/trans-1,3-di-
chloropropene to rats revealed essentially equal distribution of 1,3-dichloropropene or its metabolites to 
most organs and tissues (Waechter and Kastl 1988).  The highest concentrations of radioactivity were 
found in the nonglandular stomach and the urinary bladder.  Lower concentrations of radioactivity were
also found in blood, bone, brain, fat, heart, kidney, liver, lung, skeletal muscle, skin, spleen, ovaries, and 
testes.
2,3-Dichloropropene. Seventy-two hours after male Fischer 344 rats received an oral dose of 32 mg/kg
radiolabeled 2,3-dichloropropene, 20% of retained label was found in the liver, and lesser, but substantial
amounts (not quantified in the report) were found in the kidney, testes, lung, and brain (Medinsky et al. 
1984).  Tissues that had, on a per gram basis, label concentrations higher than the carcass (8 nmol/g), 
included the liver, kidney, testes, lung, brain, adrenals, spleen, and nasal turbinates.  
   
 
























    
 
 
   
  
      
    
  







3.4.2.3  Dermal Exposure 
No studies were located regarding the distribution of any isomer of dichloropropene after inhalation 
exposure in humans or animals.
3.4.3 Metabolism
1,3-Dichloropropene. The proposed metabolic pathways for 1,3-dichloropropene in rats are presented in 
Figure 3-5.  The major metabolic pathway is rapid conjugation with glutathione, resulting in the
formation of a mercapturic acid metabolite that is excreted in the urine.  1,3-Dichoropropene may also 
undergo hydrolysis and dechlorination to form 1-chloroallyl alcohol, an intermediate that reacts with 
alcohol dehydrogenase to form 1-chloroacrolein.  Another minor pathway involves reaction with 
cytochrome P450 to form mutagenic cis and trans epoxides that convert to the mutagen 3-chloro-
2-hydroxy-propanal (Schneider et al. 1998a). 
The N-acetyl-cysteine conjugate of cis-1,3-dichloropropene was detected in the urine of four men 
exposed occupationally to Telone II®a, indicating that glutathione conjugation is a metabolic pathway in 
humans (Osterloh et al. 1984).  Exposure levels were monitored by personal dosimeters.  A strong
correlation was found between exposure levels of 1,3-dichloropropene and urinary excretion of the
N-acetyl-cysteine conjugate (r=0.83).  These data are presented in Figure 3-6.
1,3-Dichloropropene was rapidly metabolized to the glutathione conjugate in rats after inhalation 
exposure (Fisher and Kilgore 1989).  The blood level of the glutathione conjugate reached a steady state 
of 116 nmol/mL within 15 minutes after exposure of rats to 610 ppm Telone II®a or 1 hour after exposure
to 78, 155, or 404 ppm.  These results may reflect saturation of metabolism (or depletion of co-factor).  
The increase in blood levels of the glutathione conjugate correlated with the decrease in nonprotein 
sulfhydryl (glutathione) content of nasal tissues (Fisher and Kilgore 1988a).  Glutathione levels in the
kidney and liver were also decreased after inhalation exposure of rats to 90 ppm Telone II®a (the only 
concentration tested), but lung levels were not affected (Stott and Kastl 1986).  The data indicate that
conjugation with glutathione can occur in the nasal tissue, kidney, and liver.  The glutathione conjugate of 
1,3-dichloropropene is then converted to the mercapturic acid and acetylated for excretion as the
N-acetyl-cysteine metabolite (Fisher and Kilgore 1988b).
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Figure 3-6.  Correlation of Exposure to 1,3-Dichloropropene with Urinary
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The two isomers of 1,3-dichloropropene appear to be metabolized at different rates.  Plateau blood levels
of the cis and trans isomers were 0.085±0.024 and 0.12±0.03 μg/mL, respectively, in rats exposed to 
30 ppm Telone II®a for 1 hour, and 0.20±0.04 and 0.26±0.03 μg/mL, respectively, in rats exposed to 
90 ppm Telone II®a for 1 hour.  Plateau blood levels reached after 2–3 hours in rats exposed to 300 ppm
were 0.89±0.2 and 1.87±0.27 μg/mL for the cis and trans isomers, respectively (Stott and Kastl 1986).  
In vitro studies using a rat liver enzyme preparation revealed that the cis isomer was metabolized four to 
five times faster than the trans isomer (Climie et al. 1979).
Orally administered 1,3-dichloropropene is also metabolized by conjugation with glutathione (Climie
et al. 1979).  Urine collected for 24 hours after oral administration of 14C-labeled cis-1,3-dichloropropene
in rats yielded 82–84% of the radioactivity as the N-acetyl-cysteine conjugate of 1,3-dichloropropene.  
Two other urinary metabolites that accounted for 3 and 5% of the administered radioactivity were found 
but not identified (Climie et al. 1979).  Tissue nonprotein sulfhydryl content was assayed in mice
following a single gavage administration of 50 mg/kg cis- and trans-1,3-dichloropropene (Dietz et al. 
1982).  Decreased tissue nonprotein sulfhydryl levels were observed in the forestomach, glandular
stomach, liver, and kidney, which indicated that glutathione conjugation occurred at these sites.
No differences were observed in the distribution or the rate and extent of metabolism or excretion of
1,3-dichloropropene after gavage administration between rats that received a single dose and rats that
received repeated doses.  Furthermore, no differences in distribution, metabolism, or excretion of 1,3-di-
chloropropene were observed between male and female rats (Waechter and Kastl 1988).  
The mercapturic acid metabolite of cis-1,3-dichloropropene was detected in the urine of volunteers who 
exposed their forearm skin to a vapor concentration of 86 mg/m3 (19 ppm) for 45 minutes (Kezic et al.
1996).
Alternative metabolic pathways for cis and trans 1,3-dichloropropenes (individually and as an equimolar
mixture) were studied in the liver of mice exposed by intraperitoneal injection (Schneider et al. 1998a).  
Within 150 minutes of injection, reaction with cytochrome P-450 resulted in the formation of cis- and 
trans-1,3-dichloropropene epoxides, with the cis-epoxide preferentially formed at a ratio of 4:1; the higher
level of the cis epoxide was detectable within 10 minutes of exposure.  The epoxides were stereospecific 
to the parent compound.  The 1,3-dichloropropene epoxides undergo hydrolysis, possibly catalyzed by
epoxide hydrolase, to 3-chloro-2-hydroxypropanal.  In vitro experiments confirmed the generation of
isomer-specific epoxides when cis and trans 1,3-dichloropropene were incubated in the presence of mouse
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liver microsomes plus NADPH (Schneider et al. 1998a).  No recovery of acroleins (2-acrolein or cis- and 
trans-3-acrolein) were detectable in these in vitro experiments, suggesting that oxidation by cytochrome
P-450 is a minor pathway.   
In an oral gavage study in F344 rats and B6C3F1 mice, Bartels et al. (2000) evaluated the epoxidation 
pathway proposed for 1,3-dichloropropene by Schneider et al. (1998a) on the basis of intraperitoneal 
injection.  Following gavage administration of 100 mg/kg by oral gavage, no dichloropropene oxides
were detectable in liver or blood of rats or mice during the 90 minutes postdosing (detection limit was
10 ng/g tissue).  In mice injected with 100 mg/kg, no dichloropropene oxides were detectable in liver and 
only a small amount (17 ng/g) was detected in blood.  Significant detection of dichloropropene oxides
occurred after injection of 700 mg/kg into mice, a dose that caused significant hepatotoxicity and/or
death.  Bartels et al. (2000) concluded that the epoxidation pathway was of minor significance for
exposures not leading to hepatotoxicity or death.
The metabolism of 1,3-dichloropropene was evaluated in an in vitro system in which the compound was
added as a vapor in the headspace above a mixture containing rat liver microsomes or cytosol from rat or
mouse (Granville et al. 2005).  Glutathione reacted nonenzymatically with 1,3-dichloropropene at a rate 
about half that catalyzed by glutathione transferase.  Monochloropropenes were the products of these
reactions.  The rate of glutathione transferase-dependent conjugation to glutathione was 10.3 nmol
glutathione/minute/mg protein.
In an analysis of metabolism of cis and trans isomers of 1,3-dichloropropene, Vos et al. (1991) identified 
individuals that did not express the mu class of glutathione S-transferase enzymes, but did express alpha-
and pi-class GST.  Although the mu class enzyme was demonstrated to have 2- to 3-fold higher activity
with the cis than the trans isomer of 1,3-dichloropropene, and higher activity with cis-1,3-dichloropropene
compared to alpha- and pi-class GST, individuals not expressing the mu enzyme showed no significant
differences with respect to urinary excretion ratios of cis- and trans-mercapturic acid metabolites.  These 
results suggest that glutathione S-transferases, besides mu-class enzymes, may play a more significant
role in the metabolism of 1,3-dichloropropene.
2,3-Dichloropropene. Proposed metabolic pathways for 2,3-dichloropropene are shown in Figure 3-7.  
The major pathway is a detoxifying conjugation to glutathione, leading to the elimination of mercapturic
acid metabolites in the urine (Bond et al. 1985; Eder and Dornbusch 1988; Eder et al. 1987).  Two 
secondary pathways result in the formation of mutagenic metabolites.  One involves cytochrome P450-
   
 
























Figure 3-7.  Proposed Metabolic Pathway for 2,3-Dichloropropene in the Rat
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induced formation of an epoxide that undergoes spontaneous rearrangement to form the mutagen 
1,3-dichloroacetone.  The other involves hydrolysis and dechlorination to form an intermediate
(2-chloroallyl alcohol) that can either be detoxified by conjugation to glucuronic acid or bioactivated by
alcohol dehydrogenase to form the mutagen 2-chloroacrolein (Eder and Dornbusch 1988; Eder et al. 
1986, 1987).  It is evident that depletion of glutathione stores, more likely to occur under bolus exposure
conditions, would result in the formation of proportionally more mutagenic metabolites.
1,1-Dichloropropene. The metabolism of 1,1-dichloropropene was evaluated in an in vitro system in 
which the compound was added as a vapor in the headspace above a mixture containing rat liver
microsomes or cytosol from rat or mouse (Granville et al. 2005).  Results of this study indicated that 
glutathione transferase catalyzes the bioactivation of 1,1-dichloropropene by glutathione to a single
unsaturated S-conjugate retaining one chlorine atom.  The rate of conjugation was 0.33 nmol
glutathione/minute/mg protein, which was lower than the rate for 1,3-dichloropropene (see above).  It was 
postulated that the thiolate ion of glutathione could attack 1,1-dichloropropene at either the C1 or C2 
position, with attack at the C2 position resulting in the formation of a mutagenic episulfonium ion.  This
hypothesis was supported by separate experiments showing mutagenicity of 1,1-dichloropropene in S. 
typhimurium strain RSJ100, which expresses rat glutathione transferase (GSTT1-1), but not in the
nonexpressing strain TA100.
3.4.4 Elimination and Excretion 
3.4.4.1  Inhalation Exposure 
1,3-Dichloropropene. In male volunteers exposed by inhalation to 1 ppm 1,3-dichloropropene (50.6%
cis; 45% trans; 2% epoxidized soybean oil) for 6 hours, concentrations of cis and trans isomers (parent
compound) in exhaled air reached a plateau within the first hour of exposure and fell rapidly to 
undetectable levels within 1 hour after the end of exposure (Waechter et al. 1992).  In the same study, 
urinary excretion of N-acetyl-cysteine conjugates of cis- and trans-1,3-dichloropropene in exhibited a
biphasic pattern.  The half-lives for urinary elimination of the cis and trans conjugates averaged 
4.2±0.8 and 3.2±0.8 hours, respectively, for the initial phase, and 12.3±2.4 and 17.1±6.0 hours, 
respectively, for the terminal phase.  Urinary excretion was 89–99% complete by 24 hours from the start
of exposure.  Approximately 75% of the absorbed dose of cis-1,3-dichloropropene was excreted in urine 
as 1,3-dichloropropene-N-acetyl-cysteine, whereas only 25% of absorbed trans-1,3-dichloropropene was
excreted in urine as the N-acetyl-cysteine conjugate.
   
 









   
  
 
   
      
 
     





    
  
     
    
 
    
    
    
 
  
   
     




   
  
  




A strong correlation was reported for humans between occupational exposure to Telone II®a and urinary
levels of the N-acetyl-cysteine conjugate of cis-1,3-dichloropropene (r=0.83) (Osterloh et al. 1984).  In 
12 soil fumigators exposed to 8-hour time weighted average (TWA) concentrations from 1.9 to 
18.9 mg/m3 cis/trans-dichloropropene, the half-life of elimination of N-acetyl-cysteine conjugates was 
11.4 hours for the cis isomer and 10.8 hours for the trans isomer (Verberk et al. 1990).
Rats exposed by inhalation for 1 hour to 0, 40, 107, 284, 398, or 789 ppm Telone II®a excreted 0, 0.11, 
0.49, 2.7, 3.7, or 4.0 μmol N-acetyl-cysteine conjugate/mL of urine in the 24 hours following exposure
(Fisher and Kilgore 1988b).  Uptake levels, however, were not measured, which precludes correlation 
with excretion.  
In male Fischer rats exposed by inhalation to 30, 90, 300, or 900 ppm technical-grade 1,3-dichloro-
propene for 3 hours, rapid absorption was followed by a biphasic pattern of elimination from the
bloodstream (Stott and Kastl 1986).  At concentrations up to 300 ppm, a rapid elimination phase (half-
time of 3–6 minutes) was followed by a slower phase with a half-life of 33–43 minutes.  Following
exposure to 900 ppm, the rapid elimination phase was 14–27 minutes.
2,3-Dichloropropene. In male Fischer 344 rats exposed (nose only) for 6 hours to radiolabeled 2,3-di-
chloropropene vapor at a concentration of 250 nmol/L, 54.6% of the amount absorbed was excreted as
metabolites in urine, 16.8% was eliminated in feces, 3.2% was expired as carbon dioxide, and 1.2% was
expired as the parent compound (Bond et al. 1985).  The remainder was detected in the carcass.  
Approximately 75% of the urinary and fecal elimination occurred within the first 24 hours after exposure.  
The half-times for elimination were 9.8 hours for urine and 12.9 hours for feces.  Elimination as carbon 
dioxide had a biphasic pattern:  87% exhaled within 3.4 hours and 13% exhaled within 19.7 hours.  
Levels of label in blood had a biphasic pattern of elimination, with estimated half-lives of 2.4 and 
113.6 hours, for the two phases, respectively.  
The rates and relative amounts of elimination of absorbed radiolabeled 2,3-dichloropropene in urine or
feces was not affected by inhaled concentrations between 0.4 and 44 ppm (Dutcher et al. 1985).  Half-
lives of excretion were between 9.1 and 11.3 hours for urinary excretion 10.4–16.5 hours for excretion in 
feces.  The half-time associated with the rapid phase of elimination as carbon dioxide (representing 81– 
94% of that exhaled) was 2.2–4.3 hours, whereas the half-time associated with the slow phase of
elimination (6–19% of that exhaled) was 15.3–30.8 hours.
   
 









   
 
   
 
 
   
   
   
    
  
    
     
 
        













    






3.4.4.2  Oral Exposure
1,3-Dichloropropene. No studies were located regarding excretion of 1,3-dichloropropene after oral
exposure in humans.
Significant recoveries of 14C-labeled 1,3-dichloropropene were reported in two studies with rats after oral
exposure (Climie et al. 1979; Hutson et al. 1971).  In both studies, 82–84% of the administered cis isomer
was recovered as the mercapturic acid conjugate of 1,3-dichloropropene in a 24-hour collection of urine.  
Two other minor metabolites that accounted for 3 and 5% of the radioactivity were observed, but these 
metabolites were not identified (Climie et al. 1979).  Comparison of the excretory pathways for the cis
and trans isomers of 1,3-dichloropropene revealed that 82–84% of the cis isomer was recovered as the
mercapturic acid conjugate in the 24-hour urine collection; only 55–60% of the trans isomer was
recovered as the mercapturic acid conjugate in the urine (Hutson et al. 1971).  A significant portion of the
trans isomer was recovered as 14CO2 (22–25%).  A smaller percentage of each isomer was recovered in 
the feces:  2–3% of the cis and 2% of the trans isomer.  Less than 2% of either compound remained in the
carcass after 4 days (Hutson et al. 1971).  These data indicate that neither isomer of 1,3-dichloropropene
has a tendency to concentrate in the body.
Whether administered neat or encapsulated in sucrose/starch microspheres, 1,3-dichloropropene reached 
peak blood levels in rats within 10 minutes (Stott et al. 1998).  Clearance from the blood occurred in a
biphasic manner, with a relatively rapid alpha phase with a half-life of 5–7 minutes and a slower beta 
phase with a half-life of 20–43 minutes.  Urinary excretion of mercapturic-acid conjugates of 1,3-di-
chloropropene (DMA) was evaluated in rats simultaneously dosed with equal doses of neat 13C-labeled-
1,3-dichloropropene and 1,3-dichloropropene microencapsulated in a starch/sucrose matrix (Stott et al. 
1998).  Of the total amount of DMA excreted in urine, 56% was derived from neat 1,3-dichloropropene
(58% cis-DMA and 52% trans-DMA) and 44% was derived from encapsulated compound (42% cis-DMA 
and 49% trans-DMA). 
2,3-Dichloropropene. Seventy-two hours after male Fischer 344 rats were given an oral dose of
32 mg/kg radiolabeled 2,3-dichloropropene, 66% of the dose was recovered as urinary metabolites, 21%
was eliminated in feces, 8% was exhaled as carbon dioxide, 2% was exhaled as parent compound, and 2%
remained in carcass and tissues (Medinsky et al. 1984).  The half-time for urinary excretion was
7.5 hours.
   
 











      
 
   
 
   
 
    
 
  
   
 
 






    
   
 
     
  
   
 
 
       
  




3.4.4.3  Dermal Exposure 
1,3-Dichloropropene. In volunteers whose forearms were exposed to 86 mg/m3 (19 ppm) vapor of
1,3-dichloropropene for 45 minutes, the half-life for urinary excretion of the mercapturic acid metabolite 
was approximately 6 hours (Kezic et al. 1996).
No studies were located regarding excretion of 1,3-dichloropropene after dermal exposure in animals.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.  
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
   
 









    















   









    
   
140DICHLOROPROPENES
3. HEALTH EFFECTS
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-8 shows a conceptualized representation of a PBPK model.
If PBPK models for dichloropropenes exist, the overall results and individual models are discussed in this
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species
extrapolations.
In an unpublished study, Waechter et al. (1992) developed a PBPK model based on data collected for six 
male volunteers exposed by inhalation to 1 ppm 1,3-dichloropropene (50.6% cis; 45% trans;
2% epoxidized soybean oil) for 6 hours (Figure 3-9).  The model included a poorly perfused compartment
(fat), a well-perfused compartment, and terms for the excretion of dichloropropene in blood and exhaled 
air.  Data were collected for concentrations of 1,3-dichloropropene isomers in exhaled air and in blood, as
well as for the concentrations of N-acetyl-cysteine conjugates of each isomer present in urine (results 
discussed above in Sections 3.4.1.1, 3.4.2.1, and 3.4.4.1).  The model was designed to predict average 
urinary excretion rates for the two isomeric conjugates in urine following 6-hour exposures to 0.1, 0.01, 
or 0.001 ppm cis-/trans-1,3-dichloropropene.  Based on the limit of detection (10 ng/mL) and an average
   
 





















Figure 3-8.  Conceptual Representation of a Physiologically Based
 















































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  adapted from Krishnan and Andersen 1994
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Figure 3-9.  Kinetic Model for Uptake and Elimination of 1,3-Dichloropropene
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CV Venous blood concentration
CA Arterial blood concentration
QWP Blood flow to well perfused compartment
QPP Blood flow to fat
CVPP Concentration in venous blood leaving poorly perfused compartment
CVWP Concentration in venous blood leaving well perfused compartment
KME First-order rate constant for metabolism
CWP Concentration in well perfused compartment
VWP Volume of well perfused compartment
AMWP Amount of metabolite in well perfused compartment
KELIM First-order rate constant for elimination of metabolite
Source:  Adapted from Waechter et al. 1992
   
 









   
   
 
 
    
     
 
       




      
   
  
    
     
     
 
       
  
 
    
   
    
     
  
   
  




urine output of 58.3 mL/hour, the model predicted that urinary excretion after exposure to 0.1 ppm could 
be followed for 35 hours (from the start of exposure) for the cis isomer and 24 hours for the trans isomer
and after exposure to 0.01 ppm, 20 and 10 hours, respectively. Exposure to 0.001 ppm was predicted to 
result in values below the limit of detection.  These results are considered tentative, since the model has 
not yet been validated.
3.5  MECHANISMS OF ACTION  
3.5.1 Pharmacokinetic Mechanisms
Absorption. Studies in humans and/or animals indicate that the absorption of 1,3- and 2,3-dichloro-
propene is rapid (Bond et al. 1985; Dutcher et al. 1985; Stott and Kastl 1986; Stott et al. 1998; Waechter
et al. 1992).  Given the relatively small size of the molecules and their lipid-soluble properties, absorption 
by any route is most likely by simple passive diffusion across cellular lipid membranes.  
Distribution. The small molecular size and lipid solubility properties of dichloropropenes undoubtedly
contribute to the rapid distribution following absorption by any route.  The highest concentrations of
inhaled 1,3- or 2,3-dichloropropene are found in portal-of-entry tissues (nasal turbinates, larynx, trachea, 
lung) as well as the blood and tissues involved in metabolism and elimination (liver, kidney, urinary
bladder) (Bond et al. 1985; Dutcher et al. 1985).  Similarly, oral exposure results in high concentrations in 
the stomach and urinary bladder compared to other tissues (Stott et al. 1998; Waechter and Kastl 1988).
Metabolism. It is likely that steric differences in the position of chlorine atoms with respect to the
double bond account for the different metabolic pathways among the different isomers of dichloro-
propene.  Three different metabolic pathways have been identified for 1,3-dichloropropene in the liver
(Figure 3-5).  The primary pathway is the glutathione transferase-dependent conjugation of the
chloromethyl moiety with glutathione to form mercapturic acid metabolites (Osterloh and Feldman 1993;
Osterloh et al. 1984; Stott et al. 1998).  The cis isomer of 1,3-dichloropropene has a faster rate of
conjugation than the trans isomer (Stott et al. 1998). A secondary pathway is cytochrome P450-
dependent epoxidation, which apparently becomes significant at high exposure levels (Schneider et al. 
1998a).  The rate of glutathione depletion appears to affect the degree to which the secondary pathway is
used in specific tissues.  An in vitro study indicated that glutathione transferase-dependent conjugation to 
glutathione results in the bioactivation of 1,1-dichloropropene to an episulfonium ion (Granville et al. 
2005).  Specific metabolites of inhaled 2,3-dichloropropene were not identified by Dutcher et al. (1985), 
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but these authors suggested, based on a pattern of elimination similar to that observed for 1,3-dichloro-
propene, that conjugation to glutathione was the primary metabolic pathway.    
Excretion. Human and/or animal data indicate that 1,3-dichloropropene and 2,3-dichloropropene are
rapidly eliminated from the body, primarily as urinary metabolites, with lesser amounts eliminated in 
feces and exhaled air (Dutcher et al. 1985; Medinsky et al. 1984; Waechter et al. 1992).  Both carbon 
dioxide and parent compound have been detected in exhaled air (Bond et al. 1985).  Half-lives of 
excretion have been estimated as <14 hours (Dutcher et al. 1985; Medinsky et al. 1984).  The
physicochemical properties of dichloropropenes and their metabolites likely faciliate their rapid removal
from the body. 
3.5.2 Mechanisms of Toxicity
The primary toxic effects of dichloropropenes are portal-of-entry effects resulting from the chemical
reactivity of the compounds and their physicochemical properties.  Repeated irritation results in a
hyperplastic response in the target tissues (respiratory tract for inhalation exposure, forestomach of rats 
exposed orally).  Studies that analyzed tissue retention of absorbed dichloropropenes confirmed the
relatively high concentrations in target tissues such as the nasal turbinates, but high concentrations
detected in urinary bladder, kidney, and liver may reflect the presence of parent compound or reactive
metabolites in those tissues (Bond et al. 1985; Dutcher et al. 1985; Medinsky et al. 1984)
Metabolic processes may contribute to toxicity.  The mutagenicity of cis or trans 1,3-dichloropropenes
was attributed to their biotransformation by cytochrome P-450 to stereospecific epoxides and the
hydrolysis product, 3-chloro-2-hydroxypropanal (Schneider et al. 1998a).  It is likely that depletion of
glutathione would block the major detoxification pathway for 1,3- and 2,3-dichloropropene, resulting in 
increased toxicity of organs such as the liver and kidney because of binding of reactive intermediates to 
macromolecules in cells.  On the other hand, mutagenicity of 1,1-dichloropropene has been related to its
glutathione transferase-dependent bioactivation by the thiolate ion of glutathione and the resulting
episulfonium ion (Granville et al. 2005).
There is some evidence that cytotoxicity of hepatic cells exposed to 1,3-dichloropropene in vitro is
preceded by increased levels of phospholipid hydroperoxides (phosphatidylcholine hydroperoxide and 
phosphatidylethanolamine hydroperoxide) (Suzuki et al. 1994a). This appears to confirm the role of
   
 








    
 
 
    
 
  





    
 
   
 
  
    
  
 






   
 
  






reactive intermediates inducing lipid peroxidation as a significant mechanism of toxicity for 1,3-dichloro-
propene.
3.5.3 Animal-to-Human Extrapolations 
The critical toxic effects of dichloropropenes are portal-of-entry effects relating to their irritant properties.  
In the absence of data to indicate otherwise, the portal-of-entry effects observed in animals are assumed to 
be relevant to humans.  EPA (1994) has developed dosimetry methods that are used to scale from
inhalation exposures in animals to human equivalent concentrations.  The major metabolic pathway for
elimination of 1,3- and 2,3-dichloropropenes (conjunction to glutathione) is common to both humans and 
animals.
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
   
 








   
 













   
  
   
   
 
   
 
  
    
  
   
  
 
     







scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans after exposure to 1,3-dichloropropene
or 2,3-dichloropropene.  None of the intermediate-duration inhalation rodent assays on these compounds
reported adverse effects on male or female reproductive parameters such as estrus cycling, sperm counts 
or morphology, or the outcome of a one-generation reproductive assays (Johannsen et al. 1991; NTP
1985; see Section 3.2.1.5). 
Nishihara et al. (2000) used a yeast two-hybrid screening assay, employing expression plasmids for the
estrogen receptor and a cofactor, to assay chemicals for endocrine disruption activity.  The level of
reporter gene activity was expressed as the 10% relative effective concentration compared to the optimal
concentration (10-7 M) of the agonist 17-beta-estradiol.  1,3-Dichloropropene at concentrations as high as
1x10-3 M yielded negative in this assay, suggesting that it does not disrupt estradiol signalling.  
3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
   
 








   
  
  
   
 
 
   
   
  
  
   
    
 
   
   
      
   
  
  
   
  













susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
No data are available for health effects on children from exposure to any dichloropropene isomer by any
route.
   
 










    
  
   
 
   
 
  
    
    
    
 
 
   
 
    
 
   
   
 
   
 





     
 





No adverse effects on fetuses have been noted in developmental or two-generation reproductive studies in 
animals exposed by inhalation to 1,3-dichloropropene at levels not toxic to the mother (Breslin et al. 
1989; Kloes et al. 1983).  It has been observed that decreased food and water consumption and reduced 
maternal body weight, likely resulting from irritant effects of the vapor, are the primary reason for 
observed delayed ossification effects in rat pups (Hanley et al. 1987).
Since the major effects of exposure to dichloropropenes involve portal-of-entry effects from irritant
properties of these chemicals, similar effects would be expected to occur in children.  Because the skin of 
children is thinner and surface areas to body weight ratios are larger for children (de Zwart et al. 2004), 
they would likely absorb a higher dose (per kg body weight) than adults from a similar dermal exposure.
Also, since alveolar ventilation rates are faster in children than adults (de Zwart et al. 2004), the uptake of
dichloropropene vapor would be higher in children than adults exposed by inhalation to the same
concentration of the compound.  
The small size and physicochemical properties of dichloropropenes and their distribution by passive
diffusion suggest that maternally absorbed dichloropropene is likely to be distributed across the placenta 
to the fetus.  This likely would occur only in the short term after exposure.  Dichloropropene was detected 
in only one of eight samples of human breast milk taken from nursing mothers at four locations (two in 
New Jersey, one in Louisiana, and one in Pennsylvania), limited evidence that dichloropropene could be
transferred from mother to nursing infant (Pellizzari et al. 1982).
3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures
   
 










    
  
   










   
  
  
   
 
     
 
  








from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as
copper, zinc, and selenium).  Biomarkers of exposure to dichloropropenes are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity. Note that these markers are not often substance specific.  They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by dichloropropenes are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Dichloropropene 
1,3-Dichloropropene. Inhalation exposure to various concentrations of 1,3-dichloropropene correlated 
well with the urinary level of the N-acetyl cysteine (mercapturic acid) metabolite in humans.  Urinary
excretion of the N-acetyl cysteine metabolite was measured in four men occupationally exposed to 
technical-grade 1,3-dichloropropene (Telone II®a).  Exposure levels were monitored by personal
dosimeters.  A strong correlation was found between exposure levels of 1,3-dichloropropene and urinary
excretion of the N-acetyl-cysteine metabolite (r=0.83, see Figure 3-6 in Section 3.4.3) (Osterloh et al. 
1984).  Human dermal exposure to cis-1,3-dichloropropene vapor was successfully monitored by the
urinary level of the mercapturic acid metabolite (Kezic et al. 1996).  The rapid excretion of the metabolite 
   
 

















     





   
  
 
    
 














(75% complete within the first 24 hours) limits the usefulness of this biomarker to the first 2 days after
exposure.
Blood levels of the glutathione-conjugate of 1,3-dichloropropene might also be used as a biomarker.  
Steady-state levels of the glutathione-conjugate were reached within 1 hour in rats exposed to 78, 155, or
404 ppm (Fisher and Kilgore 1989).  In this study, however, the correlation between exposure and blood 
levels was not calculated.
1,3-Dichloropropene is rapidly cleared from the body.  The elimination half-time, determined after a
1-hour inhalation exposure in rats, was 17 hours (Fisher and Kilgore 1989).  Furthermore, <2% of the
1,3-dichloropropene administered by gavage to rats remained in the carcass after 4 days (Hutson et al. 
1971).  These data indicate that 1,3-dichloropropene does not concentrate in the body.  Therefore, 
biomarkers based on tissue or blood levels of 1,3-dichloropropene are of limited value in assessing long-
term exposure.
2,3-Dichloropropene. As with 1,3-dichloropropene, most of the absorbed compound following
inhalation or oral exposure is rapidly metabolized to a mercapturic acid derivative that is detectable in the
urine (Bond et al. 1985; Dutcher et al. 1985; Eder and Dornbusch 1988; Medinsky et al. 1984).  Rapid 
clearance from the body, however, restricts the use of this biomarker to short-term exposures.
3.8.2 Biomarkers Used to Characterize Effects Caused by Dichloropropene
Few specific quantifiable biomarkers that characterize effects caused by 1,3- or 2,3-dichloropropene were
identified.  Consistent findings in animal studies involve portal-of-entry effects include hyperplasia and/or
degeneration of portions of the nasal epithelium after inhalation exposure, hyperplasia and/or neoplastic
changes in the forestomach after oral exposure, and erythema/edema after dermal exposure.  These are 
nonspecific effects and are, therefore, of little value as biomarkers.
Some occupational monitoring studies on 1,3-dichloropropene have assayed for hepatic and renal damage 
using serum or urinary concentrations of tissue-specific proteins (Osterloh and Feldman 1993; Osterloh et
al. 1989a, 1989b; Verplanke et al. 2000).  N-acetylglucosamidase and retinol binding protein as markers 
for renal tubular damage were detectable several days following exposure.
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3.9  INTERACTIONS WITH OTHER CHEMICALS
No studies were located regarding the interaction of 1,3-dichloropropene with other chemicals to produce
health effects.  1,3-Dichloropropene is widely used as a preplanting soil fumigant for the control of
parasitic nematodes.  The commercial product used in agriculture contains a mixture of the cis and trans 
isomers in approximately equal proportions, as well as stabilizers including 1,2-dichloropropene and 
epichlorohydrin or epoxidized soybean oil.  Occupational exposure would most likely occur to this
mixture.  Whether interactions occur between 1,3-dichloropropene and other components is not known.  
Comparisons of animal toxicity assays on different formulations of Telone® II indicate that the irritant
properties of 1,3-dichloropropene cause portal-of-entry effects in the nasal epithelium and stomach, but
suggest that increased tumor incidences in those tissues may be partly attributed to the presence of 
epichlorohydrin in the formulation (Lomax et al. 1989; NTP 1985; Stebbins et al. 2000).  In addition, 
there is also evidence that pure 1,3-dichloropropene can slowly undergo autoxidation to produce amounts
of highly mutagenic oxides when stored in the presence of air (see Section 3.4) (Talcott and King 1984;
Watson et al. 1987).  Thus, it appears that trace amounts of mutagens, with detectable mutagenic activity, 
will gradually appear in pure 1,3-dichloropropene unless the liquid is stored under a nitrogen atmosphere.  
Simultaneous exposure to other chemicals, such as acetaminophen, that are detoxified via conjugation to 
glutathione would tend to increase the toxicity of 1,3- and 2,3-dichloropropenes because glutathione
depletion would result in metabolism via epoxide-generating pathways (Schneider et al. 1998a).
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to 1,3-dichloropropene than will
most persons exposed to the same level of 1,3-dichloropropene in the environment.  Reasons may include
genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette 
smoke).  These parameters result in reduced detoxification or excretion of 1,3-dichloropropene, or
compromised function of organs affected by 1,3-dichloropropene.  Populations who are at greater risk due
to their unusually high exposure to 1,3-dichloropropene are discussed in Section 6.7, Populations with 
Potentially High Exposures.
No data were located regarding populations that are unusually susceptible to the toxicity of 1,3- or 2,3-di-
chloropropenes; however, glutathione availability is critical for detoxification of these isomers.  Depletion 
of glutathione pools may enhance the toxicity of 1,3- or 2,3-dichloropropene (see Section 3.11).  
   
 








   







   
   
 




   
  
     
 









    
 
  
   




Glutathione pools could be depleted by repeated exposures to 1,3-dichloropropene or other xenobiotics
that are metabolized in whole or in part by glutathione-dependent pathways.  Urinary excretion of the
mercapturic acids of 1,3- and 2,3-dichloropropenes is the primary excretory pathway for these isomers;
therefore, kidney disease or deficiencies in the mercapturic acid transport system may also enhance the
toxicity of 1,3- and 2,3-dichloropropene.  As 1,1-dichloropropene appears to become bioactivated by
glutathione (see Granville et al. 2005; also Section 3.3, Genotoxicity), glutathione depletion would not be
expected to increase susceptibility to adverse effects from exposure to this isomer.
Individuals taking drugs such as acetominophen that are also detoxified by glutathione, may be more
susceptible to the effects of glutathione depletion when exposed to 1,3- or 2,3-dichloropropene.
3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to 1,3-dichloropropene.  However, because some of the treatments discussed may be
experimental and unproven, this section should not be used as a guide for treatment of exposures to 
1,3-dichloropropene.  When specific exposures have occurred, poison control centers and medical
toxicologists should be consulted for medical advice.  The following texts provide specific information 
about treatment following exposures to 1,3-dichloropropene:
Bronstein AC, Currance PL.  1988. Emergency care for hazardous materials exposure.  Washington, DC:
The C.V. Mosby Company, 53, 155-156.
Ellenhorn MJ, Schonwald S, Ordog G, et al.  1997.  1,3-Dichloropropene.  Ellenhorn’s medical
toxicology:  Diagnosis and treatment of human poisoning.  2nd ed.  Baltimore, MD:  Williams and 
Wilkins, 1656, 1657, 1659.
Stutz DR, Janusz SJ.  1988.  Hazardous materials injuries:  A handbook for pre-hospital care.  2nd ed.  
Beltsville, MD:  Bradford Communications Corporation, v, 300-301.
3.11.1 Reducing Peak Absorption Following Exposure 
Recommendations have been made for managing and treating persons exposed to 1,3-dichloropropene
(Bronstein and Currance 1988; Ellenhorn et al. 1997; Stutz and Janusz 1988).  Common practices for
reducing peak absorption following exposure include removing the exposed person from the
contaminated area and removing contaminated clothing.  Exposed skin is decontaminated by immediately
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washing with copious amounts of soapy water to insure appropriate dilution of the chemical and rinsing
with copious amounts of water.  Contaminated eyes are thoroughly flushed with water.  If the victim is in 
respiratory distress, ventilation assistance is provided, and oxygens administered.  If oral exposure
occurred recently, the victim is given water or milk to dilute the chemical and activated charcoal to adsorb 
the chemical.  Emetics are not administered (Bronstein and Currance 1988).  Please refer to Bronstein and 
Currance (1988) and Stutz and Janusz (1988) for more complete information on treatment of specific
symptoms.
3.11.2 Reducing Body Burden
No specific information was located on reducing the body burden of dichloropropenes in exposed 
individuals.  Based on animal studies on 1,3- and 2,3-dichloropropene, the major portion of absorbed di-
chloropropenes are eliminated as urinary metabolites within 2 days and elimination in feces and exhaled
air is also rapid (Bond et al. 1985; Climie et al. 1979; Dutcher et al. 1985; Hutson et al. 1971; Medinsky 
et al. 1984).  Dichloropropenes do not appear to accumulate in the body.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
No specific information was located regarding the mitigation of effects of 1,3-dichloropropene once it has 
entered the bloodstream.  Animal studies indicated that the critical effects of inhalation exposure to 1,3-
and 2,3-dichloropropene are irritation and degenerative effects on the nasal and respiratory epithelium; 
1,3-dichloropropene also causes hyperplasia of the urinary bladder.  The major effects of oral exposure to 
1,3-dichloropropene are stomach irritation, hyperplasia, and hyperkeratosis, and mild liver and kidney
effects.  Studies on the metabolism of 1,3-dichloropropene and 2,3-dichloropropene indicate that the
major pathway occurs via conjugation of the dichloropropene with glutathione resulting in the excretion 
of inocuous mercapturic acids and N-acetyl-cysteine conjugates (see Section 3.4.3).  Inhalation exposure
of rats to 1,3-dichloropropene resulted in decreased levels of glutathione in the nasal tissue, kidney, and 
liver (Fisher and Kilgore 1988a).  Oral exposure of mice to 1,3-dichloropropene resulted in decreased 
levels of glutathione in the forestomach, glandular stomach, liver, and kidney, suggesting that the
compound is conjugated in those tissues (Dietz et al. 1982).  If the glutathione detoxification pathway
becomes saturated, secondary metabolic pathways that result in epoxidation and the formation of toxic
metabolites may become prominent (Schneider et al. 1998a).  It is possible that therapies that increase 
tissue levels of glutathione (for example, N-acetylcysteine) would help ameliorate the toxicity of 1,3- and 
   
 































    
 
      
     





2,3-dichloropropenes by reducing the use of the epoxidation pathways.  This approach may not be
suitable for 1,1-dichloropropene because there is evidence that glutathione may be involved in the
metabolism of this isomer to a mutagenic intermediate (Granville et al. 2005; see Section 3.3, 
Genotoxicity).
As studied in vitro, pretreatment with d,l-alpha-tocopherol prevented membrane phospholipid 
peroxidation and the consequent cytotoxicity of hepatic cells treated with 1,3-dichloropropene (Suzuki et
al. 1994b).
3.12  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of dichloropropenes is available.  Where adequate information 
is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to 
assure the initiation of a program of research designed to determine the health effects (and techniques for
developing methods to determine such health effects) of dichloropropenes.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Dichloropropenes 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
1,1-, 3,3-, 1,2-, 2,3-, and 1,3-dichloropropene are summarized in Figures 3-10, 3-11, 3-12, 3-13, and 3-14, 
respectively.  The purpose of this figure is to illustrate the existing information concerning the health
effects of dichloropropenes.  Each dot in the figure indicates that one or more studies provide information
associated with that particular effect.  The dot does not necessarily imply anything about the quality of the
study or studies, nor should missing information in this figure be interpreted as a “data need”.  A data 
need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data Needs Related to 
   
 


















































































































   
 


















































































































   
 


















































































































   
 


















































































































   
 


















































































































   
 

















   
     
 
 
    
    











Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), is substance-specific 
information necessary to conduct comprehensive public health assessments.  Generally, ATSDR defines a 
data gap more broadly as any substance-specific information missing from the scientific literature.
Existing information regarding the health effects of dichloropropenes in humans is limited.  No human 
toxicity data are available for 1,1-dichloropropene (Figure 3-10), 3,3-dichloropropene (Figure 3-11), 
1,2-dichloropropene (Figure 3-12), or 2,3-dichloropropene (Figure 3-13).  A limited amount of human 
toxicity data are available for 1,3-dichloropropene, mostly case reports in which levels and durations of
exposure to 1,3-dichloropropene were unknown (Figure 3-14).  For persons exposed by inhalation, there
is information on systemic effects and possible carcinogenicity, although the number of cases is too small
to provide definitive proof of carcinogenicity and the association is weak.  For oral exposure, there is
information on death and the systemic effects following ingestion of a lethal dose in one case report.  For
persons exposed dermally to 1,3-dichloropropene, there are case reports of dermatitis and allergic 
reactions at the site of contact. 
Data available on health effects of dichloropropenes in animals are more extensive than in humans.  No 
animal toxicity data are available for 1,1-dichloropropene (Figure 3-10) or 3,3-dichloropropene
(Figure 3-11).  For animals exposed by inhalation to 1,2-dichloropropene, there is one brief summary of
lethality and neurological effects in a few rats exposed to a saturated vapor atmosphere (Figure 3-12).  In 
animals exposed orally to 1,2-dichloropropene at a limit dose, there is information on survival and 
systemic effects.  Primary dermal and ocular irritation data are available for 1,2-dichloropropene.  In 
animals exposed by inhalation to 2,3-dichloropropene (Figure 3-13), there are data for acute lethality, 
complete data for systemic effects following repeated acute-duration exposures, and incomplete data for
systemic effects following intermediate-duration inhalation exposures.  In animals exposed orally to 
2,3-dichloropropene, there are data for mortality and systemic effects following acute lethal exposure.  
Data for dermal exposure to 2,3-dichloropropene include acute lethality and systemic effects, and primary
dermal and ocular irritation.  Animal data are more extensive for 1,3-dichloropropene compared to the
other isomers (Figure 3-14).  For animals exposed by inhalation to 1,3-dichloropropene, there are data for
mortality, systemic effects, genotoxic effects, and developmental toxicity following acute-duration 
exposure, systemic and reproductive effects following intermediate-duration exposure, and systemic and 
carcinogenic effects following chronic exposure.  For animals exposed orally, there are mortality, 
neurotoxicity, genotoxicity, and systemic toxicity data for acute-duration exposure, systemic effects 
following intermediate-duration exposure, and systemic and carcinogenic effects following chronic-
   
 









   
 
    
 







    
      
 
 




















duration exposure.  Studies in animals dermally exposed to 1,3-dichloropropene involve lethality, 
neurotoxicity, systemic, immunological, and possible carcinogenic effects following acute exposure.
3.12.2 Identification of Data Needs 
Information regarding the health effects of exposure to pure dichloropropenes is limited.  Although older
toxicological studies tested various commercial formulations of 1,3-dichloropropene, recent studies have 
used higher purity formulations that contain very low levels of confounding chemicals such as 1,2-di-
chloropropane, epichlorohydrin or chloropicrin.  Some acute-duration toxicological data are available for
some of the other isomers, but no reliable long-term studies.  As a consequence of their chemical
reactivity, portal-of-entry effects are the major toxicological sequelae of exposure to dichloropropenes.  
Any new tests need to include a thorough histopathological examination of portal-of-entry tissues. 
Although the following discussion covers all isomers of dichloropropene, testing to fill data gaps for
1,3-dichloropropene should take priority, since it is the only isomer currently in production at a
significant volume.
Acute-Duration Exposure.
1,3-Dichloropropene. Data regarding human exposures to 1,3-dichloropropene are limited to clinical 
reports describing isolated cases of non-Hodgkin's (histiocytic) lymphoma and acute myelomonocytic
leukemia after inhalation exposure (Markovitz and Crosby 1984), delayed-type hypersensitivity after
dermal exposure (Bousema et al. 1991; Corazza et al. 2003; van Joost and de Jong 1988; Vozza et al. 
1996), and nonspecific clinical signs such as headache, nausea, vomiting, fatigue, impotence, and malaise
after inhalation (and possibly dermal) exposure.  Respiratory symptoms such as chest discomfort, 
breathing difficulty, coughing, and mucous membrane irritation (Flessel et al. 1978; Markovitz and 
Crosby 1984) indicate that the respiratory system is a target in humans.  Animal studies of acute-duration 
exposure at high dose levels describe nonspecific clinical signs including lethargy, labored breathing, 
salivation, lacrimation, palpebral closure, and diarrhea.  The primary target organ in animals after acute 
inhalation is also the respiratory tract.  Lung hemorrhage and congestion, atelectasis, emphysema, 
pulmonary edema, and tracheal congestion have been observed (Cracknell et al. 1987; Streeter and 
Lomax 1988; Streeter et al. 1987).  Since acute-duration inhalation studies did not examine the nasal
turbinates for histopathology, a reliable NOAEL value cannot be identified in the available studies and no 
acute-duration inhalation MRL was derived for 1,3-dichloropropene. 
   
 










    
 
  
      
 
  
    
 
    
 
    
   
    
    
















One case report of acute lethal oral exposure to 1,3-dichloropropene identified gastrointestinal, 
respiratory, and cardiac effects prior to multiorgan failure (Hernandez et al. 1994).  Acute oral studies in 
rats have identified the stomach, lungs, and possibly the liver and kidney as targets (Jones and Collier
1986a; Mizell et al. 1988a), but the data are not sufficient to calculate an acute oral MRL.
Dermal exposure of humans to 1,3-dichloropropene has produced delayed-type hypersensitivity
(Bousema et al. 1991; Corazza et al. 2003; van Joost and de Jong 1988; Vozza et al. 1996).  Delayed-type
hypersensitivity to 1,3-dichloropropene has also been observed in animals (Carreon and Wall 1983;
Jeffrey 1987c; Mizell 1988b).  Animal studies have shown that 1,3-dichloropropene causes 
erythema/edema, necrosis, exfoliation, and subcutaneous hemorrhage when applied dermally (Carreon 
and Wall 1983; Jeffrey 1987c; Jones and Collier 1986b; Lichy and Olson 1975; Mizell et al. 1988a, 
1988b).  Data regarding systemic toxicity in animals are limited.  Hemorrhage of the lungs and glandular
stomach was reported in one study (Jones and Collier 1986b).
Information on the distribution of 1,3-dichloropropene following inhalation and dermal exposure is not
available to help identify other target organs across routes of exposure.  Intermediate- and 
chronic-duration studies in rats and mice, which included extensive histological examinations, have 
identified targets of inhalation and oral exposure.  Additional acute studies (single- and repeated-
exposure) by all routes should focus on histological examinations of major organs and tissues, especially
portal-of-entry tissues such as the lungs and nasal turbinates following inhalation exposure, the stomach 
following oral exposure, and the skin at the site of administration in dermal studies.  These studies of
systemic toxicity by the inhalation and oral route are needed for the derivation of acute-duration MRLs
for 1,3-dichloropropene.  Studies should be conducted in rats and mice since longer-term studies showed 
some species-specific variation in response to 1,3-dichloropropene.  Since suitable data were available for
the acute-duration inhalation MRL for 2,3-dichloropropene, an inhalation study would permit the
assessment of the relative toxicity of the two isomers. 
2,3-Dichloropropene. No data are available for effects in humans following acute-duration exposure to 
2,3-dichloropropene.  A well-conducted repeated-exposure acute inhalation toxicity study in rats and mice
revealed the respiratory tract to be the most sensitive target of inhaled 2,3-dichloropropene, with slightly
different effects observed the two species (Zempel et al. 1987).  An acute-duration inhalation MRL was
based on the lowest concentration, 5 ppm, a LOAEL for minimal nasal respiratory effects in mice and 
rats.  As a NOAEL was not observed in this study, additional testing would be useful to ascertain the
NOAEL for acute respiratory effects.
   
 



















    
  
   
   




      
   
 








    




The only animal oral toxicity data for 2,3-dichloropropene was for an acute lethality study in which 
congestion of the lung and kidney were reported in rats (Smyth et al. 1962; Union Carbide Corp. 1958).  
Repeated-dose acute-duration oral toxicity testing at nonlethal doses would be useful to identify critical
target organs and dose responses for the derivation of an acute-duration oral MRL.
The only animal dermal toxicity data for 2,3-dichloropropene was for acute lethality or skin irritation
following dermal exposure at high or unspecified doses (Monsanto 1967; Smyth et al. 1962; Union 
Carbide Corp. 1958).  Additional acute-duration dermal testing would be useful to determine thresholds
for irritant responses and necrotic effects.  This information would be relevant to possible occupational
exposures.
1,2-Dichloropropene. Acute-duration toxicity data for 1,2-dichloropropene are limited to a summary of
results for a high-concentration inhalation lethality study, an acute oral limit dose test, and primary
dermal and eye irritation tests (Dow 1962).  Results of these studies suggest that suppression of the
central nervous system may occur at high inhalation concentrations, and that irritant effects may occur
from topical exposure.  Additional testing by all routes would be useful to determine the NOAEL and 
LOAEL values for effects in critical target organs following acute exposure.  This information could be
used for the derivation of acute-duration inhalation and oral MRLs.  
1,1- and 3,3-Dichloropropene. No acute-duration toxicity data by any route of exposure are available for
either isomer.  Testing of 1,1-dichloropropene may be especially useful since it, unlike 1,3- and 2,3-di-
chloropropene, appears to be bioactivated rather than detoxified by reaction with glutathione.  Additional
testing by all routes would help to determine NOAEL and LOAEL values for effects in critical target 
organs following acute exposure to either isomer.  Results of these studies could be used for the 
derivation of acute-duration inhalation and oral MRLs. 
Intermediate-Duration Exposure. Data are not available that identify target organs in humans after
intermediate-duration exposure to any isomer of dichloropropene by any route.
1,3-Dichloropropene. Most earlier intermediate-duration studies in animals exposed to 1,3-dichloro-
propene were conducted using formulations that contained other toxic compounds such as
epichlorohydrin.  Animal studies using more purified formulations indicate that the primary target organs
of 1,3-dichloropropene toxicity after intermediate-duration inhalation exposure are the nasal epithelia and 
   
 








   
  
  





   
   









   
    




   
 
 




urinary bladder (Breslin et al. 1989; Coate 1979a; Lomax et al. 1989).  An intermediate inhalation MRL
has been calculated based on histopathology in nasal epithelia in rats.  Intermediate-duration oral toxicity
studies using dietary exposure to a microencapsulated formulation lacking epichlorohydrin demonstrated 
that the forestomach in rats and erythrocytes in dogs were the critical targets of 1,3-dichloropropene (Haut
et al. 1996; Stebbins et al. 1999).  An intermediate oral MRL has been calculated based on forestomach 
lesions in rats.
No information on target organs other than the skin (Jeffrey 1987a) was located for intermediate-duration 
dermal exposure.  No distribution data following inhalation, oral, or dermal exposure were located to help 
identify target organs of dermal exposure.  An intermediate-duration dermal study in animals that
examined organs other than skin should help identify the possible effects of repeated dermal exposure to 
internal tissues.  Because 1,3-dichloropropene is a component of a soil fumigant, contact with soil is one
way that dermal exposure of humans could occur.  Furthermore, 1,3-dichloropropene may be present in 
the soil at hazardous waste sites, where residents may be exposed for intermediate durations.
2,3-Dichloropropene. No intermediate-duration toxicity data are available for exposure to 2,3-dichloro-
propene by the oral or inhalation routes, and the available data by the inhalation route are not suitable as a
basis for an intermediate-duration MRL.  Reliable NOAEL and LOAEL values could not be identified in 
the published 13-week inhalation rat study by Johannsen et al. (1991), since the nasal turbinates were not
examined for histopathology, although clinical signs of red nasal discharge were observed at the highest
exposure level (15 ppm).  The reproduction toxicity study described in the same paper also lacks 
information about nasal effects in exposed parents.  Lung weight data from a terminated 13-week
inhalation study in mice (NTP 1989, 2006) add support to the identification of the respiratory tract as the
critical target of repeated inhalation exposure to 2,3-dichloropropene, but the lack of histopathology and 
other data render this study unsuitable as the basis for derivation for an MRL.  In addition, significant
toxicity in the liver was shown by serum parameters and in the kidneys by urinalysis results.  New testing
for intermediate-duration exposure to 2,3-dichloropropene by all routes in which respiratory and renal
tissues are adequately examined for histopathology would help to identify more reliable NOAELs and 
LOAELs for this isomer.  Results of oral and inhalation studies could be used for the derivation of
intermediate-duration MRLs.
1,1-, 1,2-, and 3,3-Dichloropropene. No intermediate-duration toxicity data by any route of exposure are 
available for any of these isomers.  Testing by all routes would help to determine the NOAEL and 
   
 









   
 
    
  
 














   
  
    
  
     








LOAEL values for effects in critical target organs following intermediate-duration exposure.  Results of
these studies could be used for the derivation of intermediate-duration inhalation and oral MRLs.  
Chronic-Duration Exposure and Cancer. There is no information in humans to identify target
organs following chronic exposure to any isomer of dichloropropene by inhalation, oral, or dermal routes. 
1,3-Dichloropropene. The chronic toxicity of 1,3-dichloropropene using formulations not containing
epichlorohydrin has been assessed in several animal studies:  a 2-year inhalation study in rats and mice 
(Lomax et al. 1989); a 2-year study in rats and mice administered a microencapsulated form in the diet
(Stebbins et al. 2000); and a 1-year study in dogs also fed the microencapsulated form in the diet
(Stebbins et al. 1999).  Lesions of the nasal epithelia in rats and mice and of the urinary bladder
epithelium of mice were the principal nonneoplastic effects following chronic inhalation exposure.  An 
increased incidence of bronchioalveolar adenomas was also observed in mice exposed by inhalation.  
Lesions of the forestomach in rats, and microcytic anemia in dogs were the critical effects of chronic oral
studies.  Data from these chronic studies were sufficient to derive chronic-duration inhalation and oral
MRLs for 1,3-dichloropropene.  No data were available for chronic dermal exposure in animals.  Such 
testing would help to evaluate the consequence of repeated dermal exposure, which might occur from
occupational exposure or residence in communities in which release of the chemical into the environment
is significant.
A few isolated case reports describing three men who developed lymphoma or leukemia following acute 
exposure (Markovitz and Crosby 1984) suggests, but does not prove, a carcinogenic potential for 1,3-di-
chloropropene in humans.  The fact that some carcinogenic effects were observed in some earlier chronic-
duration bioassays, but not observed in later studies with purer test material, indicate that impurities or
additives such as epichlorohydrin in the formulations may have contributed to carcinogenesis.  Following
inhalation exposure to a purer test material, an increased incidence of bronchioalveolar adenomas (benign 
lung tumors) in mice was the only carcinogenic effect of 1,3-dichloropropene (Lomax et al. 1989). 
Dietary exposure to the purer microencapsulated test material did not result in increased tumor incidences
in rats, mice or dogs (Stebbins et al. 1999, 2000).  It is not certain whether the lack of tumor formation in 
the dietary studies, compared to increased tumors incidences (for squamous cell papillomas and 
carcinomas of the forestomach in rats and mice and transitional cell carcinomas of the urinary bladder in 
mice) in a 2-year gavage study (NTP 1985), were related to the absence of epichlorohydrin in the later
studies, or the lack of bolus dosing.  Bolus dosing by itself could have contributed to glutathione
depletion and resultant saturation of the major detoxifying pathway, resulting in an increased generation 
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of mutagenic metabolites by minor pathways.  No additional chronic-duration toxicity testing by the
inhalation or oral routes is needed. 
An initiation-promotion study of cis-1,3-dichloropropene by dermal exposure in mice indicated that cis-
1,3-dichloropropene was not an initiator of skin tumors (Van Duuren et al. 1979).  Furthermore, cis-
1,3-dichloropropene alone did not induce skin tumors after repeated dermal application for 74 weeks.  No 
studies were located regarding the carcinogenic mechanism of action of 1,3-dichloropropene.  Available 
data indicate, however, that 1,3-dichloropropene or its unavoidable impurities is mutagenic in prokaryotic
and eukaryotic test systems and that it is a strong tissue irritant.  Both properties may underlie the
carcinogenic potential of 1,3-dichloropropene.
1,1-, 1,2-, 2,3-, and 3,3-Dichloropropene. No chronic-duration toxicity data by any route of exposure are
available for any of these isomers.  Testing by all routes would help to determine NOAEL and LOAEL
values for effects in critical target organs following chronic-duration exposure.  Results of these studies 
could be used for the derivation of chronic-duration inhalation and oral MRLs.  
Genotoxicity. No data are available regarding genotoxicity in humans after exposure to any isomer of
dichloropropene by any route.  
1,1-Dichloropropene. Mixed results for mutagenicity were reported for S. typhimurium TA100 and 
negative results in other strains (Granville et al. 2005; Neudecker et al. 1986), but positive results were
reported for a TA100-based strain that expressed glutathione transferase in the presence of glutathione.  
Granville et al. (2005) indicated that bioactivation by glutathione transferase generates the production of a
mutagenic epoxide from 1,1-dichloropropene.  The observation that no DNA fragmentation was observed 
in a cell line deficient in glutathione transferase supports this observation. The paradoxical effect of 
glutathione on this isomer (others detoxified by glutathione) suggests that any additional in vitro
genotoxicity tests should be conducted with and without glutathione transferase.  In vivo genotoxicity
tests would help to determine whether the pattern of increased mutagenicity from interaction with 
glutathione is relevant to inhalation or oral exposure.  Testing for chromosomal aberration in cultured 
mammalian cells would also be useful.
1,2-Dichloropropene. A negative result for S. typhimurium TA100 represents the only genotoxicity data
for 1,2-dichloropropene.  Additional in vitro testing on bacterial strains that detect other mutagenic 
   
 




















   
    




   
  
  
       
 
 
   
  
   
   




lesions and for chromosomal aberration in mammalian cells would help to assess the genotoxic potential
of this isomer.
1,3-Dichloropropene. Positive results for DNA fragmentation in specific tissues (stomach liver, urinary
bladder, kidney, lung, brain, bone marrow) and for micronucleus formation in one assay were reported 
following oral exposure to 1,3-dichloropropene (Ghia et al. 1993; Kevekordes et al. 1996; Kitchin and 
Brown 1994; Sasaki et al. 1998), but negative results were reported for other types of assays (unscheduled 
DNA synthesis, four of five micronucleus assays).  A single dominant lethal mutation assay in rats 
exposed by inhalation for 10 weeks was negative (Gollapudi et al. 1998), which is consistent with the lack
of toxicity in the testes in systemic toxicity assays.  In vivo genotoxicity testing for mutagenicity in target 
organs (stomach, lung, nasal epithelium, urinary bladder, and possibly lymphocytes) would be useful, 
since previous tests with formulations containing epichlorohydrin have resulted in tumor increases.  
Studies by Talcott and King (1984) and Watson et al. (1987) demonstrated that the mutagenicity of
technical-grade 1,3-dichloropropene in S. typhimurium TA100 could be entirely attributed to impurities, 
and that the purified chemical can undergo slow autoxidation to form mutagenic oxides.  This may
account for the many earlier positive results for mutagenicity in TA100 in older studies (Table 3-9).  It is
not clear whether the positive results for genotoxicity (sister chromatid exchange, mitotic aberration, 
unscheduled DNA synthesis) in cultured mammalian cells exposed to relatively pure (>95%) 1,3-di-
chloropropene were caused by the parent compound, in vivo metabolism to a mutagenic metabolite, a
mutagenic autoxidation product that formed during storage, or an impurity remaining after manufacture
(Kevekordes et al. 1996; Loveday et al. 1989; Matsuoka et al. 1998).  Cis and trans epoxides of 1,3-di-
chloropropene, as well as 3-chloro-3-hydroxypropanal, three mutagens formed by a minor metabolic
pathway, specifically form adducts to 2’-deoxyguanosine and not to 2-deoxyadenosine or 2’-deoxy-
cytidine in solution (Schneider et al. 1998b).  Additional studies to examine the potential for adduct
formation in vivo or exposed cells in vitro would help to better characterize the genotoxic potential of this
isomer.
2,3-Dichloropropene. Positive results have been reported for mutagenicity in bacteria, aneuploidy in 
yeast, and sister chromatid exchange, chromosomal aberration, and unscheduled DNA synthesis in 
mammalian cells following exposure to 2,3-dichloropropene.  Given the generally positive results of in 
vitro testing, additional studies would be helpful to ascertain the genotoxic potential of this isomer in 
vivo. Tissues subject to portal-of-entry effects, as well as the liver, kidney, and urinary bladder should be
evaluated in these studies.
   
 













     
  
 





   





   
   
  
  
     
   
  
  
     
  






3,3-Dichloropropene. In vitro genotoxicity studies for mutagenicity in bacterial cells and chromosomal
aberration in mammalian cells for 3,3-dichloropropene would help to determine the genotoxic potential of
this isomer.
Reproductive Toxicity. No information is available regarding the reproductive toxicity of any
isomer of dichloropropene by any route of exposure in humans.  
1,3-Dichloropropene. Pharmacokinetic data in rats indicate that 1,3-dichloropropene or its metabolites
are found in low concentrations in reproductive organs and tissues (Waechter and Kastl 1988).  However, 
no effects on reproductive parameters of rats were found in a two-generation inhalation study (Breslin et 
al. 1989).  Furthermore, no lesions attributable to 1,3-dichloropropene were observed after gross and 
histologic evaluation of reproductive tissues and organs in several animal studies.  These studies include a 
two-generation reproductive/developmental inhalation study (Breslin et al. 1989), a 2-year inhalation 
study (Lomax et al. 1989), and a 2-year oral study (NTP 1985).  No studies regarding reproductive effects
in animals following dermal exposure were found; however, the results of the inhalation and oral studies
indicate no reason to suspect that 1,3-dichloropropene would have reproductive effects by this route.  
Additional reproductive studies would not be useful at this time.
2,3-Dichloropropene. No histopathology of male or female reproductive organs was observed in a
repeated acute-duration inhalation exposure study in rats or mice exposed at ≤75 ppm (Zempel et al. 
1987).  A reproductive toxicity assay for rats exposed to 2,3-dichloropropene by inhalation (Johannsen et
al. 1991) reported no reproductive effects at 1 or 5 ppm, although there was a statistically insignificant 
reduction in female fertility in exposed animals.  It seems likely, based on the results of the acute-duration 
repeated inhalation assay by Zempel et al. (1987), that rat dams in the study by Johannsen et al. (1991)
experienced irritation of the nasal tissues, which was unreported because the nasal turbinates were not
examined for histopathology.  The incomplete data available for intermediate-duration inhalation toxicity
in rats and mice suggest that 2,3-dichloropropene does not have a direct adverse effect on reproductive
organs or sperm or estrus cycle parameters (NTP 1989, 2006).  Additional reproductive toxicity testing
that includes examination of portal-of-entry tissues in exposed parents would help to determine reliable
NOAEL and LOAEL values for reproductive effects and parental toxicity.  Studies in mice exposed by
inhalation would help to determine whether the more extensive damage to the respiratory tract, compared 
to rats, affects reproductive function because of irritation-induced parental stress. 
   
 









   
 
     
 
   
  
    
    
    
 
       
    
   
 
 




    
    
   
  
     
    
 
  





1,1-, 1,2-, and 3,3-Dichloropropene. Because no data are available for any of these isomers by any route 
of exposure, testing in animals would help to determine the reproductive toxicity of these isomers.  
Developmental Toxicity.
1,3-Dichloropropene. Both acute-duration developmental inhalation studies in rats and rabbits (Hanley
et al. 1987; Kloes et al. 1983) and intermediate-duration reproductive inhalation studies in rats (Breslin et
al. 1989) have shown that 1,3-dichloropropene is not teratogenic.  However, fetotoxicity in the rabbits
could not be assessed because significant maternal toxicity at the highest tested concentration (300 ppm)
resulted in the death of six of seven rabbits (Kloes et al. 1983).  Maternal toxicity in rats, also at 300 ppm, 
may have resulted in fetotoxicity and the subsequent decrease in fetuses per litter.  Lower concentrations
of 1,3-dichloropropene (≤150 ppm) were not fetotoxic in these studies, although an exposure of 120 ppm
to pregnant rats resulted in delayed ossification, which may have been due to decreased body weight of
the dams.  A weakness of these studies is that the dams were not evaluated for effects in the respiratory
tract, especially the nasal turbinates, so the NOAEL for maternal toxicity may have been overestimated.  
It seems possible that repeated irritation might contribute to maternal stress, resulting in lower feed 
intake, decreased maternal body weight gain, and fetal effects such as delayed ossification.  New
inhalation exposure studies that include examination of the nasal turbinates, as well as a pair-fed group, 
would allow the reason for delayed development to be identified.
2,3-Dichloropropene. An intermediate-duration reproductive study in rats exposed by inhalation, 
reported no fetal effects at exposures at 1 or 5 ppm, reportedly below the level of maternal toxicity
(Johannsen et al. 1991).  A weakness of this study is that the dams were not evaluated for effects in the
nasal turbinates, the primary target tissue in acutely exposed rats (Zempel et al. 1987), so the maternal
NOAEL may not have been accurately identified.  Additional developmental toxicity studies that include
examination of the maternal portal-of-entry tissues in rats, and also in mice (which had more extensive 
respiratory tract effects than rats exposed under identical conditions [Zempel et al. 1987]), would help to 
better characterize the developmental toxicity of this isomer.
1,1-, 1,2-, and 3,3-Dichloropropene. Because no data are available for any of these isomers by any route 
of exposure, testing in animals would help to determine the potential of these isomers to induce
developmental effects. 
   
 








     
 
    
   
      





   
   
   
    
 
    
    
  
 











    




1,3-Dichloropropene. Several clinical reports on the development of a delayed-type hypersensitivity
after skin contact in workers occupationally exposed to 1,3-dichloropropene (Bousema et al. 1991;
Corazza et al. 2003; van Joost and de Jong 1988; Vozza et al. 1996) indicate the possibility of
immunotoxicity in humans.  This is supported by animal studies that document the development of
delayed-type hypersensitivity in guinea pigs (Carreon and Wall 1983; Jeffrey 1987a; Mizell 1988b).  
Since the immune system may be a target of 1,3-dichloropropene toxicity, a battery of immune function 
tests appears to be warranted at this time.  However, no animal studies showed adverse effects on 
lymphocytes, despite exposure by inhalation or gavage for intermediate or chronic duration (Haut et al. 
1996; Lomax et al. 1989; NTP 1985; Stebbins et al. 2000; Stott et al. 1988; Til et al. 1973; Torkelson and 
Oyen 1977).  Furthermore, gross and histological examination of the lymph nodes and the thymus in 
several animal studies of inhalation and oral exposure revealed no lesions attributable to 1,3-dichloro-
propene as Telone II (Lomax et al. 1989; NTP 1985; Stott et al. 1988).
1,1-, 1,2-, 2,3-, and 3,3-Dichloropropene. No data are available for immunotoxicity of these isomers in 
humans or animals.  Since immunological effects have been observed in humans and animals exposed 
dermally to 1,3-dichloropropene, primary skin sensitization studies in animals would help to characterize 
the potential of these isomers to induce immunotoxicity.  Additional immune function testing could then 
be conducted based on the results of the skin sensitization studies.
Neurotoxicity.
1,3-Dichloropropene. No neurotoxicity was observed in humans accidentally exposed to 1,3-dichloro-
propene at concentrations high enough to require medical attention (Markovitz and Crosby 1984).  No 
evidence for neurotoxicity was found following gross and histological examination of brain, nerves, and 
the spinal cord from rats and mice after inhalation (Coate 1979a; Lomax et al. 1989; Stott et al. 1988) and 
oral exposure to 1,3-dichloropropene (Haut et al. 1996; NTP 1985; Stebbins et al. 1999, 2000).  Clinical
signs that indicate possible neurotoxicity, however, were noted in rabbits after inhalation exposure to high 
concentrations of 1,3-dichloropropene (Kloes et al. 1983).  These signs included ataxia, loss of the
righting reflex, lacrimation, salivation, and lethargy.  Studies determining the threshold inhalation
concentrations associated with neurological effects following acute exposure at high levels might be
helpful for identifying hazards due to neurological impairment during accidental exposure.  Such studies
would be less useful for the typical exposures experienced by the general population. 
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1,2-Dichloropropene. The only data available for neurotoxicity following exposure to 1,2-dichloro-
propene was a report of unconsciousness in rats exposed to a saturated vapor atmosphere estimated at
63,764 ppm (Dow 1962).  Additional testing would help to determine the threshold for neurotoxicity of
1,2-dichloropropene at more typical experimental exposure levels.
2,3-Dichloropropene. There is no information as to the neurotoxicity of 2,3-dichloropropene in humans
and no neurotoxic effects, clinical signs, or histopathology were observed in rats or mice exposed 
repeatedly at ≤75 ppm by inhalation in an acute study (Zempel et al. 1987).  Acute lethality studies
reported signs of suppression of the central nervous system following single inhalation exposures at levels 
of 500 ppm and higher (Dietz et al. 1985b; Monsanto 1967).  Because of reporting deficiencies, these data
do not reliably identify NOAEL or LOAEL values for neurotoxicity following single inhalation exposure.
1,1- and 3,3-Dichloropropene. As no neurotoxicity or systemic toxicity data are available for these 
isomers, acute-duration testing in animals would help to determine the thresholds for neurological effects
following oral or inhalation exposure.
Epidemiological and Human Dosimetry Studies.
1,3-Dichloropropene. One pharmacokinetic study in humans described a strong correlation between 
exposure levels during the application of 1,3-dichloropropene on farms and urinary excretion levels of
1,3-dichloropropene metabolites (Osterloh et al. 1984).  Additional monitoring studies reported slight
increases in urinary excretion of N-acetylglucosamidase, a possible biomarker for subclinical renal effects 
(Osterloh and Feldman 1993; Osterloh et al. 1989a, 1989b).  A case-control study reported an apparent
increase in risk of death from pancreatic cancer associated with long-term (20-year) residence in three 
communities in which high quantities of 1,3-dichloropropene were used for fumigation (Clary and Ritz
2003).  However, there was no direct exposure data for the subjects, and given the products available at
the time, it is possible that carcinogenic effects could have been caused by additives (for example, 
epichlorohydrin) no longer present in current products.  Given the lack of data for humans exposed long-
term to 1,3-dichloropropene, epidemiological studies of respiratory effects and possible carcinogenicity
in, for example, agricultural workers exposed occupationally, would be especially valuable.  Additionally, 
long-term follow-up studies of chronic toxicity and carcinogenicity in people exposed to high 
concentrations of 1,3-dichloropropene at the site of a spill would be valuable.  Chronic toxicity evaluation
   
 
























   
   





    
 
  
     
   




should focus on the nasal epithelia, forestomach, lungs, liver, and kidneys, which are the primary target
organs identified in animal studies.
Limited evidence suggests that the mu class of glutathione S-transferase may not play a significant role in 
the metabolism of 1,3-dichloropropene in humans (Vos et al. 1991).  Systematic evaluation of isoforms of
the enzymes involved in metabolism of dichloropropenes (glutathione S-transferase and cytochrome 
P-450) in humans would help interpret the basis of individual variability in human studies (see
Comparative Toxicokinetics below).   
1,1-, 1,2-, 2,3-, and 3,3-Dichloropropene. No studies were located regarding the epidemiology or human 
dosimetry of these isomers
Biomarkers of Exposure and Effect.
Exposure.  
1,3-Dichloropropene. The primary biomarker of exposure identified in the literature is the mercapturic 
acid metabolite of 1,3-dichloropropene found in the urine of animals exposed by inhalation (Fisher and 
Kilgore 1988b) and orally (Climie et al. 1979; Hutson et al. 1971) and humans exposed occupationally
(Osterloh and Feldman 1993; Osterloh et al. 1984; van Welie et al. 1989).  Because 1,3-dichloropropene
does not appear to accumulate in the body, only short-term and possibly intermediate-duration exposures
can be assessed using the urinary metabolite as a biomarker.  Depletion of glutathione stores would 
represent a biomarker of exposure, but would not be practical in the absence of data for preexposure
glutathione levels.  Although no pharmacokinetic studies have investigated chronic exposure, this
duration of exposure may not be assessed reliably if some period of time has passed between the last
exposure and biomarker analysis.  Since hematological and clinical chemistry analyses performed in 
animal studies of intermediate and chronic exposure have not identified significant alterations indicative
of exposure, attempts to develop biomarkers that use easily obtained biological fluids may not be fruitful. 
Studies in dogs exposed orally have shown evidence of microcytic anemia (Haut et al. 1996; Stebbins et
al. 1999), but this would not represent a specific biomarker for 1,3-dichloropropene.  Research to identify
a biomarker would facilitate future medical surveillance, which could lead to early detection and 
treatment.  If future in vivo assays for DNA adduct formation (see Genotoxicity, above) yield positive
results, it is possible that adduct frequency in blood cells might be developed as a biomarker.  However, 
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given that mutagenic metabolites of 1,3-dichloropropene form under high-exposure conditions, adduct
frequency is unlikely to be a useful biomarker for low-level exposures. 
2,3-Dichloropropene. There is no information on biomarkers in humans for exposure to 2,3-dichloro-
propene.  Based on toxicokinetic studies in animals exposed orally or by inhalation, urinary mercapturic
acid metabolite represents a biomarker of exposure for the first few days after exposure (Bond et al. 1985;
Dutcher et al. 1985; Eder and Dornbusch 1988; Medinsky et al. 1984).  Elimination is too rapid for this
metabolite to be a useful biomarker for exposures that ended several days earlier.  
1,1-, 1,2-, and 3,3-Dichloropropene. No data are available for biomarkers of exposure to these isomers.  
Toxicity studies in animals exposed by inhalation, oral, or dermal exposure would help to identify target
organ specificities for these isomers.
Effect.  
1,3-Dichloropropene. Irritant effects have been noted in humans acutely exposed to high doses by the
oral or inhalation routes, and dermal exposure resulted in contact dermatitis and delayed sensitivity
reactions.  The effects identified in animal studies include portal-of-entry effects such as lung trauma in 
acutely exposed rats, hyperplasia/hypertrophy of the nasal respiratory epithelium in rats and mice, 
hyperplasia of the nonglandular stomach in rats and mice, as well as hyperplasia of the urinary bladder in 
mice, and anemia in dogs.  It is evident that none of the effects observed in humans and animals are 
unique to dichloropropenes.  Furthermore, it is not known whether the anemia observed in orally-exposed 
dogs is relevant to humans.  Analysis of serum and urinary biomarkers for liver and renal effects did not
show significant changes in workers occupationally exposed at low levels to cis or racemic 1,3-dichloro-
propene (Boogard et al. 1993; Verplanke et al. 2000).  This is not unexpected given that neither the liver
nor the kidney is the most vulnerable target of toxicity for 1,3-dichloropropene.  Development of new
biomarkers of effect requires a thorough knowledge of the health effects and more subtle physiological or
biochemical changes caused by 1,3-dichloropropene.  Further studies on the products of the minor
metabolic pathways, which might form adducts detectable in cells circulating in the bloodstream, may
identify biomarkers of effect for this isomer.
2,3-Dichloropropene. No information is available as to toxic effects in humans exposed to 2,3-dichloro-
propene.  Effects in exposed animals appear to be similar to the portal-of-entry effects observed for
1,3-dichloropropene, except that the former causes more severe respiratory tract lesions.  Reliable 
   
 
















      
 
    
    











   








intermediate- and chronic-duration toxicity studies could help to determine whether longer-term exposure 
to 2,3-dichloropropene reveals unique biomarkers of effect. 
1,1-, 1,2-, and 3,3-Dichloropropene. No reliable data are available as to the toxicity of these isomers in 
humans or animals exposed by any route, although unspecified liver and kidney effects were observed in 
rats following gavage exposure to 1,2-dichloropropene at 2,000 mg/kg (Dow 1962).  Reliable studies, 
initially for acute-duration exposure, would help to identify target tissues and possible biomarkers of
effect for these isomers.
Absorption, Distribution, Metabolism, and Excretion.
1,3-Dichloropropene. 1,3-Dichloropropene is absorbed by all routes of exposure.  Absorption by the
pulmonary (Stott and Kastl 1986) and gastrointestinal (Climie et al. 1979; Hutson et al. 1971; Stott et al. 
1998; Waechter and Kastl 1988) tracts is extensive and rapid.  The only data for dermal absorption was
for skin in contact with cis-1,3-dichlorpropene as vapor, not liquid (Kezic et al. 1996).  Similarly, 
metabolism, primarily via conjugation to glutathione is rapid following oral or inhalation exposure, 
resulting in rapid elimination of mercapturic acid metabolites in urine and feces, and carbon dioxide in 
exhaled air (Climie et al. 1979; Fisher and Kilgore 1989; Hutson et al. 1971; Stott et al. 1998; Waechter
and Kastl 1988).  Absorbed 1,3-dichloropropene is widely distributed throughout the body, with the
highest initial concentrations found in portal-of-entry tissues (nonglandular stomach) as well as the liver, 
kidney, and urinary bladder (Dietz et al. 1985a; Waechter and Kastl 1988).  The absorption of 1,3-di-
chloropropene following dermal exposure and the distribution following inhalation or dermal exposure
have not been adequately investigated for either single- or repeated-exposure scenarios.
2,3-Dichloropropene. No data are available for the toxicokinetics of 2,3-dichloropropene in humans, but
studies are available for rats exposed by inhalation (Bond et al. 1985; Dutcher et al. 1985) and by oral
gavage (Eder and Dornbusch 1988; Medinsky et al. 1984).  The results of these studies indicate that 
metabolic pathways and patterns of excretion for 2,3-dichloropropene are similar to those described for
1,3-dichloropropene.  However, a comparison of inhalation toxicity studies shows that exposure to 2,3-di-
chloropropene results in more severe respiratory effects in rats or mice than exposure to 1,3-dichloro-
propene (Lomax et al. 1989; NTP 1989, 2006; Zempel et al. 1987).  Studies are needed to determine the
toxicokinetic basis for the apparent greater toxicity of 2,3-dichloropropene compared to 1,3-dichloro-
propene.  This may be associated with differences in rates of reaction with glutathione or relative kinetics 
   
 











     
  
 




    
 
 
     
 






    
  
    











of metabolic pathways.  Studies to determine the toxicokinetics of 2,3-dichloropropene following dermal
exposure would be useful since no data are available for this likely route of exposure.  
1,1-Dichloropropene. Currently, no data are available for the toxicokinetics of 1,1-dichloropropene in 
humans or animals.  However, in vitro data suggest that 1,1-dichloropropene, unlike 1,3- and 2,3-di-
chloropropene is not detoxified, but rather bioactivated to a mutagenic form by reaction with glutathione
(Granville et al. 2005).  Studies on the absorption, distribution, metabolism, and excretion following
exposure to 1,1-dichloropropene after oral, inhalation, or dermal exposure may help to explain this
apparent paradoxical response.
1,2- and 3,3-Dichloropropene. No toxicokinetic data are available for these compounds.  Studies on their
toxicokinetics should be deferred until the toxicity of these compounds has been adequately investigated.
Comparative Toxicokinetics.
A data need relevant to all dichloropropenes is an evaluation of the isoforms of enzymes involved in the
detoxification or bioactivation of these compounds.  Enzyme polymorphisms could explain individual
variations in human studies, possibly identifying vulnerable populations, or strain differences in responses
in animal studies.  This information would be useful in supporting valid extrapolations across species 
using PBPK models.
1,3-Dichloropropene. In humans occupationally exposed to 1,3-dichloropropene, the major urinary
metabolite found was the mercapturic acid conjugate of 1,3-dichloropropene (Osterloh and Feldman 
1993; Osterloh et al. 1984; van Welie et al. 1989).  Studies in rats (Climie et al. 1979; Fisher and Kilgore
1989; Hutson et al. 1971; Stott and Kastl 1986; Stott et al. 1998; Waechter and Kastl 1988) and one study
in mice (Dietz et al. 1982) support the identification of the mercapturic acid metabolite as the primary
1,3-dichloropropene metabolite.  The excretion data in mice and rats are similar; excretion in urine is the
primary route, followed by excretion of CO2 in the expired air and then by excretion in the feces.  It is 
reasonable to expect that excretion is similar in humans; therefore, rats provide a good model for further
pharmacokinetic and toxicity studies of 1,3-dichloropropene.  Additional pharmacokinetic studies should 
focus on the rates of absorption, distribution, metabolism, and excretion, particularly by the dermal route, 
after acute or repeated exposures.  Dose-response information on the relative depletion of glutathione
stores in target organs would help define conditions under which toxicity would be increased.
   
 










   
 
    
   
     




     
  
 








     
    
   
   
 
  








2,3-Dichloropropene. No data are available for the toxicokinetics of 2,3-dichloropropene in humans and 
the only animal studies were conducted in rats.  Studies in rats exposed by inhalation (Bond et al. 1985;
Dutcher et al. 1985) and by oral gavage (Eder and Dornbusch 1988; Medinsky et al. 1984) indicate that
metabolic pathways and patterns of excretion are similar to those described for 1,3-dichloropropene.  Rats
and mice exhibit a different pattern of toxicity in respiratory tissues following inhalation exposure to 
2,3-dichloropropene, with both species showing nasal effects, but only mice exhibiting toxicity in the
lung (NTP 1989, 2006; Zempel et al. 1987).  Additional studies on the toxicokinetic basis of this
difference could help to explain whether or not the differences could be related to differences in 
respiratory physiology, the size of glutathione stores in respiratory tissues, or the tissue-specific 
availability of other pathways for detoxification.  
1,1-Dichloropropene. Currently, no data are available for the toxicokinetics of 1,1-dichloropropene in 
humans or animals.  However, in vitro data suggest that 1,1-dichloropropene, unlike 1,3- and 2,3-di-
chloropropene is not detoxified, but rather bioactivated to a mutagenic form by reaction with glutathione
(Granville et al. 2005).  Studies on the absorption, distribution, metabolism, and excretion in rats and 
mice following exposure to 1,1-dichloropropene after oral, inhalation, and dermal exposure would help to 
establish the basis of this apparent paradoxical response.
1,2- and 3,3-Dichloropropene. No toxicokinetic data are available for these compounds.  Studies on the
comparative toxicokinetics should be deferred until the toxicity of these compounds has been adequately
investigated.
Methods for Reducing Toxic Effects. Information on the metabolism of 1,3-dichloropropene in 
humans (Osterloh and Feldman 1993; Osterloh et al. 1984; van Welie et al. 1989) and for 1,3- and 2,3-di-
chloropropene in animals (Bond et al. 1985; Dietz et al. 1982; Eder and Dornbusch 1988; Fisher and 
Kilgore 1988a; Waechter and Kastl 1988) indicates that the major detoxifying pathway occurs via
conjugation with glutathione, which can occur in target organs such as portal-of-entry tissues (nasal
epithelia and the stomach) as well as the liver and kidney.  Since depletion of glutathione results in 
saturation of the detoxification pathway, resulting in the use of secondary metabolic pathways that
produce mutagenic metabolites (Schneider et al. 1998a), research on therapies that increase tissue levels 
of glutathione (for example, N-acetylcysteine) is needed.  Conversely, since 1,1-dichloropropene
produces mutagenic metabolites upon reaction with glutathione, therapies that interfere with that reaction 
are needed.  Additional studies on the metabolism of 1,1-dichloropropene would help to identify possible
detoxifying pathways so that therapies could be developed.
   
 












      
    
  
 
    
 




     
  
 
   
 
    
 
 
     
 
 
    
 
   





Additional data are needed on the toxicity of 1,2-, and 3,3-dichloropropene before any studies can be 
conducted on methods for reducing toxic effects of these isomers.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
The scant information on the toxicity of dichloropropenes in humans is limited to studies in adults
exposed to 1,3-dichloropropene.  Data relating to health effects in children are lacking.  As physiological
parameters differ in fetuses, newborns, young children, and adults (EPA 2001d), studies should be
conducted in animals to determine the effect on those differences on toxicity of dichloropropenes.  
Especially since children and adults differ with respect to respiratory parameters, animal testing should be
conducted by the inhalation route to determine whether juveniles are at greater or lesser risk compared to 
adults following exposure.  More information is needed on transfer of dichloropropenes across the
placenta, the kinetics of transfer, and placental metabolism of dichloropropenes.  Since depletion of
glutathione stores is possibly related to increased use of bioactivating metabolic pathways by 1,3- and 
2,3-dichloropropene, studies monitoring the conditions under which placental glutathione stores are
depleted would be useful.  As dichloropropene was previously reported in one of eight samples of human 
breast milk, additional toxicokinetic research is needed to define the risk associated with transfer via milk
(Pellizzari et al. 1982). 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies 
NTP is currently evaluating the immuntoxic potential of 1,3-dichloropropene in a 28-day oral exposure
study in B6C3F1 mice (NTP 2008).  No additional ongoing studies were located on the toxicity or
mechanism of action of dichloropropenes.
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4. CHEMICAL AND PHYSICAL INFORMATION
 
4.1  CHEMICAL IDENTITY
Data pertaining to the chemical identity of 1,1-, 1,2-, cis-1,3-, trans-1,3-, 2,3-, and 3,3-dichloropropene
are listed in Table 4-1.
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
The physical and chemical properties of 1,1-, 1,2-, cis-1,3-, trans-1,3-, 2,3-, and 3,3-dichloropropene are
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Table 4-1.  Chemical Identity of the Isomers of Dichloropropene
cis- and trans-
cis-1,3-Dichloro- trans-1,3-Dichloro- 1,3-Dichloro-
Characteristics propene propene propene References
Chemical name cis-1,3-Dichloro- trans-1,3-Dichloro- 1,3-Dichloropropene Lide 2005;
propene propene NIOSH 2005
Synonyms (Z)-1,3-Dichloro- (E)-1,3-Dichloro- 1,3-Dichloropropene; ChemID
propene; cis-1,3- propene; trans-1,3- 1,3-dichloro-1- 2006a, 2006b
dichloro-1-propene; dichloro-1-propene; propene; 1,3-dichloro-
cis-1,3-dichloro- trans-1,3-dichloro- propylene; 1,3-D
propylene; cis-DCP propylene;
trans-DCP
Trade names Not applicable Not applicable PIC CLOR; TRICAL; EPA 2006i
TRI-CAL TRILONE II; 
TRI-FORM; TELONE;
INLINE
Chemical formula C3H4Cl2 C3H4Cl2 C3H4Cl2 RTECS 2006
Lide 2005;
Identification numbers:
CAS registry 10061-01-5 10061-02-6 542-75-6 RTECS 2006
NIOSH RTECS UC8325000 UC8320000 UC8310000 RTECS 2006
EPA hazardous Not available Not available U084 RTECS 2006
waste
DOT/UN/NA/IMCO UN/DOT 2047; UN/DOT 2047; IMO UN/DOT 2047; IMO DOT 2000;
shipping IMO 3.2 3.2 3.3 HSDB 2006
HSDB 1503 1504 1109 HSDB 2006
NCI Not available Not available NCI-C03985 HSDB 2006
Chemical structure Cl 
Cl 
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of the Isomers of Dichloropropene
Characteristics 1,1-Dichloropropene 1,2-Dichloropropene References




Synonyms	 1,1-Dichloro-1-propene; Propene, 1,2-dichloro-; ChemID
propene, 1,1-dichloro-; 1,2-dichloropropylene; propylene 2006c, 2006d;
1,1-dichloropropylene dichloride RTECS 2006
Trade names	 Not applicable Not applicable
Chemical formula C3H4Cl2 C3H4Cl2	 RTECS 2006
Chemical structure Cl Cl	 ChemID
2006c, 2006d:
Cl Lide 2005Cl 
Identification numbers:
CAS registry 563-58-6 563-54-2 RTECS 2006
NIOSH RTECS UC8290000 UC8300000 RTECS 2006
EPA hazardous Not available Not available RTECS 2006
waste
DOT/UN/NA/IMCO UN/DOT 2047; IMO not UN/DOT 2047; IMO 3.3 DOT 2000;
shipping available HSDB 2006
HSDB Not applicable 6175 HSDB 2006













    








    






    
     
 
     
  
 
   
  
 
   
     








4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of the Isomers of Dichloropropene
Characteristics 2,3-Dichloropropene 3,3-Dichloropropene References
Chemical name 2,3-Dichloropropene 3,3-Dichloropropene	 ChemID
2006e, 2006f;
Lide 2005;




Trade names	 Not applicable Not applicable
Chemical formula C3H4Cl2 C3H4Cl2	 ChemID
2006e, 2006f






CAS registry 78-88-6 563-57-5 ChemID
2006e, 2006f
NIOSH RTECS UC8400000 Not applicable HSDB 2006
EPA hazardous Not available Not available
waste
DOT/UN/NA/IMCO UN/DOT 2047; IMO 3.3 UN/DOT 2047; IMO not available DOT 2000
shipping
HSDB 5222 Not applicable HSDB 2006
NCI Not available Not available
CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/Intergovernmental Maritime Consultative Organization; EPA = Environmental Protection Agency;
HSDB = Hazardous Substance Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of the Isomers of Dichloropropene
cis- and trans-
cis-1,3-Dichloro- trans-1,3-Dichloro- 1,3-Dichloro-
Property propene propene propene References
Molecular weight 110.97 110.97 110.97 RTECS 2006
Color Colorless Colorless Colorless to amber Lewis 2001;
Tomlin 2003
Physical state Liquid Liquid Liquid Lewis 2001;
Tomlin 2003
Melting point Not available Not available -84 °C Verschueren 2001
Boiling point 104.3 °C 112.0 °C 108 °C O’Neil et al. 2001
Density 1.224 g/cm3 at 20 °C 1.217 g/cm3 at 20 °C 1.211 g/cm3 at 25 °C Meister et al.
2006; O’Neil et al.
2001
Odor Not available Not available Sweet, penetrating Tomlin 2003
Odor threshold
Water Not available Not available Not available
Air Not available Not available 1 ppm Verschueren 2001
Solubility
Water at 20 °C 2.7x103 mg/L 2.8x103 mg/L 2.0x103 mg/L Dilling 1977;
Tomlin 2003








solvents, esters, and 
ketones
Lide 2005; Tomlin 
2003
Partition coefficients
Log octanol/water 2.06 2.03 1.82 Tomlin 2003






















21 °C (69.8 °F) 21 °C (69.8 °F) 35 °C (95 °F) Lewis 2000, 2001
Conversion factors
ppm (v/v) to mg/m3 
in air (20 °C)
4.61
mg/m3 to ppm (v/v)








Bioconcentration Not available Not available Not available
factor (log BCF)
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of the Isomers of Dichloropropene
Property 1,1-Dichloropropene 1,2-Dichloropropene References
Molecular weight 110.97 110.97 RTECS 2006
Color Not available Not available
Physical state Liquid Liquid EPA 1981c
Melting point Not available Not available
Boiling point 76.5 °C 75 °C Lide 2005; Verschueren 
2001
Density 1.186 g/cm3 at 25 °C Not available Lide 2005 
Odor Not available Not available
Odor threshold
Water Not available Not available
Air Not available Not available
Solubility
Water at Not available 2.7x103 mg/L at 25 °C Gunther et al. 1968
Organic solvents Soluble in ether, acetone,
and chloroform




Log octanol/water Not available Not available
Koc Not available Not available
Vapor pressure 91 mm Hg at 20 °C 91 mm Hg at 20 °C EPA 1981c





Not available Not available
Flashpoint Not available Not available
Conversion factors
ppm (v/v) to mg/m3 in
air (20 °C)










Not available Not available
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of the Isomers of Dichloropropene
Property 2,3-Dichloropropene 3,3-Dichloropropene References
Molecular weight 110.97 110.97 ChemID 2006e, 2006f;
RTECS 2006
Color Straw-colored Not available Verschueren 2001
Physical state Liquid Liquid EPA 1981c; Lide 2005





1.211 g/cm3 at 20 °C
84.4 °C
1.224 g/cm3 at 20 °C
EPA 1981c; Lide 2005
Lide 2005; Meister et al.
2006; O’Neil et al. 2001
Odor Pungent Not available Verschueren 2001
Odor threshold
Water Not available Not available
Air Not available Not available
Solubility
Water 2.15x103 mg/L at 25 °C Not available Mackay and Shiu 1981 
Organic solvents Miscible in ethanol, soluble in 
ether, benzene, and chloroform
Soluble in ether, benzene,
and chloroform
Lide 2005; Tomlin 2003
Partition coefficients
Log octanol/water Not available Not available
Koc Not available Not available












Flashpoint 10 °C (50 °F) Not available Lewis 2000
Conversion factors
ppm (v/v) to mg/m3 
in air (20 °C)
4.61
mg/m3 to ppm (v/v)






Bioconcentration Not available Not available
factor (log BCF)
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187DICHLOROPROPENES
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
1,3-Dichloropropene is produced by either high-temperature chlorination of propylene or from
1,3-dichloro-2-propanol by dehydration with POCl3 or P2O5 in benzene (Hartwig et al. 2005; Krahling et
al. 2005; Yang 1986).  All commercial preparations of 1,3-dichloropropene are mixtures of the cis- and 
trans- isomers.  Before 1978, approximately 25 million kilograms (25,000 metric tons) of 1,3-dichloro-
propene were produced annually in the United States (Yang 1986).  Over 1 million kilograms
(1,000 metric tons) of pesticides containing 1,3-dichloropropene were used in California alone in 1978.  
The production volume of 1,3-dichloropropene reported by U.S. manufacturers in 1986, 1990, 1994, 
1998, and 2002 was within the range of >1 million pounds to 10 million pounds (>450–4,500 metric tons)
(IUR 2002).
2,3-Dichloropropene is produced during the chlorination of propylene as a byproduct in allyl chloride
synthesis (Krijgsheld and van der Gen 1986).  It can also be formed by treating 1,2,3-trichloropropane
with alkali or by chlorination of 2-chloro-1-propene.  Production methods for 1,1-, 1,2-, and 3,3-dichloro-
propene were not located.  Based on the International Update Rule data, the production volume of 2,3-di-
chloropropene reported by U.S. manufacturers was within the range of >1 million pounds to 10 million 
pounds (>450–4,500 metric tons) in 1986 and <10,000 pounds (4.5 metric tons) in 1990, 1994, 1998, and 
2002 (IUR 2002).  1,1-, 1,2-, and 3,3-Dichloropropene were not listed as high production volume
chemicals (>10,000 pounds or 4.5 metric tons produced per year) in 1986, 1990, 1994, 1998, or 2002 
(IUR 2002).   
According to SRI (2005), Dow AgroSciences LLC (Freeport, Texas) is the only current manufacturer of
1,3-dichloropropene.  Active registrants of 1,3-dichloropropene pesticide formulations include Dow
AgroSciences LLC (Indianapolis, Indiana), Soil Chemicals Corporation (Hollister, California), and Trical
(Hollister, California).  Current manufacturers of 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene were not
located in the literature.
After the use of ethylene dibromide (EDB) was suspended by EPA, 1,3-dichloropropene and methyl
bromide became the major substitutes for EDB (Yang 1986).  Now that the use of methyl bromide is
scheduled to be phased out by EPA in 2006, 1,3-dichloropropene is expected to become a substitute for
   
 









    
   
    
 
 
   
  
    
   
 
 








   
   
     
    
 
   
 
   




5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
this pesticide as well (Cryer and van Wesenbeeck 2001; El Hadiri et al. 2003; EPA 2006k; Kim et al.
2003a, 2003b). 1,3-Dichloropropene use permits were suspended in California during 1990 after high 
concentrations of this pesticide were detected in air samples (Baker et al. 1996; EPA 1998; Roby and 
Melichar 1997).  Reintroduction of limited use was approved by the California Department of Pesticide
Regulation in 1994.
Tables 5-1 and 5-2 list the facilities in each state that manufacture or process 1,3-dichloropropene and 
2,3-dichloropropene, respectively.  These tables give the intended use and the range of the amounts of
1,3- and 2,3-dichloropropene stored on site.  The data listed in Tables 5-1 and 5-2 are derived from the
Toxics Release Inventory (TRI05 2007).  Only certain types of facilities were required to report (EPA
1997).  Therefore, this is not an exhaustive list.  TRI data are not available for 1,1-, 1,2-, and 3,3-dichloro-
propene.
5.2  IMPORT/EXPORT
Import and export data for 1,1-, 1,2-, 1,3-, 2,3-, and 3,3-dichloropropene were not located in the literature.
5.3  USE 
1,3-Dichloropropene is the predominant component of several formulations used in agriculture as soil
fumigants for parasitic nematodes (Hartwig et al. 2005; Krijgsheld and van der Gen 1986).  Currently, 
there are 14 registered commercial preparations of fumigants that contain 1,3-dichloropropene (EPA
2006i).  The trade names of these preparations are listed in Chapter 4.  Table 5-3 contains the reported 
chemical compositions of these mixtures.  Some variation may exist in the composition of these products.  
Most of these fumigants are not diluted and are applied directly to the soil of vegetable and tobacco crops
(Yang 1986).  Much smaller quantities of 1,3-dichloropropene are used as solvents and chemical
intermediates (Krijgsheld and van der Gen 1986; Lewis 2001).
2,3-Dichloropropene is used as a chemical intermediate (Krijgsheld and van der Gen 1986).  It was
formerly used as an active ingredient along with ethylene dichloride in a pesticide formulation (EPA
2006i).  However, the registration of this pesticide was cancelled in 1985.  Uses for 1,1-, 1,2-, and 3,3-di-
chloropropene were not located in the available literature.
   
 
















     
     
      
     
     
     
     
     
        
       
     
     
     
      
     
        
     
 
  




















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produce, Process, or Use 1,3-Dichloropropene
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AR 2 1,000 99,999 12
CA 10 1,000 9,999,999 6, 7, 9
DE 4 10,000 9,999,999 6, 10
FL 2 100,000 9,999,999 7, 9
GA 3 10,000 999,999 7, 9
HI 1 1,000 9,999 10
IL 2 1,000 99,999 7, 12
LA 19 0 9,999,999 1, 3, 4, 5, 6, 12, 13
MI 7 100,000 9,999,999 1, 3, 4, 5, 7, 9, 12
MS 1 1,000 9,999 10
NC 2 100,000 9,999,999 9
NJ 2 1,000 99,999 12
OH 4 1,000 9,999,999 1, 4, 7, 12
SC 1 10,000 99,999 6
TX 20 1,000 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
WA 2 1,000,000 49,999,999 9
aPost office state abbreviations used
bAmounts on site reported by facilities in each state
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI05 2007 (Data are from 2005)
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amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
IA 2 100 9,999 1, 5, 13
IN 1 10,000 99,999 6
LA 5 10,000 999,999 1, 4, 5, 12, 13
TX 18 0 49,999,999 1, 2, 3, 5, 6, 7, 8, 11, 12, 13, 14
aPost office state abbreviations used









8.  Formulation Component
9.  Article Component
10.  Repackaging
11.  Chemical Processing Aid
12.  Manufacturing Aid 
13.  Ancillary/Other Uses
14.  Process Impurity
Source:  TRI05 2007 (Data are from 2005)
   
 










































    








5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-3.  Compositions of Actively Registered Commercial Products Containing 
1,3-Dichloropropene
Name Composition	 Manufacturer
Pic Clor 60	 39% 1,3-dichloropropene
59.4% chloropicrin
Pic-Chlor 15	 82.9% 1,3-dichloropropene
14.8% chloropicrin
Pic-Chlor 30	 68.2% 1,3-dichloropropene
29.7% chloropicrin
Tri-Cal Trilone II Soil Fumigant 94% 1,3-dichloropropene
Tri-Form 40/60	 37.6% 1,3-dichloropropene
60% chloropicrin
Telone C-15	 82.9% 1,3-dichloropropene
14.8% chloropicrin
Tri-Form 30	 68.2% 1,3-dichloropropene
29.7% chloropicrin
Tri-Form 35	 63.4% 1,3-dichloropropene
34.6% chloropicrin
Telone C-17	 81.2% 1,3-dichloropropene
16.5% chloropicrin
Telone II	 97.5% 1,3-Dichloropropene
Telone C-35	 63.4% 1,3-dichloropropene
34.7% chloropicrin
Telone EC	 93.6% 1,3-dichloropropene

















Source:  EPA 2006i
   
 









   
 
 
    





5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.4  DISPOSAL
1,3-Dichloropropene may be disposed of by using a sorbent media that is packaged in an epoxy-lined 
drum and placed in a Resource Conservation and Recovery Act (RCRA)-approved landfill.  1,3-Dichloro-
propene may also be disposed of in a high-temperature incinerator with an acid scrubber and a
temperature/dwell time that will completely destroy the pesticide (HSDB 2006).  Disposal methods
specific to 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene were not located in the literature; however, disposal
methods designed for 1,3-dichloropropene are expected to apply to these isomers as well based on the 
similarities in physical and chemical properties.
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
The majority of dichloropropene data pertaining to environmental releases, environmental fate and 
partitioning, monitoring in environmental media, and the potential for human exposure have been
provided for the 1,3- isomer only.  This is most likely because 1,3-dichloropropene is produced in much 
larger quantities than the other isomers and it is released directly into the environment as a pesticide.
Therefore, the focus of this chapter is on 1,3-dichloropropene.  Relevant data regarding 1,1-, 1,2-, 2,3-, 
and 3,3-dichloropropene are included whenever available.  
1,1-, 1,2-, 1,3-, and 2,3-Dichloropropene have been identified in at least 2, 9, 107, and 3 of the
1,699 hazardous waste sites, respectively, that have been proposed for inclusion on the EPA National
Priorities List (NPL) (HazDat 2008).  However, the number of sites evaluated for 1,1-, 1,2-, 1,3-, and 
2,3-dichloropropene is not known.  The frequency of sites where 1,3-dichloropropene has been identified
can be seen in Figure 6-3, while those where 1,1-, 1,2-, and 2,3-dichloropropene have been identified can 
be seen in Figures 6-1, 6-2, and 6-4, respectively.  3,3-Dichloropropene was not identified in any of the
1,699 hazardous waste sites that have been proposed for inclusion on the EPA NPL.
1,3-Dichloropropene is not a naturally occurring compound (IARC 1986).  It is produced synthetically 
and may be released to the atmosphere in fugitive or accidental emissions during its manufacture, storage, 
and transport.  1,3-Dichloropropene’s use as a soil fumigant for the control of nematodes in various crops
will result in its direct release to the environment (EPA 1978a; Lao et al. 1982).  1,3-Dichloropropene is
typically applied to soils prior to planting by underground injection at a depth of 12–18 inches (EPA
1998).  Due to its volatile nature, it may migrate to the soil surface where it volatilizes to air.  In order to
reduce potential emissions to air and increase the effectiveness of 1,3-dichloropropene as a fumigant, soil
sealing techniques such as immediate irrigation, soil compacting, and covering the treated fields with 
tarps are common agricultural practices when using 1,3-dichloropropene and other fumigants (EPA
1998).
1,3-Dichloropropene may leach into groundwater and soil from landfills and hazardous waste sites















     
     
    






    
   
  
   
   
 
      
  
  






      
   






   
198DICHLOROPROPENES
6.  POTENTIAL FOR HUMAN EXPOSURE
to soil occurs during the application of the chemical to agricultural fields when used as a soil fumigant
(CEPA 1982; Cohen 1986; Krijgsheld and van der Gen 1986; Maddy et al. 1982).  Accidental spills may
also release 1,3-dichloropropene to the environment (Markovitz and Crosby 1984; Sterrett et al. 1986).  
Releases of 1,1-, 1,2-, and 3,3-dichloropropene into the environment are expected to be low since these 
substances are not produced or used on a large scale for commercial or industrial purposes.  2,3-Dichloro-
propene may be released from facilities where it is produced or used.
Limited monitoring data are available for 1,3-dichloropropene in surface water, drinking water, and soil;
however, the existing data indicate that this substance is not widely detected in these media (Dowty et al. 
1975a, 1975b; EPA 2006j; Krijgsheld and van der Gen 1986; Otson 1987; Rogers et al. 1987).  1,3-Di-
chloropropene has not been detected in food (EPA 1998).  1,3-Dichloropropene was positively detected in 
air in generally <5% of urban air samples collected across the United States.  Mean concentrations among
the positive samples from both urban and rural locations across the United States ranged from 0.088 to 
0.33 ppb. 1,3-Dichloropropene air concentrations as high as 35.2 ppb have been measured at high-use 
locations.  A few nationwide surveys have been conducted in which 1,3-dichloropropene was analyzed 
for in water; however, only the STORET database lists positive detections of this substance (EPA 2006j;
Kolpin et al. 2000; Moran et al. 2004).  1,3-Dichloropropene was detected in approximately 40% of
12,673 water samples listed in STORET (EPA 2006j).  However, only 6% of the samples contained 
1,3-dichloropropene above the quantitation limit (unspecified).  The range, mean, and median of
quantifiable 1,3-dichloropropene concentrations were 0.002–25, 0.5, and 0.5 ppb, respectively.  1,3-Di-
chloropropene was detected in only 0.1% of 70,631 public water system samples collected in the United 
States between 1993 and 1997 (EPA 2001c).  
1,1-, 1,2-, 2,3-, and 3,3-Dichloropropene are not commonly found at measurable concentrations in air, 
surface water, drinking water, groundwater, soil, or food.  1,1-Dichloropropene has been detected in 
64% of 5,348 water samples listed in STORET, but only 1% of the samples contained 1,1-dichloro-
propene above the quantifiable limit.  The range of quantifiable concentrations in water was 0.001–5 ppb, 
with a mean of 0.4 ppb (EPA 2006j).  1,1-Dichloropropene was detected in only 0.01% of 97,698 public
water system samples collected in the United States between 1993 and 1997 (EPA 2001c).  
Possible routes of human exposure to 1,3-dichloropropene include inhalation, ingestion of contaminated 
drinking waters, and dermal contact.  1,3-Dichloropropene is rarely detected in foods due to its relatively
short environmental persistence; therefore, exposure to the general population through the consumption of
food is considered to be low.  High levels of exposure to 1,3-dichloropropene are most likely to occur in 
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6.  POTENTIAL FOR HUMAN EXPOSURE
occupational settings where 1,3-dichloropropene is either produced or used as a soil fumigant (Albrecht
1987b; Albrecht et al. 1986; Markovitz and Crosby 1984; Nater and Gooskens 1976; Osterloh et al. 1984, 
1989a, 1989b; van Joost and de Jong 1988; Wang 1984).  Intake by inhalation or dermal contact is the
most probable route of workplace exposure to 1,3-dichloropropene.  1,3-Dichloropropene is a volatile 
compound and, after soil application as a fumigant, a fraction of the compound will volatilize and escape
into the atmosphere (Krijgsheld and van der Gen 1986).  Inhalation and dermal contact are probably the
major sources of exposure to individuals who work in fields where 1,3-dichloroproene is applied.
The potential for human exposure to 1,1-, 1,2-, and 3,3-dichloropropene is expected to be low because 
they are not produced or used in high amounts.  Since 2,3-dichloropropene may be released from facilities
where this substance is produced or used, individuals who work or live near these facilities may be
exposed to this substance; however, exposure of the general population to 2,3-dichloropropene is not
expected to be important.
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005a).  This is not an exhaustive list.  Manufacturing and 
processing facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005a).
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6.2.1 Air
Estimated releases of 5,502 pounds (2.5 metric tons) of 1,3-dichloropropene to the atmosphere from
16 domestic manufacturing and processing facilities in 2005, accounted for about 92% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI05 2007).  Estimated 
releases of 4,447 pounds (2.0 metric tons) of 2,3-dichloropropene to the atmosphere from five domestic
manufacturing and processing facilities in 2005, accounted for about 89% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI05 2007).  These releases of
1,3- and 2,3-dichloropropene are summarized in Tables 6-1 and 6-2, respectively.  1,1-, 1,2-, and 3,3-Di-
chloropropene were not listed in the TRI.
1,3-Dichloropropene is produced synthetically and may be released to the atmosphere as fugitive or
accidental emissions during its manufacture (Leiber and Berk 1984; van Joost and de Jong 1988), 
transport (Markovitz and Crosby 1984; Sterrett et al. 1986), and storage (Albrecht et al. 1986).  For
example, on April 8, 1984, a rail accident that occurred about 45 miles southeast of Tucson, Arizona
resulted in a spill of 15,000 gallons of 1,3-dichloropropene.  During the clean-up, which took place
between August 1984 and March 1985, approximately 19,000 pounds of 1,3-dichloropropene were 
released to ambient air by an aeration process (Sterrett et al. 1986).
A major anthropogenic release of 1,3-dichloropropene to the atmosphere occurs during its application as a
soil fumigant (Albrecht 1987a; Markovitz and Crosby 1984; Osterloh et al. 1984, 1989a, 1989b).  Current
application methods involve injecting the fumigant at least 12 inches below the soil surface (EPA 1998).  
Off-gassing of 1,3-dichloropropene in chisel trace left behind during application occurs for several days 
after application.  Current methods used to minimize volatilization of 1,3-dichloropropene after
application include soil compaction, irrigation, and covering with a tarp (EPA 1998).  Modification of
current application methods and the use of organic and fertilizer amendments are being explored as ways 
to further minimize air emissions of 1,3-dichloropropene from treated fields (Gan et al. 1998a, 1998b;
Kim et al. 2003b; Wang et al. 2001a, 2001b).
1,3-Dichloropropene was detected in atmospheric samples of three sites located in Washington state, 
Arizona, and North Carolina following its application (NCFA 1997).  1,3-Dichloropropene was broadcast
applied to a 20-acre loamy sand field at an application rate of 252 lbs a.i./A at the Washington state site.  
It was row applied to a 20-acre sandy loam located in Arizona at a rate of 121.2 lbs a.i./A, and was
broadcast applied at a rate of 164 lbs a.i. to a 12-acre sandy loam plot in North Carolina used to grow
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Reported amounts released in pounds per yearb 
Total release
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site
AR 1 0 No data 0 0 0 0 0 0
CA 2 16 0 0 0 0 16 0 16
DE 1 10 No data 0 0 10 10 10 20
FL 1 1,340 No data 0 0 0 1,340 0 1,340
GA 2 1,268 No data 0 0 0 1,268 0 1,268
LA 3 402 0 0 0 0 402 0 402
NC 1 500 No data 0 0 0 500 0 500
OH 2 609 0 0 255 0 609 255 864
TX 2 1,193 16 0 202 0 1,411 0 1,411
WA 1 164 No data 0 0 0 164 0 164
Total 16 5,502 0 0 457 10 5,720 265 5,985
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.

eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs)
 
(metal and metal compounds).
 
gClass I wells, Class II-V wells, and underground injection.
 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills.





jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI05 2007 (Data are from 2005)
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Reported amounts released in pounds per yearb 
Total release
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site
IA 1 4,174 No data 0 0 0 4,174 0 4,174
LA 2 84 0 0 0 0 84 0 84
TX 2 189 470 0 60 0 719 0 719
Total 5 4,447 470 0 60 0 4,977 0 4,977
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.

eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 




gClass I wells, Class II-V wells, and underground injection.

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills.





jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI05 2007 (Data are from 2005)
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tobacco.  Atmospheric samples were monitored over a 15-day period at each site and at distances of up to 
1,600 meters from the site.  These data are summarized in Table 6-3. 
The monitoring data indicated that 1,3-dichloropropene air concentrations peaked during the first 3 days 
following treatment and then declined over a period of 14 days following treatment, which was the
duration of the air monitoring study.  
Telone II® was applied at approximately 12.8 gallons per acre (121 lbs a.i./acre) to a fallow plot in 
Nevada and 1,3-dichloropropene levels were monitored for 7 days directly above the field and at locations
up to one-half mile away (EPA 1998).  The average concentration of 1,3-dichloropropene at a 6-inch 
height above the field during 7 days was 465.31 μg/m3; at a 5-foot height at the edge of the field, it was 
94.81 μg/m3; at a 5-foot height 100 feet away from the field, it was 39.39 μg/m3; at a 5-foot height
0.25 miles from the field, it was 5.17 μg/m3; and at a 5-foot height one-half mile from the field, it was 
3.88 μg/m3. Wind velocity was determined to be the major factor in the dispersion of 1,3-dichloro-
propene.  
1,3-Dichloropropene has been identified in air samples collected at 6 of the 1,699 NPL hazardous waste 
sites where it was detected in some environmental media (HazDat 2008).  1,1-, 1,2-, 2,3-, and 3,3-Di-
chloropropene were not identified in air samples collected at any of the 1,699 NPL hazardous waste sites.
6.2.2 Water
Estimated releases of 470 pounds (0.2 metric tons) of 2,3-dichloropropene to surface water from five 
domestic manufacturing and processing facilities in 2005, accounted for <1% of the estimated total
environmental releases from facilities required to report to the TRI (TRI05 2007).  These releases are
summarized in Table 6-2.  According to TRI estimates, there were no releases of 1,3-dichloropropene to 
surface water from 16 domestic manufacturing and processing facilities in 2005 (TRI05 2007).  TRI data
for 1,3-dichloropropene are summarized in Table 6-1.  1,1-, 1,2-, and 3,3-Dichloropropene were not listed 
in the TRI.
Very little information regarding the release of 1,3-dichloropropene to water was found in the available
literature.  It has been suggested that chlorination of organic substances during treatment in water systems 
can result in the formation of low levels of 1,3-dichloropropene (Dowty et al. 1975a, 1975b; Krijgsheld 
and van der Gen 1986; Otson 1987; Rogers et al. 1987).  Trace quantities of 1,3-dichloropropene are























      
      
      
      
 
     
      
      
 
     
      
      
 
     
      
      
 
     
      
      
 
     
      
      
 
     
 





6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-3.  Maximum Concentrations (24-Hour Time-Weighted Average) of
1,3-Dichloropropene in Air at Varying Distances from Treated Fields
Maximum Maximum 
Distance from 4-hour 24-hour TWA Mean 7-day Mean 15-day
treated field concentration concentration concentration concentration 
(meters)a Location (ppb) (ppb) (ppb) (ppb)
1,600 Arizona 20.0 5.1 0.7 0.5
1,200 Arizona 34.7 10.1 1.2 0.8
800 Arizona 47.5 13.8 2.1 1.4
800 Washington 37.8 17.5 4.6 3.2
800 North 
Carolina 13.9 2.4 0.3 0.3
500 Arizona 106.1 30.9 4.1 2.6
500 Washington 40.3 20.2 5.3 3.8
500 North 
Carolina 20.3 3.5 0.5 0.3
125 Arizona 376.1 127.4 20.2 12.2
125 Washington 114.7 61.2 12.1 8.8
125 North 
Carolina 61.8 12.8 2.3 1.3
25 Arizona 786.6 397.5 43.1 24.7
25 Washington 68.6 46.7 16.5 13.7
25 North 
Carolina 86.7 49.0 5.8 3.3
5 Arizona 350.4 281.2 40.7 23.0
5 Washington 77.2 51.8 20.2 16.2
5 North 
Carolina 147.7 75.6 8.4 4.8
Onsite Arizona 509.6 234.7 69.4 37.6
Onsite Washington 77.2 58.6 33.3 25.4
Onsite North 
Carolina 74.8 57.6 16.6 8.9
aAll samples were obtained at a height of approximately 5 feet above ground.
Source:  NCFA 1997


















    






    







    
 
     
 
   
   
  




6.  POTENTIAL FOR HUMAN EXPOSURE
formed during the chlorination of cooling water, which prevents biofouling at electricity-generating
power facilities (Bean et al. 1985).  Very little information is available regarding the presence of 1,3-di-
chloropropene in drinking water.  A survey of sewage treatment facilities demonstrated that 1,3-dichloro-
propene may be released to surface waters via primary and secondary effluents (EPA 1978a; Lao et al. 
1982).  Waste water effluents from petroleum refineries may also release 1,3-dichloropropene to surface
waters (Snider and Manning 1982).  Waste water from 1,3-dichloropropene production sites can also 
release 1,3-dichloropropene to surface waters (EPA 1981a).
Due to its high mobility in soils and the fact that 1,3-dichloropropene is injected underground to a depth 
of 12–18 inches when used as a fumigant, migration to groundwater is possible (Cohen 1986; Krijgsheld 
and van der Gen 1986; Maddy et al. 1982).  1,3-Dichloropropene may also be released to groundwater via 
landfills and hazardous waste sites (Hauser and Bromberg 1982; Sabel and Clark 1984).
2,3-Dichloropropene has been qualitatively identified in groundwater collected from the Ville Mercier
hazardous waste site located in southern Quebec, Canada (Pakdel et al. 1994).
1,1-, 1,2-, 1,3-, and 2,3-Dichloropropene have been identified in groundwater samples collected at 1, 3, 
68, and 3 of the 1,699 NPL hazardous waste sites, respectively, where it was detected in some 
environmental media (HazDat 2008).  3,3-Dichloropropene was not identified in groundwater samples 
collected at any of the 1,699 NPL hazardous waste sites.  1,3-Dichloropropene has been identified in 
surface water samples collected at 10 of the 1,699 NPL hazardous waste sites, respectively, where it was 
detected in some environmental media (HazDat 2008).  1,1-, 1,2-, 2,3-, and 3,3-Dichloropropene were not
identified in surface water samples collected at any of the 1,699 NPL hazardous waste sites.
6.2.3 Soil 
Estimated releases of 457 pounds (0.2 metric tons) of 1,3-dichloropropene to soils from 16 domestic 
manufacturing and processing facilities in 2005, accounted for about 8% of the estimated total
environmental releases from facilities required to report to the TRI (TRI05 2007).  Estimated releases of 
60 pounds (0.03 metric tons) of 2,3-dichloropropene to soils from five domestic manufacturing and 
processing facilities in 2005, accounted for 1% of the estimated total environmental releases from
facilities required to report to the TRI (TRI05 2007).  These releases of 1,3- and 2,3-dichloropropene are
summarized in Tables 6-1 and 6-2, respectively.  1,1-, 1,2-, and 3,3-Dichloropropene were not listed in 
the TRI.
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The most common release of 1,3-dichloropropene to soil occurs in agricultural fields where it is applied 
as a soil fumigant (CEPA 1982; Cohen 1986; Krijgsheld and van der Gen 1986).  Accidental spills may
also release 1,3-dichloropropene to soil (Markovitz and Crosby 1984; Sterrett et al. 1986).  For example, 
on April 8, 1984, a rail accident that occurred about 45 miles southeast of Tucson, Arizona resulted in a 
spill of 15,000 gallons of 1,3-dichloropropene (Sterrett et al. 1986).
According to the National Pesticide Use Database updated by the National Center for Food and
Agricultural Policy, a total of approximately 34.7 million pounds (15,700 metric tons) of 1,3-dichloro-
propene was used in the United States in 1997 (NCFA 1997).  The estimated amounts applied, crops
grown, total acres treated in each state are provided in Table 6-4.
1,1- and 1,3-Dichloropropene have been identified in soil and sediment samples collected at 1 and 0, and 
28 and 6 of the 1,699 NPL hazardous waste sites, respectively, where it was detected in some 
environmental media (HazDat 2008).  1,2-, 2,3-, and 3,3-Dichloropropene were not identified in soil or
sediment samples collected at any of the 1,699 NPL hazardous waste sites.
6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
The transport and partitioning of an organic compound in the environment is a function of the physical
and chemical properties of that compound and the site-specific characteristics of the environment (e.g., 
percent soil organic matter).  Based upon similarities in their physical and chemical properties, 1,1-, 1,2-, 
cis- and trans-1,3-, 2,3-, and 3,3-dichloropropene should behave similarly in regards to transport and 
partitioning within the environment.
In the atmosphere, measured vapor pressures of the dichloropropene isomers ranging from 22 to 91 mm 
Hg at 20 °C (EPA 1981c) suggest that these compounds will exist predominantly in the vapor phase
(Eisenreich et al. 1981).  Water solubility values ranging from 2,000 to 2,700 mg/L (measured at 20– 
25 °C) (Dilling 1977; Gunther et al. 1968; Mackay and Shiu 1981; Tomlin 2003), indicate that wet
deposition may remove these compounds from the atmosphere.  This is confirmed by the detection of
1,3-dichloropropene in rainwater (Section 6.4.2).











   
 
    
    
    
 
     
 
 
    
     
    
     
    
    
    
    
    
    
    
 
    
    
 
    
 
    
    
  
 
    
     
 
    






6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-4.  Estimated Annual Use of 1,3-Dichloropropene in the United States
State Acres treated Pounds applied Crops grown in treated soil
Alabama 10,478 422,120 Cotton, peanuts
Arizona 18,974 971,942 Cantaloupes, carrots, cotton, melons,
watermelons
California 13,296 1,509,058 Beets, Brussels sprouts, cantaloupes,
carrots, hot peppers, melons, parsley,
potatoes, sweet potatoes
Colorado 3,668 246,759 Carrots, sugarbeets
Florida 29,115 1,826,311 Cotton, peanuts, potatoes, tobacco
Georgia 83,361 2,994,402 Cotton, peanuts, tobacco
Idaho 19,692 1,668,071 Onions, potatoes, sugarbeets
Maryland 321 36,492 Cucumbers
Michigan Not available Not available Strawberries
Montana 2,374 113,943 Sugarbeets
Nebraska 2,418 116,024 Sugarbeets
New Mexico 22,222 1,066,983 Cotton, hot peppers
New York 2,436 640,202 Onions, strawberries
North Carolina 128,557 10,846,670 Cucumbers, peanuts, sweet peppers, sweet
potatoes, tobacco
Oklahoma Not available Not available Peanuts
Oregon 35,185 5,831,260 Asparagus, blueberries, carrots, onions,
potatoes, strawberries
South Carolina 42,348 2,548,082 Cotton, cucumbers, peanuts, sweet potatoes,
tobacco
Tennessee 191 9,159 Sweet potatoes
Texas 2,268 153,721 Cantaloupes, carrots, celery, melons, onions,
peanuts, sweet peppers, sweet potatoes,
watermelons
Utah 223 60,634 Onions
Washington 24,814 3,640,768 Carrots, onions, potatoes, strawberries,
strawberries
Wisconsin 51 14,660 Strawberries
Wyoming Not available Not available Sugarbeets
Source:  data are from the National Pesticide Use Database updated in 1997 by the National Center for Food and 
Agricultural Policy (NCFA 1997).
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In surface waters, volatilization of dichloropropenes should be an important fate process that will compete
with the transformation processes of biodegradation and hydrolysis (Section 6.3.2.2).  Based on 
experimentally measured Henry's law constants for cis- and trans-1,3-dichloropropene of 2.71x10-3 and 
8.71x10-4 atm-m3/mol at 20 °C, respectively (Leistra 1970), these chemicals are expected to volatilize 
from environmental waters (Thomas 1982).  Using the method of Thomas (1982), the estimated 
volatilization half-lives of cis- and trans-1,3-dichloropropene from a model river 1 meter deep, flowing at
a velocity of 1 m/sec with a wind velocity of 3 m/sec are 3.8 and 4.2 hours, respectively.  Experimental
Koc values for cis- and trans-1,3-dichloropropene in aqueous solutions are reportedly 23 and 26,
respectively (Kenaga 1980).  Based on these Koc values, 1,3-dichloropropene is not expected to adsorb to 
suspended solids and sediment in the water column.  Based on similarities in structure, vapor pressure, 
and water solubility, volatilization of 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene from water surfaces and 
adsorption of these substances to sediment is expected to be similar to that of 1,3-dichloropropene.  
In soil, 1,3-dichloropropene can exist as a gas or dissolved in water.  The adsorption characteristics for 
each form are different.  Experimental Koc values for 1,3-dichloropropene in Arlington sandy loam, 
Chualar clay loam, Mocho silty clay loam, and Pahokee muck ranged from 18 to 60 (Kim et al. 2003b).  
Koc values measured in soils of 3.19, 10.4, and 55.1% organic carbon were 25.7, 26.3, and 27.6, 
respectively, for cis-1,3-dichloropropene and 27.8, 27.2, and 27.5, respectively, for trans-1,3-dichloro-
propene (Hamaker and Thompson 1972).  These Koc values indicate a high mobility in soil (Swann et al. 
1983) and a potential for leaching.  Although movement in saturated soils is possible, concurrent
hydrolysis and biodegradation should attenuate the amounts of 1,3-dichloropropene that may actually
leach to groundwater.  Furthermore, extensive groundwater monitoring programs, conducted in 
California, have not demonstrated that 1,3-dichloropropene is contaminating well waters in areas of 
continued field applications of the pesticide (Cohen 1986; Maddy et al. 1982).  Measured Koc values were 
not located for 1,1-, 1,2-, 2,3-, or 3,3-dichloropropene; however, the mobility of these substances in soils
is expected to be similar to that of 1,3-dichloropropene.
1,3-Dichloropropene is more likely to adsorb to soil when it is in the vapor phase than when it is
dissolved in water (Munnecke and Vangundy 1979).  Adsorption for the vapor phase depends partly upon 
the soil's temperature and organic content (Leistra 1970).  Soil adsorption isotherms show a positive
correlation between adsorption of 1,3-dichloropropene and the percentage of organic matter in soil.  It
was also observed that adsorption of vapor-phase 1,3-dichloropropene is approximately 3 times greater at
2 °C than it is at 20 °C.  Adsorption isotherms measured for humus sand, peaty sand, and peat indicate
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vapor-phase Koc values for 1,3-dichloropropene ranging from about 450 to 750. These Koc values suggest
medium to low soil mobility for 1,3-dichloropropene in the vapor phase in soil (Swann et al. 1983).
The factors influencing the volatility of 1,3-dichloropropene from a field following its application are soil 
organic matter, wind speed, soil moisture content, depth of incorporation-injection, soil temperature and 
soil porosity.  1,3-Dichloropropene was soil injected to a depth of 12–14 inches at an application rate of
346 lb. a.i. per acre into a sandy loam field, loamy sand field, and muck soil.  At 6–12 hours
posttreatment, 1,3-dichloropropene reached a maximum concentration of 0.4–20.3 μg/m3 at a height of
6 inches above the soil surface (EPA 1998).  1,3-Dichloropropene concentrations decreased to
≤0.14 μg/m3 in all air samples from all locations by seven days posttreatment.  It was not detected above
the loamy sand and sandy loam soils by 14 days or above the muck soil by 21 days.  Volatilization rates 
appeared to be inversely proportional to the amount of soil organic matter and proportional to soil
porosity.   
Field management practices such as covering the treated fields with tarps, compacting the treated soils, 
and irrigating the treated soil post injection are commonly used practices to reduce volatilization losses of 
soil fumigants such as 1,3-dichloropropene. Following application of 1,3-dichloroporpene at 98 kg/ha
(87.5 lbs/A), volatilization losses from uncovered soil columns (12.5 cm inside diameter) were 62, 47, 
and 36% at injection depths of 20, 30, and 40 cm, respectively, after 20 days (Gan et al. 1998b).  The total
volatilization loss for 1,3-dichloropropene injected to a depth of 20 cm and then covered with a high 
density polyethylene (HDPE) tarp was 53% after 20 days.  It was determined that the high permeability of
HDPE reduced its ability to act as an effective barrier for 1,3-dichloropropene.  However, volatilization 
losses were reduced substantially if the soil was immediately irrigated post injection.  Only 34% of the
nominally applied 1,3-dichloropropene was volatilized after injection at a depth of 20 cm, followed by
irrigation with 184 mL of water applied to the soil surface at a rate of 2 mL/minute.  The authors observed 
that the volatilization rate of the cis isomer was consistently greater than the trans isomer in each
experiment.  This observation is consistent with the fact that the cis isomer possesses a lower boiling
point, higher vapor pressure, and larger Henry’s law constant than the trans isomer.  
As discussed in Section 6.3.2.3, dichloropropenes can be removed from soils via hydrolysis, microbial
degradation, and volatilization.  Since the rate of these processes can vary significantly with soil
conditions, the wide range of reported persistence half-lives for 1,3-dichloropropene is not surprising and 
demonstrates that the persistence of this substance in soil depends upon specific local conditions.
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Measured bioconcentration factor (BCF) values for the dichloropropene isomers were not found in the
literature.  Using a measured log Kow of 2.0 and a regression derived equation, a BCF of 19.5 can be
estimated for 1,3-dichloropropene (Meylan et al. 1999; Tomlin 2003).  According to a classification 
scheme developed by Franke et al. (1994), this BCF value suggests that the potential for bioconcentration 
of 1,3-dichloropropene in aquatic organisms is low.  Based on their structural similarities to 1,3-dichloro-
propene, bioconcentration of 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene in aquatic organisms is also 
expected to be low.
6.3.2 Transformation and Degradation
6.3.2.1 Air
The important environmental fate process for the degradation of 1,3-dichloropropene in ambient air is the
vapor-phase reaction with photochemically produced hydroxyl radicals.  The rate constants for the
reactions of cis- and trans-1,3-dichloropropene with hydroxyl radicals have been experimentally
determined to be 7.7x10-12 and 1.3x10-11 cm3/molecule-sec at 22 °C, respectively (Tuazon et al. 1984).  
1,3-Dichloropropene will also be removed from air via reaction with ozone; however, this reaction is
expected to be secondary to photooxidation with hydroxyl radicals.  The rate constants for the reactions of
cis- and trans-1,3-dichloropropene with ozone molecules have been experimentally determined to be
1.5x10-19 and 6.7x10-19 cm3/molecule-sec at 22 °C, respectively (Tuazon et al. 1984).  
Assuming that the average yearly troposphere hydroxyl radical and ozone molecule concentrations are
5.0x105 and 7.0x1011 molecules/cm3, respectively (Atkinson et al. 1979), the corresponding half-lives for
cis-1,3-dichloropropene in air are about 2.1 days (50 hours) and 76 days.  The corresponding half-lives 
for trans-1,3-dichloropropene in air would be about 1.2 days (30 hours) and 17 days.  Tuazon et al. (1984)
calculated the respective half-lives of 52 and 12 days for cis- and trans-1,3-dichloropropene reactions
with ozone based on an average background tropospheric concentration for ozone of
1.0x1012 molecules/cm3. For the cis and trans isomers, the authors also calculated respective half-lives of 
12 and 7 hours for the reactions with photochemically generated hydroxyl radicals present at an average
concentration of 2.0x106 molecules/cm3 (Tuazon et al. 1984).
The estimates of average hydroxyl radical and ozone concentrations in air used by Tuazon et al. (1984)
are more indicative of urban atmospheres.  In general, the hydroxyl radical and ozone concentrations in 
polluted air may increase by an order of magnitude over those estimates used by Atkinson et al. (1979).  
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Therefore, the half-life of 1,3-dichloropropene in ambient air may range between 7 and 50 hours, 
depending on the concentrations of cis- and trans-isomers and hydroxyl radicals in the troposphere.
Formyl chloride and chloroacetaldehyde have been identified as reaction products of 1,3-dichloropropene
with both hydroxyl radicals and ozone.  Reaction with ozone also yields chloroacetic acid, formic acid, 
hydrogen chloride, carbon dioxide, and carbon monoxide (Tuazon et al. 1984).
1,3-Dichloropropene is also susceptible to photolysis in air.  However, direct photodegradation of 1,3-di-
chloropropene should not be an important fate process, compared to its reaction with hydroxyl radicals
(EPA 1981b).  Nevertheless, some evidence that the photodecomposition of 1,3-dichloropropene may be
enhanced by the presence of atmospheric particulates exists (Tuazon et al. 1984).
Data regarding the degradation of 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene in air are not available.  Based 
on the physical and chemical properties of these isomers, photooxidation is expected to be similar to that
of 1,3-dichloropropene.  As is expected for 1,3-dichloropropene, ozonolysis and direct photolysis may
occur for 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene; however, photooxidation is expected to be the
dominant removal mechanism for dichloropropenes in the atmosphere.  
6.3.2.2 Water
River die-away test data pertaining to the biodegradation of 1,3-dichloropropene in natural waters were 
not available in the literature.  Several aerobic biological screening studies, which used settled domestic 
waste water for inocula, demonstrated that 1,3-dichloropropene is biodegradable (Tabak et al. 1981a, 
1981b).  Within 7 days, the original cultures, added to synthetic media that contained 5 mg yeast
extract/L, were able to degrade about 50% of the 1,3-dichloropropene at an initial concentration of
10 ppm (Tabak et al. 1981a, 1981b).  Acclimation to a series of subcultures was also demonstrated.  The
third subculture, with identical concentrations and under identical conditions, showed an approximate
85% removal of 1,3-dichloropropene within the same period of time (Tabak et al. 1981a, 1981b).
Nevertheless, the rate of biodegradation for 1,3-dichloropropene in natural waters cannot be inferred from
screening study data.
Yon et al. (1991) studied the dissipation of 14C-labeled 1,3-dichloropropene at 5 μg/mL in a
sediment/water system made from ditch bottom sediments and aerobic ditch water.  Although 49–58% of
the 1,3-dichloropropene volatilized after 7 days, degradation was also observed based on the presence of
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the radiolabeled metabolite 3-chloropropenic acid and other unspecified polar products.  The authors
reported this degradation as aerobic aquatic metabolism; however, the possible role of hydrolysis was not
addressed.
In addition to losses via biodegradation, 1,3-dichloropropene may undergo hydrolysis in natural waters.  
Hydrolysis half-lives measured in buffered solutions at pH 5, 7, and 9 were 13.5 days at 20 °C (EPA
1998).  Hydrolysis half-lives measured at pH 5.5 and 7.5 were 2 days at 29 °C, 11–13 days at 15 °C, and 
90–100 days at 2 °C (EPA 1998).  McCall (1987) reported similar hydrolysis half-lives of 3.1, 11.3, and 
51 days measured at 30, 20, and 10 °C, respectively, in sterile, buffered water and stated that this process 
was independent of pH.  However, Guo et al. (2004) measured half-lives of 8.7, 7.2, and 2.8 days at pH 4, 
7, and 10, respectively, in buffer solutions at 20 °C during a more extensive examination of the effect of
pH on hydrolysis.  In contrast to McCall (1987), these authors concluded that the rate of hydrolysis of
1,3-dichloropropene increases with increasing pH.  The primary hydrolysis product of 1,3-dichloro-
propene is 3-chloroallyl alcohol, which is broken down further to 3-chloroacrylic acid and eventually to 
CO2 (Guo et al. 2004).
Aquatic biodegradation and hydrolysis data were not available for 1,1-, 1,2-, 2,3-, and 3,3-dichloro-
propene.  Based on structural similarities, these isomers are expected to biodegrade similarly to 1,3-di-
chloropropene.  Hydrolysis of 2,3- and 3,3-dichloropropene will also be similar to that of 1,3-dichloro-
propene; however, hydrolysis of 1,1- and 1,2-dichloropropene is expected to be much slower due to the 
inhibiting effect of the two vinylic chlorine atoms (Smith and March 2001).
6.3.2.3  Sediment and Soil
1,3-Dichloropropene reportedly biodegrades in soil (Castro and Belser 1966, 1968; Roberts and Stoydin 
1976; Tu 1988, van der Pas and Liestra 1987).  Belser and Castro (1971) reported that the microbial
degradative pathway for both the cis and trans isomers followed a similar sequence.  The initial step of
the reaction involves allylic dechlorination of 1,3-dichloropropene and hydroxyl substitution to form the
corresponding chloroallylalcohol (Castro and Belser 1966; Roberts and Stoydin 1976).  Again, both cis-
and trans-chloroallylalcohols undergo oxidation, resulting in the formation of the corresponding
chloroacrylic acids (Castro and Belser 1968; Roberts and Stoydin 1976).  Next, vinylic chlorines are
removed and subsequently, propanoic acid 3-aldehyde is oxidized to carbon dioxide (Belser and Castro 
1971).
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1,3-Dichloropropene is degraded more rapidly in soil that has a history of treatment with this pesticide
than in previously untreated soil (Chung et al. 1999; Ou 1989, 1998; Ou et al. 1995; Verhagen et al. 
1996).  Furthermore, while the degradation rates of the cis- and trans- isomers are similar in untreated 
soil, degradation in previously treated soil has been shown to be more rapid for trans-1,3-dichloropropene
than for cis-1,3-dichloropropene.  For example, cis- and trans-1,3-dichloropropene applied to previously
untreated soil plots (16 μg/g) were degraded by approximately 68 and 72%, respectively, after 28 days
(Ou 1998).  In a soil plot that had been previously treated with this pesticide 6 times over the past
12 years, cis-1,3-dichloropropene (16 μg/g) was degraded by approximately 100% after 28 days while 
trans-1,3-dichloropropene was degraded by approximately 99% after 14 days.  Chung et al. (1999)
observed the enhanced degradation of trans-1,3-dichloropropene over cis-1,3-dichloropropene in soils
increasing with increasing numbers of field applications; approximately 100% of cis- and trans-1,3-di-
chloropropene in these soils (16 μg/g) were degraded after 5–10 and 7–14 days, respectively.  However, 
the degradation rates of cis- and trans-1,3-dichloropropene were again similar to each other in soil that
had been left untreated for 2 years and resembled degradation rates in previously untreated control soils;
approximately 75–100% of cis- and trans-1,3-dichloropropene were degraded after 28 days.
1,3-Dichloropropene may also hydrolyze in moist soils.  In laboratory studies, hydrolysis rates have been 
measured in soil slurries and buffer solutions.  For soil-water slurries with a concentration of 10-2 M, 
1,3-dichloropropene hydrolyzed at a rate of 3.4% per day (Castro and Belser 1966).  In general, soils 
possess a relative humidity of >98%.  Under dry conditions, the relative humidity of soil may fall below
90% (U.S. Army 1985).  Therefore, 1,3-dichloropropene is likely to hydrolyze in moist soils.  Once again, 
corresponding chloroallylalcohols were reported as the products of hydrolysis for cis- and trans-1,3-di-
chloropropene (Castro and Belser 1966).  Greater than 60% of 1,3-dichloropropene applied at <61 g/kg to 
both sterile and nonsterile Arlington sandy loam with a 10% moisture content hydrolyzed within 30 days 
(Guo et al. 2004).  Initially, there was no difference between the degradation in sterile and nonsterile
soils; however, degradation in the nonsterile soil began to exceed degradation in the sterile soil after
10 days of incubation as soil microorganisms adapted to the pesticide.
Batzer et al. (1996) studied the fate of 1,3-dichloropropene in sealed aerobic soil incubation flasks.  The
degradation half-lives of 14C-labeled-1,3-dichloropropene measured in Wahiawa silty clay, Catlin silt
loam, and Fuquay loamy sand were 1.8, 12.3, and 61 days, respectively (Batzer et al. 1996; EPA 1998).  
These authors stated that the rapid degradation in the Wahiawa silty clay may have been a result of the
combination of biodegradation and abiotic hydrolysis. Major metabolites formed during the
biodegradation 1,3-dichloropropene identified during this study were 3-chloroallyl alcohol and 3-chloro-
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acrylic acid.  Minor metabolites identified (<0.4% applied 14C) were acetic acid, adipic acid, butyric acid, 
chloroacetic acid, 4-chlorobutyric acid, fumaric acid, glycolic acid, hexanoic acid, lactic acid, malonic
acid, 2-methylmalonic acid, oxalic acid, propionic acid, and succinic acid.
Anaerobic metabolism half-lives measured for 1,3-dichloropropene at 15 and 25 °C were 9.1 and 
2.4 days, respectively, in a silty clay loam soil and 7.7 and 2.4 days, respectively, in a sandy loam soil
(EPA 1998).  The metabolites identified included chloroacrylic acid and propionic acid.
The persistence of 1,3-dichloropropene in soil has been measured by a number of investigators.  
van der Pas and Leistra (1987) reported half-lives of 3–4 days in fields used for planting flower bulbs.  
Only very small amounts of 1,3-dichloropropene remained after periods up to 49 days.  Leistra (1970)
reported a much slower degradation rate of 0.035/day for a loam soil, which corresponds to a half-life of 
19.8 days.  A degradation rate of 0.01/day, which corresponds to a half-life of 69 days, was reported for
sandy and peat soils (Leistra 1970).  Albrecht (1987a) has reported half-lives of 3–25 days at 20 °C for
1,3-dichloropropene.  Radiolabeled cis- and trans-1,3-dichloropropene was applied to soils and stored in
sealed jars for 12 weeks.  In a sandy loam soil, 19% of the cis isomer and 18% of the trans isomer
remained, while 10% of the cis isomer and 22% of the trans isomer persisted in a medium loam soil 
(Roberts and Stoydin 1976).  The half-lives of 1,3-dichloropropene measured in water-saturated sandy
subsoils (24 g/m3) ranged from 16 to 64 days (Boesten et al. 1991).  Smelt et al. (1989) reported that
1,3-dichloropropene at initial concentrations of 62–80 mg/kg in moist loamy soils was quickly degraded 
(100% after 5–8 days) following a 3–6-day lag phase.  The initial and second half-lives of cis- and trans-
1,3-dichloropropene applied at 345 lb a.i./A to bare loamy sand soil were 1 and 7 days, respectively, in 
the 24-inch surface layer (EPA 1998).  1,3-Dichloropropene, applied at 342 lb a.i./A to a sand soil field 
plot, declined from a maximum concentration of 130,000 ppb in the 0.3–0.45 m layer of soil immediately
following application to below the detection limit (10 ppb) in any soil layer after 71 days (EPA 1998).
Biodegradation and hydrolysis data for 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene in soil or sediment were
not available.  Based on structural similarities, these isomers are expected to biodegrade similarly to 
1,3-dichloropropene.  Hydrolysis of 2,3- and 3,3-dichloropropene in soil will also be similar to that of
1,3-dichloropropene; however, hydrolysis of 1,1- and 1,2-dichloropropene is expected to be much slower
due to the inhibiting effect of the two vinylic chlorine atoms (Smith and March 2001).
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6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to 1,3-dichloropropene depends in part on the
reliability of supporting analytical data from environmental samples and biological specimens.  
Concentrations of 1,3-dichloropropene in unpolluted atmospheres and in pristine surface waters are often 
so low as to be near the limits of current analytical methods.  In reviewing data on 1,3-dichloropropene
levels monitored or estimated in the environment, it should also be noted that the amount of chemical
identified analytically is not necessarily equivalent to the amount that is bioavailable.  The analytical
methods available for monitoring 1,3-dichloropropene in a variety of environmental media are detailed in 
Chapter 7.
The majority of the available dichloropropene monitoring data are for the 1,3- isomer.  Therefore, the data 
reported in Section 6.4 refer primarily to 1,3-dichloropropene.  When available, monitoring data for the
other dichloropropene isomers are included.
6.4.1 Air
1,3-Dichloropropene is not a widely occurring atmospheric pollutant.  According to the National Ambient
Volatile Organic Compounds (VOCs) Database, a compilation of published and unpublished air
monitoring data from 1970 to 1987, the median urban atmospheric concentration of cis-1,3-dichloro-
propene is 23.9 ppbV (parts per billion by volume) for 148 samples collected from representative 
locations (EPA 1988).  Information regarding the occurrence of cis-1,3-dichloropropene in suburban, 
rural, remote, source-dominated (air surrounding a facility or known release of the chemical in question), 
workplace, and indoor and personal atmospheres was not included by the VOC database.  Also, no data
were reported for trans-1,3-dichloropropene (EPA 1988).
cis- and trans-1,3-Dichloropropene were detected in 15 (4.3%) and 10 (2.9%) out of 349 air samples,
respectively, collected from Camden, New Jersey; Washington, DC; Orlando, Florida; Pensacola, Florida;
Chicago, Illinois; Sauget, Illinois; Toledo, Ohio; Houston, Texas; Baton Rouge, Louisiana; Port Neches, 
Texas; and Wichita, Kansas during the 1990 Urban Air Toxics Program conducted by EPA (1991).  The
range, mean, and median of concentrations in positive samples were 0.04–0.59, 0.23, and 0.22 ppbV, 
respectively, for cis-1,3-dichloropropene and 0.01–2.62, 0.70, and 0.17 ppbV, respectively, for trans-
1,3-dichloropropene.  cis- and trans-1,3-Dichloropropene concentrations were <1 ppbV in urban air
samples from 13 sites located in Louisiana, Texas, Vermont, and New Jersey collected from
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September 1996 to August 1997 (Mohamed et al. 2002).  cis- and trans-1,3-Dichloropropene were each 
detected in only 3 out of 267 air samples from 13 semi-rural to urban locations in Maine, Massachusetts,
New Jersey, Pennsylvania, Ohio, Illinois, Louisiana, and California collected from 1997 to 1999 (Pankow
et al. 2003). Positive concentrations were 0.013–0.018 ppbV for cis-1,3-dichloropropene and 0.007– 
0.008 ppbV for trans-1,3-dichloropropene; limits of detection were not specified.  cis- and trans-1,3-Di-
chloropropene were detected in 0 and 3% of air samples, respectively, collected from six locations in the
Columbus, Ohio area; concentrations and detection limits were not specified (Spicer et al. 1996).  Out of
2,507 air samples collected from 25 sites across the state of Minnesota over a period of 8 years (1991– 
1998), cis-1,3-dichloropropene was detected above 0.14 μg/m3 (0.031 ppb) in 43 air samples and trans-
1,3-dichloropropene was detected above 0.21 μg/m3 (0.046 ppb) in 82 air samples (Pratt et al. 2000).  The
mean and maximum concentrations were 0.02 and 0.99 μg/m3 (0.004 and 0.22 ppb), respectively, for cis-
1,3-dichloropropene and 0.03 and 1.48 μg/m3 (0.007 and 0.326 ppb), respectively, for trans-1,3-dichloro-
propene.
During a study conducted by the California Air Resources Board in July 1995, 1,3-dichloropropene was 
detected in 100% of samples collected from four sites in California representative of high use areas with 
mean and maximum concentrations of 24 and 160 μg/m3 (5.3 and 35.2 ppb), respectively (Baker et al.
1996).  During measurements of airborne pesticide concentrations in an urban area of California, 1,3-di-
chloropropene was detected in 8 out of 8 samples in 1990, 16 out of 21 samples in 1996, and 14 out of
53 samples in 2000 (Lee et al. 2002).  Mean 1,3-dichloropropene concentrations in these samples were
0.9, 0.57, and 0.40 μg/m3 (0.20, 0.13, and 0.088 ppb), respectively.  In air from rural California 
communities, 1,3-dichloropropene was detected in 32 out of 32 samples in 1990, 64 out of 84 samples in 
1996, and 77 out of 267 samples in 2000.  Mean 1,3-dichloropropene concentrations in these samples 
were 24, 1.4, and 1.5 μg/m3 (5.3, 0.31, and 0.33 ppb), respectively.
The concentrations of dichloropropene (unspecified isomers) in air samples collected from Deer Park, 
Texas; Freeport, Texas; Plaquemine, Louisiana; and Baton Rouge, Louisiana during the 1970s ranged 
from 7 to 570 ppt where it was detected (Brodzinsky and Singh 1982; EPA 1979).  Dichloropropene
(unspecified isomers) was qualitatively identified in 1 out of 10 ambient air samples collected in the 
Kanawha Valley, West Virginia during 1977 (EPA 1978b).
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6.4.2 Water
According to 1999–2006 nationwide U.S monitoring data from the STORET database, 1,3-dichloro-
propene was detected in 5,465 out of 12,673 water samples; however, only 771 of these detections were 
above the quantitation limit (unspecified).  The mean, median, and range of quantifiable concentrations
were 0.5, 0.5, and 0.002–25 μg/L (ppb), respectively (EPA 2006j).  1,1-Dichloropropene was detected in 
3,443 out of 5,348 water samples; however, only 70 of these detections were above the quantitation limit 
(unspecified). The mean, median, and range of quantifiable concentrations were 0.4, 0.5, and 0.001– 
5 μg/L (ppb), respectively (EPA 2006j).  The source of 1,1-dichloropropene in these water samples is 
unknown.  1,1-Dichloropropene does not appear to be produced or used based on available data;
therefore, direct release of this substance into the environment is not expected.  1,1-Dichloropropene may
be formed as a metabolite during the anaerobic degradation of higher chlorinated propenes.  Data for 1,2-, 
2,3-, and 3,3-dichloropropene were not listed in STORET.
1,3-Dichloropropene was detected in groundwater contaminated by leachates from municipal landfills in 
New York, Minnesota, and Wisconsin at concentrations up to 18 μg/L (ppb) (Sabel and Clark 1984).  In 
California, 1,3-dichloropropene was detected in groundwater at unspecified concentrations as a result of
pesticide applications (Cohen 1986).  An extensive groundwater monitoring program for agricultural 
chemicals in California detected cis-1,3-dichloropropene in only two groundwater samples, and trans-
1,3-dichloropropene in only one groundwater sample (Cohen 1986).  By comparison, dibromochloro-
propane, another soil fumigant, was detected in 2,522 groundwater samples.  In 54 municipal wells of
varying depths of 65–1,200 feet in areas of California where Telone® or DD® had been applied for over
15 years, 1,3-dichloropropene was not detected in any sample at or above the quantification limit of
0.1 ppb (Maddy et al. 1982).
cis- and trans-1,3-Dichloropropene were not detected (detection limit 0.20 μg/L) in groundwater samples
from 1,831 sites located in 20 of the U.S. major hydrologic basins (Kolpin et al. 2000).  During the U.S. 
Geological Survey’s (USGS) National Water-Quality Assessment (NWQA) Program conducted from
1986 to 1999, concentrations of cis- and trans-1,3-dichloropropene were below the detection limit of
0.2 μg/L (ppb) in untreated groundwater from 1,685 and 1,592 rural private wells, respectively (Moran et
al. 2004).  Concentrations of cis- and trans-1,3-dichloropropene were below the detection limit of
0.09 μg/L (ppb) in 30 randomly distributed monitoring wells located in Wichita, Kansas during the High 
Plains Regional Ground-Water Study conducted in 2000 as part of the USGS NWQA Program (USGS
2002).  The concentrations of cis- and trans-1,3-dichloropropene measured in 34 wells (including 5 public
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use wells) in Cook Inlet Basin, Alaska during 1999 were below 0.09 and 0.13 μg/L (ppb), respectively
(USGS 2001).
During the registration of Telone II®, Dow AgroSciences conducted a small-scale prospective 
groundwater monitoring study at a site in Wisconsin to satisfy EPA requirements (EPA 1998).  In 
September 1997, Telone II® was applied to a sugar beet field at 28 gallons per acre (266 pounds per acre).  
Depth to the groundwater of an aquifer used for drinking water ranged from 15 to 22 feet.  Over a period 
of 11 months, the mean and maximum concentrations of 1,3-dichloropropene were 134 and 579 ppb,
respectively, in on-site wells and 26.6 and 173 ppb, respectively, in an off-site well located 65 feet
downgradient.
Dow AgroSciences performed a similar groundwater study in southern Florida (EPA 1998).  In 
December 1995, Telone C-17® was applied to a pepper field at 22.5 gallons per acre (214 pounds per
acre).  The concentration of 1,3-dichloropropene in eight shallow (1–2 feet deep) on-site wells peaked at
833 ppb and then dropped to 0.19 ppb by 110 days after application.  The concentration in five off-site 
wells ranged from trace levels to 0.23 ppb.  The mean and range of 1,3-dichloropropene concentrations
were 0.30 and 0.05–21.6 ppb, respectively, in eight on-site wells at a depth of 10 feet and 0.04 and 0.05– 
1.03 ppb, respectively, in the on-site wells that tapped the Lower Tamiami Aquifer, a possible drinking
water source, at a depth of 70 feet.  The mean concentration of 1,3-dichloropropene plus its degradates 
was 1.15 ppb in the 10 feet deep on-site wells, 0.17 ppb in the 70 feet deep on-site wells, and 0.074 ppb in 
the off-site wells.  1,3-Dichloropropene was not detected in an off-site deep well.  1,3- and 2,3-Dichloro-
propene were detected above 0.1 ppb in 5 and 3 out of 42 piezometers and domestic wells, respectively, 
in the area of the Abbotsford aquifer in southwestern British Colombia, Canada (Zebarth et al. 1998).  
Maximum concentrations ranged from 0.15 to 0.76 ppb for 1,3-dichloropropene and from 0.10 to 
0.67 ppb for 2,3-dichloropropene.
According to Round 2 data (1993–1997) reported under the EPA Unregulated Contaminant Monitoring
Program (UCM), 1,3-dichloropropene was detected in 81 out of 70,631 samples collected from public
water systems across the United States with a mean concentration of 1.282 ppb and a range of 0.20– 
39.00 ppb (EPA 2001c).  1,1-Dichloropropene was detected in 18 out of 97,698 public water system
samples with a mean concentration of 8.944 ppb and a range of 0.10–153.00 ppb.  1,2-, 2,3-, and 3,3-Di-
chloropropene were not included in the UCM data; these chemicals are not listed as drinking water
contaminant candidates by EPA (EPA 2001c). 
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1,3-Dichloropropene was qualitatively identified in New Orleans, Louisiana, drinking water collected in 
August 1974 (Dowty et al. 1975a, 1975b).  Unspecified isomers of dichloropropene were qualitatively
identified in drinking water samples collected in Philadelphia, Pennsylvania in 1995 and 1996 (Suffet et
al. 1980).  An analysis of 15 drinking water samples from Denver collected between October 1, 1985, and 
March 31, 1986, did not detect cis- or trans-1,3-dichloropropene at or above detection limits of 0.13 ppb 
(Rogers et al. 1987).  At quantities above the detection limit of 0.1 ppb, 1,3-dichloropropene was not
detected in 42 raw and 42 finished drinking water samples collected between July 1982 and May 1983 
from nine municipalities along the Great Lakes (Otson 1987).
The concentrations of cis- and trans-1,3-dichloropropene/L detected in rainwater collected in Portland, 
Oregon, in 1982 were 10 and 2 ng/L (ppt), respectively (Mazurek and Simoneit 1986).
6.4.3 Sediment and Soil
According to 1999–2006 nationwide U.S monitoring data from the STORET database, 1,3-dichloro-
propene was detected in only 2 out of 613 soil samples (EPA 2006j).  1,3-Dichloropropene concentrations
in these two samples were 0.04 and 0.005 mg/kg.  According to the STORET data, 1,3-dichloropropene
was detected in 139 out of 324 sediment samples; however, none of these detections were above the
quantitation limit (unspecified) (EPA 2006j).  1,1-Dichloropropene was not detected above the
quantitation limit (unspecified) in 74 soil samples and 37 sediment samples.  Data for 1,2-, 2,3-, and 
3,3-dichloropropene were not listed in STORET. No other information regarding the levels of dichloro-
propenes found in soil or sediment was located in the available literature.
6.4.4 Other Environmental Media 
According to the National Pesticide Use Database updated by the National Center for Food and
Agricultural Policy in 1997, 1,3-dichloropropene is applied to fields used to grow the following crops in 
the United States each year:  asparagus, beets, blueberries, Brussels sprouts, cantaloupes, carrots, celery, 
cotton, cucumbers, hot peppers, melons, onions, parsley, peanuts, potatoes, strawberries, sugarbeets, 
sweet peppers, sweet potatoes, tobacco, and watermelons.  However, 1,3-dichloropropene residues have 
not been found in crops grown in soils treated with this pesticide (EPA 1998; Roby and Melichar 1997). 
This is most likely because 1,3-dichloropropene is a preplant fumigant that breaks down quickly in the
soil and is therefore not expected to be available for plant uptake (EPA 1998).
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Neither 1,3-dichloropropene nor its metabolites were detected in carrot, lettuce, radish, tomato, and wheat
grown in soil treated with this 14C-labeled 1,3-dichloropropene; however, natural incorporation of the
14C-label was observed (Barnekow et al. 1996).  Similarly, soybean plants grown in 14C-labeled 1,3-di-
chloropropene at 380 L/ha did not contain the pesticide or its metabolites (Barnekow et al. 1995).  The
14C-label residue was detected in the fatty acids, protein, pigments, organic acids, sucrose and other
carbohydrates, and lignin of the soybean plants.
During a study of organic compounds in tobacco smoke, the concentrations of 1,3-dichloropropene in 
ultra low tar, full flavor low tar, and full flavor cigarette brands were 11.4, 11.7, and 14.4 μg/cigarette, 
respectively (Bi et al. 2005).
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Possible routes of human exposure to 1,3-dichloropropene include the inhalation of vapors, ingestion of
drinking water, and dermal contact.
Monitoring data regarding the presence of 1,3-dichloropropene in foods were not located (see 
Section 6.4.4).  This may be the result of rapid degradation of 1,3-dichloropropene taking place before the
pesticide can be taken up by the crop plants.  It has been suggested that chlorination of water can lead to 
the formation of 1,3-dichloropropene, and that the detection of 1,3-dichloropropene in various treated 
water samples confirm this (Krijgsheld and van der Gen 1986).  However, information pertaining to the
occurrence of 1,3-dichloropropene in drinking water is also very limited, and 1,3-dichloropropene is not
expected to occur at levels which are a concern to human health.  1,1-Dichloropropene was detected in 
only 0.01% of public water system samples collected nationwide; therefore, exposure to this substance via 
drinking water is expected to be very low (EPA 2001c).
Occupational exposures to 1,3-dichloropropene, occurring mainly during handling and application as a
soil fumigant, have been documented (Albrecht 1987a; Albrecht et al. 1986; Markovitz and Crosby 1984;
Nater and Gooskens 1976; Osterloh et al. 1984, 1989a, 1989b; Schenker and McCurdy 1986; van Joost
and de Jong 1988; Wang 1984).  According to the NOES conducted by NIOSH between 1981 and 1983, 
it has been estimated that 2,162 workers were potentially exposed to 1,3-dichloropropene (NIOSH 2006).  
The NOES database does not contain information on the frequency, concentration, or duration of workers'
exposure to any of the chemicals listed therein.  The survey provides only estimates on the number of
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workers potentially exposed to chemicals in the workplace.  The most probable routes of occupational
exposure are inhalation and dermal contact at places where 1,3-dichloropropene- and/or 1,3-dichloro-
propene-containing compounds are produced or used as a soil fumigant.  Albrecht (1987a) studied the
inhalation exposure of 1,3-dichloropropene to workers involved in applying Telone II® to pineapple fields
in Hawaii.  Exposures were predominantly below 1 ppm.  According to Osterloh et al. (1989a), 
15 individuals applying 1,3-dichloropropene were exposed at a mean air concentration of 2.56 mg/m3 
over a period of 2–7 hours.  The mean concentration of the metabolite, N-acetyl-S-[cis-3-chloro-prop-
2-enyl]-cysteine, in the urine of these individuals was 1.37 μg/mg creatinine following exposure.
Exposure monitoring studies were conducted for workers using 1,3-dichloropropene as a fumigant on 
treated fields in North Carolina, Washington, and Arizona (EPA 1998).  Employee exposure was 
estimated by monitoring personal air samples for product loaders, applicators, and re-entry workers over
4-hour periods or during short job specific tasks.  The 4-hour samples provided time-weighted average air
concentrations over a major portion of an actual work day, while the task-specific samples measured the
air concentrations associated only with high-contact activities.  For product loaders, these activities were 
the actual loading events.  The 4- hour loader samples included the loading events, and the time spent on 
site between loading events.  1,3-Dichloropropene was broadcast applied to a sandy loam used to grow
potatoes at an application rate of 252 lbs a.i./A at the Washington state site.  It was row applied in 
Arizona to a loamy sand used to grown cotton at a rate of 121.2 lbs a.i./A, and was row applied at a rate 
of 82 lbs a.i. to a field in North Carolina used to grow tobacco.  The exposure levels of the employees 
categorized by job function are summarized in Table 6-5.
The Monsanto Agricultural Products Company conducted research to ensure that workers in the
workplace were not being exposed to unacceptable levels of 1,3-dichloropropene in the air during its
manufacture.  Under laboratory conditions simulating the workplace environment, atmospheric levels of
1,3-dichloropropene ranged from 0.4 to 4.0 ppm (Leiber and Berk 1984). These levels can be compared 
to the NIOSH recommended 8- and 10-hour time weighed average (TWA) of 1 ppm for 1,3-dichloro-
propene (NIOSH 2005).
The primary metabolites for cis- and trans-1,3-dichloropropene in the body are the corresponding
mercapturic acids, metabolite N-acetyl-S-(cis- and trans-3-chloro-2-propenyl)-L-cysteine (abbreviated 
cis- and trans-DCP-MA) (Brouwer et al. 2000; He 1993; van Welie et al. 1991a; Verberk et al. 1990).  
Exposure to 1,3-dichloropropene can be tested by analyzing for these metabolites in urine samples.  The
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Table 6-5.  Exposure Levels of Employees to 1,3-Dichloropropene Measured 

During Loading and Application
 
Exposure Mean Median 

Job activity Site durationa Range (ppb) concentration (ppb) concentration (ppb)
 
Loading	 Washington, 4 hours 38.9–1,305 359 137
Arizona
Loading	 Washington, Task only 116–7,148 2,383 1,069
Arizona
Loading	 North Carolina Task only 11–260 102 97.2
Application	 Washington, 4 hours and 9.5–1,448 299 253
Arizona, North task
Carolina
aTask-specific operations lasted 4–46 minutes
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geometric mean and range of cis-DCP-MA concentrations in urine samples collected from 14 application 
workers in the Netherlands on 114 application days were 9.33 and 0.04–55.1 mg/g creatinine, respectively
(Brouwer et al. 2000).  The corresponding geometric mean and range of calculated 8-hour time-weighted 
average exposure concentrations were 2.7 and 0.1–9.5 mg/m3, respectively.  Twelve individuals applying
cis- and trans-1,3-dichloropropene to Dutch flower bulb fields were exposed to an 8-hour time-weighted 
average air concentrations of 0.34–10.78 mg/m3 for the cis isomer and 0.11–8.07 mg/m3 for the trans
isomer (Brouwer et al. 1991a; van Welie et al. 1991a). At comparable respiratory exposures, cis-1,3-di-
chloropropene yielded approximately 3 times more mercapturic acid in urine samples than the trans
isomer, which was attributed to differences in metabolism.  Approximate cumulative urinary excretions of
cis- and trans-DCP-MA at the maximum respiratory exposures were 50 mg (at 10.7 mg/m3) and 15 mg (at
8 mg/m3), respectively.  A related study reported that the proportion between respiratory exposure to 
1,3-dichloropropene and urinary mercapturic acid excretion for field bystanders was similar to that of
applicators (van Welie et al. 1991b).  Kezic et al. (1996) compared dermal 1,3-dichloropropene exposure
to respiratory exposure.  The estimated mean total uptake of cis-1,3-dichloropropene in five adults
dermally exposed on the forearm and hand to 86 mg/m3 of the pesticide vapor for 45 minutes was 67 μg.  
The average total cis-DCP-MA excreted in urine over a 24-hour period was 48 μg.  The authors
concluded that when whole-body dermal exposure is compared with inhalation, dermal uptake amounts to 
only 2–5% of absorption through inhalation.
Populations that live near hazardous waste sites may be exposed to 1,3-dichloropropene via inhalation, 
drinking contaminated groundwater, or dermal contact with contaminated soil.  Individuals who shower
or bathe in groundwater contaminated with 1,3-dichloropropene may be exposed through inhalation and
dermal contact.  1,3-Dichloropropene has been identified in at least 107 of the 1,699 hazardous waste 
sites that have been proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2008).
Pertinent monitoring data regarding the dermal exposure of 1,3-dichloropropene were not located in the
available literature.  Dermal exposure is possible for workers involved in fumigant applications of 1,3-di-
chloropropene.
Data regarding human exposure to 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene were not located in the
available literature.  Exposure of the general population to these substances is expected to be low since 
they are not produced or used in large quantities (IUR).  1,1-Dichloropropene has been detected in
drinking water.  However, it was found in only 0.01% of 97,698 public water system samples collected 
nationwide; therefore, exposure to this substance via drinking water is expected to be very low.  










   
 
  
   




    
   
 
    
  
     
   
     
   
  
    
 
   
  
   
 
   
 
   
 
 




6.  POTENTIAL FOR HUMAN EXPOSURE
Occupational exposure may occur through inhalation and dermal contact at facilities where the dichloro-
propene isomers are produced or used.  People who live near these facilities may also be exposed if these 
substances are released into the surrounding areas.  According to the National Occupational Exposure
Survey (NOES) conducted by NIOSH between 1981 and 1983, it has been estimated that 302 workers
(3 female workers) were potentially exposed to 2,3-dichloropropene (NIOSH 2006).  
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Dichloropropene (unspecified isomers) was qualitatively identified in 1 out of 12 samples of breast milk
collected from Bayonne, New Jersey; Jersey City, New Jersey; Bridgeville, Pennsylvania; and Baton 
Rouge, Louisiana during the late 1970s (EPA 1980; Pellizzari et al. 1982).
Current data regarding the exposure of children to dichloropropenes (including body burden data,
detection in breast milk, dietary exposure data, pathways of exposure, differences in intake compared to 
adults, and secondary exposure data) are not available.  Individuals with the greatest potential for
exposure to 1,3-dichloropropene include bystanders and residents located near fields treated with this
fumigant who may inhale 1,3-dichloropropene that has volatilized into the air (EPA 1998).  Therefore, 
children who live or play near fields where 1,3-dichloropropene is applied may be exposed to this
substance through inhalation. 
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6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
High levels of exposure to 1,3-dichloropropene are most likely to occur in occupational settings where 
1,3-dichloropropene is either produced or used as a soil fumigant.  Intake by inhalation or dermal contact
is the most probable route of high exposure to 1,3-dichloropropene.  1,3-Dichloropropene is a volatile 
compound and, after soil application as a fumigant, a fraction of the compound will volatilize and escape
into the atmosphere (Krijgsheld and van der Gen 1986).  Potentially high exposures to 2,3-dichloro-
propene should be limited to individuals who work at facilities where these substances are produced or 
used.
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of dichloropropenes is available.  Where adequate information 
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of
research designed to determine the health effects (and techniques for developing methods to determine
such health effects) of dichloropropenes. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
6.8.1 Identification of Data Needs 
Although the following discussion covers 1.1-, 1,2-, 1,3-, and 2,3-dichloropropene, testing to fill data
gaps for 1,3-dichloropropene should take priority, since it is the only isomer currently in production at a
significant volume.
Physical and Chemical Properties. The physical and chemical properties of both cis- and trans-
1,3-dichloropropene have been described and are readily available in the literature (Dilling 1977; EPA


















      
 
 
       
   
   










   
  
    
  
 
       
  
   
  
   
226DICHLOROPROPENES
6.  POTENTIAL FOR HUMAN EXPOSURE
1981a; Kenaga 1980; Leistra 1970; Lewis 2001; Lide 2005; O'Neil et al. 2001; Verschueren 2001).  Some
of these physical properties were required for assessing the fate and transport of 1,3-dichloropropene in 
the environment because experimental data were not available.  The literature values were sufficient for
performing the necessary estimates.  No data needs regarding the physical and chemical properties of
1,3-dichloropropene are identified at this time.  Measured vapor pressure values are available for 1,1-, 
1,2-, 2,3-, and 3,3-dichloropropene.  Measured log octanol/water partition coefficients, Henry’s law
constants, soil/water partitioning coefficients, and bioconcentration factors are lacking for these isomers.  
In addition, measured water solubility data are lacking for 1,1- and 3,3-dichloropropene.  Measured 
values for these end points would be helpful in predicting the fate and transport of these isomers where
experimental data are lacking.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning
and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit
substance release and off-site transfer information to the EPA.  The TRI, which contains this information 
for 2005, became available in May of 2007.  This database is updated yearly and should provide a list of 
industrial production facilities and emissions.
Current dichloropropene production and import/export volumes are unavailable in the literature.  Much of
the information regarding 1,3-dichloropropene has been included in combination with other chemicals. 
For example, USITC (1989) data for 1,3-dichloropropene are grouped with other soil fumigants.  
Historical production volumes are well documented (Yang 1986), but information regarding future
domestic production, and past, present, and future imports and exports are lacking in the literature
Literature pertaining to the use of 1,3-dichloropropene as an agricultural soil fumigant is readily available 
(Krijgsheld and van der Gen 1986).  Information on the uses of 1,1-, 1,2-, and 3,3-dichloropropene and
more detailed use information for 2,3-dichloropropene would be helpful.  Disposal methods for 1,3-di-
chloropropene have been described and appear to be satisfactory; however, methods that describe the
disposal of 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene are not available.  
Environmental Fate. Information concerning the partitioning of 1,3-dichloropropene in the
environment is available (Cohen 1986; Dilling 1977; EPA 1986; Kenaga 1980; Leistra 1970; Munnecke
and Vangundy 1979; Roberts and Stoydin 1976; Thomas and McKenry 1974; van der Pas and Leistra 
1987).  Information on the transport and degradation of 1,3-dichloropropene in environmental media is
also available (Cohen 1986; Dilling 1977; EPA 1986; Leistra 1970; Munnecke and Vangundy 1979;










    
   
  
   
  
   
 
 
      






   
  
 






       
  
   




6.  POTENTIAL FOR HUMAN EXPOSURE
Roberts and Stoydin 1976; Swann et al. 1983; Thomas 1982; van der Pas and Leistra 1987).  No data
needs are identified regarding the environmental fate of 1,3-dichloropropene.  Data regarding the
environmental fate of 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene were not located in the literature. 
Although the environmental fate of these substances is expected to be similar to that of 1,3-dichloro-
propene, there may be some differences especially pertaining to the rates of hydrolysis and ozonolysis.  
Measured data for these isomers would provide a much better understanding of their environmental fate
and partitioning.
Bioavailability from Environmental Media. Case reports of people who have experienced 1,3-di-
chloropropene poisoning following oral, dermal, and inhalation exposure indicate that 1,3-dichloro-
propene can be absorbed by these routes (Albrecht 1987a; Markovitz and Crosby 1984; Osterloh et al.
1984, 1989a, 1989b).  However, information regarding oral or dermal absorption of 1,3-dichloropropene
in water, soil, or plant material have not been found.  Studies of absorption of 1,3-dichloropropene from
air, water, soil, and plant material would allow determination of the rate and extent of absorption from
each of these media, and allow comparison of the potential hazard posed by 1,3-dichloropropene
contained in each.  A data need exists regarding the bioavailability of 1,3-dichloropropene from these
media.  Bioavailability data for 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene were not located in the literature.  
Although the bioavailability of these substances is expected to be low, additional information would be
helpful in verifying this.
Food Chain Bioaccumulation. Few data are available describing the food chain bioaccumulation 
of dichloropropenes.  Experimental data are unavailable; therefore, we do not know if the
bioconcentration potential is consistent with estimated values obtained from regression equations (Lyman 
1982).  Information concerning the potential for food chain biomagnification has not been described.  
Knowledge in this area would enable scientists to assess the dangers of human exposure to dichloro-
propenes via food such as fish and seafoods.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of dichloro-
propenes in contaminated media at hazardous waste sites are needed so that the information obtained on 
levels of dichloropropenes in the environment can be used in combination with the known body burden of
the dichloropropenes to assess the potential risk of adverse health effects in populations living in the
vicinity of hazardous waste sites.


















     
    
   
   
 
 
   
   
    
   
 
   
 
     
   
 
   
 
 





6.  POTENTIAL FOR HUMAN EXPOSURE
Air and groundwater monitoring data are available for 1,3-dichloropropene.  However, more information 
on the levels of 1,3-dichloropropene in surface water, drinking water, soil, and sediment would be helpful
since data related to these media are lacking.  Monitoring data indicate that 1,3-dichloropropene is
generally not detected in table-ready foods.  1,3-Dichloropropene is not expected to be present in crops
grown in soil treated with this pesticide; however, additional monitoring for 1,3-dichloropropene in these
types of foods would be helpful in confirming this.  Environmental monitoring data for 1,1-, 1,2-, 2,3-, 
and 3,3-dichloropropene are very limited.  Although concentrations of these substances in the
environment are expected to be low, additional information would be helpful in verifying this.
Exposure Levels in Humans. 1,3-Dichloropropene is not a naturally occurring substance (IARC
1986).  Available information shows that N-acetyl cysteine is present in the urine of people who were 
occupationally exposed to 1,3-dichloropropene (Osterloh et al. 1984, 1989a, 1989b).  Additional
information regarding the utility of this biomarker as an indicator of general population exposure to the
compound may be useful in monitoring the frequency of human exposure to 1,3-dichloropropene.  
Information concerning the numbers of persons potentially exposed to 1,3-dichloropropene near waste
sites and manufacturing, production, and use facilities is also not available.  In these areas and those of
widespread use, the potential for human exposure is high.  Human exposure data for 1,1-, 1,2-, 2,3-, or
3,3-dichloropropene were not located in the literature.  Although human exposure to these substances is
not expected to be important, information would be helpful in verifying this.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Data regarding the exposure of children to dichloropropenes (including
body burden data, detection in breast milk, dietary exposure data, pathways of exposure, differences in 
intake compared to adults, and secondary exposure data) are not available.  Exposure data for children 
who live or play near fields where 1,3-dichloropropene is applied would be particularly helpful. 
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs:  Children’s Susceptibility.
Exposure Registries. No exposure registries for the dichloropropenes were located.  These 
substances are not currently among the compounds for which sub-registries have been established in the
National Exposure Registry.  These substances will be considered in the future when chemical selection is 
made for sub-registries to be established.  The information that is amassed in the National Exposure










   
 
 
    
 
  
    





   
 
 





6.  POTENTIAL FOR HUMAN EXPOSURE
Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be
related to exposure to these substances.
6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2006) database provides additional information obtainable
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  
D.O. Chellemi and J.W. Noling of the University of Florida, Institute of Food and Agriculture, 
Gainesville, Florida are being funded by the U.S. Department of Agriculture (USDA) to conduct field-
scale demonstration/validation studies of alternatives for methyl bromide using new developments in
application technology and methods.  S.R. Yates and S.K. Papiernik, S.K. of Agricultural Research 
Service, Riverside, California are being funded by the USDA to study the fate and transport of alternative 
fumigants and methyl bromide.  L.T. Ou and A.V. Ogram of the University of Florida, Soil and Water
Science, Gainesville, Florida are being funded by the USDA to study the mechanisms and mitigation of
agrochemical impacts on human and environmental health.  This will include characterization of biotic
and abiotic processes, degradation rates, and determination of degradation products. 
Ongoing studies regarding the environmental fate and partitioning, environmental monitoring, or the
potential for human exposure of 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene were not identified in the
Federal Research in Progress database (FEDRIP 2006).
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring dichloropropene isomers, their metabolites, and other biomarkers of
exposure and effect to dichloropropene isomers.  The intent is not to provide an exhaustive list of
analytical methods.  Rather, the intention is to identify well-established methods that are used as the
standard methods of analysis.  Many of the analytical methods used for environmental samples are the
methods approved by federal agencies and organizations such as EPA and the National Institute for
Occupational Safety and Health (NIOSH).  Other methods presented in this chapter are those that are 
approved by groups such as the Association of Official Analytical Chemists (AOAC) and the American 
Public Health Association (APHA).  Additionally, analytical methods are included that modify previously
used methods to obtain lower detection limits and/or to improve accuracy and precision.
Since the majority of the analytical data on dichloropropenes are for the 1,3- isomer, the focus of this
chapter is on methods that measure for 1,3-dichloropropene.  Environmental analytical methods for 
1,1- and 1,2-dichloropropene have been located; however, most of these are adequately described in the 
context of measuring for 1,3-dichloropropene.  Analytical methods for measuring 2,3- and 3,3-dichloro-
propene in biological or environmental media were not located in the available literature.
7.1  BIOLOGICAL MATERIALS
The primary method for determining human exposure to 1,3-dichloropropene is measurement of the
mercapturic acid metabolites N-acetyl-S-(cis-3-chloropropenyl-2)-L-cysteine (or cis-DCP-MA) and 
N-acetyl-S-(trans-3-chloropropenyl-2)-L-cysteine (or trans-DCP-MA) in the urine (Osterloh et al. 1984, 
1989a, 1989b).  Van Welie et al. (1989) describes a procedure whereby these metabolites are extracted 
from urine samples and analyzed using gas chromatography (GC) followed by sulfur-selective detection 
with a flame-photometric detector (FPD).  During this study, the urine samples were collected from
applicators before, during, and up to 24 hours after finishing soil fumigation with 1,3-dichloropropene.  
These samples were stored in the dark at 4 °C until they were transported (within 2 days); thereafter, they
were stored at -18 °C.  Methods for the analysis of these metabolites in human blood have not been
located in the available literature.










   
    
   
     
   
     
    
    
   
 
  
    
    
  
    
  





   
 
 






7.  ANALYTICAL METHODS
Kastl and Hermann (1983) developed an analytical procedure for determining the level of cis- and 
trans-1,3-dichloropropene in whole rat blood.  Blood is extracted, 200 μL n-hexane is added, and the
sample is vortexed and centrifuged at 800 g for 1 minute.  Samples are either directly injected onto a GC
column for GC/mass spectrometry (MS) analysis or diluted with hexane for GC/electron capture detection 
(ECD) analysis. Percent recoveries of the GC analysis range from 80.8 to 98.5 for the cis isomer and 
from 81.3 to 98.2 for trans-1,3-dichloropropene.  For GC/MS analysis, percent recoveries are between
83.1 and 94.9 for cis- and 88.7 and 98.8 for trans-1,3-dichloropropene.  The GC/ECD method is sensitive 
to cis and trans isomeric concentrations in rat blood of 5.88–1.17x104 and 5.35–1.07x104 ng/mL, 
respectively.  The GC/MS method is sensitive to cis- and trans-1,3-dichloropropene concentrations in rat
blood of 5.18x101–1.29x104 and 4.71x101–1.18x104 ng/mL, respectively.
Fisher and Kilgore (1989) extracted the glutathione conjugate of 1,3-dichloropropene from the blood of
rats.  After collection, the blood was frozen and stored at -20 °C until analysis.  Solutions of 1 mL whole
blood and 2 mL 10 mM HCl in an acetone dry-ice slurry were repeatedly frozen and thawed and then 
finally centrifuged.  The supernatant (1 mL) was deproteinated using 0.33 mL of 70% perchloric acid and
then centrifuged again. The resulting clear supernatant was either injected into the high performance 
liquid chromatography (HPLC) or stored at -20 °C.  Schneider et al. (1998a) described a method for
analyzing 1,3-dichloropropene epoxides in mouse liver.  Livers were homogenized in 2 mL 100 mM
sodium phosphate buffer.  Ethyl acetate containing 2 μg of internal standard was added followed by
homogenization and centrifugation.  After removal of the organic layer, the pellet was extracted using
ethyl acetate without the internal standard and analyzed using GC/MS.  Recoveries for cis/trans-1,3-di-
chloropropene and cis/trans-1,3-dichloropropene epoxides were 81–95%.  Bond et al. (1985) described a
method for analyzing 2,3-dichloropropene in the urine, feces, and tissues (including blood) of rats.  Tissue
samples from rats exposed to C-14 labeled 2,3-dichloropropene were homogenized in ice-cold distilled 
water and added to acetonitrile.  Following centrifugation and extraction, the supernantant was diluted in 
water to give a final concentration of 50% water and 50% acetonitrile.  Analysis was performed using a
liquid scintillation spectrometer.  Recovery in spiked samples was >95%.
Table 7-1 summarizes the methods used to detect 1,3-dichloropropene in biological materials, including a
procedure for detecting 1,3-dichloropropene in foods (Daft 1989).
Analytical methods for measuring 1,1-, 1,2-, 2,3-, or 3,3-dichloropropene in biological media were not
located in the literature.
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Table 7-1. Analytical Methods for Determining cis- and trans-1,3-Dichloro­
propene and Metabolites in Biological Materials
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Urine	 Addition of internal
standard, extraction using 





Rat blood 	 Extract with hexane vortex
and centrifuge
Rat blood 	 Extract with hexane vortex
and centrifuge
Food 	 Extract composited, table-






























van Welie et al.
1989
Kastl and Hermann 
1983
Kastl and Hermann 
1983
Daft 1989, 1990
ECD = electron capture detection; FPD = Flame-photometric detection; GC = gas chromatography; HECD = Hall
electron capture detection; MS = mass spectrometry













   
   








   
 
     
    
 
   
  
   
    
 
  
    
   
     
  




7.  ANALYTICAL METHODS
7.2  ENVIRONMENTAL SAMPLES 
Procedures for detecting cis- and trans-1,3-dichloropropene in water and soil samples at hazardous waste 
sites are outlined in the method for semivolatiles in the Contract Laboratory Program (CLP) Statement of 
Work for Organics Analysis (EPA 1999).  The required quantification limits for both cis- and trans-
1,3-dichloropropene are 10 ppb for water samples and 10 ppb for soil samples in this monitoring
program.
For the most part, soil and sediment samples are analyzed in a similar manner to water samples, with the
exception that a small amount of water is added to soil and sediment samples.  At this point, all three 
matrices are subjected to a purge-and-trap cycle.  An inert gas is bubbled through the sample, volatilizing
1,3-dichloropropene.  The gas stream is then passed though an adsorbent tube, which recollects the 1,3-di-
chloropropene.  The sorbent tube is attached to a GC, heated, and backflushed with an inert gas to desorb 
the halocarbons onto a GC column.  Quantification can be accomplished using either a flame ionization 
detector or an MS, depending on the total concentration of organics in the sample.
EPA's Test Methods for Organic Chemical Analysis of Municipal and Industrial Wastewater (EPA 1982)
and Test Methods for Solid Waste (EPA 1986) are very similar to those already outlined.  However, the
purge-and-trap cycle may be bypassed for aqueous process wastes with expected concentrations in excess 
of 10,000 μg/L.  In these instances, the sample may be directly injected into the GC system with a 10 μL
syringe (EPA 1986).  EPA-Office of Solid Waste Methods 8021B and 8260B can be applied to solid 
waste (EPA 1996a, 1996b).  Method 8021B uses GC followed by a photoionization detector (PID) and a
Hall electron capture detector (HECD) connected in series (EPA 1996a).
It is important to note the discrepancies in detection limits between the standardized methods.  CLP cites 
a detection limit of 10 ppb, yet gives no information regarding the percent recoveries (EPA 1999).  The
EPA procedures for solid wastes (EPA Method 8010) and municipal and industrial waste waters (EPA
Method 601), however, maintain a detection limit of 0.34 ppb.  The percent recovery, according to the
Solid Waste Manual, ranges from 22 to 178 (EPA 1986).  Therefore, results from EPA Method 8010 must
be interpreted with caution.  For municipal and industrial waste waters, the average percent recoveries for 
the cis- and trans-isomers are reportedly 86.7 and 73.5 with standard deviations of 6.0 and 17.2%,
respectively (EPA 1982).  Again, the precision at which the trans-isomer can be measured is questionable.










   
 
 
    
   
 
   
 
   
  
  








   
  










7.  ANALYTICAL METHODS
Other standardized methods used for detection of 1,3-dichloropropene in water samples by purge and trap 
followed by GC/MS include EPA Methods 524.2, 624, and 1624, Standard Methods 6200B and 6200C, 
ASTM Method D5790, and USGS-NWQL Method O-4127-96 (EPA 1995a, 2001b, 2005b; NEMI 1997b, 
2001; USGS 1998).  Detection limits and percent recoveries for determination of both isomers in water
range were 0.02–10 ppb and 78–110%, respectively, using these methods. 
A few methods have appeared in the available literature.  Leiber and Berk (1984) outlined a method for
determining 1,3-dichloropropene in ambient air.  Tenax-GC sampling tubes are used for sample 
collection.  Solvent desorption is accomplished with isooctane containing 4.0 μg/L of 1,3,5-tribromo-
benzene, followed by heat treatment at 90 °C for 15 minutes; the mixture is then left to stand for 12 hours.  
After centrifugation, an aliquot of the resulting solution is injected onto the GC column.  Sample analysis
by capillary GC/ECD was validated for the range of 0.4–4.0 ppm, with a mean percent recovery of 100.  
Table 7-2 summarizes the methods for detecting cis- and trans-1,3-dichloropropene in environmental
media.
Several of the environmental methods mentioned above for measuring 1,3-dichloropropene (EPA-OSW
method 8021B and 8260B, ASTM method D5790, Standard Methods 6200B and 6200C, and USGS-
NWQL Method O-4127-96) also include 1,1-dichloropropene as an analyte (EPA 1996a, 1996b; NEMI
1997a, 1997b, 2001; USGS 1998).  Table 7-3 provides information specific to the measurement of 1,1-di-
chloropropene in environmental media using these methods.  In addition, EPA-NERL method 502.2 can 
be used to measure 1,1-dichloropropene in water using GC followed by either photoionization detection 
or electrolytic conductivity detection (EPA 1995a).
EPA method 524.2 was the only method identified for measuring 1,2-dichloropropene in environmental
media.  This method uses purge and trap followed by GC/MS to analyze for the substance in water.  The
sample detection limit and percent recovery are 0.02 ppb and 98%, respectively (NEMI 1992).  Analytical
methods for measuring 2,3- and 3,3-dichloropropene in environmental media were not located in the
available literature.
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of dichloropropenes is available.  Where adequate information 
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Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Air	 Adsorb (Tenax-GC); GC/ECD 0.4–4.0 ppm 100 Leiber and Berk
desorb (isooctane); inject 1984
aliquot
Water Purge and trap	 GC/MS (EPA 10 ppb No data EPA 1999 
CLP Method)
Water Purge and trap	 GC/MS (EPA 0.34 ppb 22–178 EPA 1986 
Method 8010)
Wastewater Purge and trap	 GC/MS (EPA 0.20 ppb 100 (cis) EPA 2001a
Method 601) 0.34 ppb 100 (trans)
Soil Add water, heat, purge GC/MS (EPA 10 ppb No data EPA 1999
and trap, thermal CLP Method)
desorption




Air, water, Purge and trap GC/MS No data No data EPA 1996b
solid waste (aqueous, solid, and (EPA-OSW





solid, oil, and tissue), or
desorption from trapping
media (air)
Water Purge and trap GC/MS 0.02 ppb (cis) 100 (cis) EPA 1995a 
(EPA Method 
524.2) 0.048 ppb 110 (trans)
(trans)
Water Purge and trap GC/MS 5 ppb (cis) 100 (cis) EPA 2005b
(EPA Method 
624) Not available 100 (trans)
(trans)
Water Purge and trap GC/MS Not available Not available EPA 2001b
(EPA Method (cis) (cis) 
1624)	 10 ppb (trans) Not available 
(trans)
Water Purge and trap	 GC/MS 0.21 ppb (cis) 93% (cis) NEMI 2001
(ASTM Method 0.2 ppb (trans) 85% (trans)
D5790)
Water Purge and trap	 GC/MS 0.04 ppb (cis) 99% (cis) NEMI 1997a
(Standard 0.05 ppb (trans) 101% (trans)
Methods 6200B)
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Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Water Purge and trap	 GC 0.06 ppb (cis) 78% (cis) NEMI 1997b
(Standard 0.02 ppb (trans) 78% (trans)
Method 6200C)
Water Purge and trap	 GC/MS 0.048 ppb (cis) 93% (cis) USGS 1998
(USGS-NWQL 0.072 ppb 85% (trans)
Method O-4127- (trans)
96)
ECD = electron capture detection; FID = flame ionization detector; GC = gas chromatography; HECD = Hall electron 
capture detection; MS = mass spectrometry; PID = photoionization detector
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Water Purge and trap GC/PID or ELCD 
(EPA-NERL
Method 502.2)
0.02 ppb 103% EPA 1995b











(aqueous, solid, and 











Not available 102% EPA 1996b
Water Purge and trap GC/MS
(ASTM Method
D5790)
0.18 ppb 107% NEMI 2001
Water Purge and trap GC/MS
(Standard 
Method 6200B)
0.04 ppb 110% NEMI 1997a
Water Purge and trap GC
(Standard 
Method 6200C)
0.01 ppb 74% NEMI 1997b
Water Purge and trap GC/MS
(USGS-NWQL
Method 
0.028 ppb Not available USGS 1998
O-4127-96)
ELCD = electrolytic conductivity detection; FID = flame ionization detector; GC = gas chromatography; MS = mass
spectrometry; PID = photoionization detector
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is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of
research designed to determine the health effects (and techniques for developing methods to determine
such health effects) of dichloropropene isomers. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Although the following discussion covers 1,1-, 1,2-, 1,3-, and 2,3-dichloropropene, testing to fill data
gaps for 1,3-dichloropropene should take priority, since it is the only isomer currently in production at a
significant volume.
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  Van Welie et al. (1989) has described a method for determining the mercapturic acid 
metabolites N-acetyl-S-(cis-3-chloropropenyl-2)-L-cysteine (or cis-DCP-MA) and N-acetyl-S-(trans-
3-chloropropenyl-2)-L-cysteine (or trans-DCP-MA) in the urine.  Additional study and the development
of standardized methods regarding the detection of dichloropropene metabolites in human biological
materials (urine, blood, and tissue) are needed.
Effect.  There are no known biomarkers of effect that are unique to dichloropropenes.  Therefore, 
standardized analytical methods for their determination are not warranted.
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Methods for determining of 1,3-dichloropropene in environmental matrices have appeared in 
the literature.  Of these, standardized methods exist only for the analysis of surface water, soil, or
sediment samples (EPA 1982, 1986, 1999).  For sediments and soils, the levels of accuracy have not been 
reported.  Both the accuracy and precision at which the trans-isomer can be measured in water is 
questionable.  Therefore, refinement of the current procedures and establishing standardized methods for
analyzing other media such as air will aid in determining levels of human exposure to 1,3-dichloro-










   
   




   
   









    
    





7.  ANALYTICAL METHODS
propene.  A limited number of methods are available for determining 1,1- and 1,2-dichloropropene in 
environmental media, while no methods were located for 2,3- or 3,3-dichloropropene.  Development of
standardized methods for determining levels of 1,1-, 1,2-, 2,3-, and 3,3-dichloropropene in environmental
materials would be helpful.
A limited number of methods is available to determine 1,3-dichloropropene in biological materials (Daft
1989; Kastl and Hermann 1983), and none of the methods have been standardized.  The establishment of
standardized methods for determining of 1,3-dichloropropene in biological materials, together with 
methods that are unique to 1,3-dichloropropene exposure, would be helpful in determining the levels of
and exposure to the general population.  No methods for determining 1,1-, 1,2-, 2,3-, or 3,3-dichloro-
propene in biological materials have been located.  Development of standardized methods for determining
levels of these isomers in biological materials would be helpful.
7.3.2 Ongoing Studies 
Ongoing studies related to analytical methods for dichloropropenes were not located in the Federal
Research in Progress database (FEDRIP 2006).  
The Environmental Health Laboratory Sciences Division of the National Center for Environmental
Health, Centers for Disease Control and Prevention, is developing methods for the analysis of
dichloropropenes and other volatile organic compounds in blood. These methods use purge and trap
methodology, high-resolution gas chromatography, and magnetic sector mass spectrometry, which give 
detection limits in the low parts per trillion (ppt) range.
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International and national regulations and guidelines pertinent to human exposure to 1,3- and 2,3-di-
chloropropene are summarized in Table 8-1.
2,3-Dichloropropene. An acute-duration inhalation MRL of 0.002 ppm was derived for very slight
hyperplasia of the nasal respiratory epithelium in female rats exposed to 2,3-dichloropropene vapor at a
minimal LOAEL of 5 ppm, 6 hours/day, for 9 out of 11 days (Zempel et al. 1987).  The MRL was based 
on 0.14 ppm, the human equivalent concentration (LOAELHEC) to the duration-adjusted minimal LOAEL
of 1.25 ppm.  An uncertainty factor of 90 (3 for the use of a minimal LOAEL, 3 for extrapolation from
animals to humans using dosimetric adjustment, and 10 for human variability) was applied to the
LOAELHEC. 
1,3-Dichloropropene. An intermediate-duration inhalation MRL of 0.008 ppm was derived for slight
hypertrophy/hyperplasia of the nasal respiratory epithelium observed in male B6CF1 mice exposed to 
1,3-dichloropropene vapor (92.1% purity) at a concentration of 60 ppm, 6 hours/day, 5 days/week, for 
6 months (Lomax et al. 1989).  The MRL was based on 0.23 ppm, the human equivalent concentration 
(HEC) to the benchmark concentration limit (BMCL10), the 95% lower confidence limit on the maximum
likelihood estimate of the concentration corresponding to 10% risk; concentrations were adjusted for 
compound purity and intermittent exposure before modeling.  An uncertainty factor of 30 (3 for 
extrapolation between animal and human using dosimetric adjustment and 10 for human variability) was
applied to the (BMCL10)HEC. A chronic-duration inhalation MRL of 0.007 ppm has been derived for
hypertrophy/hyperplasia of the nasal respiratory epithelium in female B6CF1 mice exposed to 1,3-di-
chloropropene vapor at a concentration of 20 ppm, 6 hours/day, 5 days/week for 2 years (Lomax et al. 
1989).  The MRL was based on 0.20 ppm, the human equivalent concentration to a benchmark
concentration limit (95% lower confidence limit on the maximum likelihood estimate of the concentration 
corresponding to 10% risk) ([BMCL10]HEC). An uncertainty factor of 30 (3 for extrapolation between 
animal and human using dosimetric adjustment and 10 for human variability) was applied to the
(BMCL10)HEC. An intermediate-duration oral MRL of 0.04 mg/kg/day has been derived based on a
BMDL10 of 3.6 mg/kg/day for basal cell hyperplasia of the nonglandular stomach in male Fischer rats 
(Haut et al. 1996) exposed to Telone II®b in the diet at a dose of 15 mg/kg/day for 13 weeks; a composite 
uncertainty factor of 100 (10 for extrapolation between animals and humans and 10 for human variability)











   
     
   
       
  





   




    
     
















8.  REGULATIONS AND ADVISORIES
incidence of basal cell hyperplasia in female Fischer rats (Stebbins et al. 2000) exposed to Telone II®b in 
the diet at a dose of 12.5 mg/kg/day for 2 years.  Application of a composite uncertainty factor of
100 (10 for extrapolation between animals and humans and 10 for human variability) to the BMDL10 of
3.51 mg/kg/day would result in a chronic oral MRL of 0.04 mg/kg/day.  This value is in agreement with
EPA’s chronic oral RfD of 0.03 mg/kg/day, which was based on a point of departure of 3.4 mg/kg/day for
the same data set. Therefore, 0.03 mg/kg/day was selected as the chronic-duration oral MRL for
1,3-dichloropropene.
In 2000, EPA derived an oral reference dose (RfD) value for 1,3-dichloropropene of 0.03 mg/kg/day 
based on a benchmark dose limit (95% lower confidence limit on the maximum likelihood estimate of the
dose corresponding to 10% risk) (BMDL10) of 3.4 mg/kg/day for chronic irritation in Fischer 344 rats in a
chronic feeding study (IRIS 2006); an uncertainty factor of 100 was applied (10 for interspecies
extrapolation and 10 for intraspecies variation) (IRIS 2006).
In 2000, EPA derived an inhalation reference concentration (RfC) value for 1,3-dichloropropene of
0.02 mg/m3 based on a benchmark concentration limit (95% lower confidence limit on the maximum
likelihood estimate of the dose corresponding to 10% risk) (BMCL10) of 3.7 mg/m3 (adjusted) (IRIS
2006) for hypertrophy/hyperplasia of the nasal respiratory epithelium in B6C3F1 mice during a chronic
inhalation study (Lomax et al. 1989); an uncertainty factor of 30 was applied (3 for interspecies 
extrapolation to reflect the pharmacodynamic component of interspecies uncertainty and 10 for
intraspecies variation) (IRIS 2006). 
In 1999, the International Agency for Research on Cancer (IARC) classified 1,3-dichloropropene as a 
Group 2B carcinogen (possibly carcinogenic to humans) (IARC 2004).  In 2000, EPA classified 1,3-di-
chloropropene as a B2 carcinogen (probable human carcinogen) (IRIS 2006).  The National Toxicology
Program (NTP) has classified 1,3-dichloropropene as reasonably anticipated to be a human carcinogen 
(NTP 2004).  The American Conference of Governmental Industrial Hygienists (ACGIH) has classified 
1,3-dichloropropene as an A3 carcinogen (confirmed animal carcinogen with unknown relevance to 
humans) (ACGIH 2005).  The National Institute of Occupational Safety and Health (NIOSH) has also 
identified 1,3-dichloropropene as a potential occupational carcinogen (NIOSH 2005).
OSHA has not required employers of workers who are occupationally exposed to 1,3-dichloropropene to 
institute engineering controls and work practices to reduce and maintain employee exposure at or below
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an 8- and 10-hour time-weighted averages (TWAs) of 1 ppm for 1,3-dichloropropene (ACGIH 2005;
NIOSH 2005).
1,3-Dichloropropene is regulated by the Clean Water Effluent Guidelines for the following industrial
point sources: electroplating, organic chemicals production, steam electricity power generation, asbestos 
product manufacturing, timber products processing, metal finishing, paving, roofing, paint formulating, 
ink formulating, gum and wood chemicals manufacturing, and carbon black manufacturing; see the
electronic Code of Federal Regulations for details (NARA 2006).
EPA regulates 1,3-dichloropropene under the Clean Water Act (CWA) and the Clean Air Act (CAA) and 
has designated it as a hazardous substance and a hazardous air pollutant (HAP) (EPA 2006b, 2006c).  1,3-
and 2,3-Dichloropropene are on the list of chemicals appearing in “Toxic Chemicals Subject to Section 
313 of the Emergency Planning and Community Right-to-Know Act of 1986" (EPA 2006g).  1,3- and 
2,3-Dichloropropene has been assigned a reportable quantity (RQ) limit of 100 pounds (EPA 2006f).  The
RQ represents the amount of a designated hazardous substance which, when released to the environment, 














    
    
    
     
     
     
    
 
   
    
      
     
     
 
      
   
     
   
     












     









   
     




     
     
244DICHLOROPROPENES
8.  REGULATIONS AND ADVISORIES
Table 8-1.  Regulations and Guidelines Applicable to Dichloropropenesa 
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification Group 2Bb IARC 2004
WHO Air quality guidelines









ACGIH TLV (8-hour TWA) 1 ppmd ACGIH 2005
EPA AEGL No data EPA 2006a
Hazardous air pollutant Yes EPA 2006c
42 USC 7412
NIOSH REL (10-hour TWA) 1 ppme,f NIOSH 2005
IDLH No data
OSHA PEL (8-hour TWA) for general industry No data OSHA 2005
29 CFR 1910.1000
b.  Water
EPA Designated as hazardous substances in 
accordance with Section 311(b)(2)(A) of




Drinking water standards and health 
advisories
EPA 2004
1-day health advisory for a 10-kg child 0.03 mg/L







National primary drinking water
standards
No data EPA 2003
Toxics criteria for those states not EPA 2006h
complying with Clean Water Act Section
303(c)(2)(B); human health (10-6 risk for 
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Table 8-1.  Regulations and Guidelines Applicable to Dichloropropenesa 
Agency Description	 Information Reference
NATIONAL (cont.)
c.	  Food
FDA	 Bottled drinking water No data FDA 2005
21 CFR 165.110
d.	  Other
ACGIH Carcinogenicity classification A3i ACGIH 2005
EPA Carcinogenicity classification B2j IRIS 2006
Oral slope factor 0.01 per mg/kg/day
Drinking water unit risk 1x10-6 to 3x10-6 per
mg/kg/day
Inhalation unit risk 4x10-6 per mg/m3 
RfC 0.02 mg/m3 
RfD 0.03 mg/kg/day
Identification and listing of hazardous U084 EPA 2006d
substances	 40 CFR 261,
Appendix VIII
Superfund, emergency planning, and EPA 2006f
community right-to-know 40 CFR 302.4





Effective date of toxic chemical EPA 2006g
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Table 8-1.  Regulations and Guidelines Applicable to Dichloropropenesa 
Agency Description	 Information Reference
NTP Carcinogenicity classification	 Reasonably anticipated NTP 2004
to be a human 
carcinogen
aAll regulations cited are applicable to 1,3-dichloropropene except where indicated.
bGroup 2B:  possibly carcinogenic to humans
cFor substances that are considered to be carcinogenic, the guideline value is the concentration in drinking-water
associated with an upper-bound excess lifetime cancer risk of 10-5 (one additional cancer per 100,000 of the 
population ingesting drinking-water containing the substance at the guideline value for 70 years).
dSkin notation:  refers to the potential significant contribution to the overall exposure by the cutaneous route, including
mucous membranes and the eyes, either by contact with vapors or, of probable greater significance, by direct skin 
contact with the substance.
ePotential occupational carcinogen
fSkin designation: indicates the potential for dermal absorption; skin exposure should be prevented as necessary
through the use of good work practices, gloves, coveralls, goggles, and other appropriate equipment.
gCriteria revised to reflect current agency q1* or RfD, as contained in the IRIS.  The fish tissue bioconcentration factor
from the 1980 criteria documents was retained in all cases.
hThis criterion is based on carcinogenicity of 10-6 risk.
iGroup A3: confirmed animal carcinogen with unknown relevance to humans
jB2:  probable human carcinogen
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = Acute Exposure Guideline Levels;
CERCLA = Comprehensive Environmetnal Response, Compensation, and Liability Act; CFR = Code of Federal
Regulations; DWEL = drinking water equivalent level; EPA = Environmental Protection Agency; FDA = Food and 
Drug Administration; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or 
health; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program;
OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; REL = recommended 
exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values;
TWA = time-weighted average; USC = United States Code; WHO = World Health Organization
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.   
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.














   
 
 
      




   
  
 




















   
 
 












Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure.  These may suggest potential topics for scientific research, but are not actual research studies.
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.


























     
 
 
    
 
 






   
  
 












   







Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors.  The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.






























    








   
  
 
    
   
  
 
    
   
  




   




Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 












    









   
 








   
  




       
 
    




   
 





    
 





Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.











     
  
   
 










   










    
 














Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.












    
   
  
 
    








Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.














This page is intentionally blank.



















   
  
    
    
  
    
 
   
 
 
   
 
 
   
 
  
    
 
A-1DICHLOROPROPENES
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach.  They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.














   
 




   
   
    







MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-32, Atlanta, Georgia 30333.
 












   
    
    
   
    
      
   
   
 
      
 
   
  
 









    







   




   






MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 2,3-Dichloropropene
CAS Numbers: 78-88-6 
Date: June 2008
Profile Status: Final Draft Post-public
Route: [X] Inhalation   [ ] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 3
Species: Rat
Minimal Risk Level: 0.002 [ ] mg/kg/day  [X] ppm
Reference:  Zempel JA, Grandjean M, Young JT.  1987.  2,3-Dichloropropene:  Results of a two-week
inhalation toxicity study in Fischer-344 rats and B6C3F1 mice.  Dow Chemical Company.  Submitted to 
the U.S. Environmental Protection Agency under TSCA Section FYI.  OTS0000499-1.
Note: The principal study is an unpublished study that has been peer reviewed.
Experimental design:  Groups (five/sex/concentration) of B6C3F1 mice and F344 rats were exposed to 
vapors of 2,3-dichloropropene (>99% purity) 6 hours/day for nine exposures over 11 days at
concentrations of 0, 5, 25, or 75 ppm (0, 22.7, 113.5, or 340 mg/m3).  Animals were examined daily for 
signs of toxicity.  Body weights were measured on days 1, 3, 5, and 12.  Urine samples were collected 
from rats before the last exposure on day 11.  At termination on day 12 after an overnight fast, blood 
samples were taken from rats and mice for hematology and serum chemistry analyses.  All rats and mice 
received a complete necropsy examination that, for rats, included the eyes.  Absolute and relative organ 
weights were recorded and calculated for brain, heart, liver, thymus, kidneys, and testes.  All saved tissues
were examined microscopically for all animals in the control and 75 ppm groups; in the 5 and 25 ppm
groups, target tissues were examined for histopathology (liver, kidneys, bone marrow, lungs, and nasal
tissues in both species, and also thymus, trachea, and larynx in mice).  The study was conducted under
Good Laboratory Practice standards.
Effects noted in study and corresponding doses:  NOAELs were not identified in rats or mice.  The lowest
tested concentration, 5 ppm, was a LOAEL for respiratory lesions in both species.
Rats: Treatment caused no significant changes in survival, daily activities, or hematology, serum
chemistry, or urinalysis results in rats.  Statistically significant reductions in body weight in ≥25 ppm
groups compared to controls were not biologically significant.  Observed organ weight changes reflected 
changes in body weight and were not accompanied by histopathology.  Histopathology of the respiratory
tract was the major effect of exposure, showing concentration-related increases in severity.  In all rats 
exposed at 25–75 ppm, slight-to-moderate degeneration (thinning) of the nasal olfactory epithelium was 
observed, secondarily producing inflammation and sloughing of necrotic cells. Hyperplasia of the nasal
respiratory epithelium was observed in nearly all treated rats except for one male treated at 5 ppm:  the
severity of this lesion was very slight at ≥5 ppm, slight at 25 ppm, and moderate at 75 ppm (Table A-1).  
Slight peribronchiolar infiltration of eosinophils was observed in one male at 5 ppm and most rats at 25– 
75 ppm, but the study authors were uncertain as to the toxicological significance of this lesion.  In male 
and female rats, 5 ppm was a LOAEL for hyperplasia of the nasal respiratory epithelium.













     
 
   
       
       
 
   
       
       
   
       




   
 
     
  
   
   
 
 
    
  
    




    
    
 








    
  





Table A-1.  Incidence of Significant Lesions in Fischer 344 Rats and B6C3F1 Mice 

Exposed to 2,3-Dichloropropene (>99%) Vapor 6 Hours/Day, for 9/11 Daysa
 
Control 5 ppm 25 ppm 75 ppm
Rats
Hyperplasia of nasal respiratory epithelium
Male 0/5 4/5* 5/5** 5/5***
Female 0/5 5/5* 5/5** 5/5***
Mice
Hyperplasia of nasal respiratory epithelium
Male 0/5 3/5* 5/5** 5/5***
Female 0/5 4/5* 5/5** 5/5***
Diffuse degeneration of bronchial/bronchiolar epithelium
Male 0/5 5/5** 5/5*** 5/5****
Female 0/5 5/5** 3/5***+ 2/5**** 5/5****
aSeverity: *very slight; **slight; ***moderate; ****severe
Source:  Zempel et al. 1987
Mice: Treatment had no significant effect on survival in mice.  Upon repeated exposure, reduced activity
levels were observed in all groups in a concentration-related manner; beginning with the third exposure at
25 or 75 ppm, slow and labored respiration was observed during exposure on days 3 and 5.  Food intake
(as estimated by fecal output) appeared to be reduced in the 25 and 75 ppm groups during the first week.  
Body weights were significantly lower compared to controls by 12–25% in males and 16–26% in females 
exposed at 25 or 75 ppm.  According to the study authors, hematology and serum chemistry changes
indicated mild dehydration and stress-induced lymphopenia at ≥25 ppm rather than direct toxic effects of
the compound (for example, increased ALT at 75 ppm was not accompanied by histology, but seemed to 
be a consequence of hemoconcentration).  At gross necropsy, the size and weight of the thymus were
reduced in male and female mice exposed at ≥25 ppm.  Microscopic examination showed diffuse cortical
atrophy of the thymus, which study authors considered secondary to stress, at 75 ppm.  Histopathology of
the respiratory tract was the most significant effect of exposure and showed concentration-related 
increases in severity (Table A-1).  Slight-to-moderate degeneration of nasal olfactory epithelium was 
observed at ≥25 ppm and very slight-to moderate hyperplasia of the nasal respiratory mucosa occurred at
≥5 ppm.  Hyperplasia (very slight-to-slight) of the laryngeal epithelium was observed at ≥25 ppm.  In the
bronchial/bronchiolar tissue, a diffuse degenerative lesion of the ciliated respiratory epithelium was slight
at 5 ppm (irregular cells size and apical nuclei in many cells), moderate at 25 ppm and severe at 75 ppm, 
showing flattened or cuboidal epithelium (rather than columnar) with sparse ciliation and apical rather
than basal nuclei.  In male and female mice, 5 ppm was a LOAEL for very slight hyperplasia of the nasal
respiratory epithelium and slight diffuse degeneration of the bronchial/bronchiolar epithelium.
Dose and end point used for MRL derivation: Very slight hyperplasia of nasal respiratory epithelium in 
female rats exposed to 5 ppm 2,3-dichloropropene (>99% purity), 6 hours/day, for 9/11 days.  The effect 
is considered minimal because the severity of the lesion was characterized by the study authors as very
slight.  Using EPA (1994) dosimetric adjustments (see below), a regional gas dose ratio (RGDRET) of
0.1143 for extrathoracic effects was applied to the duration-adjusted LOAEL of 1.25 ppm, resulting in a
human equivalent concentration (LOAELHEC) of. 0.1429 ppm, the point of departure for the MRL.
[ ] NOAEL   [X] [LOAEL]HEC 
  
  











    
 
     
     
   
 
    
 







     
  
 
    
       
      





   
        
 
 
     
         
       
 
 
     
       






   
  
 




Uncertainty Factors used in MRL derivation:  90 applied to the LOAELHEC of 0.1429 ppm
[X]  3 for use of a minimal LOAEL
[X]  3 for extrapolation from animals to humans using dosimetric adjustments
[X]  10 for human variability
0.1429 ppm / 90  =  0.0016 ppm, rounded to 0.002 ppm
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
EPA (1994) methods for calculating dosimetric adjustments across species for inhalation exposures were 
applied to data for nasal lesions, defined as extrathoracic (ET) effects, in rats and mice, and for bronchial
and bronchiolar lesions, defined as trachiobronchial (TB) effects, in mice.  Values used in these
calculations and the calculated regional gas dose ratios are given in Table A-2.
Table A-2.  Values Used for Calculating Human Equivalent Concentrations to 

LOAELs of 5 ppm for Fischer F344 Rats and B6C3F1 Mice Exposed

6 Hours/Day, 9/11 Days to 2,3-Dichloropropenea 

Rats Mice
Human Male Female Male Female
Intercept b0b -0.578 -0.578 0.326 0.326
Slope b1b 0.821 0.821 1.050 1.050
Time-weighted-average body 0.2326 kg 0.1502 kg 0.0254 kg 0.0211 kg
weightc (kg) 
VE (minute volume) (mL/minute) 13,800 b 169.42 118.3106 29.2857 24.1033
SA ET (surface area of extra- 200 cm2 15 cm2 15 cm2 3 cm2 3 cm2 
thoracic region)b 
RGDR ET 0.1637 0.1143 0.1415 0.1164
(LOAEL-adjusted)HEC-ET (ppm) 0.2046 0.1429 0.1769 0.1455
SA TB (surface area of tracheo- 3,200 cm2 Not applicable Not applicable 3.5 cm2 3.5 cm2 
bronchial region)b 
RGDR TB Not applicable Not applicable 1.7771 1.4305
(LOAEL-adjusted)HEC-TB ppm Not applicable Not applicable 2.2214 1.7881




cCalculated from data in Zempel et al. (1987)
 
Although 2,3-dichloropropene is a category 2 gas, the extrathoracic (ET) regional gas dose ratios
(RGDRs) were calculated from rat and mouse data using the equation for a category 1 gas by default, 
since an equation is not available for category 2 gases (EPA 1994).
RGDRET = (RGD ET)rodent /(RGD ET)human =  (VE/SA ET)rodent /(VE/SA ET)human 













       







    
 
 

















      





     









The tracheobronchial (TB) regional gas dose ratios were calculated from mouse data using the equation 
for a category 1 gas by default.
RGDRTB = (RGD TB)mouse /(RGD TB)human 
/(VE/SA TB)human ] [ (e –[SAet/VE]mouse) / (e –[SAet/VE]human)]=  [(VE/SA TB)mouse 
Where:
VE = minute volume in mL/minute
SA = surface area in cm2 
The minute volumes (VE) for male and female rats and mice were calculated using the equation
LN (VE) = b0 + b1 [LN (BW in kg)].
Slopes and intercepts for rats and mice were taken from EPA (1994).  The acute time-weighted-average 
body weights for male and female B6C3F1 mice, and male and female Fischer 344 rats, were calculated
from data reported in the key study.  Values for calculating minute volumes are in Table A-2.
The calculated regional gas dose ratios for extrathoracic effects in rats and mice and tracheobronchial
effects in mice (Table A-2) were applied to the common duration-adjusted LOAEL of 1.25 ppm.  The
lowest human equivalent concentration was 0.1429 ppm for extrathoracic effects (hyperplasia of nasal
respiratory epithelium) in female rats, which was selected as the point of departure for calculating the 
MRL since it would be protective against all effects.  
Although a NOAEL was not available in this study, benchmark dose modeling was not performed to 
estimate an exposure level without appreciable risk because the data were not suitable. The group sizes 
were too small to model data sets for each sex separately, and the dose-response data for the combined 
sets provided no information as to the shape of the response curve below the tested exposure levels 
incidences for rats or mice with respiratory tract lesions increased from 0/10 in the control to 70–100% in 
the lowest exposure groups (Table A-1).  For these reasons, the MRL was calculated using the 
NOAEL/LOAEL approach.
Was a conversion used from intermittent to continuous exposure?  Yes. The LOAEL, 5 ppm, was
adjusted for intermittent exposure (6 hours/24 hours), resulting in a duration-adjusted LOAEL of
1.25 ppm. 
Other additional studies or pertinent information that lend support to this MRL: No data were available 
for the acute-duration inhalation toxicity of 2,3-dichloropropene in humans, and acute-duration inhalation 
data for animals, aside from the principal study, are limited to lethality studies (Dietz et al. 1985b;
Monsanto 1967; Smyth et al. 1962; Union Carbide Corp. 1958).  Exposure to an unquantified
concentrated vapor of 2,3-dichloropropene resulted in effects on the eye (closure of eyelids, lacrimation), 
respiratory system (gasping, labored breathing, nasal discharge and, at necropsy, hemorrhagic lungs and 
inflammation of the nasal mucosa) and central nervous system (reduced activity, unconsciousness), and 
death within 30 minutes in rats (Monsanto 1967).  An acute lethality inhalation study in rats reported no 
mortality at 250 ppm, 50% mortality at 500 ppm, and 100% mortality at 1,000 ppm after a 4-hour
exposure (Smyth et al. 1962; Union Carbide Corp. 1958); this study provided no information about target
organ specificity.  In a 1-hour acute inhalation lethality study (for which even-numbered pages were 
missing), all rats exhibited irritant effects on the eye (lacrimation), respiratory tract (gasping, shallow
respiration), gastrointestinal system (diarrhea), and central nervous system (lethargy) during exposure at
concentrations of 693–1,963 ppm (Dietz et al. 1985b); postexposure lethargy and labored respiration were
observed in rats exposed at 1,963 ppm.  As described in Dietz et al. (1985b), results of a 6-hour range-
finding inhalation study in rats included no overt toxicity at 75 ppm, crusted noses at 250 ppm, and 














   







bloody noses, diarrhea, lethargy, and death at 500 ppm; irritation of the eyes and nose were named as the
primary treatment-related effects in the range-finding study.
The limited database indicates that irritant effects, especially on the respiratory system, are the critical
effects of acute-duration inhalation exposure to 2,3-dichloropropene.  The study by Zempel et al. (1987)
was selected as the principal study since it was adequately designed and reported, and it documented 
respiratory effects at the lowest tested concentration in rats and mice, providing reliable LOAELs for
these effects.
Agency Contacts (Chemical Managers):   Annette Ashizawa, Sharon Wilbur, and Heraline Hicks










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name:  1,3-Dichloropropene 
CAS Numbers:   542-75-6  
Date:   June 2008 
Profile Status:  Final Draft Post-public 
Route:   [X] Inhalation   [ ] Oral 
Duration:  [ ] Acute   [X] Intermediate   [ ] Chronic 
Graph Key:  20 
Species:    Mouse  
 
Minimal Risk Level:  0.008   [ ] mg/kg/day   [X] ppm 
 
Reference:  Lomax L, Stott W, Johnson K, et al.  1989.  The chronic toxicity and oncogenicity of inhaled 
technical grade 1,3-dichloropropene in rats and mice.  Fundam Appl Toxicol 12:418-431. 
 
Experimental design:  Groups (10/sex/concentration) of B6C3F1 mice and F344 rats were exposed to 
vapors of 1,3-dichloropropene 6 hours/day, 5 days/week for 6 months at concentrations of 0, 5, 20, or 
60 ppm (0, 22.7, 90.8, or 272 mg/m3).  These were designed as interim satellite groups for a 2-year study.  
The test material was 92.1% pure (49.5% cis; 42.6% trans) and contained 2.0% epoxidized soybean oil 
(ESO) as a stabilizer, 0.7% 1,2-dichloropropane, and a calculated 5.2% mixtures of hexanes and 
hexadienes.  Animals were observed after each exposure for clinical signs and moribund animals 
necropsied to minimize postmortem autolysis.  Body weights were recorded before the study began, 
weekly for the first 13 weeks, and at monthly intervals thereafter.  Urinalysis was conducted on rats 
during the week prior to termination; hematology and clinical chemistry parameters were analyzed in 
blood samples taken from rats and mice at the time of necropsy.  All animals received examination by 
gross necropsy, at which time absolute and relative brain, heart, kidney, liver, and testicular weights were 
recorded.  More than 40 tissues, in addition to gross lesions, were examined for histopathology in control 
and high-exposure animals at scheduled sacrifice and in all animals dying prematurely.  About 17 tissues, 
in addition to gross lesions, were examined in low- and mid-exposure animals at scheduled termination. 
 
Effects noted in study and corresponding doses:  Exposure to 1,3-dichloropropene for 6 months had no 
adverse effect on survival, clinical signs, or hematological or clinical chemistry parameters in mice.  Body 
weights of high-dose mice were depressed compared to controls, but the differences were not biologically 
significant at 6 months.  Reductions in liver and kidney weights in males at 60 ppm were attributed by 
study authors to the reduced body weight and were not accompanied by histopathology.  Statistically 
significant increased incidences of histopathological lesions were observed in mice treated at 60 ppm:  
hypertrophy/hyperplasia of the nasal respiratory epithelium in male and female mice and hyperplasia of 
the urinary bladder in female mice (Table A-3). 
 










Table A-3.  Incidence of Significant Lesions in B6C3F1 Mice Exposed to  
1,3-Dichloropropene (92.1%) Vapor 6 Hours/Day, 5 Days/Week  
for 6 Months 
 






Slight hypertrophy/hyperplasia of nasal respiratory epithelium 
 Male 1/10 0/10 3/10 10/10a 
 Female 0/10 0/10 0/10 7/10a 
Hyperplasia of urinary bladder 
 Male 0/10 0/10 0/10 1/10 
 Female  0/10 0/10 0/10 4/10a 
 
aDifferent from control using Fisher Exact Test 
 
Source:  Lomax et al. 1989 
 
Dose and end point used for MRL derivation:  Hypertrophy/hyperplasia of nasal respiratory epithelium in 
male and female B6C3F1 mice exposed to 60 ppm (272 mg/m3) 1,3-dichloropropene (92.1% purity), 
6 hours/day, 5 days/week for 6 months was selected as the critical effect.  Using benchmark concentration 
analysis, a BMCL10 value of 1.0678 mg/m
3 was calculated for male mice and 13.5227 mg/m3 was 
calculated for female mice (see Tables A-4 and A-6).  Using EPA (1994) dosimetric adjustments, the 
male BMCL10 value was converted to a human equivalent concentration ([BMCL10]HEC) of 1.0678 mg/m
3 
(0.2349 ppm), which was selected as the point of departure for the MRL since it was lower than the 
female value.  Note that concentrations in mg/m3 were converted to ppm by using a factor of 0.22 (see 
Table 4-2 in this profile). 
 
[ ] NOAEL   [ ] LOAEL 
[X]  [BMCL10] 
 
Uncertainty Factors used in MRL derivation:  30 applied to the [BMCL0]HEC of 0.2349 ppm for nasal 
effects in male mice 
 
 [ ]    10 for use of a LOAEL 
 [X]    3 for extrapolation from animals to humans using dosimetric adjustments 
 [X]  10 for human variability 
  
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:   
Although 1,3-dichloropropene is a category 2 gas, the extrathoracic (ET) regional gas dose ratios 
(RGDRs) were calculated from rat and mouse data using the equation for a category 1 gas by default, 
since an equation is not available for category 2 gases.  This is equation 4-18 in EPA (1994); in this 
section, all pages/equations/tables refer to EPA (1994). 
 
RGDRET = (Dose ET)mouse /(Dose ET)human  =  (VE/SA ET)mouse /(VE/SA ET)human   
 
The minute volumes (VE) for male and female mice were calculated using equation 4-4. 
LN (VE) = b0 + b1 [LN (BW in kg)]    











Intercept b0 of 0.326 and slope b1 of 1.050 for mouse were taken from Table A-6. 
 
The subchronic body weights of 0.0316 kg for male and 0.0246 kg for female B6C3F1 mice were taken 
from Table 4-5. 
 
VE mouse  = mouse minute volume (L/minute)   = 36.8353 mL/minute for male mice and 
           28.3168 mL/minute for females. 
(SA ET) mouse  = mouse surface area of extrathoracic region  = 3 cm
3, from Table A-4   
VE human  = human minute volume (L/minute)   = 13,800 mL/minute, from page 4-33  
(SA ET) human  = human surface area of extrathoracic region  = 200 cm
3, from Table A-4  
 
Extrathoracic regional gas dose ratios were calculated as 0.1779 for male mice and 0.1368 for females 
exposed in an intermediate-duration study.  These values were used to convert the respective male and 
female mouse BMCL values to human equivalent concentrations (see below). 
 
Was a conversion used from intermittent to continuous exposure?  Yes.  The exposure concentrations (in 
mg/m3 as reported by study authors) were adjusted by the purity of the compound (92.1%) and 
intermittent exposure (6 hours/24 hours x 5 days/7 days).  Benchmark concentration analyses were 
conducted using these adjusted exposure levels. 
 
Other additional studies or pertinent information that lend support to this MRL:  In the only intermediate-
duration inhalation study in humans, no evidence of renal or hepatic damage was detected in clinical 
chemistry analyses of blood and serum in pesticide applicators using cis-1,3-dichloropropene for an 
average of 521 (±230) minutes/day at a geometric mean concentration (8-hour TWA) of 2.7 mg/m3 (range 
0.1–9.5 mg/m3) (0.594 [0.22–2.09] ppm) over a 117-day period compared to unexposed controls 
(Verplanke et al. 2000).  No other end points were examined in this study.  Respiratory effects (mucous 
membrane irritation, chest pain, cough, and breathing difficulties) have been observed following 
accidental acute exposure to high concentrations (Flessel et al. 1978; Markovitz and Crosby 1984). 
 
The available data from the inhalation exposure animal studies indicate that hypertrophy/hyperplasia of 
the nasal respiratory epithelium and hyperplasia of the urinary bladder in mice are the most sensitive 
effects associated with intermediate-duration exposed to 1,3-dichloropropene.  Increased incidences of 
hypertrophy/hyperplasia of the nasal respiratory epithelium occurred in male and female B6C3F1 mice 
exposed to 60 ppm Telone II®b (92.1% 1,3-dichloropropene with 2% epoxidized soybean oil) vapor 
6 hours/day, 5 days/week for 6 months (Lomax et al. 1989).  Female mice in this study exposed at 60 ppm 
also had a marginally increased incidence of hyperplasia of the urinary bladder.  Fischer 344 rats exposed 
in this study under the same protocol did not exhibit histopathology after 6 months exposure (Lomax et 
al. 1989).  Slight reductions in body weights were observed in rats and mice exposed at 60 ppm, but the 
differences were not biologically significant (were <10% lower than controls) at 6 months (Lomax et al. 
1989).  Nasal lesions were also observed in rats exposed to ≥90 ppm Telone II®b 6 hours/day, 5–
7 days/week for 3 months in a reproductive toxicity assay (Breslin et al. 1989).  Nasal hyperplasia in rats 
and mice and urinary bladder hyperplasia in mice occurred in groups exposed to ≥90 ppm Telone II®a 
(90.9% 1,3-dichloropropene with 1.2% epichlorohydrin) 6 hours/day, 5 days/week for 13 weeks (Stott et 
al. 1988).  One 13-week study by Coate (1979a) reported nasal lesions in rats exposed 6 hours/day, 
5 days/week to Telone II®a at 30 ppm, but since the purity of the test material was not reported, the 
significance of the result is uncertain. 
 
Although increased incidences of hypertrophy/hyperplasia of the nasal respiratory epithelium and 
hyperplasia of the urinary bladder were both sensitive effects in mice at a LOAEL of 60 ppm, urinary 
hyperplasia was only observed in females and at a marginal increase (p=0.043; Fisher Exact Test) over 










controls.  Since the nasal lesions were observed in both sexes at a higher incidence, they were selected as 
the critical effect for development of the intermediate-duration MRL for 1,3-dichloropropene.  The 
6-month study with male and female mice exposed to Telone II®b by Lomax et al. (1989) was selected as 
the principal study because the study was adequately designed and reported, and because the test material 
contained a relatively high concentration of 1,3-dichloropropene without the confounding presence of 
epichlorohydrin or chloropicrin. 
 
Potential points of departure for deriving the intermediate-duration MRL, derived with benchmark dose 
(concentration) analysis, are shown in Table A-4.  Before the analysis, exposure concentrations in ppm 
were converted to mg/m3 and adjusted for 92.1% purity and discontinuous exposure.  Additional details 
of the benchmark dose (concentration) analysis are described below.   
 
For increased incidence of hypertrophy/hyperplasia of nasal epithelium in male and female mice, the 
potential point of departure was the BMCL associated with 10% extra risk; this BMR is the default 
recommended in EPA (2000a). 
 
Table A-4.  Potential Points of Departure for Determining the Intermediate-







Increased incidence of hypertrophy/hyperplasia of nasal respiratory 
epithelium in male and female mice exposed to Telone II®b vapor 
6 hours/day, 5 days/week for 6 months 






aAdjusted for <100% purity and discontinuous exposure; To convert to ppm, multiply by 0.22 
 
BMC = benchmark concentration; BMCL = 95% lower confidence limit for the benchmark concentration; 
BMR = benchmark response level; F = female; M = male; MRL = Minimal Risk Level 
 
Source:  Lomax et al. 1989 
 
The mouse BMCL10 values were multiplied by the extrathoracic regional dose ratios (mouse/human) 
(calculated above) for male and female B6C3F1 mice.  The male BMCL20 of 6.0022 mg/m
3 for 
hypertrophy/hyperplasia of nasal respiratory epithelium multiplied by an RGDR of 0.1779 results in a 
human equivalent concentration of 1.0678 mg/m3 (0.2349 ppm).  The female BMCL10 of 13.5227 mg/m
3 
for the same lesion multiplied by an RGDR of 0.1368 results in a human equivalent concentration of 
1.8499 mg/m3 (0.407 ppm).  The lower value based on male mice was selected as the point of departure 
for MRL derivation because it would be more protective of human health.  A total uncertainty factor of 30 
was applied to the male [BMCL10]HEC of 0.2349 ppm to calculate the intermediate-duration inhalation 
MRL for 1,3-dichloropropene.  
 
The intermediate-duration inhalation MRL for 1,3-dichloropropene is based on the Lomax et al. (1989) 
study which used technical grade dichloropropene containing 92.1% 1,3-dichloropropene, 0.7% 
1,2-dichloropropene, 2% epoxidized soybean oil as a stabilizer, and a calculated 5.2% mixture of hexanes 
and hexadienes.  It is unlikely that hexane significantly contributed to the toxicity of 1,3-dichloropropene.  
Although hexane and 1,3-dichloropropene both affect the olfactory epithelium, the lowest LOAEL for 
this effect by n-hexane is almost 2 orders of magnitude higher than for 1,3-dichloropropene.  As such, the 
hexane and hexadiene component is not considered to be a confounder in toxicity assessments for 
1,3-dichloropropene. 












Details of Benchmark Dose Analysis for the Intermediate-duration Inhalation MRL 
 
Male and Female Mice:  
 
All available dichotomous models in the EPA Benchmark Dose Software (BMDS version 1.3.2) were fit 
to the incidence data for hypertrophy/hyperplasia of nasal respiratory epithelium in male and female 
B6C3F1 mice exposed to 1,3-dichloropropene via inhalation for 6 months (Table A-5).  Predicted 
concentrations associated with 10, 5, and 1% extra risks were calculated. 
 
Table A-5.  Incidence of Hypertrophy/Hyperplasia of Nasal Respiratory Epithelium 




concentration Adjusted for 92.1% 
purity (mg/m3) 
Adjusted for discontinuous 
exposure and rounded (mg/m3)
Incidence 
ppm mg/m3 Males Females 
0 0 0 0 1/10 0/10 
5 22.7 20.9067 3.7 0/10 0/10 
20 90.8 83.6268 14.9 3/10 0/10 
60 272 250.512 44.7 10/10 7/10 
 
Source:  Lomax et al. 1989 
 
Hypertrophy/hyperplasia of nasal respiratory epithelium in male and female mice 
 
As assessed by the chi-square goodness-of-fit test, several models in the software provided adequate fits 
to the data (x2 p-value ≥0.1) for the incidence of hypertrophy/hyperplasia of nasal respiratory epithelium 
in male (Table A-6) and female (Table A-7) B6C3F1 mice.  Comparing across models, a better fit is 
indicated by a lower Akaike’s Information Criteria value (AIC) (EPA 2000b).  The gamma model was 
determined to be the best-fitting model for both males and females, as indicated by the AIC (Tables A-6 
and A-7; Figures A-1 and A-2).  Benchmark concentrations (BMCs and BMCLs) associated with an extra 
risk of 10, 5, and 1%, calculated from the best fitting model, are shown in Table A-8.  
 
Table A-6.  Goodness of Fit Statistics and BMC10s and BMCL10s from Models Fit 
to Incidence Data for Hypertrophy/Hyperplasia of Nasal Respiratory  
Epithelium in Male B6C3F1 Mice Exposed to 1,3-Dichloropropene  
via Inhalation for 6 Months 
 
Model AIC X2 p-valuea BMC10 (mg/m
3)b BMCL10 (mg/m
3)b 
Gammac 24.1579 0.5908 12.6179 6.00215 
Logistic 25.1526 0.3291 8.41841 5.1448 
Log-Logistic 26.1579 0.3049 13.939 7.23456 
Multistage 25.3494 0.4014 7.62026 3.9162 
Probit 25.2768 0.3167 7.64022 4.69897 
Log-probit 26.1579 0.3049 13.2999 6.97026 










Table A-6.  Goodness of Fit Statistics and BMC10s and BMCL10s from Models Fit 
to Incidence Data for Hypertrophy/Hyperplasia of Nasal Respiratory  
Epithelium in Male B6C3F1 Mice Exposed to 1,3-Dichloropropene  
via Inhalation for 6 Months 
 
Model AIC X2 p-valuea BMC10 (mg/m
3)b BMCL10 (mg/m
3)b 
Quantal-linear 31.8559 0.0529 2.70925 1.64437 
Quantal-quadratic 25.3494 0.4014 7.62026 5.43757 
Weibull 26.1579 0.3049 13.1405 5.44413 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bTo convert to ppm, multiply by 0.22. 
cBest-fitting model  
 
AIC = Akaike’s Information Criteria; BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the 
benchmark concentration; p = p-value from the Chi-squared test 
 
Source:  Lomax et al. 1989 
 
Figure A-1.  Observed and Predicted Incidences of Hypertrophy/Hyperplasia of 
Nasal Respiratory Epithelium in Male B6C3F1 Mice Exposed to 1,3-Dichloro-
propene via Inhalation for 6 Months* 
 
 
*BMCs and BMCLs indicated are for a 10% extra risk and are in units of mg/m3. 
BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the benchmark concentration 
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The form and parameters of the gamma model for the male mouse data are as follows: 
 
P[response]= background+(1-background)*CumGamma[slope*dose,power], 
where CumGamma(.) is the cumulative Gamma distribution function 
 
background  =   0.0499995 
slope   =   1.01615 
power   =     18 
 
Table A-7.  Goodness of Fit Statistics and BMC10s and BMCL10s from Models 
Fit to Incidence Data for Hypertrophy/Hyperplasia of Nasal Respiratory 
Epithelium in Female B6C3F1 Mice Exposed to 1,3-Dichloropropene  
via Inhalation for 6 Months 
 
Model AIC X2 p-valuea BMC10 (mg/m
3)b BMCL10 (mg/m
3)b 
Gammac 14.2213 1.0000 28.7185 13.5227 
Logistic 16.2173 1.0000 40.0892 17.7767 
Log-Logistic 16.2173 1.0000 37.7164 13.5983 
Multistage 16.779 0.6925 14.6277 8.36083 
Probit 16.2173 1.0000 35.9801 16.19 
Log-probit 16.2173 1.0000 32.4372 13.6137 
Quantal-linear 21.6296 0.1851 6.90725 3.87399 
Quantal-quadratic 16.779 0.6925 14.6277 10.8645 
Weibull 16.2173 1.0000 38.8344 13.5533 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bTo convert to ppm, multiply by 0.22. 
cBest-fitting model  
 
AIC = Akaike’s Information Criteria; BMC = benchmark concentration; BMCL = lower confidence limit (95%) on 
the benchmark concentration; p = p-value from the Chi-squared test 
 
Source:  Lomax et al. 1989 
 










Figure A-2.  Observed and Predicted Incidences of Hypertrophy/Hyperplasia of 
Nasal Respiratory Epithelium in Female B6C3F1 Mice Exposed to 1,3-Dichloro-
propene via Inhalation for 6 Months* 
 
 
*BMCs and BMCLs indicated are for a 10% extra risk and are in units of mg/m3. 
BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the benchmark concentration 
 
Source:  Lomax et al. 1989 
 
The form and parameters of the gamma model for the female mouse data are as follows: 
 
P[response]=background+(1-background)*CumGamma[slope*dose,power], 
where CumGamma(.) is the cumulative Gamma distribution function 
 
background  =  0 
slope   =  0.446459 



































Table A-8.  Best-fitting Model Predictions for 1, 5, and 10% Extra Risk for 
Hypertrophy/Hyperplasia of Nasal Respiratory Epithelium in Male  
and Female B6C3F1 Mice Exposed to 1,3-Dichloropropene  
via Inhalation for 6 Months 
 
Best fitting model BMR (percent extra risk) BMC (mg/m3)a BMCL (mg/m3)a 
Male mice 
Gamma 1 9.46353 1.96448 
 5 11.4494 4.23342 
 10b 12.6179 6.00215 
Female mice 
Gamma 1 21.5391 5.06945 
 5 26.059 9.93499 
 10 28.7185 13.5227 
 
aTo convert to ppm, multiply by 0.22. 
bBest-fitting model 
BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the benchmark concentration; 
BMR = benchmark response 
 
Source:  Lomax et al. 1989 
 














MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name:  1,3-Dichloropropene 
CAS Numbers:   542-75-6 
Date:   June 2008 
Profile Status:  Final Draft Post-public 
Route:   [X] Inhalation   [ ] Oral 
Duration:  [ ] Acute   [ ] Intermediate   [X] Chronic 
Graph Key:  44 
Species:  Mouse 
 
Minimal Risk Level:  0.007   [ ] mg/kg/day   [X] ppm 
 
Reference:  Lomax L, Stott W, Johnson K, et al.  1989.  The chronic toxicity and oncogenicity of inhaled 
technical grade 1,3-dichloropropene in rats and mice.  Fundam Appl Toxicol 12:418-431. 
 
Experimental design:  Groups (50/sex/concentration) of B6C3F1 mice and F344 rats were exposed to 
vapors of 1,3-dichloropropene 6 hours/day, 5 days/week for 2 years at concentrations of 0, 5, 20, or 
60 ppm (0, 22.7, 90.8, or 272 mg/m3).  Additional satellite groups (10/sex/concentration) were established 
interim sacrifices at 6 and 12 months (results for the 6-month sacrifice are given under the description for 
the intermediate-duration inhalation MRL).  The test material was 92.1% pure 1,3-dichloropropene 
(49.5% cis; 42.6% trans) and contained 2.0% ESO as a stabilizer, 0.7% 1,2-dichloropropane, and 
calculated 5.2% mixtures of hexanes and hexadienes.  Animals were observed after each exposure for 
clinical signs, and moribund animals necropsied to minimize postmortem autolysis.  Body weights were 
recorded before the study began, weekly for the first 13 weeks, and at monthly intervals thereafter.  
Urinalysis was conducted on rats during the week prior to termination; hematology and clinical chemistry 
parameters were analyzed in blood samples taken from rats and mice at the time of necropsy.  All animals 
received examination by gross necropsy, at which time absolute and relative brain, heart, kidney, liver, 
and testicular weights were recorded.  More than 40 tissues, in addition to gross lesions, were examined 
for histopathology in control and high-exposure animals at scheduled sacrifice and in all animals dying 
prematurely.  About 17 tissues, in addition to gross lesions, were examined in low- and mid-exposure 
animals at scheduled termination. 
 
Effects noted in study and corresponding doses:  Exposure to Telone II®b vapor for 2 years had no 
significant adverse effect on survival, body weight, the incidence of clinical signs, hematology, or clinical 
chemistry parameters in mice.  In the 1-year satellite group, incidences of hypertrophy/hyperplasia of the 
nasal respiratory epithelium were significantly higher than controls in males at ≥20 ppm and in females at 
60 ppm; females at 60 ppm also had increased incidences of epithelial hyperplasia and inflammation of 
the urinary bladder.  Significant lesions observed in mice after 2 years of exposure are given in Table A-9.  
Nasal and urinary bladder lesions were elevated in males at 60 ppm and in females at ≥20 ppm.  Increases 
in inflammation of the urinary bladder were not observed in males and were relatively small in females.  
Degeneration of the nasal olfactory epithelium was not statistically elevated in either sex at concentrations 
lower than 60 ppm.  Hypertrophy/hyperplasia of the nasal respiratory epithelium and epithelial 
hyperplasia of the urinary bladder in females at ≥20 ppm were the most sensitive effects in this study. 
 










Table A-9.  Incidence of Significant Lesions in B6C3F1 Mice Exposed to  
1,3-Dichloropropene (92.1%) Vapor 6 Hours/Day, 5 Days/Week  
for 2 Years 
 






Hypertrophy/hyperplasia of nasal respiratory epithelium (slight) 
 Male 5/50 1/50 4/50 48/50a 
 Female 4/50 4/50 28/50a 49/50a 
Degeneration of nasal olfactory epithelium (slight) 
 Male 1/50 0/50 1/50 48/50a 
 Female 0/50 0/50 1/50 45/50a 
Hyperplasia of urinary bladder (slight-moderate) 
 Male 4/48 7/48 11/48 37/47a 
 Female 1/47 4/46 21/48a 44/45a 
Inflammation of urinary bladder (slight-severe) 
 Male 0/48 0/48 0/48 2/47 
 Female 0/47 1/46 6/48a 8/45a 
 
aStatistically different from control 
 
Source:  Lomax et al. 1989 
 
Dose and end point used for MRL derivation:  Hypertrophy/hyperplasia of nasal respiratory epithelium in 
female B6C3F1 mice exposed at a LOAEL of 20 ppm (272 mg/m3) 1,3-dichloropropene (92.1% purity), 
6 hours/day, 5 days/week for 2 years.  Using benchmark concentration analysis, BMCL10 value of 
4.5673 mg/m3 was calculated (see Tables A-10 and A-15), and a human equivalent concentration 
([BMCL10]HEC) of 0.9130 mg/m
3 (0.2009 ppm) was calculated using EPA (1994) dosimetric adjustments.  
Note that concentrations in mg/m3 were converted to ppm by using a factor of 0.22 (see Table 4-2 in this 
profile). 
 
[ ]    NOAEL   [ ] LOAEL 
[X]  [BMCL10] 
 
Uncertainty Factors used in MRL derivation:  30 applied to the [BMCL10]HEC of 0.2009 ppm for nasal 
effects in female B6C3F1 mice 
 
 [ ]    10 for use of a LOAEL 
 [X]    3 for extrapolation from animals to humans 
 [X]  10 for human variability 
 
0.2009 ppm  /  30  =    0.0067, rounded to 0.007 ppm 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
 










If an inhalation study in animals, list conversion factors used in determining human equivalent dose:   
Although 1,3-dichloropropene is a category 2 gas, the extrathoracic (ET) regional gas dose ratios 
(RGDRs) were calculated from rat and mouse data using the equation for a category 1 gas by default, 
since an equation is not available for category 2 gases EPA (1994).  
 
RGDRET = (Dose ET )mouse /(Dose ET )human  =  (VE/SA ET )mouse /(VE/SA ET )human   
 
The minute volumes (VE) for female mice were calculated using the equation 
LN (VE) = b0 + b1 [LN (BW in kg)].    
Intercept b0 of 0.326, slope b1 of 1.050 for mouse, and chronic body weight of 0.0353 kg for chronic 
female B6C3F1 mice were taken from (EPA 1994). 
 
VE mouse  = mouse minute volume (L/minute)   = 41.3741 mL/minute for chronic  
           female mice 
(SA ET) mouse  = mouse surface area of extrathoracic region  = 3 cm
3 
VE human  = human minute volume (L/minute)   = 13,800 mL/minute 
(SA ET) human  = human surface area of extrathoracic region  = 200 cm
3 
 
An extrathoracic regional gas dose ratio of 0.1999 was calculated for female mice exposed in a chronic-
duration study.  These values were used to convert the female mouse BMCL value for nasal lesions to a 
human equivalent concentration (see below). 
 
Since epithelial hyperplasia of the urinary bladder is an extrarespiratory effect, the conversion to a human 
equivalent concentration is calculated for a category 3 gas using the ratio of animal/human blood:gas 
partition coefficients.  However, as no blood:gas partition coefficients for 1,3-dichloropropene were 
located in the published literature, the default ratio of 1 is applied.  The human equivalent BMCL10 values 
are unchanged from the mouse values. 
 
Was a conversion used from intermittent to continuous exposure?  Yes.  The exposure concentrations (in 
mg/m3 as reported by study authors) were adjusted for the purity of the compound (92.1%) and 
intermittent exposure (6 hours/24 hours x 5 days/7 days).  Benchmark concentration analyses were 
conducted using these adjusted exposure levels. 
 
Other additional studies or pertinent information that lend support to this MRL:  No data are available for 
effects in humans following chronic-duration inhalation exposure to 1,3-dichloropropene.  Fischer F344 
rats and B6C3F1 mice were evaluated for chronic-duration inhalation exposure to Telone II®b (92.1% 
1,3-dichloropropene stabilized with 2% epoxidized soybean oil) for 1 or 2 years (Lomax et al. 1989). 
 
The available data from chronic-duration studies indicate that lesions of the nasal epithelium and urinary 
bladder in mice are the most sensitive effects associated with chronic-duration inhalation exposure to 
1,3-dichloropropene.  After 1 year, incidences of hypertrophy/hyperplasia of the nasal respiratory 
epithelium were increased in male mice exposed at ≥20 ppm and in female mice at 60 ppm.  In addition, 
the incidences of hyperplasia and inflammation of the urinary bladder were increased in female mice 
exposed to 60 ppm for 1 year.  After 2 years of exposure, increased incidences of hypertrophy/hyperplasia 
of the nasal respiratory epithelium occurred in female mice at ≥20 ppm and males exposed at 60 ppm, and 
increased degeneration of the nasal olfactory epithelium occurred in male and female mice exposed at 
60 ppm.  In rats, nasal lesions were only detected at 60 ppm after 2 years of exposure and at lower 
incidences than in exposed mice:  decreased thickness of the olfactory epithelium in males and females, 
erosion of the olfactory epithelium in males, and submucosal fibrosis in males.  The incidences of 
epithelial hyperplasia of the urinary bladder were increased in female mice exposed for 2 years at 
≥20 ppm and male mice exposed at 60 ppm; the incidence of inflammation of the bladder epithelium was 










increased in female mice exposed for 2 years at ≥20 ppm, but not in males.  No histopathology of the 
urinary bladder was observed in rats. 
 
Based on these findings, hypertrophy/hyperplasia of the nasal respiratory epithelium and hyperplasia of 
the urinary bladder epithelium in mice exposed for 2 years were selected as co-critical effects for 
development of the chronic-duration inhalation MRL for 1,3-dichloropropene.  The mouse study by 
Lomax et al. (1989) is accepted as the principal study because the test material in this adequately designed 
and reported study had a purity of 92.1% and did not contain epichlorohydrin or chloropicrin as a 
possibly confounding toxic additive. 
 
Potential points of departure for deriving the chronic-duration inhalation MRL using benchmark 
concentration analysis are shown in Table A-10.  Before the analysis, exposure concentrations in ppm 
were converted to mg/m3, and adjusted for 92.1% purity and discontinuous exposure.  Additional details 
of the benchmark concentration analysis are described below.  None of the models in the EPA BMD 
software provided an adequate fit to the data for hypertrophy/hyperplasia of the nasal respiratory 
epithelium in male mice, so no BMCL could be calculated.  For increased incidence of 
hypertrophy/hyperplasia of nasal respiratory epithelium in female mice or hypertrophy of urinary bladder 
epithelium in male and female mice, the potential points of departure were the 95% lower confidence 
limits on estimated concentrations (BMCL10s) associated with 10% extra risk compared to control values.  
This benchmark response (BMR) level is the default recommended by EPA (2000a). 
 
Table A-10.  Potential Points of Departure for Determining the Chronic-duration 





Hypertrophy/hyperplasia of nasal respiratory epithelium 
(slight) in B6C3F1 mice exposed to Telone II®b vapor for 
2 years  







Hyperplasia of urinary bladder (slight-moderate) in B6C3F1 
mice exposed to Telone II®b vapor for 2 years  
BMR = 10% extra risk 
M 9.9024 
F  6.9087 
 
M 8.0838 
F  5.9079 
 
aAdjusted for <100% purity and discontinuous exposure 
bTo convert to ppm, multiply by 0.22. 
cNo models provided adequate fits to the data. 
 
BMC = benchmark concentration; BMCL = 95% lower confidence limit for the benchmark concentration; 
BMR = benchmark response level 
 
Source:  Lomax et al. 1989 
 
Mouse BMCL values were converted to human equivalent concentrations using EPA (1994) dosimetry 
methods.  The BMCL10 of 4.5673 mg/m
3 for hypertrophy/hyperplasia of nasal respiratory epithelium in 
female mice was multiplied by the extrathoracic regional dose ratio (mouse/human) of 0.1999 (calculated 
above), resulting in a human equivalent concentration of 0.9130 mg/m3 (0.2009 ppm).  The default ratio 
of 1 was applied for calculating the human equivalent concentrations for the extrarespiratory effects and 
urinary bladder lesions, resulting in values unchanged from those of male and female mice:  respectively, 
8.0838 and 5.9079 mg/m3 (1.7784 and 1.2997 ppm).  
 










The [BMCL10]HEC value of 0.2009 ppm for hypertrophy/hyperplasia of nasal respiratory epithelium in 
female mice was selected as the more sensitive point of departure for the chronic-duration inhalation 
MRL for 1,3-dichloropropene.   
 
The chronic-duration inhalation MRL for 1,3-dichloropropene is based on the Lomax et al. (1989) study 
which used technical grade dichloropropene containing 92.1% 1,3-dichloropropene, 0.7% 1,2-dichloro-
propene, 2% epoxidized soybean oil as a stabilizer, and a calculated 5.2% mixture of hexanes and 
hexadienes.  It is unlikely that hexane significantly contributed to the toxicity of 1,3-dichloropropene.  
Although hexane and 1,3-dichloropropene both affect the olfactory epithelium, the lowest LOAEL for 
this effect by n-hexane is almost 2 orders of magnitude higher than for 1,3-dichloropropene.  As such, the 




Details of Benchmark Dose Analysis for the Chronic-duration Inhalation MRL 
 
Male and Female Mice: 
 
All available dichotomous models in the EPA Benchmark Dose Software (BMDS version 1.3.2) were fit 
to the incidence data for hypertrophy/hyperplasia of nasal respiratory and urinary bladder epithelium in 
male and female B6C3F1 mice exposed to 1,3-dichloropropene via inhalation for 2 years (Table A-11).  
Predicted concentrations associated with 10, 5, and 1% extra risks were calculated. 
 
Table A-11.  Incidence of Hypertrophy/Hyperplasia of Nasal Respiratory 
Epithelium and Urinary Bladder Epithelium in Male and Female  






Concentration adjusted for 








0 0 5/50 4/50 
22.7 3.7 1/50 4/50 
90.8 14.9 4/50 28/50 




0 0 4/48 1/47 
22.7 3.7 7/48 4/46 
90.8 14.9 11/48 21/48 
272 44.7 37/47 44/45 
 
aTo convert to ppm, multiply by 0.22. 
 
Source:  Lomax et al. 1989 
 
Hypertrophy/hyperplasia of nasal respiratory epithelium in male and female mice 
 










As assessed by the chi-square goodness-of-fit test, no models in the software provided adequate fits to the 
data for the incidence of hypertrophy/hyperplasia of nasal respiratory epithelium in male B6C3F1 mice 
since all of the chi-square p-values were lower than 0.1 (data not shown).  Several models in the software 
provided adequate fits to the data for the incidence of for hypertrophy/hyperplasia of nasal respiratory 
epithelium in female B6C3F1 mice (x2 p-value ≥0.1) (Table A-12).  Comparing across models, a better fit 
is indicated by a lower AIC (EPA 2000b).  The log-probit model was determined to be the best-fitting 
model for the female data, as indicated by the AIC (Table A-12).  Benchmark concentrations (BMCs and 
BMCLs ) associated with an extra risk of 10, 5, and 1%, calculated from the best fitting model, are shown 
in Table A-15.  
 
Table A-12.  Goodness of Fit Statistics and BMC10s and BMCL10s from Models Fit 
to Incidence Data for Hypertrophy/Hyperplasia of Nasal Respiratory Epithelium 
in Female B6C3F1 Mice Exposed to 1,3-Dichloropropene  
via Inhalation for 2 Years 
 
Model AIC X2 p-valuea BMC10 (mg/m
3)b BMCL10 (mg/m
3)b 
Gamma 140.696 0.4605 5.88054 3.64206 
Logistic 141.091 0.1720 5.39501 4.3506 
Log-Logistic 140.177 0.8712 7.6296 4.86553 
Multistage 142.702 0.1047 4.9972 2.62038 
Probit 142.872 0.0716 5.19777 4.23194 
Log-probitc 140.166 0.9004 7.08327 4.56728 
Quantal-linear 150.075 0.0082 1.90984 1.53078 
Quantal-quadratic 141.085 0.1307 6.30223 5.39173 
Weibull 141.736 0.2167 4.94384 3.13411 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bTo convert to ppm, multiply by 0.22. 
cBest-fitting model  
 
AIC = Akaike’s Information Criteria; BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the 
benchmark concentration; p = p-value from the Chi-squared test 
 
Source:  Lomax et al. 1989 
 










Figure A-3.  Observed and Predicted Incidences of Hypertrophy/Hyperplasia of 
Nasal Respiratory Epithelium in Female B6C3F1 Mice Exposed to  
1,3-Dichloropropene via Inhalation for 2 Years* 
 
 
*BMCs and BMCLs indicated are for a 10% extra risk and are in units of mg/m3. 
BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the benchmark concentration 
 
Source:  Lomax et al. 1989 
 
The form and parameters of the log-probit model for the female mouse nasal lesion data are as 
follows: 
 
P[response] = Background+ (1-Background)* CumNorm(Intercept+Slope*Log(Dose)), 
 
where CumNorm(.) is the cumulative normal distribution function 
 
background  = 0.0769028 
intercept  = -4.80042 
slope   = 1.79742 
 
Slight/moderate hyperplasia of urinary bladder epithelium in male and female mice  
 
As assessed by the chi-square goodness-of-fit test, several models in the software provided adequate fits 
to the data (x2 p-value ≥0.1) for the incidence of for slight/moderate hyperplasia of urinary bladder 
epithelium in male (Table A-13; Figure A-4) and female (Table A-14; Figure A-5) B6C3F1 mice.  
Comparing across models, a better fit is indicated by a lower AIC (EPA 2000b).  The logistic model was 
determined to be the best fitting model for the male data (Table A-13), whereas the quantal quadratic 
model was determined to be the best-fitting model for the female data (Table A-14), as indicated by the 
AIC.  Benchmark concentrations (BMCs and BMCLs) associated with an extra risk of 10, 5, and 1%, 




















Log-Probit Model with 0.95 Confidence Level














Table A-13.  Goodness of Fit Statistics and BMC10s and BMCL10s from  
Models Fit to Incidence Data for Slight/Moderate Hyperplasia of  
Urinary Bladder Epithelium in Male B6C3F1 Mice Exposed to  
1,3-Dichloropropene via Inhalation for 2 Years 
 
Model AIC X2 p-valuea BMC10 (mg/m
3)b BMCL10 (mg/m
3)b 
Gamma 174.596 0.3561 12.9064 5.9353 
Logisticc 172.196 0.7929 9.90241 8.08381 
Log-Logistic 174.593 0.3576 13.1008 7.37023 
Multistage 174.403 0.4119 10.9233 4.95677 
Probit 172.305 0.7515 9.13794 7.58289 
Log-probit 174.671 0.3380 13.5586 8.28718 
Quantal-linear 177.633 0.0631 4.15472 3.1987 
Quantal-quadratic 172.465 0.6951 12.1536 10.4772 
Weibull 174.465 0.3939 12.1787 5.68456 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bTo convert to ppm, multiply by 0.22. 
cBest-fitting model  
 
AIC = Akaike’s Information Criteria; BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the 
benchmark concentration; p = p-value from the Chi-squared test 
 
Source:  Lomax et al. 1989 
 










Figure A-4.  Observed and Predicted Incidences of Slight/Moderate Hyperplasia  
of Urinary Bladder Epithelium in Male B6C3F1 Mice Exposed to  
1,3-Dichloropropene via Inhalation for 2 Years* 
 
 
*BMCs and BMCLs indicated are for a 10% extra risk and are in units of mg/m3. 
BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the benchmark concentration 
 
Source:  Lomax et al. 1989 
 
The form and parameters of the logistic model for the male mouse data are as follows: 
 
P[response] = 1/[1+EXP(-intercept-slope*dose)] 
 
background  = 0 (Specified)    
intercept = -2.19615 


































Table A-14.  Goodness of Fit Statistics and BMC10s and BMCL10s from  
Models Fit to Incidence Data for Slight/Moderate Hyperplasia of  
Urinary Bladder Epithelium in Female B6C3F1 Mice Exposed to  
1,3-Dichloropropene via Inhalation for 2 Years 
 
Model AIC X2 p-valuea BMC10 (mg/m
3)b BMCL10 (mg/m
3)b 
Gamma 119.054 0.3665 5.94769 3.5405 
Logistic 118.133 0.3632 6.93667 5.55287 
Log-Logistic 120.1 0.1816 8.84738 5.10377 
Multistage 118.241 0.9777 4.99209 2.90579 
Probit 118.606 0.2979 6.62106 5.3209 
Log-probit 120.27 0.1657 8.76593 4.86738 
Quantal-linear 126.03 0.0206 2.16273 1.72952 
Quantal-quadraticc 117.42 0.5326 6.90872 5.90793 
Weibull 118.378 0.7085 5.4465 3.42639 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bTo convert to ppm, multiply by 0.22. 
cBest-fitting model  
 
AIC = Akaike’s Information Criteria; BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the 
benchmark concentration; p = p-value from the Chi-squared test 
 
Source:  Lomax et al. 1989 
 
Figure A-5.  Observed and Predicted Incidences of Slight/Moderate Hyperplasia  
of Urinary Bladder Epithelium in Female B6C3F1 Mice Exposed to  
1,3-Dichloropropene via Inhalation for 2 Years* 
 
 
*BMCs and BMCLs indicated are for a 10% extra risk and are in units of mg/m3. 
BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the benchmark concentration 
 



































The form and parameters of the quantal-quadratic model for the female mouse data are as follows: 
 
P[response] = background + (1-background)*[1-EXP(-slope*dose^2)] 
 
background  =   0.03125 
slope   =   0.00169733 
power   =  2 (Specified) 
 
 
Table A-15.  Best-fitting Model Predictions for 1, 5, and 10% Extra Risk for 
Hypertrophy/Hyperplasia of Nasal Respiratory in Female and Urinary  
Bladder Epithelium in Male and Female B6C3F1 Mice Exposed to  
1,3-Dichloropropene via Inhalation for 2 Years  
 
Best fitting model BMR (percent extra risk) BMC (mg/m3)a BMCL (mg/m3)a 
Male miceb 
Urinary bladder epithelium:  
quantal quadratic 
1 1.30075 0.988608 
 5 5.65321 4.47585 




1 3.96085 2.0326 
 5 5.78698 3.45244 
 10c 7.08327 4.56728 
Urinary bladder epithelium:  
quantal quadratic 
1 2.13378 1.82468 
 5 4.82046 4.12218 
 10 6.90872 5.90793 
 
BMC = benchmark concentration; BMCL = lower confidence limit (95%) on the benchmark concentration; 
BMR = benchmark response 
 
aTo convert to ppm, multiply by 0.22. 
bNo models provided adequate fits for the incidence data for nasal lesions in male mice. 
cBest-fitting model 
 
Source:  Lomax et al. 1989 
 














MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: 1,3-Dichloropropene 
CAS Numbers:   542-75-6 
Date:   June 2008 
Profile Status:  Final Draft Post-public 
Route:   [ ] Inhalation   [X] Oral 
Duration:  [ ] Acute   [X] Intermediate   [ ] Chronic 
Graph Key:  10 
Species:  Rat 
 
Minimal Risk Level:  0.04  [X] mg/kg/day   [ ] ppm 
 
Reference:  Haut KT, Stebbins KE, Johnson KA, et al. 1996.  Subchronic toxicity of ingested 1,3-di-
chloropropene in rats and mice.  Fundam Appl Toxicol 32:224-232. 
 
Experimental design:  Haut et al. (1996) exposed groups of male and female Fischer 344 rats 
(10/sex/group) to 1,3-dichloropropene at doses of 0, 5, 15, 50, or 100 mg/kg/day for 13 weeks.  The test 
material, Telone II®b, was 95.8% pure 1,3-dichloropropene (50.7% cis; 45.1% trans) stabilized with 
epoxidized soybean oil, and was microencapsulated in a starch/sucrose (80:20) microsphere matrix before 
addition to the diets; separate tests showed that the microencapsulated compound was stable in feed for at 
least three weeks, but test diets were mixed fresh weekly.  Control diets received empty microspheres in 
an amount equivalent to the high-dose treated group.  Animals were examined daily for clinical signs of 
toxicity and received a weekly clinical examination.  Body weights and feed intake were recorded prior to 
testing and weekly during the study.  For rats, urinalysis was conducted during the week before the 
scheduled necropsy and at necropsy, blood samples were collected for hematology and clinical chemistry 
evaluations.  At necropsy, absolute and relative organ weights were recorded for brain, liver, kidneys, 
heart, and adrenals.  Samples of 65 tissues from all rats were preserved and those of the control and high-
dose groups were examined for histopathology; gross lesions and tissues from five organs (lung, liver, 
kidney, stomach, female mesenteric tissues) from low- and mid-dose animals were scheduled for 
histopathological examination.   
 
Effects noted in study and corresponding doses:  Treatment with 1,3-dichloropropene had no adverse 
effect on survival in rats.  Body weights were significantly reduced by 16% in male rats treated at 
50 mg/kg/day and by 11% in female rats treated at 100 mg/kg/day; statistically significant reductions in 
body weights at lower doses were not biologically significant.  The study authors indicated that 
significantly reduced feed intake at the high doses likely contributed to the reduced body weights, as well 
as the slightly reduced absolute organ weights and increased relative organ weights.  The authors 
attributed minor changes in clinical chemistry parameters in rats (e.g., reduction in triglycerides) to the 
poorer nutritional status of high-dose rats. 
 
A NOAEL of 5 mg/kg/day and a LOAEL of 15 mg/kg/day were identified for minimal basal cell 
hyperplasia of the nonglandular stomach in male rats treated at 15 mg/kg/day and female rats at 
50 mg/kg/day (Table A-16).  Female rats at 100 mg/kg/day also exhibited hyperkeratosis of the 
nonglandular stomach.  These lesions represent portal-of-entry effects from ingested 1,3-dichloropropene.   
 










Table A-16.  Incidence of Histopathological Lesions of Basal Cells in the 
Nonglandular Stomach in F344 Rats Exposed to 1,3-Dichloropropene  
(Telone II®b) in the Diet for 13 Weeks 
 
 Dose (doses in mg/kg/day; group size = 10) 
0 5 15 50 100 
Hyperplasia      
 Males 0 0 4a 10a 10a 
 Females 0 0 3 10a 10a 
Hyperkeratosis      
 Males 0 0 1 3 3 
 Females 0 0 0 3 5a 
 
aStatistically different from control, Fisher Exact Test performed by Syracuse Research Corporation. 
 
Source:  Haut et al. 1996 
 
Dose and end point used for MRL derivation:  Minimal hyperplasia of the nonglandular stomach mucosa 
in male Fischer 344 rats treated at 15 mg/kg/day for 13 weeks.  The calculated BMDL10 value of 
3.5722 mg/kg/day (see Table A-17) was used as the point of departure for the MRL 
 
[ ] NOAEL   [ ] LOAEL   [X]  BMDL10  
 
Uncertainty Factors used in MRL derivation:  100 applied to the BMDL10 of 3.5722 mg/kg/day for 
increased incidence of forestomach basal cell hyperplasia in male rats 
 
 [ ]  10 for use of a LOAEL 
 [X]  10 for extrapolation from animals to humans 
 [X]  10 for human variability 
 
3.5722 mg/kg/day / 100 = 0.0357, rounded to 0.04 mg/kg/day  
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.  Study authors 
reported doses as calculated from feed intake. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:   
Not applicable. 
 
Was a conversion used from intermittent to continuous exposure?  Not applicable.  Intake was ad libitum. 
 
Other additional studies or pertinent information that lend support to this MRL:  No data are available for 
effects in humans following intermediate-duration oral exposure to 1,3-dichloropropene.  Intermediate-
duration oral exposure studies with rats, mice, and dogs exposed to different commercial formulations of 
1,3-dichloropropene isomers have been conducted by oral gavage or dietary exposure.  
 
The available data from the oral exposure animal studies indicate that lesions in the nonglandular stomach 
mucosa in rats and microcytic anemia in dogs are the most sensitive effects associated with intermediate-
duration oral exposure to 1,3-dichloropropene (see Chapter 3 for more detailed discussion of health 
effects associated with 1,3-dichloropropene).  Increased incidences of basal cell hyperplasia of the 










nonglandular stomach occurred in male Fischer 344 rats exposed to doses ≥15 mg/kg/day Telone II®b 
microencapsulated in feed for 13 weeks; female rats displayed hyperkeratosis of the nonglandular 
stomach epithelium at doses of 100 mg/kg/day in this study (Haut et al. 1996).  B6C3F1 mice exposed to 
Telone II®b via the same protocol for 13 weeks did not display any adverse effects on histologic or 
hematologic end points (Haut et al. 1996).  Microcytic anemia (decreased hematocrit, hemoglobin 
concentration, and corpuscular volume) occurred in beagle dogs exposed to doses ≥15 mg/kg/day 
Telone II®b encapsulated in feed for 13 weeks (Stebbins et al. 1999).  Reductions in terminal body weight 
were observed in rats, mice, and dogs exposed to Telone II®b in feed for 13 weeks, but reduced food 
intake associated with decreased palatability may have contributed to these effects (Haut et al. 1996; 
Stebbins et al. 1999).  In an earlier 13-week study with Telone®, a commercial formulation of lesser 
1,3-dichloropropene purity than Telone II®b, increased liver or kidney weights were observed in rats at 
doses as low as 10 and 30 mg/kg/day, respectively, but the lack of renal or kidney adverse noncancer 
effects in the intermediate- or chronic-duration studies with Telone II®b suggests that these organs are not 
consistently observed noncancer toxicity targets of 1,3-dichloropropene.   
 
Basal cell hyperplasia in the nonglandular stomach of male rats and decreased hemoglobin concentration 
and corpuscular volume in male or female dogs were sensitive effects occurring at the same exposure 
levels.  However, the intermediate-duration study in dogs by Stebbins et al. (1999) was judged to be 
inadequate as a critical study because no histopathology examination was conducted and the group sizes 
were small.  Therefore, basal cell hyperplasia in the nonglandular stomach of male rats was selected as 
the critical effect for development of the intermediate-duration MRL for 1,3-dichloropropene.  The 
13-week study with male rats (Haut et al. 1996) exposed to microencapsulated Telone II®b was selected 
as the principal study, because the test material in these adequately designed and reported studies was the 
most purified 1,3-dichloropropene formulation tested and did not contain potentially confounding toxic 
materials such as epichlorohydrin or chloropicrin.   
 
Potential points of departure for deriving the intermediate-duration MRL, derived with benchmark dose 
analysis, are shown in Table A-17.  Details of the benchmark dose analyses are given below.   
 
Table A-17.  Potential Points of Departure for Determining the Intermediate-







Increased incidence of basal cell hyperplasia of nonglandular 
stomach mucosa in male rats exposed to Telone II®b in feed for 
13 weeks (Haut et al. 1996) 
BMR = 10% extra risk 
9.0030 3.5722 
 
BMD = benchmark dose; BMDL = 95% lower confidence limit for the benchmark dose; BMR = benchmark response 
level; MRL = Minimal Risk Level 
 
For increased incidence of basal hyperplasia in nonglandular stomach mucosa of rats, the potential point 
of departure was the BMDL associated with 10% extra risk; this BMR was the default recommended in 
EPA (2000a).   
 
An intermediate-duration oral MRL of 0.04 mg/kg/day was derived by dividing the rat BMDL10 of 
3.5722 mg/kg/day for basal cell hyperplasia by a composite uncertainty factor of 100 (10 for extrapolation 
from animals to humans and 10 for human variability).  The MRL is based on the Haut et al. (1996) study 
which used Telone II®b containing 95.8% 1,3-dichloropropene with no other constituents reported. 











Details of Benchmark Dose Analysis for the Intermediate-duration Oral MRL 
 
Male Rats:  
 
All available dichotomous models in the EPA Benchmark Dose Software (BMDS version 1.3.2) were fit 
to the incidence data for basal cell hyperplasia of nonglandular stomach mucosa in male rats exposed to 
1,3-dichloropropene in the diet for 13 weeks (Table A-18).  Predicted doses associated with 10, 5, and 1% 
extra risks were calculated (Table A-20). 
 
Table A-18.  Incidence of Basal Cell Hyperplasia of Nonglandular Stomach 
Mucosa (minimal) in Fisher 344 Rats Exposed to 1,3-Dichloropropene  
in the Diet for 13 Weeks  
 
 Doses in mg/kg body weight/day 
Control 5  15  50  100 
Males 0/10 0/10 4/10a 10/10a 10/10a 
 
aStatistically different from control (Fisher Exact Test performed by SRC March 2006) 
 




As assessed by the chi-square goodness-of-fit test, several models in the software provided adequate fits 
to the data for the incidence of basal cell hyperplasia of nonglandular stomach mucosa in male rats 
(x2 p-value ≥0.1) (Table A-19).  Comparing across models, a better fit is indicated by a lower AIC (EPA 
2000b).  A 3-degree polynomial multi-stage model was determined to be the best-fitting model, as 
indicated by the AIC (Table A-19; Figure A-6).  Benchmark doses (BMDs and BMDLs) associated with 
an extra risk of 10, 5, and 1%, calculated from the best fitting model, are shown in Table A-20.  
 










Table A-19.  Goodness of Fit Statistics and BMD10s and BMDL10s from Models Fit 
to Incidence Data for Basal Cell Hyperplasia of Nonglandular Stomach Mucosa 
in Male Rats Exposed to 1,3-Dichloropropene in the Diet for 13 Weeks 
 
Model AIC X2 p-valuea BMD10 (mg/kg/day) BMDL10 (mg/kg/day) 
Gamma 15.4607 1.0000 11.5681 5.1935 
Logistic 17.4602 1.0000 14.0398 6.8305 
Log-Logistic 17.4602 1.0000 13.5206 6.25073 
Multistageb 15.8298 0.9957 9.00298 3.57217 
Probit 17.4602 1.0000 13.1012 6.25656 
Log-probit 17.4602 1.0000 12.213 5.92308 
Quantal-linear 22.7351 0.3922 2.40324 1.53389 
Quantal-quadratic 16.6383 0.9616 7.05272 5.01843 
Weibull 17.4612 1.0000 12.4316 4.82232 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bBest-fitting model  
 
AIC = Akaike’s Information Criteria; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the 
benchmark dose; NA = not applicable; p = p-value from the Chi-squared test 
 
Source:  Haut et al. 1996 
 










Figure A-6.  Observed and Predicted Incidences of Basal Cell Hyperplasia of 
Nonglandular Stomach Mucosa in Male Rats Exposed to  



















Multistage Model with 0.95 Confidence Level
10:08 03/20 2006
BMDBMDL




*BMDs and BMDLs indicated are for a 10% extra risk and are in units of mg/kg/day. 
BMD = benchmark dose;  BMDL = lower confidence limit (95%) on the benchmark dose 
 
Source:  Haut et al. 1996 
 
The form and parameters of the multi-stage model for the male rat data are as follows: 
 
P[response] = background + (1-background)*[1-EXP(-beta1*dose^1-beta2*dose^2-beta3*dose^3)] 
 
background  =   0 
Beta(1)  =  0 
Beta(2)  =   0 
Beta(3)  =   0.000144384 
 










Table A-20.  Best-fitting Model Predictions for 1, 5, and 10% Extra Risk for Basal 
Cell Hyperplasia of Nonglandular Stomach Mucosa in Male Rats Exposed to 
1,3-Dichloropropene in the Diet for 13 Weeks 
 
Best fitting model BMR (% extra risk) BMD (mg/kg/day) BMDL (mg/kg/day) 
Male:  Multistage 1 4.11358 0.416759 
 5 7.0824 1.76019 
 10 9.00298 3.57217 
 
BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark dose; BMR = benchmark 
response 
 
Source:  Haut et al. 1996 
 
Agency Contacts (Chemical Managers):  Annette Ashizawa, Sharon Wilbur, and Heraline Hicks 
 
 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name:  1,3-Dichloropropene 
CAS Numbers:   542-75-6 
Date:   June 2008 
Profile Status:  Final Draft Post-public 
Route:   [ ] Inhalation   [X] Oral 
Duration:  [ ] Acute   [ ] Intermediate   [X] Chronic 
Graph Key:  18 
Species:  Rat 
 
Minimal Risk Level:  0.03   [X ] mg/kg/day   [ ] ppm 
 
References:  Co-principal studies:  
 
Stebbins KE, Johnson KA, Jeffries TK, et al. 2000.  Chronic toxicity and oncogenicity studies of ingested 
1,3-dichloropropene in rats and mice.  Regul Toxicol Pharmacol 32:1-13. 
 
Stebbins KE, Quast JF, Haut KT, et al.  1999.  Subchronic and chronic toxicity of ingested 1,3-dichloro-
propene in dogs.  Regul Toxicol Pharmacol 30:233-243. 
 
Experimental design:  Stebbins et al. (2000) exposed groups of male and female Fischer 344 rats 
(50/sex/group) to 1,3-dichloropropene in the diet at doses of 0, 2.5, 12.5, or 25 mg/kg/day for 2 years; 
satellite groups of 10/sex/group were scheduled for interim sacrifice at 12 months.  Stebbins et al. (1999) 
exposed beagle dogs (4/sex/group) to dose of 0, 0.5, 2.5, or 15 mg/kg/day for 1 year.  In both studies, the 
test material, Telone II®b, was 95.8% pure 1,3-dichloropropene (50.7% cis; 45.1% trans) with 2% ESO as 
a stabilizer and was microencapsulated in a starch/sucrose (80:20) microsphere matrix before addition to 
the diets; separate tests showed that the microencapsulated compound was stable in feed for at least three 
weeks, but test diets were mixed fresh weekly.  Control diets received empty microspheres in an amount 
equivalent to that given to the high-dose treated group.  Animals were examined daily for clinical signs of 
toxicity and received a weekly clinical examination.  Body weights and feed intake were recorded prior to 
testing and weekly during the first 13 weeks of the study and at monthly intervals thereafter.  For rats, 
urinalysis samples and blood samples for hematology and clinical chemistry and were obtained from the 
satellite groups at 6 and 12 months and from survivors in the main group at 18 months (10 animals/sex/
group) and 24 months (20 animals/sex/group).  For dogs, blood samples were collected prior to testing 
and after 3, 6, and 9 months of dosing and during the week prior to termination; urine samples were taken 
from dogs at necropsy.  At necropsy, absolute and relative organ weights were recorded for brain, liver, 
kidneys, testes, ovaries, heart, and adrenals in both species and for thyroids plus parathyroids in dogs.  
Complete sets tissues from all animals were preserved and, in rats, those of the control and high-dose 
groups and animals dying prematurely were examined for histopathology; gross lesions and tissues from 
selected organs (lung, liver, uterus, kidney, stomach, and testes) from low- and mid-dose animals were 
scheduled for histopathological examination.  All dogs were examined for histopathology in the full range 
of tissues.  
 
Effects noted in study and corresponding doses:  Both studies:  Dietary exposure to Telone II®b had no 
effect on survival in rats exposed for 2 years or dogs exposed for 1 year.   
 
Rats:   
 
Body weights of high-dose male and female rats were 15–16% lower than controls, but feed consumption 
was also reduced by 12–13%.  Exposure had no significant effect on hematology, clinical chemistry, or 










urinalysis parameters.  Reduced triglyceride counts in high-dose males and females were attributed by the 
authors to the decreased body weights, rather than a toxicological response.  
 
In rats, the most sensitive effect of exposure after 2 years was basal cell hyperplasia of the nonglandular 
stomach mucosa observed in male and female rats exposed at 12.5 or 25 mg/kg/day (Table A-21).  The 
incidence of this lesion was also significantly elevated in the satellite group after 1 year of exposure in 
males at 12.5 mg/kg/day and in females at 25 mg/kg/day.  The incidence of hepatic foci of any type was 
not increased with treatment, but treated rats showed increases of eosinophilic foci compared to 
basophilic foci.  The incidence of benign hepatocellular adenomas was significantly increased in male rats 
at 25 mg/kg/day (incidence 2/50, 1/50, 6/50, 9/50), whereas females showed a positive trend for these 
tumors (incidence 0/50, 0/50, 0/50, 4/50).  One male rat treated at 25 mg/kg/day had a hepatic carcinoma. 
 
Table A-21.  Incidence of Histopathological Lesions of Basal Cells in the 
Nonglandular Stomach in F344 Rats Exposed to 1,3-Dichloropropene 
(Telone II®b) in the Diet for 2 Years 
 
 Dose (doses in mg/kg/day; group size = 50) 
0 2.5 12.5 25 
Hyperplasia     
 Males 3 3 20a 30a 
 Females 0 1 20a 37a 
 
aStatistically different from controls 
 
Source:  Stebbins et al. 2000 
 
Dogs:   
 
Terminal body weights were significantly lower than controls by 11% in male dogs and 15% in female 
dogs exposed at 15 mg/kg/day.  Exposure had no effect on feed consumption or urinalysis results.  The 
study authors indicated that changes in clinical chemistry parameters were not associated with 
histopathology in any organ.  In dogs, the most sensitive effects were reductions in hemoglobin, 
hematocrit, and mean corpuscular volume, all characteristic of microcytic anemia observed in dogs at a 
LOAEL of 15 mg/kg/day (Table A-22); the NOAEL was 2.5 mg/kg/day in dogs. 
 










Table A-22.  Hematological Effects in Beagle Dogs Exposed to  
1,3-Dichloropropene (Telone II®b) in the Diet for 1 Year 
 
 Dose (doses in mg/kg/day; group size = 4/sex/dose) 
0 0.5 2.5 15 
Hemoglobin (g/dL)     
 Males  17.4±1.6 17.5±1.0 13.7±1.3 12.3±3.1a 
 Females 17.3±2.1 17.1±1.2 18.0±0.6 12.6±1.2a 
Hematocrit (%)     
 Males  57.0±4.1 56.6±3.0 55.7±1.4 40.5±10.4a 
 Females 57.3±5.7 56.6±3.4 60.4±2.8 40.9±3.5a 
Mean corpuscular volume (fL)     
 Males 73±1 72±2 69±4 44±4a 
 Females 75±3 73±2 72 ±3 43±5a 
 
aStatistically different from control 
 
Source:  Stebbins et al. 1999 
 
Dose and end point used for MRL derivation:  Basal cell hyperplasia of the nonglandular stomach mucosa 
observed in female rats exposed at a LOAEL of 12.5 mg/kg/day for 2 years.  BMDL values were 
calculated for these and other effects (see Table A-23).  If the BMDL10 value of 3.5124 mg/kg/day for 
female rats was used as the point of departure, the derived MRL would be 0.04 mg/kg/day.  This is in 
agreement with the EPA (2000a) chronic oral RfD of 0.03 mg/kg/day based on a BMDL10 of 
3.4 mg/kg/day for the same data.  Therefore, EPA’s BMDL10 of 3.4 mg/kg/day was selected as the point 
of departure for the chronic-duration oral MRL. 
 
[ ] NOAEL   [ ] LOAEL  [X]  BMDL10 
 
Uncertainty Factors used in MRL derivation:  100 applied to EPA’s BMDL10 of 3.4 mg/kg/day for 
increased incidence of forestomach basal cell hyperplasia in female rats. 
 
 [ ]  10 for use of a LOAEL 
 [X]  10 for extrapolation from animals to humans 
 [X]  10 for human variability 
3.4 mg/kg/day / 100  =  0.034, rounded to 0.03 mg/kg/day 
  
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.  Study authors 
reported doses based on feed intake data. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable. 
 
Was a conversion used from intermittent to continuous exposure?  Not applicable.  Intake was ad libitum. 
 
Other additional studies or pertinent information that lend support to this MRL:  No data are available for 
effects in humans following chronic-duration oral exposure to 1,3-dichloropropene.  Chronic-duration 
oral exposure studies with rats, mice, and dogs exposed to different commercial formulations of 1,3-di-
chloropropene isomers have been conducted by oral gavage or dietary exposure.  











As with the animal data for intermediate-duration exposure, the available data indicate that lesions in the 
nonglandular stomach mucosa in rats and microcytic anemia in dogs are the most sensitive effects 
associated with chronic-duration oral exposure to 1,3-dichloropropene (see Chapter 3 for a more detailed 
discussion of health effects associated with 1,3-dichloropropene).  Basal cell hyperplasia of the 
nonglandular stomach mucosa was observed in male and female Fischer 344 rats exposed to doses as low 
as 12.5 mg/kg/day Telone II®b (but not 2.5 mg/kg/day) encapsulated in feed for 1 or 2 years (Stebbins et 
al. 2000), and in male and female F344 rats and female B6C3F1 mice exposed to gavage doses of 
25 mg/kg/day Telone II®a (89% dichloropropene isomers plus 1% epichlorohydrin) 3 times/week for up 
to 2 years (NTP 1985).  Increased incidences of this lesion did not occur in male or female B6C3F1 mice 
exposed to 2.5, 25, or 50 mg/kg/day Telone II®b encapsulated in feed for 1 or 2 years (Stebbins et al. 
2000) or in male or female beagle dogs exposed to 0.5, 2.5, or 15 mg/kg/day Telone II®b encapsulated in 
feed for 1 year (Stebbins et al. 1999).  However, male and female beagle dogs exposed to 15 mg/kg/day, 
but not 2.5 mg/kg/day, Telone II®b encapsulated in feed for 1 year showed decreased values for mean 
hematocrit, hemoglobin concentration, and corpuscular volume, compared with control values, which are 
indicative of microcytic anemia.  Exposure-related reductions in terminal body weight were observed in 
rats, mice, and dogs exposed to Telone II®b in feed for 1 or 2 years, but reduced food intake associated 
with decreased palatability may have contributed to these effects (Stebbins et al. 1999, 2000).   
 
Adverse noncancer effects on the liver or kidney are not as clearly associated with chronic-duration oral 
exposure to 1,3-dichloropropene as forestomach basal cell hyperplasia in rats or microcytic anemia in 
dogs.  Exposure-related kidney effects include increased incidence of hydronephrosis in female, but not 
male, B6C3F1 mice exposed to gavage doses of 100 mg/kg/day Telone II®a , but not 50 mg/kg/day, for 
up to 2 years (NTP 1985) and increased incidence of nephropathy in female, but not male, Fischer 344 
rats exposed to 25 or 50 mg/kg/day Telone II®a for up to 2 years (NTP 1985).  However, no exposure-
related kidney effects were observed in Fischer 344 rats, B6C3F1 mice, or beagle dogs exposed to 
Telone II®b encapsulated in feed for 1 or 2 years at doses as high as 25 mg/kg/day for rats, 50 mg/kg/day 
for mice, and 15 mg/kg/day for dogs (Stebbins et al. 1999; 2000).  Observed noncancer effects in the liver 
include decreased size of hepatocytes in male, but not female, B6C3F1 mice exposed to 50 mg/kg/day, 
but not 25 mg/kg/day, Telone II®b encapsulated in feed for 1 year, but not in mice exposed for 2 years 
(Stebbins et al. 2000) and increased incidence of slight or very slight eosinophilic foci of altered liver 
cells in male and female Fischer 344 rats exposed to 2.5, 12.5, or 25 mg/kg/day Telone II®b encapsulated 
in feed for 2 years.  The toxicological significance of these apparent liver effects is equivocal given the 
inconsistency of the findings in the mouse study and the common spontaneous occurrence of liver foci 
(eosinophilic or basophilic) in aged Fischer 344 rats.  
 
Based on the findings from the chronic-duration oral exposure animal studies, basal cell hyperplasia in the 
nonglandular stomach of male rats and decreased hemoglobin concentration and corpuscular volume in 
male or female dogs were selected as co-critical effects for development of the chronic-duration MRL for 
1,3-dichloropropene.  The 2-year rat study (Stebbins et al. 2000) and 1-year dog study (Stebbins et al. 
1999) involving exposure to microencapsulated Telone II®b were selected as the principal studies, 
because the test material in these adequately designed and reported studies was the most purified 1,3-di-
chloropropene formulation tested (95.8% pure 1,3-dichloropropene—50.7% cis; 45.1% trans—with 2% 
epoxidized soybean oil as a stabilizer) and did not contain potentially confounding toxic materials such as 
epichlorohydrin or chloropicrin.   
 
Potential points of departure for deriving the chronic-duration MRL, derived with benchmark dose 
analysis, are shown in Table A-23.  Additional details of the benchmark dose analysis are described 
below.   
 










For decreased hemoglobin concentration, which was as an index of 1,3-dichloropropene-induced 
microcytic anemia in dogs, potential points of departure were 95% lower confidence limits on estimated 
doses (i.e., BMDLs) associated with a value lower than 10th percentile values for the distribution of 
hemoglobin concentrations in a sample of normal beagle dogs (Table A-23).   
 
Table A-23.  Potential Points of Departure for Determining the Chronic-duration 







Decreased hemoglobin concentration in beagle dogs exposed to 
Telone II®b in feed for 1 year (Stebbins et al. 1999). 
BMR = 10th percentile hemoglobin concentrations in normal beagle 
dogs, age >1year: 14.6 mg/dL males (n=169) and 14.1 mg/dL 
females (n=185) (Wolford et al. 1986). 
 M  8.3455 
 F  10.978 
 M  6.0453 
 F  8.8294 
Increased incidence of basal cell hyperplasia of nonglandular 
stomach mucosa in Fischer 344 rats exposed to Telone II®b in 
feed for 2 years (Stebbins et al. 2000) 
BMR = 10 % extra risk 
M  5.3432 
 F  5.4209 
 M  4.2568 
 F   3.5124 
 
BMD = benchmark dose; BMDL = 95% lower confidence limit for the benchmark dose; BMR = benchmark response 
level; F = female; M = male 
 
For increased incidence of basal hyperplasia in nonglandular stomach mucosa of rats, the potential point 
of departure was the BMDL associated with 10% extra risk.  This benchmark response (BMR) level is the 
default recommended by EPA (2000a). 
 
The lowest BMDL, the BMDL10 of 3.5124 mg/kg/day for increased incidence of nonglandular stomach 
basal cell hyperplasia in female rats, was selected as the point of departure for deriving the chronic-
duration oral MRL since it should be protective against all effects. 
 
A chronic-duration oral MRL of 0.04 mg/kg/day was derived by dividing the BMDL10 of 
3.5124 mg/kg/day for basal cell hyperplasia of the forestomach in female rats by a total uncertainty factor 
of 100 (10 for extrapolation from animals to humans and 10 for human variability).  The MRL is based on 
the Stebbins et al. (1999, 2000) studies which used approximately 96% 1,3-dichloropropene with 2% 
epoxidized soybean oil as a stabilizer; no other constituents were reported. 
 
Details of Benchmark Dose Analysis for the Chronic-duration Oral MRL 
Male and Female Rats:  
 
All available dichotomous models in the EPA Benchmark Dose Software (BMDS version 1.3.2) were fit 
to the incidence data for basal cell hyperplasia of nonglandular stomach mucosa in male rats, female rats, 
and combined male and female rats exposed to 1,3-dichloropropene in the diet for 2 years (Table A-24).  
Predicted doses associated with 10, 5, and 1 extra risks were calculated. 
 










Table A-24.  Incidence of Basal Cell Hyperplasia of Nonglandular Stomach 
Mucosa (Slight or Very Slight) in Fisher 344 Rats Exposed to  
1,3-Dichloropropene in the Diet for 2 Years 
 
 Control 2.5 mg/kg/day 12.5 mg/kg/day 25 mg/kg/day 
Males 3/50 3/50 20/50 30/50 
Females 0/50 1/50 20/50 37/50 




As assessed by the chi-square goodness-of-fit test, several models in the software provided adequate fits 
to the data for the incidence of basal cell hyperplasia of nonglandular stomach mucosa in male rats 
(x2 p-value ≥0.1) (Table A-25).  Comparing across models, a better fit is indicated by a lower AIC (EPA 
2000b).  The log-probit model was determined to be the best-fitting model, as indicated by the AIC 
(Table A-25; Figure A-9).  Benchmark doses (BMDs and BMDLs) associated with an extra risk of 10, 5, 
and 1%, calculated from the best fitting model, are shown in Table A-27.  
 
Table A-25.  Goodness of Fit Statistics and BMD10s and BMDL10s from Models Fit 
to Incidence Data for Basal Cell Hyperplasia of Nonglandular Stomach Mucosa 
in Male Rats Exposed to 1,3-Dichloropropene  
in the Diet for 2 Years 
 
Model AIC X2 p-valuea BMD10 (mg/kg/day) BMDL10 (mg/kg/day) 
Gamma 187.302 0.2589 4.89969 2.57775 
Logistic 189.052 0.0784 7.13438 5.92049 
Log-Logistic 186.872 0.3554 4.96556 2.47384 
Multistage 188.102 0.1603 4.06715 2.46921 
Probit 188.191 0.1202 6.62804 5.54609 
Log-probitb 184.503 0.7769 5.34316 4.25684 
Quantal-linear 186.563 0.3216 3.09733 2.41788 
Quantal-quadratic 188.62 0.0871 7.96066 6.94702 
Weibull 187.529 0.2243 4.63368 2.54375 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bBest-fitting model  
 
AIC = Akaike’s Information Criteria; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the 
benchmark dose; NA = not applicable; p = p-value from the Chi-squared test 
 
Source:  Stebbins et al. 2000 
 










Figure A-7.  Observed and Predicted Incidences of Basal Cell Hyperplasia of 
Nonglandular Stomach Mucosa in Male Rats Exposed  





















Probit Model with 0.95 Confidence Level
21:49 03/15 2006
BMDL BMD




*BMDs and BMDLs indicated are for a 10% extra risk and are in units of mg/kg/day. 
BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark dose 
 
Source:  Stebbins et al. 2000 
 
The form and parameters of the log-probit model for the male rat data are as follows: 
 
P[response] = Background+ (1-Background)* CumNorm(Intercept+Slope*Log(Dose)), 
 
where CumNorm(.) is the cumulative normal distribution function 
 
background  =   0.0531859 
intercept  =   -2.95737 




As assessed by the chi-square goodness-of-fit test, several models in the software provided adequate fits 
to the data for the incidence of basal cell hyperplasia of nonglandular stomach mucosa in female rats 
(x2 p-value ≥0.1) (Table A-26).  Comparing across models, a better fit is indicated by a lower AIC (EPA 
2000b).  The log-logistic model was determined to be the best-fitting model, as indicated by the AIC 
(Table A-26; Figure A-8).  Benchmark doses (BMDs and BMDLs) associated with an extra risk of 10, 5, 
and 1%, calculated from the best fitting model, are shown in Table A-27.  
 










Table A-26.  Goodness of Fit Statistics and BMD10s and BMDL10s from Models Fit 
to Incidence Data for Basal Cell Hyperplasia of Nonglandular Stomach Mucosa 
in Female Rats Exposed to 1,3-Dichloropropene  
in the Diet for 2 Years 
 
Model AIC X2 p-valuea BMD10 (mg/kg/day) BMDL10 (mg/kg/day) 
Gamma 138.598 0.9121 5.25023 3.31605 
Logistic 148.131 0.0176 7.67354 6.23867 
Log-Logisticb 138.416 0.9973 5.4209 3.51236 
Multistage 139.663 0.5468 5.29306 2.91991 
Probit 145.812 0.0404 7.31771 5.93502 
Log-probit 138.52 0.9461 5.07542 3.57721 
Quantal-linear 143.267 0.1648 2.39166 1.92514 
Quantal-quadratic 138.493 0.5372 6.49982 5.81197 
Weibull 139.013 0.7530 5.08921 3.1648 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bBest-fitting model  
 
AIC = Akaike’s Information Criteria; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the 
benchmark dose; NA = not applicable; p = p-value from the Chi-squared test 
 
Source:  Stebbins et al. 2000 
 










Figure A-8.  Observed and Predicted Incidences of Basal Cell Hyperplasia of 
Nonglandular Stomach Mucosa in Female Rats Exposed  

















Probit Model with 0.95 Confidence Level
22:29 03/15 2006
BMDL BMD




*BMDs and BMDLs indicated are for a 10% extra risk and are in units of mg/kg/day. 
BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark dose 
 
Source:  Stebbins et al. 2000 
 
The form and parameters of the log-logistic model for the female rat data are as follows: 
 
P[response] = background+(1-background)/[1+EXP(-intercept-slope*Log(dose))] 
 
background  =   0 
intercept  =   -5.8536 
slope   =     2.14828 
 










Table A-27.  Best-fitting Model Predictions for 1, 5, and 10% Extra Risk for Basal 
Cell Hyperplasia of Nonglandular Stomach Mucosa in Male and Female Rats 
Exposed to 1,3-Dichloropropene in the Diet for 2 Years 
 
Best fitting model BMR (% extra risk) BMD (mg/kg/day) BMDL (mg/kg/day) 
Male:  Log-Probit 1 2.10426 1.25833 
 5 3.7369 2.48751 
 10 5.34316 4.25684 
Female:  Log-logistic 1 1.13014 0.258277 
 5 3.13078 1.23116 
 10 5.4209 3.51236 
 
BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark dose; BMR = benchmark 
response 
 
Source:  Stebbins et al. 2000 
 
Male and Female Dogs: 
 
The linear model in the EPA Benchmark Dose Software (BMDS version 1.3.2) was fit to the data 
(Table A-28) for decreased hemoglobin concentration in beagle dogs exposed to 1,3-dichloropropene in 
the diet for 1 year.  The linear model was selected as it is the simplest model available in the BMD 
software which adequately fits the hemoglobin concentration data.  Hemoglobin concentration was 
selected as the most clearly adverse variable associate with 1,3-dichloropropene-induced microcytic 
anemia.  BMDs and BMDLs associated with a value lower than the 10th percentile value for hemoglobin 
in normal beagle dogs were calculated (Table A-29, Figures A-9 and A-10).  The 10th percentile 
hemoglobin concentrations in normal beagle dogs, age >1 year for the 1-year exposure were 14.6 mg/dL 
for males and 14.1 mg/dL for females (Wolford et al. 1986).   
 
 
Table A-28.  Hemoglobin Concentrations in Male and Female Beagle Dogs 





mean hemoglobin  
concentration ± standard deviation 
(g/dL) 
Female 
Mean hemoglobin concentration ± 
standard deviation (g/dL) 
0 17.4±1.6 17.3±2.1 
0.5 17.5±1.0 17.1±1.2 
2.5 13.7±1.3 18.0±0.6 
15 12.3±3.1* 12.6±1.2* 
 
Source:  Stebbins et al. 1999 










Table A-29.  Linear Model Predictions for the Dose Associated with the  
10th Percentile Value for Hemoglobin Concentration  
in Normal Beagle Dogs with the  








 Malea 8.3455 6.04528 
 Female 10.978 8.82939 
 
aNonhomogeneous variance model 
 
BMD = benchmark dose; BMDL = lower confidence limit (95%) on the benchmark dose
 
Figure A-9.  Linear (Nonhomogeneous Variance) Model Predicted Change in 
Hemoglobin Concentration in Male Beagle Dogs Exposed  



















Linear Model with 0.95 Confidence Level
14:57 03/30 2006
BMDBMDL




*BMDs and BMDLs indicated are doses associated with the 10th percentile value for hemoglobin concentration in 
normal beagle dogs and are in units of mg/kg/day. 
BMD = benchmark dose;  BMDL = lower confidence limit (95%) on the benchmark dose 
 
Source:  Stebbins et al. 1999 










Figure A-10.  Linear Model Predicted Change in Hemoglobin Concentration in 

















Linear Model with 0.95 Confidence Level
15:03 03/30 2006
BMDBMDL




*BMDs and BMDLs indicated are doses associated with the 10th percentile value for hemoglobin concentration in 
normal beagle dogs and are in units of mg/kg/day 
BMD = benchmark dose;  BMDL = lower confidence limit (95%) on the benchmark dose 
 
Source:  Stebbins et al. 1999 
 
Agency Contacts (Chemical Managers):  Annette Ashizawa, Sharon Wilbur, and Heraline Hicks 
















   














   
 
   
 
   
 






   
 
 
     
 
    
  
 
   




   
  
B-1DICHLOROPROPENES
APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.  
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not













   




     
     
    
 
 
   
    
     
 
 




   
  
  
   












   
   
  
  




   
   
B-2DICHLOROPROPENES
APPENDIX B
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2,
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.















   




    
 
 
   









   
  
 
   
 






















See Sample LSE Table 3-1 (page B-6)
(1)	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7)	 System. This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 















    
   
    
 
 
    
 
   
 
    
 
 









   
 
 




   
 
  
   






      
    
 
     





which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
(9)	 LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists.  The same health effects appear in the LSE table.
(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.




















(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).






         
 













    
      





























































































































1 →	 Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Key to 	 frequency/ NOAEL Less serious Serious (ppm)





5 6 7 8 9 10
→ Systemic ↓	 ↓ ↓ ↓ ↓ ↓
18 Rat	 13 wk Resp 3b 10 (hyperplasia)





38 Rat	 18 mo 20 (CEL, multiple Wong et al. 1982
5 d/wk organs)
7 hr/d
39 Rat	 89–104 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk nasal tumors)
6 hr/d
40 Mouse	 79–103 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk hemangiosarcomas)
6 hr/d
12 →	 a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD benchmark dose
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation










   
           























   
  
   
  








   
  














DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level























   
   
  





































MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
OW Office of Water






























































OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization











   
  
  

















≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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alanine aminotransferase (see ALT) ........................................................................................................... 31
 
ALT (see alanine aminotransferase) ..................................................................................................... 31, 67
 








bioavailability ................................................................................................................................... 128, 227
 
bioconcentration factor ............................................................................................................. 210, 226, 246
 
biodegradation............................................................................................................... 7, 208, 211, 212, 213
 
biomarker .................................................... 9, 66, 68, 69, 148, 149, 150, 171, 172, 173, 174, 228, 231, 239
 
body weight effects ........................................................................................................................... 104, 112
 
breast milk......................................................................................................................... 148, 177, 224, 228
 
cancer .................................................................................... 10, 12, 13, 36, 73, 74, 106, 115, 147, 171, 246
 
carcinogen............................................................................................................................... 4, 13, 242, 246
 
carcinogenic .............................................. 10, 12, 13, 14, 15, 35, 36, 74, 106, 160, 165, 166, 171, 242, 246
 
carcinogenicity...................................................................................................... 12, 13, 106, 160, 171, 246
 
carcinoma............................................................................................................................ 13, 103, 106, 165
 
cardiovascular ........................................................................................................................... 9, 64, 98, 112
 
cardiovascular effects........................................................................................................................ 9, 64, 98
 




death.................................................... 9, 13, 14, 16, 22, 35, 60, 61, 73, 74, 75, 97, 107, 134, 160, 169, 171
 
deoxyribonucleic acid (see DNA)............................................................................................................... 13
 
developmental effects ..................................................................................... 10, 16, 73, 106, 115, 169, 177
 




endocrine................................................................................................................................... 112, 145, 146
 






gastrointestinal effects .................................................................................................. 9, 11, 22, 65, 99, 112
 
general population............................................................................. 2, 8, 148, 170, 198, 199, 223, 228, 240
 
genotoxic............................................................................................................. 35, 115, 122, 160, 167, 168
 
genotoxicity................................................................................... 13, 35, 122, 123, 124, 160, 166, 167, 168
 
groundwater .............................................................................. 7, 8, 193, 198, 205, 208, 217, 218, 223, 228
 
half-life.................................................................................................. 7, 128, 137, 138, 139, 149, 211, 214
 
hematological effects .......................................................................................... 10, 12, 23, 65, 66, 100, 101
 
hepatic effects ....................................................................................................................... 66, 67, 101, 102
 
hydrolysis.......................................................... 7, 8, 125, 130, 133, 136, 144, 208, 209, 212, 213, 214, 227
 
hydroxyl radical ............................................................................................................................ 7, 210, 211
 
immune system ................................................................................................................................... 71, 170
 
immunological .............................................................................................................. 35, 70, 104, 161, 170
 










   
   
   
   
   
   
   
   
   
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   








LD50........................................................................................................................... 22, 32, 75, 97, 107, 128
 
leukemia................................................................................................................................ 12, 74, 161, 165
 
metabolic effects ....................................................................................................................................... 104
 
micronuclei ....................................................................................................................................... 116, 117
 
milk ................................................................................................................................................... 153, 177
 
musculoskeletal effects ............................................................................................................... 66, 101, 112
 




neurological effects............................................................................................. 71, 105, 114, 160, 170, 171
 




partition coefficients ........................................................................................................................... 22, 226
 
pharmacodynamic ............................................................................................................................. 139, 242
 




placenta ............................................................................................................................................. 148, 177
 
rate constant ...................................................................................................................................... 142, 210
 
renal effects..................................................................................................... 68, 69, 70, 102, 103, 171, 173
 
reproductive effects..................................................................................................... 72, 105, 115, 160, 168
 




salivation................................................................................................................................... 114, 161, 170
 
solubility ....................................................................................................................... 8, 143, 206, 208, 226
 
systemic effects............................................................................................................... 16, 61, 97, 112, 160
 




toxicokinetic........................................................................ 13, 14, 15, 33, 35, 125, 173, 174, 175, 176, 177
 
tumors ................................................................................................... 10, 62, 100, 102, 106, 115, 165, 166
 
vapor phase ....................................................................................................................................... 206, 208
 
vapor pressure ................................................................................................................... 206, 208, 209, 226
 
volatility ................................................................................................................................................ 8, 209
 
volatilization ............................................................................................................................. 200, 208, 209
 
   
 
 
 
 
 
 
 
 
 
 
 
 
